genetic loci for retinal arteriolar microcirculation text s1 · resolution using a 35-mm film...
TRANSCRIPT
1
Genetic Loci for Retinal Arteriolar Microcirculation
Text S1
Text S1 contains the following information:
1. Sample selection and retinal vascular caliber measurements for each study cohort.
a. Discovery cohorts
i. Age, Gene/Environment Susceptibility – Reykjavik Study (AGES)
ii. Atherosclerosis Risk in Communities Study (ARIC)
iii. Cardiovascular Heart Study (CHS)
iv. Rotterdam Study (RS)
v. Blue Mountain Eye Study (BMES)
b. Replication cohorts
i. Australian Twin Study
ii. Multi-Ethnic Study of Atherosclerosis (MESA)
2. Genotyping quality control filters and imputation of discovery cohorts
3. Meta-analysis
4. Analyses with Macrovascular diseases
5. References
2
1. Sample selection and retinal vascular caliber measurements for each study cohort.
a. Discovery cohorts
i. Age Gene/Environment Susceptibility – Reykjavik Study (AGES)
The original Reykjavik Study cohort consisted of a random sample of 30,795 men and
women born from 1907 to 1935 and residing in Reykjavik in 1967 [1]. The AGES study re-
examined 5,764 survivors from the original study. Among these, 3,219 participants were
genotyped on the Illumina 370CNV BeadChip array. Sample exclusion criteria included sample
failure, genotype mismatch with reference panel and gender discordance. Finally, 2,949
participants had both genome wide data and retinal vessel measurements.
Retinal images of each eye, centered on the macula and optic disc, were captured
digitally using a 6.3 megapixel Canon R6 nonmydriatic camera with a Canon D-60 camera after
maximal pharmacologic pupil dilation. Images with suboptimal quality, judged by a trained
photographer, were retaken immediately. Throughout the study, the Ocular Epidemiology
Reading Center (Madison, Wisconsin) provided routine feedback for the assessment of retinal
images. Using a computer-assisted program and a standard protocol, measurements of retinal
vessel caliber were made for all arterioles and venules in the area between 0.5 and 1.0 disc
diameters from the optic disc margin [2]. Individual vessels measurements were combined by the
Parr-Hubbard-Knudston formulas and summarized as the central retinal arteriole and venular
equivalents (CRAE, CRVE) [3]. The inter-grader and intra-grader intra-class correlation
coefficients ranged from 0.85 to 0.95 for CRAE and were consistently at 0.99 for CRVE.
In addition, the study was approved by the Icelandic National Bioethics Committee,
VSN: 00-063 with written informed consent from all participants [4].
ii. Atherosclerosis Risk in Communities Study (ARIC)
The ARIC study is a prospective population-based study to investigate the etiology of
atherosclerosis in four different US communities including non-Hispanic whites and African
3
Americans [5]. Detailed study design can be found on the ARIC study website
(http://www.cscc.unc.edu/aric/). At baseline examination in 1987 to 1989, participants were
between the age of 45 and 64. Blood was drawn at baseline for DNA extraction. Participants were
genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 at the Broad Institute. For
this study, only the non-Hispanic whites are included.
Retinal photos were taken at examination 3. Briefly, a 45° nonstereoscopic color retinal
photograph was taken of one eye of each participant using a fundus camera that does not require
pharmacologic dilation of the pupil (Canon CR-45UAF; Canon USA, Inc., Lake Success, New
York). At the central reading center, a technician digitized the color slides at 3175 dots/inch
resolution using a 35-mm film scanner (Nikon LS 3510 AF, Tokyo, Japan). The measurement
module was custom programmed in Khoros (public domain image processing software from the
University of New Mexico - Albuquerque) and the retinal measurements were summarized in
micrometer (μm) using the Parr-Hubbard-Knudtson formulas [2,3]. Among three graders, the
intra-grader and inter-grader intra-class correlation coefficients were 0.69 and 0.74 for CRAE and
0.89 and 0.77 for CRVE [2].
iii. Cardiovascular Health Study (CHS)
The CHS is a population-based cohort study of risk factors for coronary heart disease and
stroke in 5,201 persons, including 4,925 Europeans recruited in 1989 – 1990 [6]. An additional
687 African-Americans were enrolled into the study subsequently. At baseline, DNA was
extracted from blood samples of participants who gave consent to genetic testing. The
participants were genotyped on the Illumina 370CNV Duo BeadChip at the General Clinical
Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai. There were 1,263
participants, who were free of clinical cardiovascular disease at baseline and had both genotype
data and retinal arteriole vessel measurements available for this study. Only those of European
ancestry were included for this study.
4
Similar to the ARIC study, a 45° retinal photograph centered between the optic disc and
the macula was obtained of one randomly selected eye using a non-mydriatic fundus camera after
5 minutes of dark adaptation (Canon CR-45UAF; Canon USA, Inc., Lake Success, New York).
Photographs were digitized with a high-resolution scanner and evaluated according to a
standardized protocol at the Fundus Photograph Reading Center in Madison, Wisconsin. The
retinal measurements were summarized as CRAE and CRVE (in μm) using the Parr-Hubbard-
Knudtson formulas [2,3]. The intra-grader and inter-grader intra-class correlation coefficients
ranged from 0.67 to 0.91.
iv. Rotterdam Study (RS)
The Rotterdam Study is a population-based cohort study conducted in a district of
Rotterdam to examine the determinants of neurogeriatric, cardiovascular, bone, and eye diseases
and health in the elderly [7]. Baseline measurements were obtained from 1990 to 1993 and
consisted of an interview at home and two visits to the research center for physical examination,
with written informed consent. In addition, DNA was extracted from all participants who
consented to genotyping at baseline. Genotyping was performed in high-quality extracted DNA
using the Illumina Infinum II HumanHap550chip v3.0 beadchip. Finally, a total of 4,820
participants had data on genotyping and retinal vessel measurements for the current analyses.
A full eye examination was implemented at baseline including taking fundus color
transparencies of the optic disc (200 field, Topcon Optical Company, Tokyo, Japan) after
pharmacological mydriasis. The transparencies from both eyes were digitized with a high-
resolution scanner (Nikon LS-4000, Nikon Corporation, Japan), and the digitized image of one
eye with the best quality was analyzed with the Retinal Vessel Measurement System (Retinal
Analysis, Optimate, WI; Department of Ophthalmology & Visual Science, University of
Wisconsin-Madison). For each participant one summary value was calculated for the arteriolar
diameters (CRAE in μm) and one for the venular caliber (CRVE) [2,3]. Pearson’s correlation
5
coefficients for inter-grader agreement were 0.67 – 0.80 for CRAE and 0.91 – 0.94 for CRVE.
The corresponding figures were 0.69 – 0.88 and 0.90 – 0.95 for intra-grader agreement.
v. Blue Mountain Eye Study (BMES)
The Blue Mountains Eye Study (BMES) is a population-based cohort of a predominantly
white population in west of Sydney, Australia. At baseline (1992 – 1994), 3,654 permanent
residents aged 49 years or older participated (participation rate of 82.4%) [8]. During 1997 –
1999 (BMES IIA), 2,335 participants (75.1% of survivors) returned for examinations during after
5 years. During 1999 – 2000, 1,174 (85.2%) new participants took part in an Extension Study of
the BMES (BMES IIB). BMES cross-section II thus includes BMES IIA (66.5%) and BMES IIB
(33.5%) participants (n = 3,509). From the BMES cross section II who had blood samples
collected, DNA was extracted for 3,189 (90.1 %) participants.
Stereoscopic retinal photographs (30º) were taken for the macula, optic disc and other
retinal fields of both eyes at each visit, using a Zeiss FF3 fundus camera (Carl Zeiss, Oberkochen,
Germany) after pupil dilation. The retinal arteriolar and venular calibre was measured from the
optic disc-centered photographs taken at baseline examinations, using a validated computer-
assisted method [9]. A digitized grid was placed over the image and all vessels passing
completely through a zone between 0.5 to 1 disc diameters away from the disc margin were
measured, using the Retinal Analysis software (termed Howard program, Optimate, WI;
Department of Ophthalmology & Visual Science, University of Wisconsin-Madison). For each
vessel and branch, five equidistant measures were taken in μm. Estimates of CRAE and CRVE
obtained from the Parr-Hubbard formulas were further converted into estimates equivalent to
measures that were based on six largest arterioles and venules respectively of each eye, following
the Parr-Hubbard-Knudtson formulas that was used by a newer computer-assisted program
(IVAN program) [2,3]. Quadratic weighted kappa values were 0.85 for CRAE and 0.90 for
6
CRVE for inter-grader reliability respectively, and between 0.80-0.93 and 0.80-0.92 for intra-
grader reliability of graders 1 and 2, respectively.
Participants of the BMES cross section II who had DNA available were genotyped (N =
2,761) using the Illumina Human 670-Quadv1 custom genotyping array at the Wellcome Trust
Centre for Human Genetics, Sanger Institute, Cambridge as part of the Wellcome Trust Case
Control Consortium 2 (WTCCC2). A smaller subset (N = 1,356) was also independently
genotyped using the Illumina 610-Quad genotyping array at the Hunter Medical Research
Institute, Newcastle, Australia, facilitating a detailed assessment of genotyping quality and
reproducibility. Principal components (up to four dimensions) were used as covariates in the
association analysis.
Imputation was performed using the Hapmap release 24 CEU panel (NCBI Build 36.1) as
the imputation backbone, using only single nucleotide polymorphism (SNP) passing quality
control (minor allele frequency MAF > 0.01, genotyping call rate > 0.95, Hardy-Weinberg
Equilibrium (HWE) P-value > 1 x 10-6) in both the WTCCC2 and Newcastle datasets. Genotype
imputation was performed for autosomal SNPs using Markov Chain Haplotyping (MaCH)
package v1.0.16 (http://www.sph.umich.edu/csg/abecasis/MACH/). Imputed genotypes were
excluded if their ratio of observed to expected variance of imputed allele dosages (R2) < 0.3 OR
minor allele frequency < 0.01 OR Hardy-Weinberg P-value < 1 x 10-6.
b. Replication cohorts
i. Australian Twins Study
The Australian Twin Eye Study consisted of participants examined as part of the Twins
Eye Study in Tasmania (TEST) or the Brisbane Adolescent Twins Study (BATS) [10].
Participants were genotyped on the Illumina Human Hap610W Quad array, with part of the
samples genotyped along with the UK Twins Cohort and the rest with DeCODE genetics.
Complete phenotype and genetic data were available for 1,709 individuals.
7
Optic disc photographs were taken with a Nidek 3-Dx simultaneous stereoscopic 15°
fundus camera (Nidek, Gamagori, Japan) in all subjects after instillation of tropicamide 1%.
Images were developed on colored 35 mm slides (Ektachrome, Eastman Kodak, Rochester, New
York) and further digitized (Nikon CoolScan IV ED slide scanner, Nikon Corp., Tokyo, Japan).
Retinal vascular caliber was measured using the Parr-Hubbard-Knudtson formulas with
computer-assisted software (IVAN, University of Wisconsin) and summarized as CRAE and
CRVE [11]. Intra-grader and inter-grader intra-class correlation coefficients were very high for
both CRAE (0.95, 0.93) and CRVE (0.99, 0.98).
For genotyping filters, the exclusion criteria for SNPs were MAF ≤ 1%, HWE P-value <
10-6, SNP call rate ≤ 95% and Illumina Beadstudio Gencall Score < 0.7. Imputation was done
against the backbone of Hapmap II release 22 CEU using MaCH2
(http://www.sph.umich.edu/csg/abecasis/MACH/) [12]. To account for the relatedness of the
individuals, the association analysis was performed using the score test on Merlin (–fastAssoc
option) (http://www.sph.umich.edu/csg/abecasis/merlin/) [13].
ii. Multi-Ethnic Study of Atherosclerosis (MESA)
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of
subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical
signs and symptoms) and the risk factors that predict progression to clinically overt
cardiovascular disease or progression of the subclinical disease. MESA researchers study a
diverse, population-based sample of 6,814 asymptomatic men and women aged 45 – 84 recruited
from six field centers across the United States in 2000 and 2001. Among the recruited
participants, 38% were white, 28% African-American, 22% Hispanic and 12% Asian,
predominantly of Chinese descent [14]. Genome wide association scan (GWAS) and retinal data
were available for 2,170 European subjects. Genotyping was performed using the Affymetrix
Genome-Wide Human SNP Array 6.0.
8
Fundus photography was offered to all participants at the second examination. Retinal
images were acquired using a standardized protocol and a 45-degree nonmydriatic camera
(Canon, Lake Success, New York) [15]. Retinal arteriolar caliber was, measured by the Ocular
Epidemiology Reading Center (Madison Wisconsin) and employed the same standardized
protocol and software used for the AGES study. The Parr-Hubbard-Knudtson formulas were
used to compute summary measures for CRAE and CRVE in micrometer (µm).
IMPUTE version 2.1.0 [16] was used to perform imputation for the MESA European
participants (chromosomes 1-22) using HapMap Phase I and II - CEU as the reference panel
(release #24 - NCBI Build 36 (dbSNP b126)). SNPs with MAF less than 0.01 or HWE P-value <
0.0001 were removed from the analysis. Association tests were performed by SNPTEST v2 [17].
2. Genotyping quality control filters and imputation of discovery cohorts
Sample specific quality control filters used in the discovery cohorts included sample
failure, sample call rate, sample heterozygosity, excessive Mendelian errors in the samples,
outliers identified by IBS clustering analysis and gender discordance [18]. SNP quality control
filters included call rates, minor allele frequency, Hardy-Weinberg equilibrium and differential
missingness by outcome or genotype [18].
The discovery cohorts were screened for latent population substructure using suitable
programs (i.e, EIGENSTRAT in ARIC and AGES [19,20], an identity-by-descent IBD matrix in
Rotterdam, principal component analysis in CHS and multi-dimensional scaling in BMES [21])
and found no evidence of occult population admixture. BMES in addition, corrected for the first
four principal components in their regression analysis, to retain more samples.
For imputation, high quality SNP data was used as seed for imputation in each study.
These criteria included call rates (> 97% in AGES, > 95% in ARIC and CHS, ≥ 95% in BMES, >
98% in RS), MAF filtering of greater than 0.01 in each study, Hardy-Weinberg filtering (HWE P-
9
value > 1 x 10-5 in CHS and P-value > 1 x 10-6 in AGES, ARIC, RS and BMES), and differential
missingness filter of P-value > 1 x 10-9 in each study. Genotype imputation for discovery cohorts
was performed using the MACH package (http://www.sph.umich.edu/csg/abecasis/MACH) [12]
(version 1.0.15 for ARIC and RS; v1.0.16 for AGES and BMES) and BIMBAM10 v0.99 [22] for
CHS. All the cohorts imputed with the reference panel of Hapmap II CEU release 22 build 36,
except CHS which imputed against the reference panel of Hapmap II CEU release 21A build 35.
The ratio of the empirically observed dosage variance to the expected binomial dosage variance
was estimated as a reliability measure of imputation for each SNP.
We checked bivariate plots of –log10 observed P-value against –log10 empirical P-value
(P-P) plots to ensure that the p-value distribution in each of the discovery cohorts conformed to a
null distribution except at the extreme tail. The genomic inflation factor (λgc) measuring the over-
dispersion of test-statistics from association tests were 1.040 for AGES, 1.036 for ARIC, 1.041
for CHS, 1.039 for RS and 1.004 for BMES.
3. Meta-analysis
Each cohort had approximately 2.5 million SNPs either genotyped or imputed for meta-
analysis (2,408,992 for AGES, 2,475,681 for ARIC2, 250,210 for CHS and 2,447,961 for RS and
2,411,691 for BMES). 2,137,729 SNPs were common across all the discovery cohorts and only
SNPs that were present in all 5 cohorts were selected for follow-up.
The inverse variance fixed effects meta-analysis method was used for the meta-analysis,
with genomic control applied to each cohort prior to meta-analysis. Larger weights were given to
studies with bigger samples sizes, directly genotyped SNPs and SNPs with high quality
imputation. The meta-analysis was implemented using METAL
(http://www.sph.umich.edu/csg/abecasis/Metal/index.html). The genomic inflation factor after
meta-analysis was 1.022812.
10
4. Analyses with Macrovasular Diseases
i. Wellcome Trust Case Control Consortium (WTCCC)
The Wellcome Trust Case Control Consortium (WTCCC) was established to look into the
design and analyses of GWA studies and published their landmark paper on the case control
analyses of seven common diseases and a set of common controls [17]. The seven diseases
included bipolar disorder (BD), coronary artery disease (CAD), Crohn’s disease (CD),
hypertension (HT), rheumatoid arthritis (RA), type 1 diabetes (T1D), and type 2 diabetes (T2D).
CAD cases were defined as having a validated history of either myocardial infarction or coronary
revascularization (coronary artery bypass surgery or percutaneous coronary angioplasty) before
their 66th birthday and verified from hospital records or the primary care physician. The control
samples were from two sources, the 1958 Birth Cohort and a new UK Blood Service which was
established specifically for this study and is a UK national repository of anonymized DNA
samples from 3,622 consenting blood donors. Imputation was performed using the Markov Chain
Haplotyping (MaCH) package (http://www.sph.umich.edu/csg/abecasis/MACH) [12] with
Hapmap CEU as the reference panel. Logistic regression was performed using, the estimated
dosage of the effective allele from MaCH and the ProbABEL program
(http://mga.bionet.nsc.ru/~yurii/ABEL/) [23] with no adjustment for covariates.
ii. The Heart and Vascular Health Study (HVH)
The Heart and Vascular Health Study (HVH) is a population-based case-control study within
Group Health (GH) in western Washington State. Myocardial Infarction (MI) cases were GH
enrollees, 30 to 79 years of age, who had an incident MI between 1995 and 2006, and alive at the
time of study recruitment. Stroke cases were also GH enrollees, 30 to 79 years of age, who had an
incident stroke between 1995 and 2008, and alive at the time of study recruitment. Hospital
discharge diagnosis codes were used to identify cases and further validated by medical record
review as previously described [24]. Control subjects were made up of a stratified random sample
11
of GH enrollees frequency matched to MI cases on age (within decade), sex, hypertension status,
and calendar year of identification. If participants were recent enrollees at GH, had a history of
prior MI or stroke, or if the incident MI or stroke was a complication of a procedure or surgery,
they were excluded from the study. All participants provided written informed consent.
iii. Global Blood Pressure Genetics (Global BPgen) Consortium
The Global BPgen consortium comprises of 17 individual GWAS studies [25]: the Baltimore
Longitudinal Study of Aging (BLSA), British 1958 Birth Cohort (B58C-T1DGC and B58C-
WTCCC), Cohorte Lausannoise (CoLaus), Diabetes Genetics Initiative (DGI), European
Prospective Investigation of Cancer-Norfolk-Genome Wide Association Study (EPIC-Norfolk-
GWAS), Fenland Study, Finland-United States Investigation of NIDDM Genetics (FUSION)
study, Invecchiare in Chianti (InCHIANTI), Kooperative Gesundheitsforschung in der Region
Augsburg (KORA), the Myocardial Infarction Genetics Consortium (MIGen), Northern Finland
Birth Cohort of 1966 (NFBC1966), SardiNIA, Study of Health in Pomerania (SHIP), the
Precocious Coronary Artery Disease (PROCARDIS), Supplementation en Vitamines et
Mine´raux Antioxydants (SU.VI.MAX) and TwinsUK. Individuals >70 years of age, ascertained
on case status for type 1 or 2 diabetes (DGI, FUSION), coronary artery disease (MIgen,
PROCARDIS) or hypertension (BRIGHT), were excluded for analysis. Hypertension was defined
as either (i) systolic blood pressure ≥ 140 mm Hg or (ii) diastolic blood pressure ≥90 mm Hg or
(iii) self-reported hypertension medication. Normotensive controls were defined as individuals
not taking any antihypertensives and having a systolic blood pressure ≤ 120 mm Hg and a
diastolic blood pressure ≤ 85 mm Hg. Analysis of hypertension was done using logistic
regression to adjust for age, age2, sex and body mass index (BMI) for 34,433 individuals.
iv. Genetics of Diabetes and Audit Research in Tayside Scotland (GoDARTS)
12
GoDARTS is a population based case control study in Tayside, Scotland to study the
epidemiology and genetics of Type 2 Diabetes [26]. Participants were recruited between 2004 to
2009 and linked to routinely collected medical records available for the Tayside region.
Participants with coronary artery disease (CAD) were identified from medical records. These
included hospital admissions and deaths due to myocardial infarction and unstable angina, and
participants who underwent coronary revascularization. Stroke was defined as hospital
admissions and deaths associated with ischemic stroke.
Quality controlled genotyping data for the SNPs of interest were available for 3,328
diabetics genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0.
A multivariate Cox regression analysis was performed on incident CAD and incident
ischemic stroke using the survival package in R (http://CRAN.R-
project.org/package=survival) [27]. Incident events were defined as events that occurred after
participants were recruited into the study. They were followed up until their first stroke or CAD
event or death from other causes or until the end of the censoring period. Baseline measures were
recorded at the time of recruitment. An additive mode was used where the effect allele was coded
as the allele that reduced arteriolar caliber with age, gender, body mass index, history of smoking,
previous coronary artery disease/stroke events at baseline included as covariates in the analysis.
A multivariable logistic regression analysis was also performed in prevalent cases of
CAD in GoDARTS, corrected for age, gender, BMI, history of smoking and use of hypertension
medication.
13
5. References
1. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, et al. (2007) Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol 165: 1076-1087. 2. Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, et al. (1999) Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 106: 2269-2280. 3. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, et al. (2003) Revised formulas for summarizing retinal vessel diameters. Curr Eye Res 27: 143-149. 4. Qiu C, Cotch MF, Sigurdsson S, Garcia M, Klein R, et al. (2008) Retinal and cerebral microvascular signs and diabetes: the age, gene/environment susceptibility-Reykjavik study. Diabetes 57: 1645-1650. 5. (1989) The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 129: 687-702. 6. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, et al. (1991) The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1: 263-276. 7. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, et al. (2009) The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 24: 553-572. 8. Mitchell P, Smith W, Attebo K, Wang JJ (1995) Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 102: 1450-1460. 9. Leung H, Wang JJ, Rochtchina E, Tan AG, Wong TY, et al. (2003) Relationships between age, blood pressure, and retinal vessel diameters in an older population. Invest Ophthalmol Vis Sci 44: 2900-2904. 10. Mackey DA, Mackinnon JR, Brown SA, Kearns LS, Ruddle JB, et al. (2009) Twins eye study in Tasmania (TEST): rationale and methodology to recruit and examine twins. Twin Res Hum Genet 12: 441-454. 11. Sun C, Zhu G, Wong TY, Hewitt AW, Ruddle JB, et al. (2009) Quantitative genetic analysis of the retinal vascular caliber: the Australian Twins Eye Study. Hypertension 54: 788-795. 12. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34: 816-834. 13. Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30: 97-101. 14. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, et al. (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156: 871-881. 15. Klein R, Klein BE, Knudtson MD, Wong TY, Cotch MF, et al. (2006) Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 113: 373-380. 16. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39: 906-913. 17. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678. 18. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, et al. (2009) Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of
14
prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2: 73-80. 19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909. 20. Patterson N, Price AL, Reich D (2006) Population structure and eigenanalysis. PLoS Genet 2: e190. 21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575. 22. Servin B, Stephens M (2007) Imputation-based analysis of association studies: candidate regions and quantitative traits. PLoS Genet 3: e114. 23. Aulchenko YS, Struchalin MV, van Duijn CM (2010) ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11: 134. 24. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274: 620-625. 25. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 26. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, et al. (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315: 524-528. 27. Therneau T (2011) Survival: Survival analysis, including penalised likelihood. 2.36-9 ed.
SNP (chr: position) Ref/Effective allele (+) Cohort Eff allele freq Beta (SE) P-value Genes of interest rs2194025 (5: 87833992) C/G AGES 0.95 -1.30 (0.79) 9.74 x 10-2 TMEM16B ARIC 0.90 -1.25 (0.36) 4.33 x 10-4 MEF2C CHS 0.91 -3.14 (0.99) 2.00 x 10-3 RS 0.90 -1.46 (0.48) 2.29 x 10-3 BMES 0.90 -2.45 (0.74) 9.72 x 10-4 Cohort Eff allele freq Beta (SE) P-value Genes of interest rs3744061 (17: 72244998) A/G AGES 0.46 -0.96 (0.35) 6.23 x 10-3 SFRS2 ARIC 0.44 -1.03 (0.21) 1.53 x 10-6 MFSD11 CHS 0.43 -1.16 (0.60) 6.00 x 10-2 JMJD6 RS 0.42 -0.27 (0.30) 3.72 x 10-1 MXRA7 BMES 0.45 -0.52 (0.45) 2.43 x 10-1 Cohort Eff allele freq Beta (SE) P-value Genes of interest rs2281827 (13: 27899721) T/C AGES 0.78 -1.27 (0.44) 4.09 x 10-3 FLT1 ARIC 0.77 -0.40 (0.26) 1.18 x 10-1 CHS 0.73 -1.08 (0.70) 1.20 x 10-1 RS 0.78 -1.61 (0.37) 1.47 x 10-5 BMES 0.76 -0.96 (0.52) 6.46 x 10-2 SE: standard error, AGES: Age Gene/Environment Susceptibility – Reykjavik Study, ARIC: Atherosclerosis Risk in Communities Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study, BMES: Blue Mountains Eye Study. The allele that decreases retinal arteriolar caliber is presented as the effective allele. Diabetes mellitus, in AGES, ARIC, CHS and BMES, is defined by self-reported, fasting blood glucose ≥ 126 mg/dL (7.0 mmol/L), and/or medication use. In RS, diabetes mellitus was defined as defined as a non-fasting glucose level ≥ 11.0 mmol/l and/or antidiabetic medication use.
SNP (chr: position) Next best SNP (r2) (G/I) Ref/Effective allele (+) Cohort Eff allele freq Beta (SE) P-value Genes of interest rs2194025 (5: 87833992) rs2194026 (r2 = 1) (GIGGG) G/T Discovery cohorts combined 0.91 -1.56 (0.25) 2.35 x 10 -10 TMEM16B MESA Whites 0.91 -2.01 (0.76) 8.00 x 10-3 MEF2C Australian Twins 0.91 -1.14 (0.83) 1.68 x 10-1 Replication cohorts combined 0.91 -1.62 (0.56) 3.97 x 10-3 Discovery + Replication cohorts combined 0.90 -1.56 (0.22) 3.43 x 10-12 Cohort Eff allele freq Beta (SE) P-value Genes of interest rs3744061 (17: 72244998) rs9916811 (r2 = 0.844) (GGGGG) C/T Discovery cohorts combined 0.48 -0.75 (0.14) 1.05 x 10-8 SFRS2 MESA Whites 0.48 -0.49 (0.51) 2.50 x 10-1 MFSD11 Australian Twins 0.50 1.70 (0.49) 4.84 x 10-4 JMJD6 Replication cohorts combined 0.49 0.44 (0.32) 1.62 x 10-1 MXRA7 Discovery + Replication cohorts combined 0.48 -0.55 (0.13) 1.77 x 10-5 Cohort Eff allele freq Beta (SE) P-value Genes of interest rs2281827 (13: 27899721) rs722503 (r2 = 0.529) (GIGGG) T/C Discovery cohorts combined 0.76 -0.84 (0.17) 9.38 x 10-7 FLT1 MESA Whites 0.74 -0.25 (0.51) 6.30 x 10-1 Australian Twins 0.25 -0.57 (0.57) 3.08 x 10-1 Replication cohorts combined 0.52 -0.40 (0.38) 2.94 x 10-1 Discovery + Replication cohorts combined 0.72 -0.72 (0.16) 9.75 x 10-7 SE: standard error, OR: odds ratio, MESA: Multi-Ethnic Study of Atherosclerosis. The allele that decreases retinal arteriolar caliber is presented as the effective allele (refer to Table 2). r2: linkage disequilibrium r2 between the SNP reported in the main paper and the next best index SNP from SNAP (http://www.broadinstitute.org/mpg/snap/ldsearch.php) using Europeans from Hapmap II. (G/I): Indicates if the SNP is directly genotyped (G) or imputed (I), given in the following order: AGES: Age Gene/Environment Susceptibility – Reykjavik Study, ARIC: Atherosclerosis Risk in Communities Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study, BMES: Blue Mountains Eye Study.
Table S3 – Membership of Wellcome Trust Case Control Consortium 2 Management Committee Peter Donnelly (Chair)1,2, Ines Barroso (Deputy Chair)3, Jenefer M Blackwell4, 5, Elvira Bramon6 , Matthew A Brown7 , Juan P Casas8 , Aiden Corvin9, Panos Deloukas3, Audrey Duncanson10, Janusz Jankowski11, Hugh S Markus12, Christopher G Mathew13, Colin NA Palmer14, Robert Plomin15, Anna Rautanen1, Stephen J Sawcer16, Richard C Trembath13, Ananth C Viswanathan17, Nicholas W Wood18 Data and Analysis Group Chris C A Spencer1, Gavin Band1, Céline Bellenguez1, Colin Freeman1, Garrett Hellenthal1, Eleni Giannoulatou1, Matti Pirinen1, Richard Pearson1, Amy Strange1, Zhan Su1, Damjan Vukcevic1, Peter Donnelly1,2 DNA, Genotyping, Data QC and Informatics Group Cordelia Langford3, Sarah E Hunt3, Sarah Edkins3, Rhian Gwilliam3, Hannah Blackburn3, Suzannah J Bumpstead3, Serge Dronov3, Matthew Gillman3, Emma Gray3, Naomi Hammond3, Alagurevathi Jayakumar3, Owen T McCann3, Jennifer Liddle3, Simon C Potter3, Radhi Ravindrarajah3, Michelle Ricketts3, Matthew Waller3, Paul Weston3, Sara Widaa3, Pamela Whittaker3, Ines Barroso3, Panos Deloukas3. Publications Committee Christopher G Mathew (Chair)13, Jenefer M Blackwell4,5, Matthew A Brown7, Aiden Corvin9, Mark I McCarthy19, Chris C A Spencer1 1 Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK; 2 Dept Statistics, University of Oxford, Oxford OX1 3TG, UK; 3 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK; 4 Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia 6008; 5 Cambridge Institute for Medical Research, University of Cambridge School of Clinical Medicine, Cambridge CB2 0XY, UK; 6 Department of Psychosis Studies, NIHR Biomedical Research Centre for Mental Health at the Institute of Psychiatry, King’s College London and The South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AF, UK; 7 Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia; 8 Dept Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT and Dept Epidemiology and Public Health, University College London WC1E 6BT, UK; 9 Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine, Trinity College Dublin, Dublin 2, Eire; 10 Molecular and Physiological Sciences, The Wellcome Trust, London NW1 2BE; 11 Centre for Digestive Diseases, Queen Mary University of London, London E1 2AD, UK and Digestive Diseases Centre, Leicester Royal Infirmary, Leicester LE7 7HH, UK and Department of Clinical Pharmacology, Old Road Campus, University of Oxford, Oxford OX3 7DQ, UK; 12 Clinical Neurosciences, St George's University of London, London SW17 0RE; 13 King’s College London Dept Medical and Molecular Genetics, School of Medicine, Guy’s Hospital, London SE1 9RT, UK; 14 Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 15 King’s College London Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK; 16 University of Cambridge Dept Clinical Neurosciences, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK; 17 NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK; 18 Dept Molecular Neuroscience, Institute of Neurology, Queen Square, London WC1N 3BG, UK; 19 Oxford Centre for Diabetes, Endocrinology and Metabolism (ICDEM), Churchill Hospital, Oxford OX3 7LJ, UK.
Table S4 – Membership of the Global Blood Pressure Genetics (Global BPgen) consortium Christopher Newton-Cheh1,2,3, Toby Johnson4,5,6, Vesela Gateva7, Martin D Tobin8, Murielle Bochud5, Lachlan Coin9, Samer S Najjar10, Jing Hua Zhao11,12, Simon C Heath13, Susana Eyheramendy14,15, Konstantinos Papadakis16, Benjamin F Voight1,3, Laura J Scott7, Feng Zhang17, Martin Farrall18,19, Toshiko Tanaka20,21, Chris Wallace22,23, John C Chambers9, Kay-Tee Khaw12,24, Peter Nilsson25, Pim van der Harst26, Silvia Polidoro27, Diederick E Grobbee28, N Charlotte Onland-Moret28,29, Michiel L Bots28, Louise V Wain8, Katherine S Elliott19, Alexander Teumer30, Jian’an Luan11, Gavin Lucas31, Johanna Kuusisto32, Paul R Burton8, David Hadley16, Wendy L McArdle33, Wellcome Trust Case Control Consortium34, Morris Brown35, Anna Dominiczak36, Stephen J Newhouse22, Nilesh J Samani37, John Webster38, Eleftheria Zeggini19,39, Jacques S Beckmann4,40, Sven Bergmann4,6, Noha Lim41, Kijoung Song41, Peter Vollenweider42, Gerard Waeber42, Dawn M Waterworth41, Xin Yuan41, Leif Groop43,44, Marju Orho-Melander25, Alessandra Allione27, Alessandra Di Gregorio27,45, Simonetta Guarrera27, Salvatore Panico46, Fulvio Ricceri27, Valeria Romanazzi27,45, Carlotta Sacerdote47, Paolo Vineis9,27, Ineˆs Barroso12,39, Manjinder S Sandhu11,12,24, Robert N Luben12,24, Gabriel J. Crawford3, Pekka Jousilahti48, Markus Perola48,49, Michael Boehnke7, Lori L Bonnycastle50, Francis S Collins50, Anne U Jackson7, Karen L Mohlke51, Heather M Stringham7, Timo T Valle52, Cristen J Willer7, Richard N Bergman53, Mario A Morken50, Angela Do¨ring15, Christian Gieger15, Thomas Illig15, Thomas Meitinger54,55, Elin Org56, Arne Pfeufer54, H Erich Wichmann15,57, Sekar Kathiresan1,2,3, Jaume Marrugat31, Christopher J O’Donnell58,59, Stephen M Schwartz60,61, David S Siscovick60,61, Isaac Subirana31,62, Nelson B Freimer63, Anna-Liisa Hartikainen64, Mark I McCarthy19,65,66, Paul F O’Reilly9, Leena Peltonen39,49, Anneli Pouta64,67, Paul E de Jong68, Harold Snieder69, Wiek H van Gilst26, Robert Clarke70, Anuj Goel18,19, Anders Hamsten71, John F Peden18,19, Udo Seedorf72, Ann-Christine Syva¨nen73, Giovanni Tognoni74, Edward G Lakatta10, Serena Sanna75, Paul Scheet76, David Schlessinger77, Angelo Scuteri78, Marcus Do¨rr79, Florian Ernst30, Stephan B Felix79, Georg Homuth30, Roberto Lorbeer80, Thorsten Reffelmann79, Rainer Rettig81, Uwe Vo¨lker30, Pilar Galan82, Ivo G Gut13, Serge Hercberg82, G Mark Lathrop13, Diana Zeleneka13, Panos Deloukas12,39, Nicole Soranzo17,39, Frances M Williams17, Guangju Zhai17, Veikko Salomaa48, Markku Laakso32, Roberto Elosua31,62, Nita G Forouhi11, Henry Vo¨lzke80, Cuno S Uiterwaal28, Yvonne T van der Schouw28, Mattijs E Numans28, Giuseppe Matullo27,45, Gerjan Navis68, Go¨ran Berglund25, Sheila A Bingham12,83, Jaspal S Kooner84, John M Connell36, Stefania Bandinelli85, Luigi Ferrucci21, Hugh Watkins18,19, Tim D Spector17, Jaakko Tuomilehto52,86,87, David Altshuler1,3,88,89, David P Strachan16, Maris Laan56, Pierre Meneton90, Nicholas J Wareham11,12, Manuela Uda75, Marjo-Riitta Jarvelin9,67,91, Vincent Mooser41, Olle Melander25, Ruth JF Loos11,12, Paul Elliott9, Goncalo R Abecasis92, Mark Caulfield22, Patricia B Munroe22 1. Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA 2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA 3. Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, 02142, USA 4. Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland 5. University Institute for Social and Preventative Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1005 Lausanne, Switzerland 6. Swiss Institute of Bioinformatics, Switzerland 7. Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109, USA 8. Departments of Health Sciences & Genetics, Adrian Building, University of Leicester, University Road, Leicester LE1 7RH 9. Department of Epidemiology and Public Health, Imperial College London, St Mary’s Campus, Norfolk Place, London W2 1PG, UK 10. Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA 21224 11. MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK 12. Cambridge - Genetics of Energy Metabolism (GEM) Consortium, Cambridge, UK
13. Centre National de Génotypage, 2 rue Gaston Crémieux, CP 5721, 91 057 Evry Cedex, France 14. Pontificia Universidad Catolica de Chile, Vicuña Mackenna 4860, Facultad de Matematicas, Casilla 306, Santiago 22, Chile, 7820436 15. Institute of Epidemiology, Helmholtz Zentrum München, German Research Centre for Environmental Health, 85764 Neuherberg, Germany 16. Division of Community Health Sciences, St George’s, University of London, London SW17 0RE, UK 17. Department of Twin Research & Genetic Epidemiology, King’s College London, London SE1 7EH 18. Department of Cardiovascular Medicine, University of Oxford 19. The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK 20. Medstar Research Institute, 3001 S. Hanover Street, Baltimore, MD 21250, USA 21. Clinical Research Branch, National Institute on Aging, Baltimore, MD, 21250 USA 22. Clinical Pharmacology and The Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ 23. JDRF/WT Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research University of Cambridge, Wellcome Trust/MRC Building, Addenbrooke’s Hospital Cambridge, CB2 0XY 24. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge CB2 2SR, UK 25. Department of Clinical Sciences, Lund University, Malmo University Hospital, SE-20502 Malmo, Sweden26. Department of Cardiology University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands 27. ISI Foundation (Institute for Scientific Interchange), Villa Gualino, Torino, 10133, Italy 28. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, STR 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands 29. Complex Genetics Section, Department of Medical Genetics - DBG, University Medical Center Utrecht, STR 2.2112, PO Box 85500, 3508 GA Utrecht, The Netherlands. 30. Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany 31. Cardiovascular Epidemiology and Genetics, Institut Municipal d’Investigació Mèdica, Barcelona, Spain 32. Department of Medicine University of Kuopio 70210 Kuopio, Finland 33. ALSPAC Laboratory, Department of Social Medicine, University of Bristol, BS8 2BN, UK 34. A full list of authors is provided in the supplementary methods online. 35. Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, UK CB2 2QQ 36. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK G12 8TA 37. Department of Cardiovascular Science, University of Leicester, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK 38. Aberdeen Royal Infirmary, Aberdeen, UK 39. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK 40. Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 1011, Switzerland 41. Genetics Division, GlaxoSmithKline, King of Prussia, PA 19406, USA 42. Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) 1011 Lausanne, Switzerland 43. Department of Clinical Sciences, Diabetes and Endocrinology Research Unit, University Hospital, Malmö 44. Lund University, Malmö S-205 02, Sweden 45. Department of Genetics, Biology and Biochemistry, University of Torino, Torino, 10126, Italy 46. Department of Clinical and Experimental Medicine, Federico II University, Naples, 80100, Italy 47. Unit of Cancer Epidemiology, University of Turin and Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, 10126, Italy 48. National Institute for Welfare and Health P.O. Box 30, FI-00271 Helsinki, Finland 49. Institute for Molecular Medicine Finland FIMM, University of Helsinki and National Public Health Institute 50. Genome Technology Branch, National Human Genome Research Institute, Bethesda, MD 20892, USA 51. Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA
52. Diabetes Unit, Department of Epidemiology and Health Promotion, National Public Health Institute, 00300 Helsinki, Finland 53. Physiology and Biophysics USC School of Medicine 1333 San Pablo Street, MMR 626 Los Angeles, California 90033 54. Institute of Human Genetics, Helmholtz Zentrum München, German Research Centre for Environmental Health, 85764 Neuherberg, Germany 55. Institute of Human Genetics, Technische Universität München, 81675 Munich, Germany 56. Institute of Molecular and Cell Biology, University of Tartu, 51010 Tartu, Estonia 57. Ludwig Maximilians University, IBE, Chair of Epidemiology, Munich 58. Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA 59. Framingham Heart Study and National, Heart, Lung, and Blood Institute, Framingham, Massachusetts 01702, USA 60. Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, 98101 USA 61. Department of Epidemiology, University of Washington, Seattle, Washington, 98195 USA 62. CIBER Epidemiología y Salud Pública, Barcelona, Spain 63. Center for Neurobehavioral Genetics, Gonda Center, Room 3506, 695 Charles E Young Drive South, Box 951761, UCLA, Los Angeles, CA 90095. 64. Department of Clinical Sciences/Obstetrics and Gynecology, P.O. Box 5000 Fin-90014, University of Oulu, Finland 65. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK 66. Oxford NIHR Biomedical Research Centre, Churchill Hospital, Old Road, Headington, Oxford, UK OX3 7LJ 67. Department of Child and Adolescent Health, National Public Health Institute (KTL), Aapistie 1, P.O. Box 310, FIN-90101 Oulu, Finland 68. Division of Nephrology, Department of Medicine University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands 69. Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands 70. Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK 71. Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital Solna, Building L8:03, S-17176 Stockholm, Sweden 72. Leibniz-Institut fü r Arterioskleroseforschung an der Universität Münster, Domagkstr. 3, D-48149, Münster, Germany 73. Molecular Medicine, Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden 74. Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro (Chieti), Italy 75. Istituto di Neurogenetica e Neurofarmacologia, CNR, Monserrato, 09042 Cagliari, Italy 76. Department of Epidemiology, Univ. of Texas M. D. Anderson Cancer Center, Houston, TX 77030 77. Laboratory of Genetics, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA 21224 78. Unitá Operativa Geriatria, Istituto Nazionale Ricovero e Cura per Anziani (INRCA) IRCCS, Rome, Italy 79. Department of Internal Medicine B, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany 80. Institute for Community Medicine, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany 81. Institute of Physiology, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany 82. U557 Institut National de la Santé et de la Recherche Médicale, U1125 Institut National de la Recherche Agronomique, Université Paris 13, 74 rue Marcel Cachin, 93017 Bobigny Cedex, France 83. MRC Dunn Human Nutrition Unit, Wellcome Trust/MRC Building, Cambridge CB2 0XY, U.K 84. National Heart and Lung Institute, Imperial College London SW7 2AZ
85. Geriatric Rehabilitation Unit, Azienda Sanitaria Firenze (ASF), 50125, Florence, Italy 86. Department of Public Health, University of Helsinki, 00014 Helsinki, Finland 87. South Ostrobothnia Central Hospital, 60220 Seinä joki, Finland 88. Department of Medicine and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA 89. Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA 90. U872 Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine Paris Descartes, 15 rue de l’Ecole de Médecine, 75270 Paris Cedex, France 91. Institute of Health Sciences and Biocenter Oulu, Aapistie 1, FIN-90101, University of Oulu, Finland 92. Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109 USA
✵
✺
✶✵
✶✺
✷✵
✷✺
✸✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✻✼✶✼✽✺✽
✠ ✡ ☛ ☛☛☛ ☞ ✌✍ ✎ ✏ ✑✒✓ ✔ ✕✖ ✗ ✕✕ ✘✍✙✒✒✒✚✒✒✒✒✒✚✒✒✒✒✒✒✒✚✒✒✒✒✛✒✒✒✒✚✒✒✚✒✒✒✒✒✒✒✒
✒✒✜✒✒✒✒✢✒✒✒✒✒✒✡✒✒✒✒✒✒✒✒✒✒✒✒✒✒✣✒✒✒✒✒✏✒✒✒
✒✤✒✒✢✒✒✥✒✒✒✒✒✒✒✒✒
✒✧✒✒✒✒✒★✒✒✒✒✒✒✒✒✒✩✩✒✒✒✒✒✒✒
✚✚✒✒✚✒ ✒ ✚ ✒✒✪✒✢✒✣✢✒✏✤✒✢
✒
✒
✫✒
✒✢
✒
✢✢✛✛
✒
✓
✒✒✒
✓✓✒✒✒✢✢✢✢✒
✒
✒✒✒
✤✢
✒
✓✫✒✒
✚✒
✒
✒
✤✒✚
✒✒✒✒✒
✒
✒✒✒✒✒✒✒✒✒
✒
✒
✩
✒✒✒
✒
✒
✒✒✤✒✒✒✓✒✒✒✒✒✒✒✒✓✒
✒✥✒✒✒✒✒✛✒✒✒✒✒✒✒✒✬✒✒✒✯✒✒✫✒✒✒
✒✢✒✒✥✒✒✒✒✒✒✒
✒
✒✒
✓
✒✒
✒
✰✒
✰
✒
✒
✒✒
✒
✓
✒
✩✒✒
✒✒
✒
✒✒
✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒
✒✒
✒✒✒
✒✒✒
✒✒✒✒✒
✒
✒ ✒ ✒ ✒ ✒ ✒✒✒
✒✒✒✒✒✒ ✒✒
✒✒ ✒✒
✛
✒
✒✛
✒✒
✱✳✲
✱✳✾
✱✳✿
✱✳❀
❁❂
●❃❇❄❅ ❈❖❇▲▲❄
❙◆❖❃❆❉❊❋
✶✻✺❍✶ ✶✻✺❍✷ ✶✻✺❍✸ ✶✻✺❍✹
P■s❏❑❏■◗ ■◗ ❚❤✟✷ ❯❱❲❳
❙◆❖❃❆
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✻✼✶✼✽✺✽
☛ ❨ ❩ ❬❩❬ ❭
✖☛
✪ ❪❫✓❴
❵❞ ❢ ❢❢✡
❥❦❫❫❫
q
❫❫❫❫❫
q
❫❫❫❫❫❫
❫q
❫❫❫
❫✇❫❫❫❫
q
❫
❫
q❫❫
❫
❫❫
❫
❫❫
❫
❫q
❫❫
❫
❫
①❫❫
❫
❫❫
❫❨❫❫❫❫
❫
❫❫❫❫❫❫❫❫❫✕❫❫❫❫❫
②❫❫
❫❫
q❫❫
①❫
❫③❫❫
❫
❫❫❫❫
❫
❫❫
③❫
❫
❫
❫
❫
④
❫❫
❫
❫
❫
❫
❫
❫❫✡✡❫❫❫❫❫❫❫②②❫❫②❫❫
②
❫❫⑤❫✕❫⑥①❫✪✖❫✕❫
❫✛❫❫✕❫✕①✇✇❫✓❫❫❫✓✓❫❫
❫✕✕✕✕❫❫❫❫❫✖①❫
✓
✛❫❫q❫❫❫✖❫q❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫⑦❫❫❫❫❫❫❫②❫❫❫
✓
❫
❫
❫❫❫❫❫❫
✓
❫ ❫✪
❫❫❫
❫❫✇❫❫❫
❫❫❫❫
❫
✡
❫❫❫☞❫❫
✛❫❫
❫❫✕❫❫✪❫❫❫❫❫❫❫
❫ ❫❫✓
❫❫❫⑧❫
⑨
❫ ❫❫❫ ❫
✓
❫⑦
❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫
❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫ ❫❫
❫❫❫ ❫ ❫❫❫❫❫❫❫❫
❫ ❫ ❫ ❫ ❫ ❫❫ ❫❫❫❫❫❫❫ ❫❫❫❫ ❫❫ ✇
❫❫✇❫❫
✱✳✲
✱✳✾
✱✳✿
✱✳❀
❁❂
●❃❇❄❅ ❈❖❇▲▲❄
❙◆❖❃❆❉❊❋
✶✻✺❍✶ ✶✻✺❍✷ ✶✻✺❍✸ ✶✻✺❍✹
P■s❏❑❏■◗ ■◗ ❚❤✟✷ ❯❱❲❳
❙◆❖❃❆
✵
✺
✶✵
✶✺
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✻✼✶✼✽✺✽
⑩ ❶ ❷ ❸❷❸ ❹ ❺ ❻ ❼ ❽❾✓ ❦
❿➀➁➂➂➃➄➅
❾❾❾➆❾❾❾❾❾➆❾❾❾❾❾❾
❾➆❾❾❾❾
➇
❾❾❾❾➆
❾
❾➆❾❾❾❾❾❾❾❾❾❾➆❾❾
❾
❾
❾❾❾
❾
❾❾
❾➈❾❾❾❾❾❾❾❾❾❾❾
❾❾❾➉❾❾❾❾❾❼❾❾❾❾➆❾❾
➊❾❾➋❾❾❾❾❾❾❾❾❾❾➄❾
❾❾❾❾❺❾❾❾❾❾❾❾❾❾➌➌❾❾❾❾❾❾❾➍
➍❾❾➍❾ ❾ ➍ ❾❾❿❾
➊
❾➉➊❾❼➎❾
➊
❾
❾✒❾❾➊
❾
➊➊
➇➇
❾
✓❾❾❾✓✓❾
❾❾
➊➊➊➊❾❾
❾❾
❾
➎➊
❾
✓✒❾❾
➆❾
❾
❾
➎
❾➍
❾❾❾❾❾
❾
❾❾❾❾❾❾❾❾❾❾❾
➌
❾❾❾
❾❾❾❾➆❾❾❾✓❾❾❾❾❾❾❾❾✓❾ ❾❼❾❾❾
❾❾➇❾❾
❾
❾❾❾❾❾➌❾❾❾❶❾❾✒❾❾❾
❾➊❾❾❼❾❾❾❾❾❾
❾
❾
❾❾
➏
❾❾
❾
➐
❾
✧
❾
❾
❾❾ ❾
✓
❾
➑
❾
❾❾❾
❾
❾
❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾
❾❾ ❾❾❾
❾❾❾❾❾❾❾
❾
❾
❾ ❾❾ ❾ ❾ ❾❾ ❾
❾❾❾❾❾❾ ❾❾❾❾ ❾❾➇
❾
❾
➇
❾❾
✱✳✲
✱✳✾
✱✳✿
✱✳❀
❁❂
●❃❇❄❅ ❈❖❇▲▲❄
❙◆❖❃❆❉❊❋
✶✻✺❍✶ ✶✻✺❍✷ ✶✻✺❍✸ ✶✻✺❍✹
P■s❏❑❏■◗ ■◗ ❚❤✟✷ ❯❱❲❳
❙◆❖❃❆
✵
✶✵
✷✵
✸✵
✹✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✷✽✷✵✹✹✸
➒ ✕✓ ➓ ✖✪✪ ➔ ①
✤✏✤✤ →➣ ✓✩✒↔✤✯ ↕ ✗
➙
✒
✒✒ ➐✣✩ ✣➛ ➜✡ ➝ ✗✒✏
✡ ✓ ✯➞✒✡➟ ➠ ➡➢ ➤➤
➥✬✒✒✒✒✒✒✒✒✒✓✛✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✩✒✒✒✒✒✒✒✒✫✒✒✒✒✒✒✒✒✒✒✓✒✒✒➦✒✒✒✒✒✒✒✒✒✤✒✒✒✒✒✒✒✏✒✒✏✒✒✏✏✏✒✒✒✒✒✏✒✬✒✏✒✒✒✒✒✒✒✒✒✒✧✤✒✒✒✧✒✒✒✒✒✒✒✒✧✒✒✒✒✒✒✒✒✒✩✬✒✒✒✒✒✒✒✙✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✩✒✒✒✒✒✒✒✒✒✒✒
✒
✒✚✒✒✒✩✒✒✒✒✒✒✤✒✒
✒
✒✒✒
✒✒
✒✒✩✒➦✒✓✫✒✒✒✒✒✒✒
✒
✒✒✒✒✒✒✒✒
✒
✤✒✒✒✒✒
✒
✩
✒
✒✒✒✩✙
✒
✒✒✒✒
✒
✒✙✧✧
✒
✧✍➐➐✒✥✒✫✓✒
✒
✒
✒✒
➧✒✒✒✒✒✒✤✒✒✒ ✒✒✤✒✢✒✢
✒✚
✤✒✒✒✒✒✒✡✒✒
✒
✒✒
✒
⑥
✒✤
✒
✒
✒
✒
✒✒✒
✒✒✒
✒✯
✒
✒✒✒
✒✒
✒✒
✒✒
✒✒
➨➨✒✒✤✚
✒✤✗✢✒
✒✤✤✤✤✤✣✤✒
✤✣✢✢✤✤✢✒✢✢✒✢✢✢✒✒➛➛✣✣✒✣✒✒✒✒✒✒✒✣✣✩✒✒➩
✒✒✒✒✢✒✒✒
✒✚
✒✡✬✒
✬
✒✛✒✒
✣✣✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✧✒✒✒✒✒✒✏✗✒✒✒✏✒✒✒✒✒✒✒✫✒✏✒✒✤✒✒✚✒✏✏✤✤✒✏✒✒✤✒✒✒✒✤✒✒✒✒✒✒✒✤✒✤✒✒✤✒✤✒✤✤✤✩✒✩✒✒✒✒✤✒✒✒✒✒✒✒✤✤✏✤✒✒✒✤✒✫✒✒✒✒✒✒✒✒
✤
✒✒✒✒✯❨✤✫➫✒✒✒➭✒✛✒✒✒✓✒✒✒✒✒✒✒✩✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒
✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒
✒
✒✒✒✩✒✒✒➯
✒✒✒✒✒✤✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✖✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✩✒✒✒✒✒✫✒✒✒✒✒✢✒✒➲➲★✒✒✒✒➳✣✒✒✒➵✒✩✩✒✒✒✤✒✒✒➐✒✒✒✒✒✒➸✒✛✬✒✒➺✒①✒➸✚✒✒✒✒✒✒✒✒✒✒✒✒✒✓✒✒✒✓✩✒✒ ✒✒
✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒
✒✒✒✒✒✒✒✒✤✒✒✒✒✒✒✒✒✒✒✒
✒✒✒✒
✒
✒✒✒✒✒✒✒✒✒
✒✒
✒
✒✒✒✒✒✒✒✒ ✒✒✒✒
✒✒✒✒✒✩✒✒ ✒
✒✒✒✒✒✫✒✒✒✒✒
✒
✒✒✒✒✒✒
✩
✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒
✒✒✒✒✒✒✒
✒✒✒✒✒
✒✒
✢✢
✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒✒
✢
✒✒✒✒✒✒✒
✒✒✒✒✒
✩✩
✒✒✒✒ ✢
✱✳✲
✱✳✾
✱✳✿
✱✳❀
❁❂
▲➻➼▲❆▲❄ ➽❈➾➚❄❄❇ ❃◆➪➶❋➹❄
❙▲❈➾❊❆❄❊
✷✶✼❍✹ ✷✶✼❍✻ ✷✶✼❍✽ ✷✶✽ ✷✶✽❍✷
P■s❏❑❏■◗ ■◗ ❚❤✟✶ ❯❱❲❳
➽❈➾
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✷✽✷✵✹✹✸
➘
✓
➩ ➴➷➷✡ ➬ ➮✖②✖✖ ➱✃
⑦❫❐✖⑦
❒❮ ❰❥❫❫❫❥
✕
✡
✕
Ï
Ð
⑦Ñ✡Ï❫
②
❨❨✓ ⑦Ò
❫ÓÔ
ÕÖ× ØØÙ
✡
❫❫❫❫❫❫❫❫❫✓✇❫❫❫❫❫❫❫❫❫
❫❫❫❫❫❫❫❫❫❫
⑦
❫
❫❫
❫❫
❫
❫❫✛
❫❫❫
❫
❫❫❫❫
❫
❫✓❫❫❫
↕
❫❫❫
❫❫❫
❫❫❫
✖❫❫❫❫
❫
❫❫②❫❫②❫❫②②②❫❫❫❫❫②❫
✡
❫②❫❫❫❫❫❫❫❫❫❫Ú✖❫
❫❫Ú❫❫❫❫❫❫
❫❫
Ú❫❫
❫
❫❫❫❫❫
❫
⑦⑦
❫❫
❫
❫❫❫❫Ú❫❫❫❫
❫❫❫❫❫❫❫
❫
❫❫❫❫❫✡❫
❫
❫❫❫❫❫
❫❫❫❫❫❫
q
❫
❫❫
✡
❫❫❫❫❫❫✖
❫
❫❫
❫❫❫❫❫
❫❫✡❫↕
❫✛✓
❫
❫❫❫❫
❫❫❫
❫❫
❫❫❫❫❫❫❫
②
❫❫❫❫❫❫✡
❫
❫❫❫
✡Û❫❫❫❫❫❫❫
ÛÛÛ
❫
➩Ü❥⑥❫
❥
❫✛✓❫❫❫❫❫Ý❫❫❫❫❫❫✖❫❫❫ ❫❫❫❫❫❫❫
❫✖
②❫❫❫❫❫❫☞❫❫❫❫❫❫Þ❫q❫❫❫❫❫❫❫❫❫❫❫⑦❫❫❫❫❫❫❫❫❫❫❫❫
ßß❫❫✖
①
❫✖Ï
✕
❫❫✖❫✖✖✖
✕
❫❫✖
✕✕
①✖q
✕
❫①
✕
❫
✕✕✕
❫❫❢❢
✕✕❫✕
❫❫❫❫❫❫❫
✕✕
⑦❫❫à❫❫❫❫①❫❫❫❫④❫
☞✡❫✡❫✇❫❫
✕✕
❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫
❦
❫❫❫❫❫❫
②
Ï❫❫❫
②
❫❫❫❫❫❫❫✛❫
②
❫❫②❫❫
②
❫
②②✖✖❫
②
❫❫✖❫❫❫❫✖❫❫❫❫❫❫❫✖❫✖❫❫✖❫✖❫✖q✖✡❫✡❫❫❫❫✖❫❫❫❫❫❫❫✖✖
②
✖❫❫❫❫❫✛❫❫❫❫❫❫❫❫✖❫❫❫❫⑦
↕✖❪✛❫❫❫Ó❫✇❫❫❫✓❫❫❫❫❫❫❫⑦❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫✡❫❫❫➩❫❫❫❫❫②❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫à❫❫❫❫❫❫❫❫❫
❫❫
❫❫❫❫⑦❫❫
❫❫
❫✛❫❫
❫
❫❫①❫
❫
✖✖③
❫❫❫❫➢❫❫❫❫❻❫⑦✡❫❫❫②❫❫❫②❫❫❫❫❫❫á❫✇✡❫❫
❞❫❵❫á②❫❫❫❫❫❫❫❫❫❫❫❫❫✓❫
❫❫
✓✡❫
❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫
❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫②❫❫
❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫
❫❫❫❫❫❫❫❫❫❫❫ ❫❫
❫❫❫❫❫❫❫
⑦
❫❫ ❫❫❫❫❫❫✛❫❫❫❫❫❫
❫❫❫❫❫❫⑦❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫ ❫
❫❫❫❫❫❫
①①❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫❫ ①❫❫❫❫❫❫❫❫❫❫❫❫
⑦✡❫❫❫❫ ①
✱✳✲
✱✳✾
✱✳✿
✱✳❀
❁❂
▲➻➼▲❆▲❄ ➽❈➾➚❄❄❇ ❃◆➪➶❋➹❄
❙▲❈➾❊❆❄❊
✷✶✼❍✹ ✷✶✼❍✻ ✷✶✼❍✽ ✷✶✽ ✷✶✽❍✷
P■s❏❑❏■◗ ■◗ ❚❤✟✶ ❯❱❲❳
➽❈➾
✵
✺
✶✵
✶✺
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✷✽✷✵✹✹✸
â ✓ ã❿ää å æ
➆❼➆➆çè
➌❾é➆➑❬ ê
ë
❾
❾❾ì➉➌➉➁í î
ï❾❼ ➈✓ ➑ð
❾
ñò
❷ ó❫ ✗✗
➛
➌❾❾❾❾❾❾❾❾❾✓➇❾❾
❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾➌❾❾❾❾❾❾❾❾✒❾❾❾❾❾❾❾❾❾❾✓❾❾❾ô❾❾❾❾❾❾❾❾❾➎❾❾❾❾❾❾❾➍❾❾➍❾❾
❼➍➍❾❾❾❾❾
➍
❾➌❾
➍
❾❾❾❾❾❾❾❾❾❾õ➎
❾❾❾õ❾❾❾❾❾❾
❾❾õ❾❾❾❾❾❾❾❾❾➌➌❾❾❾❾❾❾❾➅❾❾❾❾❾❾❾❾❾❾❾
❾❾❾❾❾❾➌❾❾❾❾❾
❾❾
❾
❾❾❾❾❾➆❾❾❾➌❾❾❾❾❾❾➎
❾
❾❾❾❾
❾❾❾❾❾➌❾ô❾ö✒
❾
❾❾❾❾❾❾❾❾❾
❾❾❾❾❾❾❾➆❾❾❾❾❾
❾➌
❾
❾❾❾➌÷❾
❾❾❾❾❾
❾
ë÷÷❾➅õì➍
❾
➋
❾✓✒❾
❾
❾
❾❾
ð❾❾❾❾❾❾➆❾❾❾ ❾❾ø❾❾❾❾
❾
➆
➆❾❾❾❾❾❾❶❾❾
❾
❾❾
❾
❿
❾➆
❾
❾
❾
❾
❾❾❾
❾❾❾
❾➑
❾
❾❾❾
❾❾
❾❾
❾❾
❾
❾ùë❾
❾
➎
➎
❾
➎ï➊❾
❾
➎
➉
➎➎➎➉➉❾
➎➉➊➊➎➆➊❾➊➊❾➊➊➊❾❾úú➉➉
❾
➉❾
❾
❾
❾
❾❾❾➉➉➌
❾❾
û
❾❾
❾
❾➊❾❾❾
❾➍
❾
❶➌
❾
➌
❾
➇
❾❾
➉➉❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾õ❾❾❾
❾❾❾❼ï❾❾❾❼❾❾❾❾❾❾❾✒❾❼❾❾➆❾❾➍❾❼❼➎➎❾❼❾❾➎❾❾❾❾➎❾❾❾❾❾❾❾
➎❾➎❾❾➎❾➎❾➎➆
➎➌❾➌❾❾❾❾➎❾❾❾❾❾❾❾
➎
➎❼➎❾❾❾➉❾✒❾
❾❾❾❾
❾
❾
❾
➎
❾❾❾
❾➑❹
➎
ü✒❾
❾
❾ý❾➇❾
❾❾✓❾❾❾❾❾
❾❾➌
❾❾❾❾❾❾❾❾❾❾❾❾❾❾
❾❾
❾❾❾
❾❾❾❾❾
❾
❾❾❾❾❾❾❾❾❾
❾
❾❾❾
➌
❾❾
❾
þ
❾❾❾❾❾➆❾❾❾❾❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾ÿ❾❾❾❾❾❾❾❾❾
❾❾
❾❾
❾❾
➌
❾
❾
❾❾
❾✒❾❾
❾
❾❾➊
❾
❾øøì❾
❾
❾❾✦➊❾❾❾➴❾➑➌❾❾❾
➆❾❾❾❼❾❾❾❾❾❾í❾➇➌❾
❾
ÿ❾❿❾í➍❾❾❾❾❾❾❾❾❾❾❾❾❾✓❾❾❾✓➌❾❾ ❾❾❾❾❾❾❾❾❾❾❾❾❾❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾
❾❾❾❾❾❾❾❾➆❾❾❾❾❾❾❾❾❾❾❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾
❾❾
❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾➌❾❾ ❾❾❾❾
❾❾✒❾❾❾❾❾
❾❾❾❾❾❾❾
➌
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾
❾❾
❾❾❾
❾❾
➊➊
❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾❾
➊
❾❾❾❾❾❾❾
❾❾❾❾❾
➌➌
❾❾❾❾ ➊
✱✳✲
✱✳✾
✱✳✿
✱✳❀
❁❂
▲➻➼▲❆▲❄ ➽❈➾➚❄❄❇ ❃◆➪➶❋➹❄
❙▲❈➾❊❆❄❊
✷✶✼❍✹ ✷✶✼❍✻ ✷✶✼❍✽ ✷✶✽ ✷✶✽❍✷
P■s❏❑❏■◗ ■◗ ❚❤✟✶ ❯❱❲❳
➽❈➾
✵
✺
✶✵
✶✺
✷✵
✷✺
✸✵
✸✺
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✸✺✽✾✽✵
� ✁ ✓ ✓ ✂✂✂✒✩✄✒✒✒ ✒
✒✒✒
➴➡☎ ☎☎✆✝ ✝☎Ò✬➇☎✆☎✞☎ ➡➡➴ ×✟✓ ✖ ➙➯Ú
✒✒✠✒➇
✯✒➲✒➙ ① ⑥⑥
➮➮à�✍
✒✒★✒
✍
✒✒✒
✍✍✚✍✍
✒
✢
✒✍✍✍
✒
➮✒✏✣✡
✡
✒
⑧
✒✒✒✡✬
✒✒✒✢✒✒
✢
✒✒✒
✒
✒✚
✱✳✲
✱✳✾
✱✳✿
✱✳❀
❁❂
❱❊●❋❆
✹✸❍✽✹ ✹✸❍✽✻ ✹✸❍✽✽ ✹✸❍✾ ✹✸❍✾✷
P■s❏❑❏■◗ ■◗ ❚❤✟✻ ❯❱❲❳
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✸✺✽✾✽✵
×☛
➬➬❫✡✇ ❫❫❫ ❫❫ ❫❫ ☞⑩
✌
✌✍
✎✏ ✑
✒✓✔✕✒✎
✒✖
✒ ✗✗
✘✑✙✚
✛✜✢✣
✤✤✥✧★✩✧✧✧✪ ✪ ✫✬
✭✭✭✭
✮ ✤✤✯✤✮✤✤✤✮✮✰✮✮✤✱✤✮✮✮✤
✖
✤
✰✧✲
✳
✤✴✤✤✤
✳
✔
✤
✤✤
✱
✤✤
✱
✤✤✤
✤✤✰
✵✶✷
✵✶✹
✵✶✻
✵✶✽
r✸
✺✼●❋❆
✹✸✿✽✹ ✹✸✿✽✻ ✹✸✿✽✽ ✹✸✿❀ ✹✸✿❀✷
P♦s✐t✐♦♥ ♦♥ ❝❤✟✻ ❁▼❜❂
✵
✷
✹
✻
✽
✶✵
✶✷
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✸✺✽❀✽✵
❃❄
❅❅
❇❈❉❇❇❇ ❇
❇❇❇
❍
❉■
■■❏✮ ✜■❑❈
▲■❏■◆■
❉❉❍❖◗✚❘ ❙❚❯
❇❇❲❇▲❳❇❨❇
❚ ▲ ❩❬
❭❭❪❫
❴
❇❇
❵
❇
❴
❇❇❇
❴❴❛❴❴
❇
❞
❇
❴❴❴
❇
❡
❇
❛❨❢
❣❇
❥
❇❇❇❣❈ ❇
❇❇
❞
❇❇❞
❇ ❇❇❇
❇❛
✵✶✷
✵✶✹
✵✶✻
✵✶✽
r✸
✺✼●❋❆
✹✸✿✽✹ ✹✸✿✽✻ ✹✸✿✽✽ ✹✸✿❀ ✹✸✿❀✷
P♦s✐t✐♦♥ ♦♥ ❝❤✟✻ ❁▼❜❂
✵
✷
✹
✻
✽
✶✵
✶✷
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✶✼✹✸✸✵✸
❦❧
♠♠
♣qs✉❉ ✈
✇❦① ②③③
❍④
⑤ ③ ⑥ ⑦ ✣✣✣❭ ❍⑧ ⑨
✇⑩ ❶
✇❷❸❷❸❸①
❍
✬❸❹❺❺❍❻
❼❡
❸
③❡❡❡❽✲
✚❾❿❡
➀
➁➂✛➃➄ ➃
➅✩ ➆❦ ➇
➈➉ ✚
➊
➋➌➍❭
❍❍❍❍❍❭❍❺❍❪❍❍❺❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❭❍❍❺❪❍❍❍❍❍❍❍❍❍❍❍❺❍❍
➎❍s➏➐❷✇➑➒➓➆➆➆➔➆→→❥❥➆➣
➣
→❥➆❥→➆↔➍s✛✛❏✳➆➆↕✖➓➓
■❪➍❍❭✈❪③➙❺✣✈❪➛➜❺❪❍❺✈❪❺❪❺❺❪❍❺❪✇❪❍■❍❺❍❍❍❍❺❍❍❍❍③❍❍❍❍❍❍❍❍③❍❭③❪③③③③③❪❍❺❍❍❍❍❍❍❺❍③❍❍❍❍❍❍❍✇❍❭③❍❺❍❍❍❍❍❍❍❍❍❍
❭❪❍❍❍❍
❺
❍❍
❍
❍❍❍
➝❺❺
➆
➝❡❍❍❍❍❍❍❍❍❍❍❍❍❍❖❍❍❍❍✇❍❍❍❍❍❍➎❍❍s
❍❍❸❍❍❍❍❍❍❍❍❺❍❍❍❍✈❍❍❍
❍❍❍❍❍❍❍❍❭❭❍❍❍❍❍❍❍❍❍❍❍❍❍❺❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍➎❍❍❍❍❺❍❍❍❍❍❍❍❭❍❍❍❍❍❍❍❍❭❍❍❍
❍❭➞❡❍❍■❍❺
❪
❍❸❍❪❍❍❪❍❸❍
❍❍❍❭❍❍❭❍❍
❺❭❍❍❍❍❺❍❍❍
❺❍❍❍
❍
❍❍❍❍✣
➟❍
❍❍❍③❍❍❍❍❍❍❍✇❍❍❍❺❺❍❍
❍
❍❍❍❍❍③❫❺
❍❍
❫❫❫❫❫❫❫➠
❍❪✱❍❍❪✰✰✰➡✰❍❍❍➢❍❍❪❍❍❍❺❍❍❍❍❍❍❍❍❍✇❍❍❺❍❍❍❍❍❍❺❍❺❍❍❍❺❍❍✚✣❍❍❍❺❍❍❍❪❺❍❺❺❍❍❍❺❺
❍❍❍❍❍✣❍❪❪❪❍❪❪❍
❍❍❍
❍
■
❍
❍❪❭
❍❍
❍
❍❍❍
❍❍❭
❍❍
❍❍❭❍❍◆
❪
❍❍❪❍❸❪❍❍❪❺❍❍❍
❍❍❍❍
❺
❍
❍
❍❍❍➞❍❍❍❍❍✇❍❍❍❍❍❍■
❪❸❍❺❺❺❸
❍❍
❍
❍
❍
❍❍❺
❺
❍
❸➤
❺❺❍
❫
❺
❪❍❸❍↔➞❍➥❍❪
❪
❺❪✚
❍❍❪❍❍❪❍❸
❍❍❍❺
❍❍
❍
❍
❍❍❺❺❍
❍❪❍
❍❍❍
❍
❺
❸
❺❍
❍❺❍❍❍❺
❪✣
✣❺❍✈✇❭❺■❏❺❍❭
❏❍❍❍❭❍❍❍❍✈❍➦❽➦
❍❍❍✚❍
❍❷❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❭
❸
❍❺❍❍❍❍❍❸❍❍❍❍❍❍❍❍❍❍✱◆❍❍❍❍❍❪◆❍❺❍
➀❪➀❍❪◆❍❍
➀
❍❍
➀
❍❍❍❪❍
➀
❪❍❍❪❍❭
✣❪✣➧❍❸
❪
❸❍❺◆❍✜❍❪❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍◆✇❭❍❍❍❍❍❍➨❍
❍
❍❍
❍
❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❍❭❪❍❍❍❍❺❍❍❍❍❍❍❍❍❍❍❍❍❍✇❍❍❍❍❍❍❍❍❍❍
❪❭❺❍❍❍❍❍❍
❍
❍❏❍❍
❍
❍✣✣❍❍❍
❍❍✇
❍❍✚❍➌❍❺❍❍
❍❍
❍
❍❍
➆
❫❍
❍
❍❍
❍
❍
➍
❍
❍
③❍❡❺➦❍❍
❍❍❍❺❍❫
❍❍❍❺
❸
❍❍❍
❺
❍
③
❍❍❍❍❺❺
✇
➠
❭
❍
❺❍❍❪❺❺❍❍❍❺❺❺❺
❍
❍❺❍❺❍❍❭
❪❍
❍
❍❍■❍
❺
❺❍❺❍❺❍❍❍❍❍❭❍❍❍
❍
❍
❍
❺❍➠❍❍❍❍❍❍❍❍
❍❍
❍❍
❍
❍❍❍❺③❍❍❍❍❍
❍
■❍↕❍❍❍❺
✚❍❍➩❫✚❍❍❍❍❍❍
❍
❍
❍
❍❍❍❍❍
❍
❍
❍
❍❍
❍
❍❍➥❍❍❍➫❍❍
❍
❍
❍
❪
❍❍❺
❺❍❺❍❍❍❍❍
✵✶✷
✵✶✹
✵✶✻
✵✶✽
r✸
❆➭➯➲➳➵➵ ➸❆➺➻➯➼
✺✺✿✹ ✺✺✿✻ ✺✺✿✽ ✺✻ ✺✻✿✷
P♦s✐t✐♦♥ ♦♥ ❝❤✟✺ ❁▼❜❂
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✶✼✹✸✸✵✸
➽➾✗➚➪➶➹
❃
➘
❼➧ ➴
➑➑
➷➬
➮ ↕ ➱ ✃qqq
❷
❷❐ ❿
➘ ❒ ❮✔➨❰➨❰❰✭➷Ï❰Ð❷
❷➷
Ñ
➱➓ ❰↕➒➒➒➒Ò ✚ÓÔÕÖ×
ØÙ
➇Ú ➘➇Û➽Ü
Ý
Þß
à❹á â➩
↕
❷❷➷
➷➷Õ❷
❷
➷Õ➷❷❷
➷
➷
➷
➷
➷
❷
➷➷
➷➷➷➷➷
➷
➷
➷➷
➷➷➷❷❷
❷❷➷➑❷➷❷↕➷➷➷➷➷➷➷➷➷➷➷❷➷➷✉❷➹➣
➑
✜✔➹➹ã✬✬✬⑤✬✣✣ää✬å
å
✣ä✬ä✣✬➡✮✮æ➀çè✬✬✕é✬✬❃↕
✮
➷↕❃↕↕
ê
❃ë❃
↕
ì
✩❃
↕
❷
❃
❃↕❃↕❃
❃↕
❷
❃↕
✔
↕
➷❃➷❷➷❷
❷
❷❃➷➷➷➷
↕
❷➷➷➷➷➷➷➷
➑
➷Õ
➑❑➑➑➑➑➑❑
➷❷❷❷❷❷❷❷❷➷↕➷➷➷➷➷❷➷✔➷↕↕➷➷➷➷❷➷➷➷➷➷➷➷↕
↕❷➷❷➷❷➷➷➷➷➷❷✰❷❷í➡➒❷➷➷➷➷➷➷➷➷➷❷➷➷♣➷➷➷➷
➘
➷➷➷➷➷➷✉➷➷
❏
➷➷↕
➷
➷
❷➷
➷➷➷➷❷➷
➷➷➷❑➷➷➷➷➷➷➷➷➷➷
➷
ÕÕ
❷
➷➷
➷➷❷❷➷
➷➷➷➷➷❷➷➷➷
➷
➷
➷➷➷➷➷➷➷❷➷➷➷❷➷➷➷➷➷✉➷➷➷➷
❷
➷➷➷➷➷➷➷❑❷➷❷➷➷➷➷➷Õ❷➷❷➷➑î➓➷❷❃➷❃Õ➷
❰
➷↕➷➷↕➷✤➷
➷➷➷❑➷➷❑❷➷❷❑➷❷➷➷❷
❷❷➷❷❷❷➷➷➷➷➷➷ïë➷➷➷➷↕➷➷❷❷➷❷➷➘
❷➷❷❷❷➷❷❷➷➷➷❷➷↕➓❷➷➷
↕↕↕➆↕↕↕❰
❷
↕
✪❷❷❑★★★✕★➷➷➷✔➷➷❑❷➷➷❷➷➷➷➷➷➷➷➷➷
➘
➷➷❷➷➷➷➷➷➷❷➷❷❷❷➷❷➷➷
ë✚➷➷➷❷➷❷➷
↕
❷➷❷❷❷
➷➷➷❃➷➷➷➷➷ë➷↕↕↕➷↕↕
➷➷➷➷➷❉➷➷Õ❑➷❷
❷➷❷➷➷❷Õ➷➷➷❷
❑
➷➷➆↕➷➷↕➷➆❑➷➷↕➷➷❷➷➷❷➷➷❷➷➷➷❷❷î➷
❷
➷➷
❷
✔
➷➷
➷➷➷➷❃↕❰❷❷
❷
❷❰❷➷➷➷❷❷➷➷❷➷❰ð❷❷➷➓❷↕➷➆➷
✤
î❷í➷↕Õ
❷
↕✚❷➷❑➷❷
↕❷❰➷➷❷❷❷❷❷❷➷➷❷❷➷❷❑➷➷➷➷❷❷
❰
❷❷➷❷➷❷❷❷↕ëë❷❷❑✔
Õ❷❃➂❷➷Õ➂➷
➷❷Õ➷➷❷➷↕❷✧➒✧❷➷❷✚❷➷
í
➷➷➷➷❷➷➷➷➷➷➷➷➷➷➷❷➷➷❷↕❰➷❷➷➷➷➷➷❰➷➷➷➷❷❷❷❷➷❷ñ➆➷➷➷➷➷↕✤❷❷❷Ö↕Ö
❷↕➆➷➷Ö➷➷Ö❷❷➷↕➷Ö↕
❷➷↕
➷Õë↕ë✎
➷
➩↕➩
❷❷
➆❷➎➷❑
❷➷➷➷
➷➷➷➷➷➷❷➷
➷
➷❷➷❷
➷➷❰✔↕➷➷➷➷➷➷➫➷➷➷➷➷➷➷➷❷➷
❷❷➷➷➷➷➷➷➷➷➷➷➷❑❑
➷➷
➷➷❷❷➷➷➷➷➷❷➷➷➷➷➷➷➘❷➷➷➷❷➷➷➷➷➷↕Õ❷➷➷➷➷➷❷➷➷ò➷➷➷
➷
ëë➷➷➷➷➷✔❷
➷✚➷✬➷➷➷
➷
➷➷➷➷
➷✬➑
➷➷➷➷➷❷✜❷
➷➑➷➓❷✧❷➷➷➷➷➷➷➑
➷➷
➷❷
➓
➷➷➷❷
❷
↕➷➷➷➷❷❷➘
✧Õ➷➷➷➷↕➷❃❷➷➷❷❷➷➷❷➷➷➷❷❷➷Õ
Õ
➷➷➷❷❉
➷❷❷➷
❷➷❷
➷❷➷
❷➷Õ➷➷
➷➷➷➷❷❷✧➷
➷➷➷➷➷➷➷➷➷➷➷➷➷➷
➷❷➑❷
➷
➷➷
❷➷❃➷Ü❷➷➷❷✚
➷❷óôõööööö
öööö÷ööö÷ööööööööøöööùö
öö ö
ö ú÷÷
÷
÷ö
÷
ööööö
ûüý
ûüþ
ûüÿ
ûü✽
r✷
❆◆❑❘❉✺✺ ▼❆P✸❑✶
✺✺✳✹ ✺✺✳✻ ✺✺✳✽ ✺✻ ✺✻✳✷
�♦s✐t✐♦♥ ♦♥ ❝❤✟✺ ✭✁❜✮
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✶✼✹✸✸✵✸
✦✂✄☎✆✝✞
✟✠✡☛ ☞
✌✌
✍✎ ✏ ✑ ✒✓✔✔✔✟
✍✕✖✗✘ ✙ ✠✚✛✚✛✜✢
✍
✣✛✤✥✍✍
✧★✩
✜
✌✪✪✪✪✫õ✓✬✌
✯
✰✱✲✡✴ ✡
✵✹✻ ✼
✾
✿ ❀❁❂❃❄❅
✍✍
✍✍✍❅✍
✥✍
❅
✍✍
✍✍
✍
✍
✍
✍
✍
✍✍✍✍✍✍✍
✍
✍
✍
✍✍✍✍✍✍✍✍✍✑✍✍✍✑✍✍✍✍✍✍✍✍✍✍✍✍✍✍❇✍❈❊❅❋✠●●❍■■■❏■▲▲❖❖■◗◗▲❖■❖▲■❙❚❚❯❇❱❲■■✚❳❍❍❨✑❚
✍❅
✟
✑✑
✔
✥
❩✟
✑
❬✗✥
✑✍✥
✟
✑✥✑
✥
✥✑✍✥✑
✠
✑
✍❨✍✥✍✍✍✍✥✍✍✍✍
✑
✥✍✍✍✍✍✍✍
✌
✍❭
✌❅
✌✌✌✌✌❅
✍✍✍✍✍✍✍✍✥✍✌✍✍✍✍✍✍✍✠✍❅✌✍✥✍✍✍✍✍✍✍✍✍✍❅✑✍✍✍✍✥✍✍✍✍✍✍❪✍✍
✻
❫✪✍✍✍✍✍✍✍✍✍✍✍✍✍❴✍✍✍✍✠✍✍✍✍✍✍❇✍✍❵✍✍✪✍✍
✍✍✍✍✍✍✍✍✍✍✍❭✍✍✍✍✍✍✍✍✍✍✍❭❭
✍✍
✍
✍✍✍✍✍✍✍✍✍✍✍✍✍
✍✍✍
✍
✍
✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍❇✍✍✍✍✍✍✍✍✍✍✍✍❅✍✍✍✍✍✍✍✍❭✍✍✍✍✑❛✪✍✍❨✍✥
❅
✍✜✍✑✍✍✑✍✛✍✍✍✍❅✍✍❅✍✍✥❅✍✍✍✍✥✍✍✍✍✍✍✍✍✍✍✍✍❞❩✍✍✍✍✑✍✍✍✍✍✍✍✠
✍✍✍✍✍✍✍✍✍✍✍✍✍✑✩✥✍✍✌✌✌✪✌✌✌✛✍
✑❡✍✍✑❢❢❢❣❢✍✍✍✠✍✍❅✍✍✍✍✍✍✍✍✍✍✍✍✍
✠
✍✍✍✍✍✍✍✍✍
✍
✍
✥✍✍✍✍✍
✍❥
❩✍✍✍✥✍✍✍✑✥✍✥✍✍
✍✍✥✥✍✍✍✍✍
❩✍✑✑✑✍✑✑✍✍✍✍✍❨✍✍❅❅
✍✍✍✍✍✍✍
✍❭✍✍✍✍
❅
✍✍✜✑✍✍✑✍✜❅✍✍✑✥✍✍✍✍
✍
✍✍✍✍✍✍✍✍❛✍✍✍
✍✍✠
✍
✍✍✍✍✍❨
✑✜✍✍
✥
✥✛
✍✍
✍
✍
✍
✍✍✥✥✍
✜❫✍✥✍
✩
✍✑✍✜✍❦❛✍❈✍✑
❅
✍✑❧✍✍❅✍✍✑✍✜✍✍✍✍✍✍✍
✍✍✍✍✍✍✍❅✍
✍✍✍
✍
✥
✛
✍
✍
✍✥✍✍✍✍✑
❩❩✥✍❭✠❭✍❨♠
✍✍❭♠
✍✍✍❭✍✍✍✍❅✍♣✪♣
✍✍✍õ✍
✍
✞
✍✍✍✍
✍✍
✍✍✍✍✍✍✍✍✍✍✍✍✍❅
✜
✍✍
✍✍✍✍✍✜
✍
✍✍
✍✍✍✍
✍✍✍■q✍
✍
✍✍✍✑✜✍✍✍
✯✑✯
✍
✑q✍✍
✯
✍✍
✯
✍✍✍
✑
✍
✯
✑✍✍✑✍❭❩✑❩s
✍❦✑❦✍✍q✍✉✍❅✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✜✠❅✍✍✍✍✍✍❯✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍✍❅❅✍✍✍✍✥✍✍✍✍✍✍✍✍✍✍✍✍✍✠✍✍✍✍✍✍✍✍✍✍✑❭✥✍✍✍✍✍✍
✍
✍
✈
✍✍✍
✍
❩❩✍
✍✍✍✍✠
✍✍
❧✍
✇
✍
✍
✍
✍✍✍
✍✍
✍■✌✍
✍
✍✍
✍
✍✞✍
✍
✌✍✩✍♣✍✍✍✍✍✍✍✌
✍✍
✍✥
q
✍✍✍
✍
✍
✑
✍✍✍✍✥✥
✗❦❅
✍
✥
✍✍
❅✥✥✍✍✍
✥✥✥✥
✍
✍✥✍✥✍✍❭❅✍
✍
✍
✍
❨
✍✥✥✍
✍✍✍
✍✍✍
✍✍❭✍✍
✍
✍
✍
✍
✥
✍
❦✍
✍✍✍✍✍
✍
✍
✍✍
✍✍
✍
✍✍
✍✍✌✍
✍
✍✍✍
✍
❨✍●✍✍✍✍
õ
✍✍♠✌õ✍✍✍✍✍
✍
✍
✍
✍
✍✍✍✍✍
✍
✍
✍
✍✍
✍
✍✍①✍✍✍
②✍
✍✍ ✍✍ ✑
✍✍
✥
✥
✍
✍
✍
✍✍✍✍
ûüý
ûüþ
ûüÿ
ûü✽
r✷
❆◆❑❘❉✺✺ ▼❆P✸❑✶
✺✺✳✹ ✺✺✳✻ ✺✺✳✽ ✺✻ ✺✻✳✷
�♦s✐t✐♦♥ ♦♥ ❝❤✟✺ ✭✁❜✮
✵
✺
✶✵
✶✺
✷✵
✷✺
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✷✸✼✶✼✻✼
③
④⑤⑥⑦✎ ⑧ ⑨ ⑩ ❶❷ ❸
õ❹ ❺☎ ❻❼ ✄❽❾ ❿➀☎☎☎➁ ➂ ➃➃☎ ø ➄➅ ➆☛☛☛☛☛☛☛☛☛☛☛☛☛
☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛✏
☛✏☛☛☛☛☛➇☛☛☛õ➇☛☛☛☛☛☛☛❀☛☛☛☛☛☛☛➈☛☛❺☛☛☛☛☛☛☛☛☛☛➂☛☛➂☛✏☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛❺☛
☛☛☛☛☛❀☛☛➉➉➉☛☛☛☛☛☛☛☛❇
☛☛☛☛☛☛
❇
☛
☛☛☛☛
☛☛☛☛☛☛☛
➂➊❾☛
☛
➉☛➋➋➉
☛☛☛☛☛➉☛
ö☛
➉☛☛☛
☛☛
❺☛☛☛☛➌☛☛ö☛ö☛☛÷❺❺➃☛➍❺☛☛☛☛☛☛☛☎❺
÷☛
❺❺☛❺☛❺❺❺
☛☛☛☛☛
☛☛☛☛☛❺☛☛☛☛
☛☛
☛☛
☛☛
☛
❺❺☛ö☛
☛
➉☛☛☛☛☛☛☛☛➎
☛☛☛➇õ⑧
☛☛☛
☛☛
☛☛☛
☛
➏☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛☛➂☛☛☛☛☛☛☛☛☛☛☛❇☛☛☛☛❺☛☛☛❺☛❀☛☛☛➉☛☛
❇
☛
➅☛☛✏☛❇☛❇
☛☛
☛❇❇☛
☛
☛☛➍❇☛
☛☛☛☛☛❇☛➂☛☛☛⑩➉☛✫➍☛❺☛☛
➂☛☛⑩☛☛☛☛☛⑩⑩☛☛☛☛☛☛⑩
☛☛❺☛☛☛☛
õ
✏
❺
☛
☛☛☛☛
❀
☛☛☛☛☛☛☛☛☛
ûüý
ûüþ
ûüÿ
ûü✽
r✷
❆❉❆▼➐➑➒
❆❉❆▼➐➑➒➓❆➑➔
▼→❘✺➣↔❆◆
✻✹✳✺✺ ✻✹✳✻ ✻✹✳✻✺ ✻✹✳✼ ✻✹✳✼✺ ✻✹✳✽ ✻✹✳✽✺
�♦s✐t✐♦♥ ♦♥ ❝❤✟✸ ✭✁❜✮
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✷✸✼✶✼✻✼
➁ õ ↕➙➛➛➜
➝s ➞
➟ ➠õ
➡
➊✯ ➢
➤
➥❂➦ ➠➧➥➥➥
➨õ➄
❏❏❏ ➩ ➫
s➭øøøøøøøøø
øøøøøøøø
øøøøøøøøø
ø
ø
ø
øø
ø
ø
➯ø
➯øø
øø
ø
✏øø
ø✏
õ
øøø
øøøø
➄
øøø
øøøø✗
ø
ø➲øø
øø
øøøøøø➁øø➄ø➯øøøøøøøøøøøøøøøøøø
øøøø
øøøøøøø➊øøøøøø➄øø➲➲➲øø
øøøøøø
➀
øøøø
ø
ø
➀
ø
øøø
ø
øø
ø
øøø
ø➄➳➳øø➲ø❹❹➲øøøøø➲ø
②ø➲øøøøø➊
øøøø
❹
øø②ø②øø
②➊➊
➵ø
②➊
øøøøøø
ø✯➊
②
ø➊➊
ø
➊
ø
➊➊
➊
øøøøøøøøøø➲øøøø
øøøøøøø➊➊ø②øø➲
øøøøøøøø➠ ø
øø✏
õ
➁øø
ø
øøøøøø➸ øøø
øøøøøøøøøøøøø➄øøøøøøøøø
ø
ø➀øøøø➊øøø➺ø➄øøø
s➊ø➀øsøø➯ø➀ø➀øøø➀➀
øøøø➲➀øøøøøø➀ø
➁ø
ø
ø
➲➺ø
➻➲øøøø➁
➊
ø
➲
øøøø
ø➲➲ø
øøøø
ø
➲
øø➺øøøø
õ➯➊
ø
øøøø ➄øø
øøø
ø
øøø
ûüý
ûüþ
ûüÿ
ûü✽
r✷
❆❉❆▼➐➑➒
❆❉❆▼➐➑➒➓❆➑➔
▼→❘✺➣↔❆◆
✻✹✳✺✺ ✻✹✳✻ ✻✹✳✻✺ ✻✹✳✼ ✻✹✳✼✺ ✻✹✳✽ ✻✹✳✽✺
�♦s✐t✐♦♥ ♦♥ ❝❤✟✸ ✭✁❜✮
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵
❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✷✸✼✶✼✻✼
➼
➽
ô➃➢ ❻
❄ ú➾★õ
➚ ❫
❡ ➪
➦
✚
➶
❢ ➾■➹➹➹
➘ ✠
✚✚➹
■ ➘❵➴✛
✛✛✛✛✛✛✛✛✛✛✛✛✛✛✛✛
✛✛✛
✛✛✛✛✛✛
✛✛✛✛✛
✛✛➷✛➷✛✛✛✛
✛
☛
✛✛
✛õ☛✛✛✛
✛✛✛✛
✠
✛✛
✛✛✛✛✛➬
✛
✛❫✛✛
✛✛
✛✛✛
✛✛✛✠✛✛
✠✛➷✛✛✛✛✛✛
✛✛
✛✛✛✛✛✛✛✛✛✛✛✛✛
✛✛✛✛✛✛✛
✛①✛
✛
✛
✛✛
✛
✠✛✛❪❪❪✛✛✛✛✛✛✛✛❦✛✛✛✛✛✛❦✛✛✛
✛✛✛✛✛✛✛✛
✛
✠❢❣✛
✛
❪✛❋❋❪
✛✛✛✛✛❪✛
❈✛
❪
✛✛✛
✛
✛
❫✛✛
✛
✛
➮
✛✛❈✛❈✛✛❈❫❫➹✛❚❫✛✛✛✛✛✛✛
❡
❫
❈
✛❫❫✛❫✛❫❫
①✛
✛
✛
✛
✛
✛✛✛✛✛❫✛✛✛
✛
✛✛
✛✛
✛✛
✛①❫
✛❚✛
✛
❪
✛
✛
✛
✛
✛✛✛✛
✒
✛✛✛
☛
õ
✗
✛
✛✛✛
✛
✛✛✛
✛
⑦✛✛
✛✛✛✛✛✛✛✛✛✛✛✛
✛
✛
✠
✛
✛
✛
✛✛✛✛✛✛✛✛❦✛✛✛✛①✛✛✛❫✛✠✛✛✛❪❦✛❦
✛
❵✛✛➷✛❦✛❦
✛✛
✛❦❦✛
✛
✛✛❵❦✛
✛✛✛✛✛❦✛
✠
✛✛✛❪❪✛♣❵✛♣✛✛
✗♣✛❪✛✛✛
✛✛❪❪✛✛✛✛✛
✛❄
✛✛❫✛✛✛✛õ➷❫✛
✛✛✛✛
✠
✛✛
✛✛✛
✛
✛✛✛
ûüý
ûüþ
ûüÿ
ûü✽
r✷
❆❉❆▼➐➑➒
❆❉❆▼➐➑➒➓❆➑➔
▼→❘✺➣↔❆◆
✻✹✳✺✺ ✻✹✳✻ ✻✹✳✻✺ ✻✹✳✼ ✻✹✳✼✺ ✻✹✳✽ ✻✹✳✽✺
�♦s✐t✐♦♥ ♦♥ ❝❤✟✸ ✭✁❜✮
A B C
GRB14 / COBLL1 WHRadjBMI
LYPLAL1 / SLC30A10 WHRadjBMI
VEGFA WHRadjBMI
MAP3K1 WCadjBMI
ADAMTS9 WHRadjBMI
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵ ❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✵✹✼✽✹✷✹
✠✡☛☞✌✍
✎
✍✏✑✏✏✒✡✑
✓
✔✕✖✔
✗✗✗✗✘✙☞
✚
✛✜✛✛✛✛✢✢✛✘✣✏✤✥
✧✏✔★✩✪
✜✫ ✬✒
✯✰✥
✱✱✱✱
✲
✳
✔✡✡☛✡✡✡
✙✕✕☛✑✕✫✕✔
✕✸✔✺✾✿❀
❁✡
✕☛❂✑❃❄✬
❅✑
❆
✑
❆ ✕✑❇❄❈✡
❁✥
✢ ❉ ✠❊❋●❍✕■✖
❏
✚✚✯ ✔✛✛❑✡❄✡❄✕ ▲
✯◆✏✚✤☛✔❖☞☞☞P☞☞◗✍✚✕✕❙❚✪
☞
✡✡✕
✯
✪✪✰✚❯❱❲❳✡✤✤✫
✕
✫✬✤✤✯✫
❨✡❩❬❨❭❄❄❄❄❄✳
❄❄✡❇✳
❄❄❄❄❄❄❄❪❄❄❫❄❄❴❄❄❄✡❵✡✡✡✡
✡✡✡✡❵✡✡✕✳✓✏
✡✏✡❙✡✏✡✡✡✛✫✏✡✡❞
✡❢✡✡✡✕❄✡✡✡✜✜✡✡✡✡✡✡✡✡✡✡✡❤✡✡✡✡✱❥✡✡✔✔✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡❦✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✏✡✡✡✡✡❵✡✡✡✡✏✡✡✡✡✡✡❵✡❵✡✡✡✡✡✡❆✡✡✡✡❢✡✡✡✡✡✡✡✡✥✔✡✡q✡✡✡✡✡✡✡✡✡✡✡✡✡✡✏✡✇✡✏✡✏✡❄✯❄
✡✡✡✡
✡✡✡✡
✡✡
✡
✡
✡✡❢
✡
✡
✡
✡
✡
❢✡✡✡✡✡✡✡✓✡✡✡✡✡✡
✡
❄✏✡
✡
✓❄
✡❄✡✡✡✡✡✡
✡
✡✡✡✓✡❄✡✡✡✡✡✡✡❄❄❄✡
✡①✕✡
✡✡❄✡✡✜②✡✡
✡
✡
✡
✕
✡✡
✕◗✡②
✜
✡
✡
✡✡✜③✡✡
✡
✡✡✡✡✡✡✡✡✡✡✡
✡
✡✡✡✡✡✡✡✡✡✡✡✡✡✡
✡✡
✡✡
✡
✡
✓
✡
✡
✡✡
✡
✡❄✡✡✡✡✡✡✡
✡
✡✡✡
✡
✡
✡
✡
✡✡
✡✡✡
✡✡
✡✡✏✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡❄✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡
✓
✡✡✡✡✡✡✓✡✡✡✓✡✡✡✡✡✡✡✡✡✡❄✡✡✚
✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✚
✡✡✡
✚✡✡✡✡✡✡✳✜✜✜✡✡✡✡✡✜✜❢❄✡✓✏✡
❄✓❄✓✡✓✡✡
✡
✏✡✡✡✡✡✡✡✡✡✡✏✏✏✏❄✏✡✡✡✡✡✡✡q✡✡✡✡✡✡✏✡✡✰✡✡✡✕✜✡
✡
✡✡✡✡✡✡✡✡❢✡✡✡✡✡✡❵✡❢✡✡✡✡✡✡✏✡✡✡✡✡✡✡✡✡✡✓
✡✡✡✡✡✡✡✡✡✜
✕✡✡✡✡✔✡✡✕✣✡✡✡✡✡✡✡
❄✡✡✡❄✡✡✡✡❄
✕✡✡✡✡✡✡✡④✡✡❢✜✡✕✚✡✕✡✡✡✡✡q⑤
✡
◗✡
✡◗✡✡✡✡✏✡✡✡✕✕✡✡✡✡✕✕
⑥⑥
✡❄✡❄✡✡✡✜✌
✡✡✡
❄✡
✡✡
✡
✡✡✡✡
✡
✡✡✡✡
✡
✡✡✡✕✡✡✡❄✡✕✡✡✡⑦✡✡✡✡✡✡✡✡
✡✡
☛✡
✡✡
✡✚
✡✡✡✡✡✡✡✡
✡
✡✡✡✡✡
✡✏✡✕✔✔☛✡✡✕
✱
✏
✱
✡
✱
✡
✡
✱✡
✡✡
✱❄
✡✡✡✡
✡✏
✡
✡✡✡✡✡✡✡✡✡
✡
✡✡✡✡✡
✡
✡
✡
✡✡✡✡
✡
✡✡✡✡✡❢✡✡❢✡✡✡✡❢❢❢
❄
☞✏❄✏✏
❄
✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✕✡✡✡
✕❢❢✔✡❢✡❢❢✡✡✡
✡❢❢
✡
❢✡❆✡
✡
❩❩✡✡✡✡✡✡✡✡
✡
✡
✡✡✡✾✡✡
✡✡✜✜✜✡
✾✡✡✡✾✡✡✡✾✡✡✡✜
⑧
✌✾✾✡✡✛
❄✡✡
✡✡✡✡✡✡⑨✕
✜
✜✾✡✡
✡
✾✡✡
✾
✡✡✾✾✡q✡✡✡✡✡
❄
✡
✾✾✡
❄
✡✡✡✡
❄
✡❴✡✡✡
✡
✡✡✡✡
✡✡✡✡✡✡✡✡✡✡
❄✡✡✡✡✡✡✡
⑩
✜✡
✡✜✔✜✡✡✡❨✡
✡
✡
✡
✡
❢
✡✡✥✔✡☛✡
✡✡
✡
✡
✡
✡✡
✡✡✡
✡
✡
✡
✡
✡
✡✡
✡✡✡
✡
✡
❄
✡✡
❄
✡✡✏✏
✡
✡
✡✡✡
✡✡✡✡
✡
✡✡✡✡
✜
✡✜✜✜✜✜✡☛✡
✡✡
✡✡
✡✡
✡✡q✡✡
✡
✡✡✡
✡
✡
✡✡✡✡✡
✡✡✡✡
✡✡✡❩✡✡✡✡❶✡✡✡✡✡✡✡✡✡✡✡
✔
✡✔✡✡✡✡✡✡❴✡✔✡✡✜✡✡✖✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡❴
✡✡✡✡✡✡
✡✡✡✡
✔✡✡✡✜✡
✡
✡✡✡✡✥❢
✡
❢
✡✡✡✡✡✡
✡
✡✡
✡✡✡
✡
✡
✡✡
✡✡
✡
✡
✡✡
✡✡✡✡
☛
✡
✡✡
✡
✡✡
✡✡✡✡✡✡
✡
✡
✡
✡
✜
✡
✡✱✡✡✡
✡
✡
✡❄✡✡✡✡✡✡✡✡✡
✡✡
✡✡✡
✡
✡
✡
✡
✡✡②✜✕✜✡✡✡❶
✡✡
✤
✡✡✡
✪✪✔✪
❢
✡✡✡✡✡
✡
✡✡✡❢✡✡❄✡✡✡✡✡❢✡✡✡✡✡✡✡✜✡✡✡✡✡✡✡
✣✡✡✡✡✡✡✡✡✜◗✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡
✯
✡✡✡✡✔✡✡q✡✔✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡
✡✡
✡
✜✡✡✡✡✡✡✡✡☞✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡☛✡✡✡
✕✜✜✡✡
✡✪✡✡✡✡✡✡✡✯✡❷✡
q✡✡✔✑
✡✡✕❵❍✓✡❄❄✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡❄✡✡✡✡✡✡✡✡✡✡
❸
✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✜✡✡
✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡
✡✪✕✡❹✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡
✡✡✡
✖
✡✡❢✡❢✡✡✡
❄
✡✡✡✡✡✡✡✡✡❢✡
❢❢❢
❢
❢✜❢❢❢✑
✡
❢❩❄
✏✡✡✡
✯
✡✡
✯
✡✡✡✡
❄
✡
❄
✡
❺✡❄✡✡✡✡✡✡✡✡✡✡✡
✪✳✪
✡✡✡✡✪✡✡✡✡✡✡✡✡✡✡✏✡✡✡✡
✡✡
✡☛✡
✡
✑✡✥✡
✡✡
✔✏
✡✡✡
✡
✡
✡
☞
✡✡
✡✡
✏✡✜✕✡✡✡
✏
✡✡❄❄❄✜✡
✡❄✡
✡❄✡✡✡✡✡❄✡❄✪❄✏✡✡✡✏✪
✡✏✡
❄❄✡❄✡✡✡✡✡✡✏✏✡
✡
✡✡✜✜
②✡✡✫✡
✡✡✡✡✡✡✡✡✡❄✡✡✡✡✡
❄✡✡✡✡❶✡q✡✡✡✡✡
✡✡✍✡❄❄✡✡✏✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡
❄✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡
❄
✡✡✡☛✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✏✑✱❨✡✡✡✡✡✡✡☞❻✏✡✡✡✡✡✡✡✡✡✡✡✡✡
✡✡✡✡✡✡✡✡❢✡✡✰✏✡✡☛❼
✡✡✡✡✡
✡✡✡✡✡✡✰✡✪✡✡✡✡✡✡✪✪✡✡✡✡✪✡✰✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✪✪✡✡✡✡✡✡✡✡✡✡✡
✏
✡✡✡❯❯✡
✏
✡✡✡✡❯✡✡✡✡✡❢✡
✕❢
✡✡✡✱✱
✡
✡
✡✡
❄
✡✡✡✡
✡✡
✡
✡
✡
✡✡✡✡✡✡✡❽✡
✡
✡✡✡
✡✡✡✡✡✡
✡✡✡✡✡✡✡✡✡
✡✡✡✡✡
✡
✡✡
✡
✡✡✡✡
✡✜✜✡✡✡
✡
✡✡
✡✡
✡✡
❄
✡✡✡✡✡
✡
✡
❄
✡✡
✡✡✡✡
✡✡✡✡✡✡✡✡❄✡✡q✡✡✡✡✡✡✡✡✜✡✡✡✡✡✡✜
✡✡✡✡
✜✡✡✡✡✡✡✡✡
✏
✡✡❄✡✡✡✡✯✡✡❄✡✡✡✡❄✡✡✡
✡
❾✔
✡❿✡
✡✡✡✡✡✡✡✡✡✡✡✡✚✡✡✡✡
✡
✡✡
✡✡✡✡✡❤✡✡✔✡❢
✡✛✡✡✡✡✤✡✤✡✡✡✡✤✡✡q✡✡✡✡❨❨✡✡✡✡✱❨✡✡✡✡✡✕✡❨✡✡✡❨❨✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡➀
✡
✡✡✡✡✡✥✡✡✡✡
✔✥
✡✡✡✡✡✔☛✡✡✡✡❢❄✡✡
❄❄✡✡✡✡✡❄❄❄❄❄✡✡❄✡✡✡✡✡✡✡✡✡✡❄✡✡✡✏✡✡❄✡✡✡✡✡
✡✡✪✡✡✡✡✡✡✡✡✜✡✡✡✡✡✡✡
✡✡✡✡✡✡
✡
✡
✡✡✡✜✕❯✡✡✡✡✡✡✜✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✏✡✡❯✡✡✡✡✏✡❄❄❄
❊✡❄✡✡✡
✡✡✡✡✡✡✡❄✡
❄✡✡❄❄✡❄❄✡✡
✑
❄
✯
✡✡✡✡✡✏❄✜✔✡✡✜✡❄✡✡✡✡✡✡✡✡✜✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✡✔✡✕✡✡✡✡✡✡✡✡✡✡✡✡✡✡❄✡✬➁✡❾➂✜✡✡✡✡✡✡➃✡✡✡
✡✡✡✡✡✡✡✡✡✡✡✡✡✡
q
✡✡✡✡✡ ✡✡
✡
✡✡✡
✡✡❄✡
✥
✡✡✡✡✡
✡
✡
✡
✡✡✡❄✡✡ ✪
✡✡✡✡✡✡
✡✡✡✡
✡✡
✡
➄➅➆
➄➅➇
➄➅➈
➄➅➉
➊➋
➌➍➎➌➏
➐➑➒➓➏➔➔→➓
➐➑➒➓➏➔➔→➏
➐➑➒➓➏➔➔→➣
➌➐↔↕➓
➍➙➛➜➑➝➞
➟➠➌➓➡➢➔
➛➜➐➓➡➤➜
➝➒➒➓➥
✶✶✽ ✶✶✽➦➧ ✶✶➨ ✶✶➨➦➧ ✶✷✵
➩➫s➭➯➭➫➲ ➫➲ ➳➵✟➧ ➸➺➻➼
➌➍➎➌➏
➐➑➒➓➏➔➔→➓
➐➑➒➓➏➔➔→➏
➐➑➒➓➏➔➔→➣
➌➐↔↕➓
➍➙➛➜➑➝➞
➟➠➌➓➡➢➔
➛➜➐➓➡➤➜
➝➒➒➓➥
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵ ❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✵✹✼✽✹✷✹
➽✖✕➾➚➪➶➪
✙
❽✙✙✠
✘✖✕❽➁✑✑✕➹✠➘P➴➷✬➬➪➁➪
➮
➪◆◆◆
➮➮
➱✃
❐
✙
❒✘❮
✙❰
Ï❷
q➹
▲ ✕Ð
✠
Ñ✕➁❷❷❷❷●ÑÒ✖✖✑✖✖✖
Ó✕
✕
✑✘✕
❻
✕✠✕Ô✑➬
➹
✿Õ✧✖✕✑Ö✃✠✕✖×Ø❽✃❾❽❂
➚
❽Ù❾Ú✖
Û ✘Ü❽⑥ Ý ✃
Þ❋×ßàá
â
➪➪➪❳✑❇❇❳
✩
✖❾✖❀
✕
❁➾Ö❷➾ã✑✠ä➱➱➪å➱➱Ò➪➾✕✕❚æ✙➱✖✖✕➱◆◆➪➪◆çèé✖ÑÑÑá▲
❏❏ã❏Ñ
✖êë❏➚❾❾❾❾❾á❾❾✖ìá❾❾❾❾❾❾❾
❞❾❾❞❾❾í❾❾❾✖❾✖✖✖✖✖✖✖✖⑦➚
✘✖✖✕❻
❷✙✖✙✖î✖✙✖✖✖◆➬✙✖
✖ï✖❩✖✖✖✕
✙
✖✖✖qq✖✖✖✖✖✖✖✖✖✖✖✺✖✖✖✖❷ð✖✖✑
✠
✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖➘✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✙
✖✖✖✖✖❂✖✖✖✖
✙
✖✖✖✖✖✖❂✖❂✖✖✖✖✖✖⑦✖✖✖✖❩✖✖✖✖✖✖✖✖✠✠✖✖ñ✖✖✖✖✖✖✖✖✖✖✖✖✖✖
✙✖
ò
✖✙
✖✙
✖❾➪✙✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❩✖✖✖✖✖✖✖➁✖✖✖✖✖✖✖❾❷✖✖➁❾✖❾✖✖✖✖✖✖✖✖✖✖➁✖❾✖✖✖✖✖✖✖❾❾❾✖✖ó
✕✖✖
✖❾✖✖Òq✖✖✖✖✖✕✖✖✕
Ò
✖Òq✖
✖
✖✖qô
✖✖✖✖
✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖➁✖✖✖✖
✖✖❷✖✖✖✖
✖✖✖
✖
✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✙✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖➁✖✖✖✖✖✖➁✖✖✖
➁✖✖✖✖✖✖✖✖✖✖❾✖✖➁✖✖✖✖✖
✖
✖✖✖✖
✖✖✖✖✖✖✖✖➁✖✖✖➁✖✖
✖
✖
✖✖❻qqq✖✖✖✖✖qq
❩
❾✖
➁
❷✖❾
➁✖➁
✖
➁
✖✖✖
✙
✖✖✖✖✖✖✖✖✖✖
✙✙✙✙
❾
✙
✖✖✖✖✖✖✖ñ✖✖
✖
✖✖✖
✙✖
✖➁✖
✖
✖q
✕✖
✖✖✖✖✖✖✖✖✖❩✖✖✖✖
✖✖
✙✖❩
✖
✖
✖✖✖✖✙
✖✖
✖
✖✖✖
✖
✖
✖✖➁✖
✖✖✖✖✖✖✖✖q✕
✖✖✖✖✠✖✖✕õ✖✖✖✖✖✖✖❾✖✖✖❾✖✖✖✖❾✕✖✖✖✖✖✖✖Ò✖✖❩
q✖✕➾✖✕✖✖✖✖✖ñ②✖Ò✖✖Ò✖✖✖✖❷✖✖✖✕✕✖✖✖✖✕✕❊❊✖✙✖❾✖✖✖qö✖✖✖❷✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✕✖✖✖❾✖✕✖✖✖÷✖
✖✖✖✖✖✖✖✖✖
✑✖✖✖✖➾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✙✖✕✠✑
✑
✖✖✕❷✙❷✖❷✖✖❷✖✖✖❷❷✖✖✖✖✖❷✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❩✖✖❩✖✖✖✖❩❩❩❾
❷❷❾❷❷❾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✕✖✖✖
✕
❩❩✑✖❩✖❩❩✖✖✖✖❩❩✖❩✖⑦✖✖ìì✖✖✖✖✖✖✖✖✖✖✖✖✖
➹
✖✖✖✖qqq✖
➹
✖✖✖
➹
✖✖✖
➹
✖✖✖qöø
➹➹
✖✖◆❾
✖✖✖✖✖✖✖✖
ù
q✕q
➹
✖✖✖
➹
✖✖
➹
✖✖
➹➹
✖ñ✖✖✖✖✖❾✖
➹➹
✖❾✖✖✖✖❾✖❳✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❾
✖✖✖✖✖✖✖q
ú✖✖✠qq✖✖✖
➹✖✖✖✖✖❩✖✖✠
✠
✖
✑✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❾✖✖✖✖✖✙✙✖✖✖✖✖✖✖✖✖✖✖✖✖✖
q
✖qqqqq
✖✑✖✖✖✖✖✖✖✖✖ñ✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖ì✖✖✖✖✌✖✖✖✖✖✖✖✖✖✖✖✠✖✑✖✖✖✖✖✖❳✖✠✖✖q✖✖ã✖✖✖✖
✖✖✖✖✖✖✖✖✖✖✖✖✖❳
✖✖✖✖✖✖✖✖✖✖✠✖✖✖q✖✖✖✖✖✖✠❩✖❩✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖
✑
✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖q✖✖❷✖✖✖✖✖✖❾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖
✖✖qÒ✕q✖✖✖û✖✖❻✖✖✖❇❇✠
❇❩✖✖✖✖✖✖✖✖✖❩✖✖❾✖✖✖✖✖❩✖✖✖✖✖✖✖q✖✖✖✖✖✖✖⑥✖✖✖✖✖✖✖✖Òq✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖➪✖✖✖✖✠✖✖ñ✖✠✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖q✖✖✖✖✖✖✖✖◆✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖
✖✖✑✖✖✖✕qq✖✖✖❇✖✖✖✖✖✖✖
ã
✖÷✖ñ✖✖✑❽✖✖✕
❂Ð➁✖❾❾❾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖
❾
✖✖✖✖✖✖✖✖✖✖ü✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖q✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖
❇✕
✖❋✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖ì✖✖❩✖❩✖✖✖❾✖✖✖✖✖✖✖✖✖❩✖❩❩❩❩❩q❩❩❩✘✖
❩
Ù❾✙✖✖✖➪✖✖➪✖✖✖✖❾✖❾✖❭✖✙✖✖✖✖✖✖✖✖✖✖✖
❇
➹
❇
✖✖✖✖✙✖✖✖✖✖✖✖✖✖✖
✙
✖
✖✖✖
✖✖✖
✑
✖✖
✘
✖
✘✖
✖✖
✑
✙
✖✖✖
✖
✖✖
❻
✖✖✖✖
✙
✖
q✕✖
✖✖
✙
✖✖
❾❾❾q✖✖
❾
✖✖❾✖✖✖✖✖❾
✖
❾◆❾
✙
✖✖✖
✙
◆
✖✙✖
❾❾
✖
❾✖✖✖✖✖✖✙✙
✖✖✖✖
qqÒ✖
✖
ã✖
✖✖✖✖✖✖✖✖✖
✙
✖
✖✖✖✖❾✖
✖✖
✖
✌✖ñ✖✖✖
✖
✖
✖✖➱✖✙✙
✖
✖✙✖✖✖✖✖✖✖✖✖✖✖✖✖✖
✖❾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❾✖✖✖✑✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❾✘
❷➹✖✖✖✖✖✖✖
➱
➬❾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❩✖✖Ó❾✖✖✑ý✖✖✖✖✖✖✖✖✖✖✖ì✖◆✖✖✖✖✖✖◆◆✖✖✖✖◆✖
➁
✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖➾➾✖✖✖✖✖✖✖✖✖✖✖❷✖✖✖➁◆✖❷✖✖✖✖◆✖✖✖✖✖❩✖✕❩✖✖✖❩❩✖✖✖✖❾✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✃✖✖✖✖
✖
✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖qq✖✖✖✖✖✖✖✖✖✖❾✖✖✖✖✖✖✖❾✖✖✖✖✖✖✖✖✖✖✖
✖
✖✖❾✖
✖
ñ✖✖✖✖✖✖✖✖q✖✖✖✖✖✖q✖✖✖✖q✖✖✖✖✖✖✖✖❾✖✖❾✖✖✖✖❒✖✖❾✖✖✖✖✖✖
✖✖✖þ✠✖ÿ✖✖✖✖✖✖✖✖✖✖✖✖✖
➾
✖✖✖✖✖✖✖✖✖✖✖✖❀✖✖✑✖❩✖✺✖✖✖✖❒✖❒✖✖✖✖❒✖✖ñ✖✖✖
✖
ÑÑ❾✖✖✖❷Ñ✖✖✖✖✖✕✖Ñ✖✖✖❏❏✖✖✖✖✖✖✖
✖✖✖✖
✖✖✖✖✦✖✖✖✖✖✖✘✖✖✖✖✑✠✖✖✖✖✖✑✑✖✖✖✖❩❾✖✖❾❾✖✖✖✖✖❾❾❾❾❾✖✖❾✖✖✖✖✖✖✖✖✖✖❾✖✖✖❷✖✖❾✖✖✖✖✖✖✖✙✖✖✖✖✖✖✖✖q✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖
✕
q
✺✖✖✖✖✖✖q✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖❷✖✖✺✖✖✖✖❷✖❾❾❾�✖❾✖✖✖✖✖✖✖✖❾✖❾✖❾✖✖❾❾✖❾❾✖✖✘❾➪✖✖✖✖✖❷❾q✠✖✖q✖❾✖✖✖✖✖✖✖✖q✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖✖
✠✖✕✖✖✖✖✖✖✖✖✖✖✖✖✖✖❾✖✁Ö✖Ù✂
q✖✖✖✖✖✖
✄
✖✖✖ ✖✖✖✖✖✖✖✖✖✖✖✖✖✖ñ✖✖✖✖✖
✖✖✖✖✖✖ ✖✖
❾✖✠✖✖✖✖✖✖✖✖✖✖✖✖✖✖
❇✖✖✖✖✖✖ ✖✖✖✖
✖✖✖
➄➅➆
➄➅➇
➄➅➈
➄➅➉
➊➋
➌➍➎➌➏
➐➑➒➓➏➔➔→➓
➐➑➒➓➏➔➔→➏
➐➑➒➓➏➔➔→➣
➌➐↔↕➓
➍➙➛➜➑➝➞
➟➠➌➓➡➢➔
➛➜➐➓➡➤➜
➝➒➒➓➥
✶✶✽ ✶✶✽➦➧ ✶✶➨ ✶✶➨➦➧ ✶✷✵
➩➫s➭➯➭➫➲ ➫➲ ➳➵✟➧ ➸➺➻➼
➌➍➎➌➏
➐➑➒➓➏➔➔→➓
➐➑➒➓➏➔➔→➏
➐➑➒➓➏➔➔→➣
➌➐↔↕➓
➍➙➛➜➑➝➞
➟➠➌➓➡➢➔
➛➜➐➓➡➤➜
➝➒➒➓➥
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵ ❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✶✵✹✼✽✹✷✹
☎✆✝✞✟✠
✡
✠
☛
☞☛☛
❚✆
✌
✍î ✕✎✏
✑✑
✒
✓
✔✕✖✗✘
✙
✘✚✚✚
✛✛
✘✔✜✢✣✏✤✢✑
✥✢
✡
✧
★
✩
✣✪✫✫✫✫✬✭✮✯✯✰✯✯✯ ✱✲
✲✰✳✲✭✲✰✲✴✰✵✶✷✸
✹✯
✲✰✺✻✼✽✾
✙✳
✽✳✽
✿
✳✵❀❁✯ ✹
✳
❂ ❃✻❄✹
❅
❆❇✶❈❉❉❉✰
✚✚
❊✯❀✯✚❋
❅❉
✕
✫❉✣✰✰●✖✖
✖❍
✖✖
■❏✗✲✲❑▲
▼
❏
✯✯✲
✖
▼▼✗❉◆❖P◗✯
✭✭✭❘❙✭✭✖✧✧
✯
❚❯✶◗❀❀❀❀❀✭❀❀✯❱✭❀❀❀❀❀❀❀❲❀❀❳✫✫❨✫✫✫✯✽✯✯✯✯✯✯✯✯✽✯✯✲❩✚
✢✯✢✯
❬✯
✢✯✯✯✚❭
✢✯
✯❪
✯
❫✯✯✯✲
✫✯✯✯✡✡✯✯✯✯✯✯✯✯✯✯✯◆✯✯✯✯❀
❴
✯✯✰✏✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✜✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯
✢✯✯✯✯✯✽✯✯✯✯✢✯✯✯✯✯✯✽✯✽✯✯✯✯✯✯❵✯✯✯✯✯✯✯✯✯✯✯✯✯✏✰✯✯✒✯✯✯✯✯✯✯✯✯✯✯✯✯✯
✢✯❛✯
✢✯✢
✯❀❉✫✯✯✯✯✯✯✯✯✯✯
✯
✯
✯✯✯✯✯✯✯✯
❫✯✯✯✯✯✯✯✪✯✯✯✯✯✯✯❀
✢
✯
✯
✪❀✯❀✯✯✯✯✯✯
✯✯✯✯
✪
✯
❀✯✯✯✯✯✯✯❀❀❀✯✯❜✲✯✯✯❀✯✯✡
❝✯✯
✯
✯
✯✲✯✯✲■
✯
❝
✡✯
✯
✯✯
✥✡
✯
✯
✯
✯
✯✯✯✯✯✯✯✯✯
✯
✯✯✯
✯✯✯✯✯✯✯✯✯✯✯
✯✯✯
✯✯
✯
✯
✪
✯
✯
✯
✯✯
✯✫✯✯✯✯
✯✯✯✯✯
✯✯
✯
✯
✯
✯
✯✯✯✯✯✯✯
✯✯✢✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯❀✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✪✯✯✯✯✯✯✪✯✯✯✪✯✯✯✯✯✯✯✯✯✯❀✯✯✗✯✯✯✯✯✯✯✯
✯✯✯✯✯✯✯✯✯✯✗✯✯✯✗✯✯✯✯✯✯❩
✡✡
✡✯✯✯✯✯✡✡❫❀✯✪✢✯❀✪
✽
✪✯✪✯✯✯✢✯✯✯✯✯✯✯✯✯✯✢✢✢✢❀✢✯✯✯✯
✯✯✯✒✯✯
✯
✯✯✯✢
✯
✯✪✯
✯
✯✲✡
✯
✯✯✯✯✯✯✯✯✯
❫✯✯✯✯✯✯
❀✯❫
✯
✯✯✯✯✯✢✯✯
✯
✯✯✯
✯
✯
✯✯✪✯✯✯✯✯✯✯✯✯✡✲✯✯✯✯✰✯✯✲❞✯✯✯✯✯✯✯✫✯✯✯❀✯✯✯✯❀✲✯✯✯✯✯✯✯❡✯✯❫
✡✯✲✗✯✲✯✯
✯✯✯
✒❢✯■✯
✯■✯✯✯✯✢✯✯
✯✲✲
✯✯✯✯✲✲
❣❣
✯✫✯❀✯
✯✯✡❤✯✯✯
✫✯
✯✯
✯✯✯✯✯✯✯✯✯✯✯✯✯✯✲✯✯
✯❀✯✲✯✯✯✱✯✯✯✯✯✯✯✯✯✯✰
✯✯✯✯✗✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✢✯✲✰✰
✰✯✯✲✫✢✫✯✫✯
✯✫✯✯✯✫✫✯✯✯✯
✯✫✯
✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯
✯✯✯✯✯
✯
✯✯✯✯✯❫✯✯❫✯✯✯✯❫❫❫
❀
✘✢❀✢✢❀✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯
✲✯✯✯✲❫❫
✰✯❫✯❫❫✯✯✯
✯❫❫
✯
❫✯❵✯
✯
✐✐✯✯✯
✯✯✯✯
✯✯✯✯✯✯✶✯✯
✯✯✡✡✡✯✶✯✯✯✶✯✯✯✶✯✯✯✡❤
❥✶✶✯✯✚
❀
✯✯✯✯✯✯✯✯❦✲
✡
✡✶✯✯✯✶✯✯✶✯✯✶✶✯✒✯✯✯✯✯
❀
✯✶✶✯
❀
✯✯✯✯
❀
✯✤✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯
❀
✯✯✯✯✯✯✯❧✡✯✯✡✰✡
✯✯✯✶✯
✯
✯
✯
✯
❫
✯✯✏✰✯
✰✯✯✯✯
✯
✯
✯✯
✯✯✯
✯✯
✯
✯
✯
✯✯
✯✯✯
✯
✯
❀
✯✯
❵
✯✯✢✢
✯
✯
✯✯✯✯✯✯✯✯✯✯✯✯✡✯✡✡✡✡✡✯✰✯✯✯✯✯✯✯✯✯✒
✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✐✯✯✯✯♠✯✯✯✯✯✯✯✯✯✯✯✰✯✰✯✯✯✯✯✯✤✯✰✯✯✡✯✯✧✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✤✯✯✯✯✯✯✯✯✯✯✰✯✯✯
✡✯✯✯✯✯✯✏❫✯❫✯✯✯✯✯✯
✯
✯✯✯✯✯✯✯✯✯
✯✯✯✯✯✯✯✯✯✯
✰
✯✯✯✯
✯✯
✯✯✯✯✯✯✯
✯
✯
✯
✡
✯
✯✫✯✯✯✯✯
✯❀✯✯✯✯✯✯✯✯✯
✯✯
✯✯✯✯
✯✯✯✯✯✡❝✲
✡
✯✯✯♥✯✯✣✯✯✯▼▼✰▼❫✯✯✯✯✯✯✯✯✯❫✯✯❀✯✯✯✯✯❫✯✯✯✯✯✯✯✡✯✯✯✯✯✯✯♦✯✯✯✯✯✯✯✯✡■✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯
✯✯✯✯❉✯✯✯✯✰✯✯✒✯✏✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✡✯✯✯✯✯✯✯✯✗✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✰✯✯✯✡✲✡✯✯✯▼✯✯✯✯✯✯✯✖✯♣✯✒✯✯✰✳✯✯✲✽q✪✯❀❀❫✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯❀✯✯✯✯✯✯✯✯✯✯
r
✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✡✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯▼
s
✯t✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯❭✯✯❫✯❫✯✯✯❀✯✯✯✯✯✯✯✯✯❫✯❫❫❫❫❫✡❫❫❫✳✯
❫♣❀✢✯✯✯❉✯✯❉✯✯✯✯✫✯✫✯✉✯✫✯✯✯✯✯✯✯✯✯✯✯▼✈▼✯✯✯✯✢✯✯✯✯✯✯✯✯✯✯✢✯
✯✯✯✯✯✯✰✯✯
✳✯✏✯
✯✯✰
✢
✯✯✯✯✯✯✣✯✯✯✯
✢
✯✡✇✯✯✯
✢
✯✯❀❀❀✡✯✯❀✯✯❀✯✯✯✯✯❀✯❀▼❀
✢
✯✯✯
✢
▼✯
✢
✯❀❀✯❀✯✯✯✯✯✯✢✢✯✯✯✯✡✡❝✯
✯❩✯
✯✯✯✯✯✯✯
✯✯
✫
✯
✯✯✯✯❀
✯
✯✯
✯
♠✯✒✯✯
✯
✯
✯
✯✯❏✯✫✫
✯
✯✢✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯
❀
✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯❀
✯✯✯✰✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✫✳✫✶✯✯✯✯✯✯✯
❏
①✫✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯❫✯✯✣✫✯✯✰②
✯✯✯✯✯✯✯✯✯✯✯✭✯▼✯✯✯✯✯✯▼▼✯✯✯✯▼✯
✪
✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯◆◆✯✯✯✯✯✯✯✯✯✯✯
✢
✯✯✯✘◆✯
✢
✯✯✯✯◆✯✯✯✯✯❫✯③❫✯✯✯✽✽✯✯✯✯❀✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯④✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✡✡✯✯✯✯✯✯✯✯✯✯❀✯✯✯✯✯✯✯❀✯✯✯✯✯✯✯✯✯✯✯✯✯✯❀✯
✯
✒✯✯✯✯
✯✯✯✯✡✯
✯✯✯✯✯✡✯✯
✯✯✡✯✯✯✯✯✯✯✯✫✯✯
❀✯✯✯✯❏✯✯❀✯✯✯✯❵
✯✯✯✯
✐✰✯t✯✯✯✯✯✯✯✯✯✯✯✯✯
✗
✯✯✯✯✯✯✯✯✯✯✯✯✘✯✯
✰✯❫✯✚✯✯✯✯❩✯❩✯✯✯
✯❩✯✯✒✯✯✯✯✧✧❫✯✯✯✫✧✯✯✯✯✯✲✯✧
✯
✯✯✶✶
✯✯✯✯✯
✯✯
✯✯✯✯
✯✯✯✯♦
✯✯✯✯✯✯✏✯✯✯✯
✰
✏✯✯✯✯✯✰✰
✯✯✯✯❫❀✯✯❀❀✯✯✯✯✯❀❀❀❀❀✯✯❀✯✯✯✯✯✯✯✯✯✯❀✯✯✯✢✯✯❀✯✯✯✯✯✯✯✢✯✯✯✯✯✯✯✯✡✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✡✲◆✯✯✯✯✯✯✡✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✢✯✯◆✯✯✯✯✢✯❀❀❀❍✯❀✯✯✯✯✯✯✯✯❵✯❀✯❀✯✯❀✫✯✫❀✯✯
✳
✫
❉
✯✯✯✯✯✢❀✡✰✯✯✡✯❀✯✯✯✯✯✯✯✯✡✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯✯
✰
✯✲✯✯✯✯✯✯✯✯✯✯✯✯✯✯❀✯⑤✵✯⑥⑦✡✯✯✯✯✯✯
✛
✯✯✯ ✯✯✯✯✯✯✯✯✯✯✯
✯✯✯✒
✯✯✯✯✯ ✯✯✯✯✯✯✯✯❀
✯✏✯✯✯✯✯✯✯✯✯✯✯❵✯✯ ▼
✯✯✯✯✯✯✯✯✯✯ ✯✯
✯
⑧⑨⑩
⑧⑨❶
⑧⑨❷
⑧⑨❸
❹❺
❻❼❽❻❾
❿➀➁➂❾➃➃➄➂
❿➀➁➂❾➃➃➄❾
❿➀➁➂❾➃➃➄➅
❻❿➆➇➂
❼➈➉➊➀➋➌
➍➎❻➂➏➐➃
➉➊❿➂➏➑➊
➋➁➁➂➒
✶✶✽ ✶✶✽➓➔ ✶✶→ ✶✶→➓➔ ✶✷✵
➣↔s↕➙↕↔➛ ↔➛ ➜➝✟➔ ➞➟➠➡
❻❼❽❻❾
❿➀➁➂❾➃➃➄➂
❿➀➁➂❾➃➃➄❾
❿➀➁➂❾➃➃➄➅
❻❿➆➇➂
❼➈➉➊➀➋➌
➍➎❻➂➏➐➃
➉➊❿➂➏➑➊
➋➁➁➂➒
✵
➔
✶✵
✶➔
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✹✻✽✹✽➔✹
➢
❥
➢
✛
➤✲ ➥ ✲➦➧➨
✲
➩ ➫✡
❥
➭✡ ❥
✡
✡✡
✡
✡➯➢
✡
✡✡
✡
➲✡ ✡✡
✡
✡✡➯✡
➭
➳✡✡✡✡➭➵✡
✡
✡➭✡✡✡
✡➭
✡
➭ ✡✡
➸➭➭➭➭✡
➵
✡
✡✡
✡✡
✡
✡
✡
✡✡➺
✡
✲
✡✡
✲
✡✡✡ ✡✡✡ ✡✡✡✡
➲
✡✡
✡
✡
✡✡✡✡✡ ✡
✡✡ ➯
✡ ✡✡
⑧⑨⑩
⑧⑨❶
⑧⑨❷
⑧⑨❸
❹❺
➋➋➊➁➻
✶✷➓✹ ✶✷➓✹✷ ✶✷➓✹✹ ✶✷➓✹✻ ✶✷➓✹✽ ✶✷➓➔
➣↔s↕➙↕↔➛ ↔➛ ➜➝✟➼ ➞➟➠➡
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✹✻✽✹✽➔✹
➽➦
✲
➾➚
✲ ➳✲➪➶
➹➘ ④
➽ ➽
❜
➽
➽➽
➽ ➽➽➽➴➦✲➽
➽➽
➽➷➽ ➽➽
➽➽
➽
➴➽❜➬➽
➽
➽➽❜➮➽
➽
➽❜➽➽➽ ➽❜➽❜ ➽ ➽
➷❜❜❜❜➽ ➱➽➽
➽
➽➽
➽
➽➽➽➽
✃
➽✲➽
➽
✲ ➽
➽➽
➽
➽➽ ➽➽➽
➽✠ ➽➽
➽
➽➽➽➽➽➽ ➽➽
➽
➴➽ ➽ ➽
⑧⑨⑩
⑧⑨❶
⑧⑨❷
⑧⑨❸
❹❺
➋➋➊➁➻
✶✷➓✹ ✶✷➓✹✷ ✶✷➓✹✹ ✶✷➓✹✻ ✶✷➓✹✽ ✶✷➓➔
➣↔s↕➙↕↔➛ ↔➛ ➜➝✟➼ ➞➟➠➡
✵
✷
✹
✻
✽
✶✵
✦❧♦❣�✁✭♣✂✈❛❧✉❡✮
✵
✷✵
✹✵
✻✵
✽✵
✶✵✵❘✄❝☎♠❜✐♥✆t✐☎♥r✆t✄✝❝▼✴▼❜✞
✟s✹✻✽✹✽➔✹
✯
✏
❵
❐✲
✚✲④④❒ ❤ ❑
✯
✯
❀ ✯
✯
✯ ✯✯ ✯✯✒✳
✯
✯✯✯✰✯
✯✯✯✯
✯ ✒✯❀⑥✯✯✯✯❀❮✯
✯
✯❀✯✯✯✯❀
✯
❀ ✯
✯
✰❀❀❀❀✯
✸
✯
✯
✯
✯✯✯✯ ✯ ✯✯
✢✯✲✯
✯
✲✯✯✯
✯✯✯ ✯✯✯
✯✰
✯✯
✯
✯✯✯✯✯✯ ✯✯
✯
✒
✯✯✯
⑧⑨⑩
⑧⑨❶
⑧⑨❷
⑧⑨❸
❹❺
➋➋➊➁➻
✶✷➓✹ ✶✷➓✹✷ ✶✷➓✹✹ ✶✷➓✹✻ ✶✷➓✹✽ ✶✷➓➔
➣↔s↕➙↕↔➛ ↔➛ ➜➝✟➼ ➞➟➠➡
A B CHSD17B4 WHRadjBMI
PPARG WHRadjBMI
nmen nwomen nmen nwomen nmen nwomen nmen nwomen nmen nwomen nmen nwomen
Discovery Stage:
ADVANCE Cases . . 114 160 . . 114 161 114 161 114 161
ADVANCE Controls . . 128 179 . . 128 181 128 181 128 182
AGES Reykjavik . . 1351 1865 . . 1352 1867 1351 1856 1351 1856
Amish 465 435 465 435 465 435 470 437 468 437 468 437
ARIC 3821 4283 3821 4283 3821 4283 3823 4287 3822 4286 3822 4286
B58C-T1DGC 1198 1292 1198 1292 1198 1292 1261 1330 1259 1328 1259 1328
B58C-WTCCC 700 722 700 722 700 722 741 738 741 738 741 738
BRIGHT 667 982 668 984 667 982 719 1087 719 1087 719 1087
CAD-WTCCC . . . . . . 1491 388 1489 387 1489 387
CAPS1 Cases . . . . . . 489 . 484 . 485 .
CAPS1 Controls . . . . . . 491 . 483 . 485 .
CAPS2 Cases . . . . . . 1483 . 1423 . 1424 .
CAPS2 Controls . . . . . . 519 . 500 . 504 .
CHS 1274 1943 1274 1944 1274 1943 1277 1955 1276 1952 1276 1952
CoLaus 2544 2861 2546 2862 2544 2861 2547 2862 2547 2861 2547 2861
DECODE 2610 3273 2610 3273 2610 3273 9213 17586 9213 17586 9213 17586
DGI Cases 509 449 509 449 509 449 687 630 688 629 688 629
DGI Controls 241 228 241 228 241 228 553 537 553 535 553 535
EGCUT 195 228 195 228 195 228 697 720 697 720 697 720
EPIC-Obesity Study 1130 1284 1130 1284 1130 1284 1621 1931 1131 1284 1131 1284
ERF (EUROSPAN) 890 1170 890 1170 890 1170 890 1170 890 1170 890 1170
Fenland 615 787 615 787 615 787 615 787 615 787 615 787
FamHS Cases 208 233 208 233 208 233 208 233 208 233 208 233
FamHS Controls 207 207 207 207 207 207 208 207 208 207 208 207
FRAM 1562 1715 1562 1715 1562 1715 3700 4389 3706 4388 3706 4388
FTC . 120 . 120 . 120 . 125 . 125 . 125
FUSION Cases 620 464 620 465 620 464 617 465 623 469 623 469
FUSION Controls 571 598 571 598 571 598 569 598 572 599 572 599
GENMETS Cases 425 423 425 423 425 423 410 414 425 432 410 414
GENMETS Controls 401 423 401 423 401 423 401 422 401 423 401 422
GerMiFSI . . . . . . 394 206 394 206 394 206
GerMiFSII . . . . . . 901 223 901 223 901 223
KORAS3 812 826 812 827 812 826 813 830 813 829 813 829
KORAS4 883 929 883 929 883 929 883 928 883 928 883 929
MICROS 118 175 118 175 112 169 467 612 475 622 468 612
MIGEN . . . . . . 1622 1030 1619 1028 1623 1028
NBS-WTCCC . . . . . . 696 745 694 743 694 743
NFBC1966 2246 2245 2246 2245 2246 2245 2250 2249 2250 2247 2250 2247
NHS . 1632 . 1632 . 1632 . 2265 . 2265 . 2265
NSPHS 307 339 . . . . 308 344 307 340 307 342
NTRNESDA 1206 2303 1206 2303 1206 2303 1211 2311 1210 2306 1210 2306
ORCADES 324 371 324 371 324 371 324 371 332 384 324 371
PLCO . . . . . . 2244 . 2238 . 2238 .
PROCARDIS 612 346 612 346 612 346 1700 612 1700 612 1700 612
RS-I 2266 3202 2266 3205 2266 3202 2372 3375 2372 3372 2375 3383
RUNMC . . . . . . 1777 1096 1777 1096 1777 1096
SARDINIA 1886 2415 1886 2416 1886 2415 1883 2415 1885 2416 1883 2415
SASBAC Cases . . . . . . . 794 . 793 . 794
SASBAC Controls . . . . . . . 758 . 755 . 760
SEARCH / UKOPS . . . . . . . 1592 . 1556 . 1581
BMI WEIGHTHip WC WHR HEIGHT
SHIP 2019 2073 2019 2073 2019 2073 2019 2073 2019 2073 2019 2073
T2D_WTCCC 1085 786 1085 786 1085 786 1105 798 1105 798 1105 798
TwinsUK . 1096 . 1096 . 1094 . 1479 . 1477 . 1477
VIS 325 458 325 459 325 458 325 459 328 467 325 445
Follow-Up Stage - InSilico:
FamHS 1027 1194 1027 1194 1027 1194 1028 1195 1028 1195 . .
BSN 537 748 537 749 536 748 558 770 558 769 . .
Corogene Cases 1015 881 1015 881 1015 881 1005 880 1005 880 . .
Corogene Controls . . . . . . 1128 549 1127 549 . .
EGCUT 358 357 358 357 358 357 351 349 358 357 . .
FINGEST . . . . . . 756 206 750 204 . .
GOOD 938 . 938 . 938 . 938 . 938 . . .
HBCS 735 988 735 989 735 988 736 990 736 990 . .
Hypergenes Cases 170 152 170 152 170 152 1072 538 1072 538 . .
Hypergenes Controls 120 146 120 146 120 146 998 684 998 684 . .
Lifelines 1373 1993 1373 1993 1373 1993 1373 1994 1373 1994 . .
MGS . . . . . . 1247 1350 1247 1350 . .
PLCO2 Cases . . . . . . 2043 934 2041 933 . .
PLCO2 Controls . . . . . . 649 544 645 544 . .
PREVEND 1964 1873 1964 1873 1964 1873 1966 1872 1966 1871 . .
QIMR . . . . . . 1470 2157 1470 2157 . .
RS2 877 1035 877 1035 877 1035 876 1035 876 1035 . .
RS3 842 1085 842 1085 842 1085 877 1129 877 1129 . .
Sorbs 361 515 363 516 361 515 361 515 361 515 . .
WGHS . 20538 . 20566 . 20529 . 23099 . . . .
YFS 907 1075 907 1075 907 1075 911 1084 908 1081 . .
Follow-Up Stage - MetaboChip:
ADVANCE-CAD Cases . . 678 222 . . 678 222 678 222 678 222
ADVANCE-CAD Controls . . 421 247 . . 421 247 421 247 421 247
AMCPAS Cases 368 122 . . . . 368 122 368 122 368 122
B58C 1231 897 1232 897 1231 897 1234 901 1232 902 1232 902
BHS Cases 79 40 80 40 79 40 83 42 82 42 82 42
BHS Controls 85 51 86 51 85 51 87 51 87 51 87 51
CARDIOGENICS Cases 328 51 . . . . 328 51 328 51 328 51
CARDIOGENICS Controls 148 227 . . . . 148 227 148 227 148 227D2D2007.DPS.DRSEXTRA.FUSIONS2.METSIM 757 2150 757 2150 757 2152 759 2152 759 2152 759
CasesD2D2007.DPS.DRSEXTRA.FUSIONS2.METSIM 2957 3669 2955 3669 2954 3672 2963 3672 2963 3672 2963
Controls
DILGOM 1769 2098 1765 2098 1763 2092 1775 2114 1769 2115 1769 2115
EAS 353 378 . . . . 353 378 353 378 352 377
EGCUT CAD Cases 346 354 346 354 346 354 346 354 346 354 346 354
EGCUT Controls 340 600 340 600 340 600 341 601 341 601 341 601
EGCUT DB Cases 272 417 272 417 272 417 355 613 355 613 355 613
Ely 736 852 736 853 735 852 744 855 744 855 744 856
EPIC Cases 432 295 432 295 432 295 432 294 432 291 432 292
EPIC Controls 410 549 411 550 410 549 410 552 410 551 411 551
Fenland 1485 1698 1485 1698 1484 1698 1486 1698 1486 1698 1486 1698
GLACIER 2381 3666 874 1445 . . 2381 3666 2381 3666 2381 3666
GO-DARTS Cases 1926 1347 1750 1215 . . 1926 1347 1922 1345 1923 1346
GO-DARTS Controls 1918 1789 1917 1787 . . 1918 1789 1918 1788 1918 1788
HNR 2262 2256 2262 2256 2262 2256 2262 2256 2262 2256 2262 2256
3669
2151
HUNT.TROMSO Cases 492 470 492 470 492 470 651 637 651 636 651 636
HUNT.TROMSO Controls 566 546 566 547 566 546 749 718 748 717 748 718
IMPROVE 1663 1775 1663 1775 1663 1775 1650 1776 1666 1783 . .
KORAS3 603 660 603 660 603 660 603 671 599 659 599 659
KORAS4 585 624 585 624 585 624 585 632 582 624 582 624
LURIC Cases 1652 567 1652 567 1652 567 1678 573 1678 574 1678 574
LURIC Controls 327 310 327 310 327 310 330 315 330 315 330 315
MORGAM Cases 984 222 983 222 983 222 1707 246 1707 246 1708 246
MORGAM Controls 1084 287 1084 287 1084 287 2094 319 2095 319 2095 320
NSHD 463 519 463 519 463 518 464 520 464 515 464 516
PIVUS 485 483 485 483 485 483 490 488 490 488 490 488
SCARFSHEEP Cases 886 309 886 310 893 311 893 311 882 310 716 259
SCARFSHEEP Controls 1171 510 1173 512 1181 514 1181 514 1177 509 944 433
STR 563 778 563 780 563 778 808 1377 838 1378 . .
THISEAS Cases 423 78 423 78 423 78 423 78 423 78 423 78
THISEAS Controls 416 530 416 530 416 530 416 530 416 530 416 530
ULSAM 1095 . 1095 . 1095 . 1112 . 1112 . 1116 .
Whitehall 1700 535 1700 536 1700 535 1699 535 1699 535 1700 536
Mar
kerN
ame
Gen
e
Trait
Gen
der
CHR
POS_B
36
Effect_a
llele_a
dj
Oth
er_a
llele_a
dj
DIS
COVE
RY.M
EN.p
.fdr
rs6717858 COBLL1 WHRadjBMI W 2 165247907 t c 0.998
rs2820443 LYPLAL1 WHRadjBMI W 1 217820132 t c 0.99
rs1358980 VEGFA WHRadjBMI W 6 43872529 t c 0.974
rs11743303 MAP3K1 WCadjBMI W 5 55895709 g a 1
rs2371767 ADAMTS9 WHRadjBMI W 3 64693298 g c 0.991
rs10478424 HSD17B4 WHRadjBMI W 5 118816919 a t 1
rs4684854 PPARG WHRadjBMI W 3 12463882 c g 1
rs16970956 DBF4B HEIGHT M 17 40164017 a g 0.0356
rs12887636 PRKD1 BMI W 14 28772341 t g 0.988
rs6091540 ZFP64 BMI W 20 50521269 c t 1
rs718314 ITPR2 WHRadjBMI W 12 26344550 g a 0.988
rs1443512 HOXC13 WHRadjBMI W 12 52628951 a c 0.989
rs4460442 FBP1 HEIGHT W 9 96483162 a c 1
rs1316952 DNAH10 WHRadjBMI W 12 122965503 t c 1
rs4325879 CCNL1 HEIGHT W 3 158334678 c t 0.965
rs1936805 RSPO3 WHRadjBMI W 6 127493809 t c 0.315
rs6921207 EPB41L2 HEIGHT W 6 131369649 a g 0.955
rs2867131 TMEM18 WEIGHT W 2 600603 c t 0.0000973
rs987469 FAM13A1 WHRadjBMI W 4 89925666 g c 0.979
rs3824867 RAPSN HEIGHT W 11 47425145 a g 0.481
rs2399915 CCDC3 HEIGHT M 10 12976787 t g 0.0189
rs2301573 PLXND1 WHRadjBMI W 3 130788609 t c 1
rs1051920 ZBTB10 BMI M 8 81600975 c t 0.0135
rs12036473 TNNI3K BMI W 1 74752563 t a 0.602
rs703990 ZMIZ1 HEIGHT W 10 80600445 t c 0.83
rs10132280 STXBP6 WEIGHT M 14 24998019 c a 0.0435
rs7591613 SOCS5 HEIGHT M 2 46813135 g a 0.0456
rs2035344 ADAMTS17 HEIGHT W 15 98507671 g a 0.972
rs7102710 SPON1 HEIGHT W 11 14222189 c t 0.96
rs6512577 ZNFX1 HEIGHT W 20 47299191 t c 0.92
rs9376970 SHPRH HEIGHT W 6 146283165 c a 0.967
rs1194758 SCYL1 HEIGHT M 11 64994661 a t 0.000196
rs10771408 CCDC91 HEIGHT W 12 28191879 c t 0.247
rs12612395 TTLL4 HEIGHT W 2 219329886 g c 0.76
rs6887597 GHR HEIGHT M 5 42252722 a g 0.0225
rs7162542 ADAMTSL3 HEIGHT W 15 82305294 g c 0.000347
rs902143 ZNF462 HEIGHT M 9 108221732 t c 0.00432
rs17318596 ATP5SL HEIGHT M 19 46628935 a g 0.0000538
rs4129299 CADM2 WEIGHT W 3 85806754 g a 0.718
rs2072268 ARSG HEIGHT M 17 63814947 g a 0.0458
rs11866219 NFAT5 HEIGHT W 16 68107250 c a 0.955
rs2273654 C10orf6 HEIGHT W 10 102679207 c t 0.998
rs9907102 VPS53 HIPadjBMI W 17 411582 g a 0.981
rs10495502 ALLC WC M 2 4569916 t c 0.0293
rs2860555 FKBP9 HEIGHT M 7 32987183 t c 0.00974
rs1172294 RBJ HEIGHT W 2 25022704 a g 0.287
rs2062708 NPR3 HEIGHT M 5 32789429 c t 0.0000296
rs10236884 PDIA4 HEIGHT W 7 148290549 g a 0.991
rs2341459 C2orf34 HEIGHT M 2 44621706 t c 0.000207
rs6824258 BBS7 HEIGHT M 4 122989417 c t 0.000908
rs7488867 C12orf42 HIP W 12 102223815 c t 1
rs3110496 GIT1 HEIGHT M 17 24941897 g a 0.00371
rs2034461 FGF2 HEIGHT M 4 124003745 g a 0.0285
rs2941580 SPTBN1 HEIGHT M 2 54715507 g a 0.00355
rs1895585 TBX5 WCadjBMI W 12 113286521 g a 1
rs33852 FBXW11 HEIGHT W 5 171122176 g a 0.723
rs2602943 AK5 WC M 1 77524538 t c 0.00804
rs1393786 PPP2R3A HEIGHT W 3 137336725 c a 0.84
rs6420435 MPHOSPH6HEIGHT M 16 80741702 a c 0.0411
rs2076529 BTNL2 WHRadjBMI W 6 32471933 c t 0.827
rs7584473 LTBP1 HEIGHT M 2 33274521 g t 0.0282
rs884970 GRK5 HEIGHT M 10 121114491 a g 0.0266
rs6450922 NPR3 HEIGHT W 5 32725475 c g 0.784
rs17608726 NHEJ1 HEIGHT W 2 219655246 a g 0.709
rs9970392 FMO3 WC W 1 169355282 c t 1
rs17803745 MAFB HEIGHT W 20 37975983 c t 0.99
rs6767671 RARB WEIGHT M 3 25081764 t g 0.0011
rs17488051 TEAD1 HEIGHT M 11 12818570 g a 0.00944
rs10759832 PAPPA HEIGHT W 9 117970134 t c 1
rs1814336 ANAPC13 WCadjBMI W 3 135683513 c g 0.845
rs6879260 GFPT2 HEIGHT W 5 179663620 c t 0.495
rs10947552 TEAD3 HEIGHT W 6 35571033 a t 0.854
rs6923431 LAMA2 HEIGHT M 6 129866447 c a 0.0497
rs2682587 XRCC1 HEIGHT W 19 48774269 a c 1
rs17016663 REG3A WEIGHT W 2 79347442 c g 0.961
rs765684 TACR1 WHR M 2 75313176 g a 0.0116
rs2943636 IRS1 WCadjBMI M 2 226795528 g a 0.00587
rs6453220 IQGAP2 WCadjBMI M 5 75754584 c t 0.0429
rs6675701 DTL HIPadjBMI M 1 210328315 a g 0.0117
rs2041990 IGFL2 WHR M 19 51342164 g a 0.00133
rs16847466 LRP1B WEIGHT M 2 142352490 a c 0.0214
rs927900 CSRP1 WHRadjBMI W 1 199726581 c t 1
rs7771165 KLHL31 HIPadjBMI W 6 53643729 c t 0.998
rs721367 ABCC4 WCadjBMI M 13 94344651 t c 0.00265
rs4801600 ZNF446 HIPadjBMI M 19 63692268 t c 0.00288
rs4762099 MSRB3 WHRadjBMI M 12 64154192 a g 0.0399
rs12153375 SRFBP1 HEIGHT W 5 121307152 c a 1
rs607987 FSHB WEIGHT M 11 30180150 g a 0.00805
rs17023901 LONRF2 HEIGHT W 2 100273560 g a 0.963
rs17097239 RAB11FIP2 HIP W 10 119754385 t c 1
rs1528450 UBE2E3 HIP M 2 181225887 c t 0.0101
rs8067781 CA10 WCadjBMI W 17 47525664 c a 0.987
rs12723724 RFWD2 WEIGHT W 1 174205099 c a 0.921
rs4474021 LONRF1 WHRadjBMI W 8 12677274 t g 1
rs1656316 TSSC1 WCadjBMI W 2 2846082 c t 1
rs4656906 VANGL2 HEIGHT M 1 158649674 t c 0.0333
rs16989550 PRAME HIPadjBMI M 22 21225813 c g 0.00448
rs381771 TRIML1 WC M 4 189620422 a c 0.00829
rs200810 C6orf167 WEIGHT M 6 98028905 t c 0.00766
rs7306586 SOX5 HIPadjBMI M 12 23586354 a t 0.0318
rs12820411 CCDC91 HEIGHT W 12 28843609 g c 0.919
rs2909430 TP53 HEIGHT M 17 7519370 t c 0.0281
rs6471766 EFCAB1 WCadjBMI M 8 49503084 c t 0.00308
rs777397 C4orf40 WCadjBMI M 4 71042250 g a 0.00602
rs6601981 CALML3 WHR W 10 5622060 g a 0.998
rs7539416 CHD1L HEIGHT W 1 145348210 t c 0.988
rs1264420 PPP1R10 WCadjBMI M 6 30683582 a g 0.0103
rs4885693 SPRY2 WEIGHT M 13 79548118 g c 0.00789
rs16830255 PLCL1 HEIGHT M 2 199193008 a g 0.0312
rs16843742 PTPRC WC M 1 196938922 c t 0.0253
rs17704365 GLDN HEIGHT M 15 49429781 a g 0.0183
rs9584256 SOX21 WCadjBMI M 13 94254921 g c 0.00144
rs1035822 ZEB2 WEIGHT M 2 144972248 a g 0.00916
rs16967162 OTOP2 HIP M 17 70438474 c t 0.00921
rs11046741 ETNK1 WCadjBMI M 12 23072530 t c 0.0157
rs4550441 TOX3 HIPadjBMI W 16 51220214 a g 1
rs7679189 FAT HIP M 4 188245662 t a 0.0495
rs7017026 MLZE HEIGHT M 8 130058917 g t 0.00117
rs10194680 LRP1B HIPadjBMI W 2 140201398 a g 0.994
rs11135768 NKX3-1 WHRadjBMI W 8 23629223 t c 1
rs4790580 ANKFY1 HIP M 17 4013268 t c 0.0127
rs12590590 ERO1L WC M 14 52231486 g t 0.0484
rs10747492 DPYD WEIGHT W 1 98115005 g a 1
rs11945371 TMEM165 HEIGHT M 4 55969987 t g 0.044
rs1881973 FAM131A WEIGHT M 3 185538795 g c 0.0138
rs7946703 PPFIBP2 WCadjBMI W 11 7634881 c t 1
rs6729179 CYBRD1 HEIGHT W 2 172138153 a g 1
rs10250103 FOXP2 BMI W 7 114082178 t c 1
rs1835851 MLZE WHRadjBMI M 8 130422409 g a 0.0123
rs17639207 PABPC4L WCadjBMI M 4 136412790 t c 0.0476
rs17464492 MYC WHRadjBMI W 8 128412048 a g 1
rs7771861 LOC100129128HIPadjBMI W 6 73998691 a c 1
rs1340491 PCDH20 WHR W 13 62966154 g t 1
rs17097042 INADL HIPadjBMI W 1 62350338 t g 1
rs9491842 C6orf58 WHRadjBMI M 6 127979594 g t 0.0416
rs6915443 DACT2 WC M 6 168499960 t c 0.00247
rs4307377 CHD7 WCadjBMI M 8 61918520 g a 0.0332
rs4775635 RPS27L HEIGHT W 15 61243360 c a 1
rs4919613 PPRC1 WEIGHT W 10 103895769 g a 1
rs6995698 ZHX2 WCadjBMI M 8 123779856 a t 0.048
rs2546110 APC WEIGHT M 5 112190312 a g 0.0229
rs753613 NBL1 HIP M 1 19851252 g a 0.043
rs10068613 GPR98 WCadjBMI M 5 90422270 t g 0.0402
rs2489015 HIF1AN BMI M 10 102380717 a c 0.0205
rs1852269 PLEKHM1 WCadjBMI W 17 41011056 g a 1
rs10859417 EEA1 WCadjBMI W 12 91964100 g a 1
rs4006794 CD300A WCadjBMI W 17 69999430 g a 1
rs11207068 TRIT1 BMI M 1 40126542 a g 0.0269
rs17081663 PCDH9 HIP M 13 63539097 t g 0.0272
rs7200137 C16orf73 WEIGHT M 16 1841212 g t 0.0251
rs1413515 CXCL12 WEIGHT M 10 44233433 g a 0.0291
rs10410815 NLRP12 WHR M 19 58959088 t g 0.0293
rs10753823 PRRX1 HEIGHT M 1 169065068 g a 0.0252
rs17070943 BCL2 WHR W 18 59083041 c t 1
rs1518159 RIT2 BMI W 18 39014144 c t 1
rs11590161 SYT14 WEIGHT M 1 208232551 g c 0.0297
rs7096633 TAF3 WHRadjBMI M 10 8058113 g a 0.0394
rs8357 PLCG2 BMI M 16 80549365 g c 0.0299
rs11689339 EXOC6B HIP W 2 72729217 c t 1
rs12259741 PLXDC2 WEIGHT M 10 20540716 g a 0.0362
rs655229 CASP4 WHR W 11 104213441 c t 1
rs4267326 MKL2 WC W 16 14186538 g a 0.888
rs17118549 JUN WCadjBMI M 1 59256915 t c 0.0362
rs41322845 ZNF45 HIP W 19 49108895 t c 1
rs16911034 SVIP HIPadjBMI M 11 23258897 t c 0.0364
rs4284387 LRRC4C HIPadjBMI W 11 40832262 g a 1
rs11159781 FLRT2 WCadjBMI W 14 86135518 g c 1
rs17513809 CITED2 WHR M 6 139871610 g a 0.00338
rs1354162 CASR WCadjBMI W 3 123436767 g t 1
rs13199474 EGFL11 WEIGHT M 6 67521918 a g 0.0341
rs2115107 MAP2K7 WCadjBMI W 19 7874168 a g 1
rs9818349 FHIT HIP M 3 60447147 a g 0.00721
rs17028692 NPHP4 HIP M 1 5688866 a g 0.0387
rs16833832 RGS18 WCadjBMI W 1 190055744 g a 1
rs544023 SCG3 BMI M 15 49794814 a g 0.0208
rs290826 DPYD WEIGHT M 1 97246295 c t 0.0408
rs9520908 MYO16 WEIGHT M 13 107949808 c t 0.0408
rs10896348 SAPS3 WCadjBMI W 11 68113944 c t 1
rs12706599 LOC136157 WC M 7 123818847 t c 0.0062
rs11858967 AGBL1 WC M 15 84926556 a g 0.0148
rs3789353 SPTLC3 WCadjBMI M 20 12977437 a g 0.0429
rs1030723 OR51F1 WHR W 11 4747047 g a 1
rs9508647 KATNAL1 WHR M 13 29606574 c t 0.0455
rs2836162 DSCR4 WHRadjBMI W 21 38426226 a g 0.987
rs4313235 KIAA1797 HIP W 9 20974803 a t 1
rs12814276 SLC2A13 WEIGHT M 12 38776334 t c 0.0476
rs6933434 C6orf138 WHRadjBMI W 6 48612776 a t 1
rs12628051 TNRC6B BMI M 22 38984222 t c 0.0393
rs7126121 MS4A4A HIPadjBMI M 11 59829360 a g 0.0467
rs16842906 MAP2 WC M 2 210022051 t c 0.0498
rs7394653 PRMT3 HIPadjBMI M 11 20477948 a g 0.0484
rs2540334 TRAK2 WC M 2 201979592 c t 0.043
rs41410848 LRRC44 WHR M 1 74179126 t g 0.0497
rs4723327 C7orf50 HIP M 7 1001726 c t 0.0498
rs31553 FBXL21 HIPadjBMI M 5 135302047 c t 0.0248
rs10819930 HSD17B3 WHR W 9 97963089 g a 0.998
rs11664745 APCDD1 WHR M 18 10337975 t c 0.0403
rs1551594 PDZRN4 WC M 12 40128555 c t 0.00352
rs4901706 C14orf101 WCadjBMI M 14 56184138 g a 0.00526
rs1584406 PIK3C2G BMI W 12 18706971 g a 0.985
rs8016570 DAAM1 HEIGHT W 14 58735687 t c 0.984
rs1711049 LIPC HIPadjBMI M 15 56417105 a c 0.0292
rs1152691 CTBP2 WEIGHT W 10 126786489 a g 1
rs609682 CTNNA2 BMI M 2 80068331 c t 0.0281
rs16956840 GRIN2A WHRadjBMI M 16 10074935 c g 0.0351
rs9966047 SOCS6 HEIGHT M 18 66150259 t c 0.0216
rs7044106 MEGF9 WHR W 9 122533883 g c 1
rs17047143 ASXL2 HIPadjBMI W 2 25871393 g c 0.998
rs587271 SSBP3 WC W 1 54515699 t c 0.986
rs471953 RPS6KA2 HIPadjBMI M 6 167088819 c g 0.0276
rs13015620 VPS24 BMI W 2 86647379 a g 1
rs307945 PRKCG WCadjBMI W 19 59084638 c a 0.992
rs17573475 TMEM133 BMI M 11 100196037 a c 0.0319
rs2908871 CBLN1 WEIGHT W 16 47612862 g c 0.994
rs301571 C3orf31 HEIGHT M 3 11793619 t c 0.0424
rs754593 MAPT WC W 17 41410532 g a 1
rs9858200 CPNE4 BMI W 3 133068096 a g 0.998
rs10499028 MCHR2 WHRadjBMI M 6 100459334 a g 0.0414
rs4858223 SGOL1 WC M 3 20556153 c t 0.0242
rs3745329 MED26 HEIGHT W 19 16558499 c g 0.998
rs7824823 RBPMS HEIGHT M 8 30442277 g t 0.0394
rs1822913 CCDC6 WCadjBMI W 10 61265116 t c 0.947
rs2731707 SH3PXD2B WC W 5 171720982 t a 1
rs10765931 MICAL2 WCadjBMI W 11 12218676 a g 1
rs6868418 BTNL9 WCadjBMI M 5 180391419 c t 0.0192
rs238596 FRK WCadjBMI W 6 115523490 t a 0.967
rs552153 ZP4 HEIGHT W 1 236160995 a g 1
rs10214406 CDH10 BMI W 5 25507040 g t 1
rs2140345 ZBTB20 HEIGHT M 3 115954621 c a 0.0391
rs12511340 TAPT1 WHRadjBMI W 4 15963318 a g 1
rs591842 RNASEN WCadjBMI W 5 31429174 g c 0.998
rs1619442 PSAT1 BMI W 9 80538120 t c 1
rs4907948 OLFM3 WCadjBMI W 1 101870774 t c 1
rs6043409 SIRPG WHR W 20 1564206 a g 1
rs11247009 GALNT9 WHRadjBMI M 12 131267137 g a 0.0229
rs17017441 TRAF5 HIPadjBMI M 1 209619434 t c 0.00854
rs12001982 OR1J1 WHRadjBMI M 9 124288725 c t 0.0427
rs2856330 ETV6 HIP M 12 11834044 c t 0.0298
rs2155231 TNKS1BP1 HEIGHT W 11 56793824 g t 0.986
rs17078840 SACS HIPadjBMI M 13 22962119 a g 0.0429
rs992561 TMC3 WHR M 15 79726978 g c 0.0221
rs6117980 HAO1 HIPadjBMI W 20 7824255 g a 1
rs11079258 C17orf67 HEIGHT W 17 52213578 t c 0.977
rs6538017 KIAA0649 HIPadjBMI M 9 137372128 c t 0.0487
rs9380603 CPNE5 WHRadjBMI W 6 36891083 a g 1
rs3122712 FAM71A HIPadjBMI W 1 210865600 a g 1
rs29454 MYO10 WCadjBMI W 5 16966578 c t 0.992
rs7815606 SGCZ WCadjBMI W 8 14921659 t g 1
rs825804 PCDH15 BMI M 10 55107690 g a 0.0264
rs9388442 HEY2 WC W 6 126014307 c g 1
rs11675086 OTOF HEIGHT W 2 26584025 g c 1
rs4485744 ECT2 WC M 3 174014354 a g 0.0411
rs17152634 ZNF608 HIPadjBMI M 5 124680214 a g 0.0342
rs197422 KCND3 WC W 1 112119035 a c 1
rs11832440 ZNF26 WCadjBMI M 12 132075309 c t 0.0446
rs7778553 PLXNA4 WCadjBMI W 7 131526224 g a 1
rs2178895 NRIP1 HIP M 21 15255277 c t 0.0237
rs7308917 FAM19A2 BMI W 12 59468037 t c 1
rs6227 FURIN HEIGHT W 15 89226236 c t 1
rs7109584 GRIK4 WHR W 11 120159610 a g 1
rs4324883 PAG1 HIPadjBMI W 8 82203915 g t 1
rs2043375 SNTB1 WCadjBMI W 8 122165442 t c 1
rs10108822 ZNF703 WCadjBMI W 8 37372630 t c 0.897
rs4266263 COX7B2 WC M 4 46403132 a t 0.0187
rs12414594 C10orf137 HIP M 10 127358532 g a 0.05
rs1604913 ZC3HAV1L WHRadjBMI M 7 138342804 a c 0.00348
rs8138001 SMC1B WHR W 22 44164504 g a 1
rs6883068 PRR16 HIPadjBMI W 5 119823664 a t 1
rs10973665 SHB WHRadjBMI W 9 38093118 t c 1
rs198665 HIVEP2 WHRadjBMI M 6 143196579 c a 0.016
rs10886852 BRWD2 HIPadjBMI W 10 122858586 t c 1
rs10962418 BNC2 HIPadjBMI W 9 16387959 a c 1
rs7963923 NUAK1 WHR W 12 104782879 t c 1
rs12927290 FAM92B WCadjBMI W 16 83899214 c a 1
rs10060005 RANBP3L HEIGHT W 5 36372834 a c 1
rs11231808 SLC22A11 HIPadjBMI W 11 64058917 g a 1
rs13269815 DEFA5 WC M 8 6891039 g t 0.0419
rs2834928 RUNX1 WHRadjBMI W 21 35695290 t c 0.983
rs2382948 LMF1 WCadjBMI W 16 965984 a g 1
rs10418716 NFIX BMI M 19 13016405 c a 0.00817
rs13156223 PIK3R1 HEIGHT M 5 67561296 g c 0.0264
rs10925605 ZP4 BMI W 1 236513033 c a 1
rs841859 SLC2A1 HIPadjBMI M 1 43140462 t c 0.0255
rs11874286 BRUNOL4 WEIGHT M 18 34418247 g a 0.014
rs6442263 VGLL4 HEIGHT M 3 11610166 a g 0.0451
rs7502514 MED24 BMI W 17 35442370 g a 1
rs8058512 CPNE2 HIP W 16 55709297 t c 0.985
rs11038081 CD82 HIPadjBMI M 11 44597053 a g 0.044
rs6759822 STK39 HIP W 2 168715739 t c 1
rs7016498 TMEM55A WHR M 8 92119780 t g 0.0104
rs12438064 SQRDL BMI W 15 44310007 t c 0.984
rs12864716 KLHL1 HIPadjBMI W 13 68001874 t g 1
rs12244278 ADARB2 WC M 10 2348532 a g 0.0378
rs6813967 SMARCA5 HIP W 4 144632451 g a 1
rs11048689 ITPR2 WCadjBMI M 12 26848668 g a 0.0292
rs4794779 GPR179 WHRadjBMI M 17 33745974 c a 0.0469
rs952503 PCSK5 HIP W 9 78021235 a g 1
rs17476669 NRXN1 WC W 2 50579975 g a 0.998
rs7628649 ADIPOQ HIP M 3 188068075 c t 0.0017
rs6121796 CDH4 WHR W 20 59745782 t g 1
rs3739516 GCNT1 HEIGHT W 9 78279585 g c 1
rs4773844 ABCC4 HIP M 13 94653501 t c 0.0124
rs1487940 NCAM2 WC M 21 20525155 t c 0.0489
rs9564659 KLHL1 BMI W 13 69614425 t g 1
rs6992171 MSC WC W 8 72794644 t g 1
rs1273511 CYP4F22 WC M 19 15490819 c g 0.0131
rs4856389 GBE1 WHR M 3 82590686 a t 0.0174
rs11594014 ZNF503 BMI M 10 76958051 c t 0.035
rs1539330 HHEX HIP W 10 94492718 c t 1
rs17732997 MITF WEIGHT M 3 70553524 g c 0.0371
rs11591606 CUBN HIP W 10 16951121 t c 1
rs4899873 FLRT2 HIPadjBMI M 14 85111046 t c 0.046
rs26991 MCC WEIGHT M 5 112816439 t c 0.0139
rs7097930 CUGBP2 WCadjBMI M 10 10349551 c t 0.0353
rs17197261 OR10G3 HIPadjBMI W 14 21108002 c a 1
rs10739502 TLR4 WHR W 9 119576335 t g 1
rs9311099 ARPP-21 HIPadjBMI W 3 35540319 g c 1
rs40055 PIK3R1 WC M 5 67683590 c t 0.0277
rs338220 DLG1 HIP W 3 198513793 c t 0.87
rs7798199 THSD7A WC W 7 11820135 a g 0.998
rs4757844 NAV2 WHR M 11 19746096 a g 0.00373
rs1690278 GNS HIPadjBMI W 12 63419911 c g 0.99
rs10164112 STARD6 HIP W 18 50135378 t c 0.989
rs12471022 DPP10 BMI W 2 116028529 a t 1
rs3843558 GRHL2 BMI W 8 102570410 g a 0.955
rs2133165 TRAF6 WHR M 11 36508823 g a 0.0316
rs12592508 C15orf33 WHRadjBMI M 15 47460180 a t 0.0197
rs3948759 MYO18B BMI M 22 24664630 c a 0.0371
rs190488 NR3C1 WC W 5 142650501 g t 1
rs28819715 SPATA18 HIPadjBMI M 4 52888317 a g 0.0486
rs10795044 PITRM1 HIP M 10 3451722 t c 0.0139
rs35550489 ZNF516 WHRadjBMI W 18 72454377 g a 0.964
rs1119723 UQCRFS1 HIP M 19 33260354 g t 0.0432
rs650913 FAM5C BMI W 1 189030715 c t 1
rs10980410 SVEP1 WHR W 9 112296996 g c 1
rs17025323 C2orf29 WHRadjBMI W 2 101185491 g a 0.998
rs2975424 CSGALNACT1HIPadjBMI W 8 19538066 t c 1
rs1573163 SRC WHRadjBMI W 20 35503067 g a 1
rs11702396 ERG WHRadjBMI W 21 38670394 g a 1
rs1471896 NRG1 BMI M 8 32255927 c t 0.014
rs6737011 SLC8A1 HIP W 2 40504646 g a 1
rs1969391 PEG10 WHR W 7 94152060 g a 1
rs2777860 APBA1 WHR M 9 71218143 a g 0.0156
rs308071 OCM HIP W 7 5861701 g c 1
rs4681770 FLNB WC W 3 57938612 a g 1
rs17699284 CACNG1 HIP W 17 62470885 t a 1
rs9787488 OPTN HIP M 10 13140275 a c 0.0429
rs17757096 PIK3C3 BMI M 18 36684424 a g 0.0425
Effect_a
llele_a
dj
Oth
er_a
llele_a
dj
DIS
COVE
RY.M
EN.p
.fdr
DIS
COVE
RY.W
OM
EN.p
.fdr
DIS
COVE
RY.M
EN.G
CIn
.GCOut
.P.value
DIS
COVE
RY.W
OM
EN.G
CIn
.GCOut
.P.value
DIS
COVE
RY.M
ENvs
WOM
EN.G
CIn
.GCOut
.P.value
INSIL
ICO.M
EN.G
CIn
.GCOut
.P.value
INSIL
ICO.W
OM
EN.G
CIn
.GCOut
.P.value
INSIL
ICO.M
ENvs
WOM
EN.G
CIn
.GCOut
.Gon
calo.P
.value
1.52E-10 0.30867991 2.78E-15 6.49E-07 0.15508247 7.21E-12 0.00000179
3.81E-13 0.1911427 3.69E-18 1.25E-07 0.80633021 6.64E-13 0.00044131
4.75E-09 0.11028226 1.11E-13 0.0000302 0.78584456 0.00000106 0.00283601
0.00974 0.97364789 0.00000227 0.00062386 0.36683604 0.00047671 0.01041724
0.000165 0.19571125 1.63E-08 0.00184782 0.54450818 1.26E-08 0.02288285
0.031 0.3991657 0.0000102 0.00983839 0.27274732 0.0000741 0.00300473
0.000227 0.95498459 2.36E-08 0.0000646 0.20916727 0.00395297 0.69099279
0.994 0.0000124 0.2306 0.00868734 0.001129 0.3914 0.02160883
0.00974 0.1739 0.00000227 0.01302014 0.7059 0.0000289 0.00483513
0.0000253 0.5188 1.79E-09 0.0000733 0.9422 0.002429 0.08965711
0.0000127 0.17693704 8.29E-10 0.00061134 0.39239229 0.0000626 0.21414797
0.0000208 0.18423734 1.43E-09 0.00063593 0.23692252 0.00039651 0.44108713
0.00324 0.4407 5.76E-07 0.00202691 0.2741 0.0001623 0.16676384
0.00111 0.85660845 1.53E-07 0.00026867 0.61238584 0.0000121 0.00912195
0.00727 0.08819 0.00000158 0.02375235 0.2474 0.002682 0.39817861
3.95E-09 0.00044584 9.1E-14 0.00524682 0.00510594 4.04E-09 0.51327336
0.00582 0.07114 0.0000012 0.03127153 0.7639 0.003744 0.04001386
9.49E-14 8.67E-09 7.67E-19 0.03542639 NA NA NA
0.025 0.12860725 0.00000764 0.03534846 0.03239379 0.21511405 0.22437147
0.0000124 0.001282 8.1E-10 0.04795496 0.3529 0.005708 0.3481917
0.969 0.00000535 0.09721 0.01391551 0.0488 0.1155 0.44438558
0.00000203 0.83090702 9.93E-11 0.00000832 0.21299202 0.01982943 0.02064336
0.935 0.00000345 0.05054 0.03350554 0.06195 0.2967 0.35400983
0.0000514 0.002656 4.05E-09 0.03921479 0.4224 0.03513 0.53908885
0.000663 0.01467 8.23E-08 0.03832072 0.3308 0.03191 0.65177781
0.995 0.0000164 0.2419 0.01286659 NA NA NA
0.963 0.0000175 0.08469 0.02778823 0.01544 0.03493 0.38836605
0.00123 0.1036 1.76E-07 0.00962747 0.1175 0.003684 0.65795719
0.00391 0.07908 7.34E-07 0.02261876 0.03493 0.03989 0.60314488
0.000027 0.03958 1.92E-09 0.01309961 0.000763 0.00000105 0.93362252
0.026 0.09393 0.00000809 0.04363074 0.4634 0.04131 0.52378832
0.874 1.99E-08 0.02284 0.00528771 0.002808 0.01637 0.25738336
1.93E-07 0.0002744 6.61E-12 0.03015238 0.008714 0.0000342 0.76596
0.0000504 0.008045 3.96E-09 0.02180187 0.02218 0.0006219 0.87839628
0.892 0.0000067 0.02798 0.04511504 0.1081 0.01219 0.88916718
8.03E-13 3.87E-08 8.35E-18 0.04095402 0.0003124 3.59E-11 0.42340694
0.963 8.33E-07 0.08437 0.00714175 0.006469 0.01561 0.37745171
0.352 4.27E-09 0.0005748 0.02905203 0.0009725 0.0001121 0.73362704
0.00031 0.005863 3.39E-08 0.04848697 NA NA NA
1 0.0000176 0.4198 0.00369233 0.005605 0.0008745 0.6673758
0.00768 0.0711 0.00000169 0.03181031 0.2659 0.0000466 0.12950538
0.00562 0.2905 0.00000115 0.00477204 0.1943 0.01918 0.74943249
0.0338 0.1364 0.0000115 0.04640788 0.29992568 0.15713202 0.85271246
1 0.00000945 0.7266 0.00183039 0.0000595 0.01251344 0.02367566
0.944 0.00000227 0.05765 0.02959189 0.06915 0.5641 0.25145326
1.27E-08 0.0003684 3.17E-13 0.01153061 0.001357 0.00000939 0.98749257
0.495 2.14E-09 0.001395 0.01471234 0.4491 0.005569 0.28084428
0.0411 0.1982 0.000015 0.02718916 0.002347 0.02148 0.21219167
0.688 2.13E-08 0.004753 0.01779457 0.04394 0.01222 0.87152303
0.703 1.19E-07 0.005272 0.03165777 0.7773 0.032 0.28105055
0.0162 0.7933 0.00000434 0.00269164 0.06019336 0.00532308 0.83973416
0.886 6.85E-07 0.02623 0.02090791 0.02957 0.00533 0.87581757
0.97 0.00000911 0.0987 0.01752759 0.2192 0.001622 0.36013982
0.981 6.48E-07 0.1384 0.0035644 0.02199 0.06456 0.38457293
0.0237 0.51906449 0.00000714 0.00620333 0.91808272 0.11074271 0.36051359
0.0000219 0.006071 1.52E-09 0.02270726 0.04558 0.0000591 0.46423848
1 0.00000178 0.6687 0.00091789 0.32435543 0.15112359 0.88025347
0.000558 0.01619 6.74E-08 0.03660474 0.01084 0.05222 0.31258069
0.956 0.0000151 0.07308 0.03249514 0.1171 0.0009514 0.52527775
0.000652 0.01415007 8.08E-08 0.04316827 0.30779892 0.1532372 0.84551503
0.985 0.00000901 0.1579 0.0113441 0.03903 0.0001968 0.73752598
0.998 0.00000834 0.3213 0.00449784 0.3349 0.00815 0.43424172
0.00000584 0.009701 3.36E-10 0.00858616 0.001109 0.0004633 0.47576688
0.0000667 0.005479 5.54E-09 0.03386292 0.001236 0.1117 0.07050582
0.0172 0.963 0.00000473 0.00125609 0.03221467 0.0564272 0.33838081
0.0232 0.1872 0.00000696 0.02270726 0.07462 0.231 0.41454524
0.748 1.52E-07 0.007385 0.03752571 NA NA NA
0.964 0.00000218 0.0864 0.01067068 0.9177 0.009907 0.10092369
0.0216 0.3711 0.00000637 0.00749879 0.0817 0.05762 0.74019293
0.000709 0.01707206 8.92E-08 0.04078702 0.85543019 0.16895812 0.61169924
0.0000106 0.001401 6.73E-10 0.03848456 0.002865 0.1966 0.07246731
0.000552 0.01872 6.63E-08 0.02325387 0.08855 0.3384 0.36651289
1 0.0000198 0.715 0.00145898 0.966 0.0002947 0.02428262
0.0291 0.6055 0.00000934 0.00377566 0.000263 0.1703 0.0186275
0.00185 0.08014 2.89E-07 0.01286735 NA NA NA
0.969 0.00000285 0.09604 0.00000223 0.00716805 0.73479369 0.03268396
0.987 0.00000121 0.16959497 0.00000449 0.28192591 0.90416469 0.31720922
1 0.000016 0.44632189 0.00017318 0.0423773 0.63838847 0.04316052
1 0.00000286 0.4318 0.00306011 0.0135363 0.15469853 0.13091911
0.995 1.92E-07 0.2451 0.00521116 NA NA NA
1 0.00000627 0.6092 0.00178952 NA NA NA
0.04 0.74901263 0.0000145 0.00076384 0.87855262 0.00533112 0.11830859
0.0204 0.337 0.00000591 0.00008 0.59542601 0.00833893 0.37686644
1 4.49E-07 0.98695045 0.00561172 NA NA NA
1 4.97E-07 0.5799 0.00033031 NA NA NA
1 0.0000145 0.84750567 0.00276322 0.20946926 0.5697278 0.58772897
0.0103 0.442 0.00000243 0.00359596 0.2061 0.03773 0.84658207
0.98 0.00000179 0.1321 0.00948608 NA NA NA
0.0156 0.08406 0.00000413 0.04129957 0.1696 0.1329 0.03375902
0.00334 0.7429 5.99E-07 0.000021 NA NA NA
1 0.00000239 0.8019 0.00076102 0.07010246 0.0859881 0.48886323
0.00348 0.17039651 6.34E-07 0.00011649 NA NA NA
0.00106 0.04048 1.45E-07 0.02081416 NA NA NA
0.0482 0.98105231 0.0000189 0.0027294 0.68811419 0.00367939 0.07839031
0.00442 0.37044823 8.56E-07 0.00339469 NA NA NA
0.956 0.0000113 0.07255 0.02764836 0.03052 0.8053 0.08912017
1 8.71E-07 0.6666 0.00214342 NA NA NA
1 0.00000186 0.5579 0.00144408 0.20350777 0.86779462 0.4428864
0.866 0.00000168 0.02113 0.04540018 NA NA NA
1 0.0000106 0.6155 0.00020878 0.03163334 0.73303249 0.08513414
0.0054 0.03879 0.0000011 0.04540668 0.3709 0.1049 0.82435997
0.966 0.00000896 0.08943 0.01878423 0.4235 0.01122 0.41859579
1 5.42E-07 0.72983972 0.0000665 0.57101345 0.52857073 0.86625871
1 0.00000125 0.87758031 0.00042247 NA NA NA
0.00462 0.3362 9.03E-07 0.00734774 0.83412984 0.2331404 0.44539508
0.031 0.1764 0.0000102 0.0229805 0.2401 0.0359 0.73782688
1 0.00000244 0.44759807 0.00290786 0.71163979 0.36889196 0.43865909
1 0.00000174 0.6096 0.0000354 NA NA NA
0.99 0.0000103 0.1912 0.00803615 0.0545 0.4831 0.21549832
1 0.00000778 0.7879 0.00130275 0.07296259 0.93166297 0.10380361
1 0.00000511 0.3545 0.00273789 0.09934 0.16 0.58221612
1 2.13E-07 0.78880386 0.0000736 NA NA NA
1 0.0000021 0.3834 0.0021036 NA NA NA
0.998 0.00000211 0.3198 0.00418694 NA NA NA
1 0.00000418 0.64329416 0.00014935 0.23145863 0.45191518 0.48074696
0.0157 0.8309 0.00000419 0.00068619 0.4873169 0.25661788 0.77614765
0.998 0.0000197 0.2922 0.01359485 0.03077192 0.54102989 0.11622392
0.986 1.64E-07 0.1631 0.00141649 0.2226 0.7709 0.38427904
0.0119 0.2347 0.00000294 0.01337275 NA NA NA
0.0486 0.98840446 0.0000192 0.00208866 0.45016959 0.03398527 0.07995433
0.998 0.00000319 0.3183 0.00649373 NA NA NA
1 0.000019 0.8899 0.00072351 0.03007056 0.67692059 0.03680606
0.0247 0.4594 0.00000752 0.00477385 NA NA NA
0.995 0.0000167 0.2511 0.00960535 0.07661 0.4073 0.31223494
0.935 0.00000355 0.05026 0.033133 NA NA NA
0.0153 0.65618199 0.00000406 0.0000873 NA NA NA
0.0399 0.6707 0.0000145 0.00332685 0.2925 0.115 0.91661902
0.0489 0.4404 0.0000193 0.01110471 0.8187 0.03962 0.30172626
0.967 0.00000307 0.09357426 0.0000043 0.45275723 0.96279194 0.52219744
0.966 0.0000186 0.08937291 0.000011 0.10270631 0.84516637 0.12266519
0.0269 0.57002668 0.00000847 0.00030662 0.31060035 0.08439924 0.07850716
0.0192 0.7369 0.00000546 0.00019745 NA NA NA
0.0198 0.9839 0.00000566 0.00089608 NA NA NA
0.0197 0.6965 0.00000562 0.00038169 NA NA NA
1 0.0000154 0.82959108 0.00091188 0.15093344 0.5847644 0.31231056
0.978 4.12E-07 0.1248 0.00000077 0.8720489 0.30675063 0.50508195
1 0.0000112 0.6248121 0.00342224 0.251041 0.45429919 0.5337834
0.0246 0.4056 0.00000748 0.00773719 0.3819 0.2354 0.98761927
0.0195 0.8768 0.00000555 0.00046892 NA NA NA
1 0.0000188 0.93050717 0.00123063 0.14810145 0.57146889 0.32803856
0.988 0.00000683 0.1753 0.01279383 NA NA NA
1 0.0000161 0.5654 0.00032743 0.11525202 0.27793052 0.05144125
1 0.0000146 0.85218296 0.00079892 0.24344442 0.77152451 0.23982845
0.962 0.00000593 0.08178 0.02560341 0.00327 0.4207 0.06822051
0.0273 0.43655687 0.00000858 0.00019172 0.05630796 0.14632907 0.01593623
0.0258 0.40737867 0.00000799 0.00077067 NA NA NA
0.0262 0.81572724 0.00000815 0.00065637 NA NA NA
1 0.00000846 0.8468 0.00281075 NA NA NA
0.998 0.00000856 0.2959 0.00955962 NA NA NA
1 0.00000769 0.4269 0.00363493 NA NA NA
1 0.00000936 0.5707 0.00388558 NA NA NA
1 0.00000946 0.8018 0.0000594 NA NA NA
0.995 0.00000774 0.2445 0.00670189 0.2959 0.09635 0.90859924
0.0301 0.5915 0.00000979 0.0029304 NA NA NA
0.00346 0.9553 6.29E-07 0.00022536 0.03682 0.0716 0.50259972
0.988 0.00000963 0.1776 0.01578824 NA NA NA
1 0.0000143 0.85900122 0.00252759 0.28687589 0.66924602 0.46246109
1 0.00000974 0.4848 0.00746448 0.02966 0.7707 0.23569389
0.033 0.5874 0.0000111 0.0000502 NA NA NA
1 0.0000126 0.5856 0.00013061 NA NA NA
0.0333 0.4025 0.0000112 0.00771888 NA NA NA
0.000794 0.02676 1.02E-07 0.03100988 0.83246553 0.21903511 0.43058326
1 0.0000126 0.48976823 0.0000855 NA NA NA
0.036 0.4959 0.0000125 0.01609467 NA NA NA
0.996 0.0000127 0.2647 0.00737732 NA NA NA
0.000427 0.7369 4.93E-08 0.00030208 0.95375647 0.59959331 0.83550825
0.0369 0.37046352 0.000013 0.000064 NA NA NA
1 6.09E-07 0.645 0.0000533 0.23495513 0.17955211 0.08595061
0.0129 0.37759207 0.00000326 0.00687019 0.57044601 0.34530284 0.96868933
1 0.0000116 0.4348 0.00483043 NA NA NA
0.0384 0.44345216 0.0000137 0.00113356 NA NA NA
1 0.00000156 0.402 0.0000292 0.70127541 0.07464912 0.51826243
1 0.0000138 0.4672 0.01487669 NA NA NA
0.0393 0.99186876 0.0000141 0.00017819 NA NA NA
0.939 0.00000606 0.05392 0.04113499 0.3393 0.1137 0.88820091
1 0.0000149 0.383 0.00678662 NA NA NA
1 0.0000149 0.4685 0.0000779 NA NA NA
0.0425 0.81072353 0.0000158 0.00354978 0.69735143 0.26613482 0.83124004
0.983 0.0000013 0.1464 0.00000305 0.86112035 0.4619527 0.85362909
0.997 0.00000388 0.2782 0.0000193 0.56546391 0.19873472 0.86369366
0.97 0.0000161 0.09952209 0.02137373 NA NA NA
0.0433 0.722 0.0000163 0.0000985 NA NA NA
1 0.0000174 0.4552 0.01132842 NA NA NA
0.00496 0.16549209 0.00000099 0.01121338 0.27765849 0.95639354 0.32908585
0.0401 0.423 0.0000146 0.01266771 0.09987972 0.09705121 0.57950699
0.968 0.0000185 0.09474 0.03442136 NA NA NA
0.0479 0.98998735 0.0000188 0.00280479 NA NA NA
0.971 0.0000142 0.1028 0.03399151 0.2879 0.5567 0.58889561
1 0.0000181 0.8424 0.00066175 0.25047674 0.30493853 0.62726893
1 0.0000199 0.4155 0.0076633 0.22409538 0.08914097 0.04501353
0.985 0.0000191 0.1549 0.04560822 NA NA NA
1 0.0000161 0.5023 0.00531277 0.34813257 0.29662798 0.17483793
1 0.0000198 0.9287 0.00106386 NA NA NA
1 0.0000199 0.8084 0.00566679 NA NA NA
1 0.00000758 0.4094 0.00486459 0.48316889 0.23337792 0.21900521
0.0109 0.3306 0.00000261 0.000072 0.83250295 0.33210263 0.4913328
0.886 0.0000147 0.02613 0.00000159 0.30744445 0.98675578 0.37932186
0.998 6.42E-07 0.3044 0.00222446 0.43239897 0.18213465 0.9926539
1 0.00000106 0.94614025 0.00049172 0.55540774 0.1264985 0.65430704
0.00686 0.156 0.00000147 0.00021545 0.5252 0.02309 0.32395517
0.00189 0.1524 2.97E-07 0.00659691 0.7184 0.4536 0.43782077
1 0.00000938 0.9644 0.0009034 0.48162179 0.60890183 0.37612117
0.00506 0.6175 0.00000102 0.0008507 NA NA NA
1 0.00000896 0.8915 0.00039373 0.2208 0.08673 0.95910805
1 0.0000121 0.67729913 0.00423773 0.60445117 0.76473252 0.54502373
1 0.00000638 0.5754 0.0012899 0.6727 0.6513 0.91672986
0.0155 0.3872 0.0000041 0.00011618 0.67798352 0.34195725 0.91574572
0.00294 0.334 5.11E-07 0.00468162 0.69820988 0.52513265 0.51198064
0.0257 0.1588 0.00000796 0.03445927 0.41768253 0.97081177 0.48145228
0.993 0.00000876 0.2262 0.0000228 0.51429448 0.86499503 0.63562833
0.0213 0.955 0.00000623 0.00019962 0.0479 0.7577 0.08588347
0.0355 0.20773012 0.0000123 0.000051 0.68766007 0.17095184 0.77648348
1 0.0000106 0.6812 0.00183623 0.4577 0.5924 0.34783856
0.0331 0.2343 0.0000112 0.01687853 NA NA NA
0.998 0.0000158 0.2934 0.00840365 0.4903 0.8496 0.4843404
0.0157 0.9902 0.00000417 0.00097181 0.20047615 0.35381937 0.10911433
0.0065 0.3079 0.00000137 0.0052819 0.5142 0.03188 0.06729165
0.948 0.0000152 0.06210732 0.00000737 0.59185271 0.59732344 0.84011572
0.993 0.00000733 0.2205 0.01172845 0.80794076 0.12370094 0.56514923
0.0301 0.3241 0.00000983 0.01176449 0.003928 0.419 0.04585495
0.976 0.0000143 0.1176 0.0195934 0.6663 0.01608 0.26299753
0.0212 0.06076835 0.00000621 0.00000357 0.18021299 0.91674298 0.21907256
0.0435 0.9766 0.0000163 0.00198406 0.15963653 0.27916186 0.0737299
0.0449 0.91967823 0.0000171 0.00141758 0.48694847 0.08954909 0.77557228
1 0.00000548 0.85080375 0.00052708 0.36135514 0.29261925 0.18000918
0.05 0.09162991 0.0000199 0.03348494 0.80453623 0.86014117 0.95834594
0.00409 0.6499 7.77E-07 0.00098606 0.7326 0.9297 0.72757183
0.0402 0.764 0.0000146 0.00272636 0.3716 0.34 0.18827234
0.955 0.0000141 0.07024 0.03165146 0.7617 0.04707 0.35205922
0.0231 0.38995766 0.00000692 0.00010836 0.12010387 0.52874107 0.09377679
0.0216 0.3311229 0.00000635 0.01045565 0.86112423 0.3573183 0.75550511
0.00397 0.5734 7.47E-07 0.00128127 0.4844 0.9734 0.54638887
0.0288 0.7050198 0.00000927 0.00382646 0.12670128 0.96821586 0.16823322
0.0029 0.5513 5.02E-07 0.00239442 0.58583064 0.32165846 0.32841705
1 0.00000683 0.39530372 0.0000867 0.99268215 0.35879977 0.63517877
1 0.00000192 0.7067 0.00010586 0.33227424 0.9607936 0.46876144
0.986 0.0000159 0.16346821 0.0000302 0.87331001 0.88048808 0.82909469
0.996 0.00000966 0.2599 0.00739088 0.41984492 0.66144791 0.37078017
0.035 0.1599 0.000012 0.03080046 0.4356 0.508 0.78388386
1 0.000016 0.407 0.00724254 0.85105935 0.57425052 0.89775248
1 0.00000653 0.9463 0.00061773 0.83880302 0.15934214 0.3663926
0.05 0.7725 0.00002 0.00486265 0.16275755 0.26699334 0.47816048
0.00841 0.1221 0.00000189 0.02132104 0.001115 0.9751 0.00459047
1 0.0000192 0.7576 0.00246355 0.83645204 0.29312359 0.71581599
0.0212 0.84559098 0.0000062 0.00190352 0.23280293 0.62410997 0.19547154
0.0315 0.957 0.0000104 0.0016155 0.35559492 0.43637409 0.22997455
0.021 0.20604285 0.00000612 0.01936601 0.33445732 0.40444041 0.66199504
0.0229 0.4684821 0.00000685 0.00013306 0.54052912 0.70101649 0.46683305
1 0.00000823 0.6268 0.00017189 0.8809 0.6303 0.86532455
0.016 0.8032 0.00000429 0.00180331 0.38841842 0.47836747 0.25951983
0.034 0.8093 0.0000116 0.00042386 0.4453 0.7493 0.39581525
1 0.0000151 0.6085 0.00025294 0.72929749 0.4964457 0.5214852
1 0.0000117 0.5552 0.00018042 0.84452239 0.76803485 0.7434591
0.00566 0.8338 0.00000116 0.00092664 0.14661421 0.08283102 0.72381414
1 0.000017 0.7796399 0.00288572 0.36623212 0.9017808 0.39398404
0.0264 0.87764158 0.00000824 0.00091375 0.25956831 0.28980714 0.12963459
1 0.00000713 0.6115 0.00206366 0.61336169 0.22260283 0.84791967
0.0348 0.8813 0.0000119 0.00074349 0.3033 0.581 0.5976999
0.0488 0.6273 0.0000193 0.00632956 0.1487 0.3083 0.53975736
0.00558 0.6921 0.00000114 0.00027952 0.46638391 0.70591866 0.66225453
0.0139 0.4303 0.00000358 0.00727493 0.71724823 0.78934477 0.64957281
0.0318 0.5230524 0.0000106 0.00681483 0.32028778 0.80648096 0.4394687
0.00525 0.0296918 0.00000106 0.04808587 0.03275059 0.47864926 0.026094
0.986 0.00000526 0.1608 0.01475858 0.5321048 0.6717242 0.75309995
1 0.00002 0.9149 0.0009006 0.9344369 0.26329416 0.5039176
1 6.32E-07 0.42000185 0.00215134 0.37194428 0.16106394 0.1340565
0.049 0.5272 0.0000194 0.00058171 0.25449749 0.53108018 0.18899402
0.0144 0.3816 0.00000374 0.0000753 0.75896354 0.79913748 0.68766384
0.035 0.60619887 0.000012 0.00043092 0.7628808 0.82592593 0.88478652
0.98 0.00000426 0.13176231 0.02368676 0.10443477 0.93188179 0.14604614
0.0107 0.8888 0.00000256 0.00130409 0.52597185 0.88525074 0.52613593
0.0152 0.7695 0.00000401 0.0022001 0.01230862 0.47733409 0.0739116
0.00617 0.7524 0.00000129 0.00029124 0.28641619 0.8297756 0.41283994
0.0255 0.59171185 0.00000788 0.00935456 0.64544089 0.1121689 0.1440839
0.0235 0.3635 0.00000707 0.0000388 0.5389 0.9112 0.64292997
0.0457 0.6626 0.0000175 0.0069549 0.35309098 0.59840892 0.2749497
1 0.0000155 0.3465 0.00913258 0.62646241 0.73550244 0.80677603
0.0276 0.14601688 0.0000087 0.03278898 0.23330538 0.40613204 0.52839608
0.00934 0.61890137 0.00000215 0.00016436 0.52233774 0.73623573 0.46375858
1 0.00000182 0.5852 0.0000431 0.256 0.6919 0.23884927
1 0.00000826 0.4769 0.00216807 0.4905 0.2907 0.2127854
0.0281 0.7842 0.00000899 0.00215049 0.3183 0.8954 0.45209411
1 0.00000789 0.6872 0.00023033 0.29992568 0.1160975 0.88384609
0.963 0.00000361 0.08476 0.02171839 NA NA NA
0.955 0.0000172 0.07135 0.03415196 0.5279 0.047 0.07543029
0.0252 0.9531 0.00000776 0.00113004 0.4303 0.9585 0.49157334
0.0457 0.1554 0.0000175 0.0000368 0.2654684 0.38154033 0.15271263
1 0.0000167 0.6206 0.0009983 0.95548201 0.42744134 0.65894697
0.0425 0.3695 0.0000158 0.01448942 0.88413072 0.62290532 0.79997667
0.958 0.00000248 0.07533 0.00000179 0.10491001 0.407263 0.06607856
0.0434 0.1521 0.0000163 0.0343664 0.6098 0.7832 0.8012272
0.05 0.8819 0.00002 0.0017061 0.29191221 0.73162788 0.45046791
1 0.0000135 0.4266 0.0062522 0.35561825 0.87590216 0.38265394
0.0456 0.4954 0.0000175 0.00038352 0.26897425 0.88584704 0.38560364
1 0.0000094 0.80752109 0.00056697 0.59210857 0.7918982 0.74250671
0.998 0.0000182 0.31105013 0.0173645 0.56714359 0.20946245 0.86023482
0.0267 0.9093 0.00000838 0.00200437 0.92167431 0.81587046 0.97061905
0.0429 0.3384 0.000016 0.01753955 0.52675632 0.97676665 0.57039199
1 2.61E-07 0.367 0.00105579 0.98230553 0.68837999 0.83356467
0.022 0.8238 0.00000649 0.00298144 0.51915826 0.84140889 0.50712408
0.0307 0.6347 0.0000101 0.00020218 0.7767 0.6799 0.99456028
1 0.00000309 0.8926 0.00031549 0.11694279 0.65224058 0.10582666
1 0.0000193 0.5491 0.00022545 0.24222419 0.31806305 0.60495033
0.0468 0.9286 0.0000181 0.00180474 0.5552 0.9601 0.64425824
0.0481 0.8441 0.0000188 0.00337435 0.90817674 0.99199528 0.91592656
1 0.00000332 0.3935 0.00198691 0.69043624 0.50098719 0.96724654
1 0.00000478 0.7023 0.0002091 0.33791809 0.25562232 0.15705751
1 0.000012 0.4607 0.00361803 0.4169 0.1551 0.86731392
0.0181 0.5391 0.00000505 0.00702191 0.10347736 0.99370701 0.14817844
0.997 0.0000131 0.2726 0.01003958 NA NA NA
0.023 0.5145 0.00000691 0.01243969 0.72589996 0.95069963 0.7991522
1 0.0000177 0.6733 0.00307923 0.24960143 0.61008369 0.44120525
0.992 0.00000356 0.208 0.00831628 NA NA NA
1 0.0000122 0.7831795 0.00082875 0.15390555 0.76144955 0.25078615
0.0307 0.8677 0.0000101 0.00245769 0.56981431 0.87381284 0.66176095
0.0414 0.55 0.0000152 0.00058081 0.58365843 0.79617364 0.72032714
0.049 0.6753 0.0000194 0.0008652 0.1319156 0.91073293 0.16598551
1 0.0000088 0.5906 0.00267758 0.03064415 0.72492865 0.08102978
0.00883 0.02183 0.00000201 0.00359487 0.62535146 0.33871125 0.75822512
0.0218 0.288 0.00000643 0.01460122 0.56803628 0.20980717 0.86437361
0.975 0.00000069 0.1156 0.00946089 0.79280591 0.51537291 0.55111222
0.0393 0.1935 0.0000142 0.03537073 0.4679187 0.58752225 0.35798381
0.0343 0.1798 0.0000117 0.04438361 0.11083354 0.76747639 0.21032219
0.0209 0.4136 0.0000061 0.00597486 0.0891 0.8927 0.15768863
0.0149 0.07007 0.00000391 9.37E-07 0.6618 0.781 0.87682057
1 0.0000105 0.414 0.0000931 0.03498769 0.56778656 0.12620823
1 0.00000564 0.45023348 0.00012086 0.60405441 0.26704071 0.30368796
0.968 0.0000131 0.09484 0.0320205 0.4613 0.6216 0.73100558
0.0122 0.7433 0.00000305 0.00178454 0.61025777 0.89973281 0.70261061
1 0.0000192 0.602 0.00064612 0.91499161 0.66497396 0.83832879
0.996 0.00000357 0.2602 0.0074923 0.31848883 0.35012391 0.66310918
0.0325 0.08666087 0.0000109 0.03859977 0.83749839 0.31904369 0.544859
1 0.0000162 0.6499 0.00351966 0.06981899 0.37683437 0.04019326
0.0318 0.4496 0.0000106 0.00723788 0.8003 0.6396 0.94420326
0.0429 0.8925 0.000016 0.00431052 0.64190537 0.33176111 0.91536713
0.0459 0.33611974 0.0000177 0.01820714 0.95718023 0.80770014 0.86335727
0.0323 0.4571 0.0000108 0.01051447 0.49618892 0.19711087 0.20300571
0.0279 0.69991378 0.00000889 0.00069014 0.54679204 0.10508167 0.69947274
0.0118 0.45218286 0.0000029 0.00452732 0.9575758 0.16898293 0.44773523
0.772 0.00000362 0.008933 6.69E-08 0.2607 0.872 0.56488632
0.0284 0.6497 0.00000907 0.00483895 0.21055134 0.14897504 0.72804507
0.0286 0.6887 0.00000917 0.00062697 0.04218611 0.07714388 0.38676158
0.913 0.00000413 0.03605 0.04972822 0.42812386 0.40119869 0.77744391
0.0333 0.9062 0.0000113 0.00151332 0.73898785 0.2304398 0.3708006
0.0267 0.3979 0.00000837 0.00012028 0.99104467 0.52081909 0.73258576
0.0465 0.4756 0.000018 0.00037477 0.05502983 0.13989756 0.01416952
1 0.000016 0.8612 0.00068645 0.02104451 0.43397477 0.09993495
1 0.0000158 0.5088 0.00435544 0.4699 0.1108 0.75232647
INSIL
ICO.M
EN.G
CIn
.GCOut
.P.value
INSIL
ICO.W
OM
EN.G
CIn
.GCOut
.P.value
INSIL
ICO.M
ENvs
WOM
EN.G
CIn
.GCOut
.Gon
calo.P
.value
META
BOCHIP
.MEN
.GCIn
.GCOut
.P.value
META
BOCHIP
.WOM
EN.G
CIn
.GCOut
.P.value
META
BOCHIP
.MEN
vsW
OM
EN.G
CIn
.GCOut
.Gon
calo.P
.value
REP2W
AY.M
EN.P
.value
.1side
d
REP2W
AY.W
OM
EN.P
.value
.1side
d
REP2W
AY.M
ENvs
WOM
EN.P
.value
.1side
d.xls
REP2W
AY.s
2.M
ENvs
WOM
EN.P
.value
.1side
d.xls.fd
r
0.2124 0.0000115 0.0000181 0.96477 3.635E-16 1.075E-11 7.992E-10
0.8093 5.53E-09 0.00000213 0.5318 9.15E-21 2.6E-10 9.62E-09
0.1214 7.24E-15 3.45E-07 0.11175 1.375E-19 4.53E-08 1.1174E-06
0.5558107 0.00085014 0.00279455 0.17165 7.15E-07 5.3519E-05 0.00098975
0.01107 1.41E-09 0.0024602 0.00608 8.55E-17 0.00021383 0.003108
NA NA NA 0.86405 0.00003805 0.00167193 0.02059667
0.5593 0.00000814 0.00198011 0.1317 1.48E-07 0.00421828 0.04461143
NA NA NA 0.00057 0.1949 0.01519662 0.1406
0.15630763 0.19975898 0.9842054 0.1639 0.0000583 0.03004602 0.2470778
0.23163642 0.026277 0.36694012 0.149 0.0000967 0.04283941 0.2764517
0.07721 0.0071 0.35400985 0.02457 0.0000009 0.04425491 0.2764517
0.1232 0.001552 0.14777339 0.02748 9.95E-07 0.04482559 0.2764517
0.2187 0.0322 0.3995639 0.0506 0.00001125 0.0511934 0.2913892
0.01758 0.0684 0.86154293 0.036425 0.00000303 0.05674907 0.2958694
0.1645 0.002418 0.1479274 0.03602 0.00000995 0.06444596 0.2958694
0.00000376 2.9E-09 0.11221763 2.97E-08 3.445E-17 0.06462694 0.2958694
0.2375 0.1688 0.80473318 0.2209 0.0010095 0.06797112 0.2958694
2.64E-07 3.81E-10 0.17743252 1.32E-07 1.905E-10 0.1074145 0.406815
0.7772 0.0001207 0.00489603 0.08685 0.00030645 0.1092297 0.406815
0.01461 0.0001207 0.19114738 0.006055 1.925E-06 0.10994811 0.406815
0.003022 0.05034 0.43480527 0.0002178 0.007155 0.12408227 0.4223045
0.03345 0.06268 0.98530385 0.13545 0.0014345 0.12554768 0.4223045
0.01924824 0.07684279 0.75628597 0.0013795 0.02506 0.18022212 0.5565108
0.0946895 0.0059232 0.36755527 0.034655 0.00031645 0.18048974 0.5565108
0.04351 0.001314 0.25791389 0.013345 0.00008815 0.19181437 0.5677576
0.00097884 0.06786835 0.36074132 0.00048942 0.03393417 0.20030553 0.5699919
NA NA NA 0.00765 0.01733 0.20796604 0.5699919
0.03891 0.007868 0.50461944 0.0048215 0.00004065 0.23024847 0.6085179
0.07949 0.000704 0.14456937 0.004272 0.00005835 0.23987203 0.6120821
0.0000886 0.00000513 0.4308085 1.285E-07 1.065E-11 0.2610212 0.6392906
0.07342 0.02766 0.65166031 0.030735 0.00142 0.27300298 0.6392906
0.01216 0.02137 1 0.00008035 0.000455 0.27644615 0.6392906
0.000539 0.0002725 0.67626648 0.00000745 1.765E-08 0.31124528 0.6666367
0.1361 0.1392 0.91787413 0.00528 0.0001976 0.31750227 0.6666367
0.03645 0.4949 0.31586183 0.004234 0.010155 0.34505466 0.6666367
1.89E-11 1.34E-09 0.9775653 1.845E-14 1.4E-19 0.36310319 0.6666367
0.00429 0.002574 0.72871822 0.0000477 0.00006925 0.36627004 0.6666367
0.001375 0.01196 0.66773344 0.00000276 2.565E-06 0.36700673 0.6666367
0.01233581 0.00739718 0.71395497 0.0061679 0.00369859 0.36801059 0.6666367
0.02748 0.2135 0.52121142 0.0003614 0.000509 0.371613 0.6666367
0.003037 0.225 0.22139223 0.0011045 0.00006105 0.38018602 0.6666367
NA NA NA 0.09725 0.009595 0.38173236 0.6666367
0.2298 0.06668 0.53375446 0.05845 0.01155 0.38736574 0.6666367
0.9071 0.7601 0.87606728 0.021415 0.022525 0.41839136 0.7036559
0.364 0.02392 0.21192141 0.031795 0.030635 0.47687433 0.7841862
0.0000146 0.0001151 0.947683 3.725E-08 2.175E-09 0.51363114 0.8262743
0.000484 0.01524 0.52685161 0.000656 0.00011845 0.53016144 0.8262785
0.1785 0.04843 0.53821831 0.002078 0.001197 0.53924075 0.8262785
0.001466 0.0002144 0.50588035 0.00008755 0.00000745 0.56102709 0.8262785
0.007876 0.09916 0.57936309 0.0155 0.0035675 0.56467947 0.8262785
NA NA NA 0.030095 0.0026615 0.57844854 0.8262785
0.03812 0.02388 0.74879934 0.0015055 0.0001615 0.59025732 0.8262785
0.08632 0.6241 0.37809203 0.017615 0.0035995 0.59761499 0.8262785
0.358 0.01524 0.21361641 0.01478 0.001555 0.6029639 0.8262785
0.01109538 0.2090903 0.3996794 0.014355 0.021845 0.62352088 0.8389178
0.000016 0.01538 0.22326473 0.00000165 0.00000197 0.64096096 0.8469829
0.318 0.05762 0.42983195 0.08965 0.00944 0.70486308 0.9081914
0.003469 0.002553 0.77518044 0.00005405 0.000284 0.71600022 0.9081914
NA NA NA 0.0589 0.0004677 0.72537078 0.9081914
0.01399 0.1658 0.57365923 0.0041275 0.02402 0.74860104 0.9081914
0.001285 0.0001439 0.4910456 0.00006735 5.15E-08 0.75291001 0.9081914
NA NA NA 0.16745 0.0040775 0.76941214 0.9081914
0.0000352 0.003785 0.45609168 8.8E-08 0.00000363 0.77319075 0.9081914
0.004779 0.001481 0.60734154 0.00001505 0.0004522 0.80194682 0.9233785
NA NA NA 0.016075 0.02807 0.82734436 0.9233785
0.002065 0.01873 0.70037825 0.0001848 0.0066 0.83402982 0.9233785
0.07412414 0.00357107 0.28047246 0.03706207 0.00178554 0.83955951 0.9233785
0.1104 0.1234 0.95272506 0.1068 0.0015415 0.8485073 0.9233785
0.005702 0.7308 0.07270486 0.000553 0.049585 0.90519133 0.9707835
0.0000915 0.2323313 0.06670824 0.0001824 0.03511 0.93351666 0.9852792
0.001323 0.03767 0.48718547 0.00000685 0.0095 0.95044846 0.9852792
0.0003088 0.08395 0.19607635 0.00004735 0.033625 0.958645 0.9852792
NA NA NA 0.48295 0.00013655 0.98304388 0.98672
NA NA NA 0.00012725 0.08605 0.98671818 0.98672
0.56342806 0.03068872 0.16158679 NA NA 0.09878725 NA
NA NA NA NA NA 0.01730579 NA
0.02768227 0.1349612 0.00675711 NA NA 0.00472357 NA
0.01064629 0.6114471 0.1543683 NA NA 0.00929407 NA
NA NA NA NA NA 0.07001945 NA
NA NA NA NA NA NA NA
0.00788459 0.92760142 0.06143379 NA NA 0.04272724 NA
NA NA NA NA NA 0.06126316 NA
NA NA NA NA NA 0.19367168 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
0.009858 0.705 0.04389348 NA NA 0.02460968 NA
NA NA NA NA NA 0.42768059 NA
0.03691092 0.51574293 0.32689974 NA NA 0.18361215 NA
0.2385 0.04999 0.45487126 NA NA 0.05997088 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.24925095 NA
NA NA NA NA NA NA NA
0.06587049 0.17242799 0.80994702 NA NA 0.58751459 NA
0.9386 0.4366 0.57646917 NA NA 0.02997025 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.05468546 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.22591502 NA
0.06042073 0.19509673 0.75877794 NA NA 0.3888064 NA
NA NA NA NA NA 0.04615786 NA
NA NA NA NA NA 0.41717275 NA
0.01895 0.009088 0.0000939 NA NA 0.04099027 NA
0.06525956 0.4161306 0.05335091 NA NA 0.04718891 NA
NA NA NA NA NA NA NA
0.3696 0.05379 0.36481082 NA NA 0.18075298 NA
NA NA NA NA NA 0.37634083 NA
0.08527882 0.1060175 0.978609 NA NA 0.17525895 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.12155212 NA
NA NA NA NA NA 0.05475377 NA
NA NA NA NA NA 0.30212957 NA
0.514167 0.04808771 0.04358186 NA NA 0.97300316 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.24351516 NA
NA NA NA NA NA 0.3909196 NA
NA NA NA NA NA 0.06196657 NA
0.5533 0.2381 0.59747008 NA NA 0.41432209 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.0417689 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.02023093 NA
0.28770089 0.08671118 0.52292164 NA NA 0.27837654 NA
NA NA NA NA NA 0.17057762 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
0.2851 0.1541 0.71055113 NA NA 0.35103621 NA
NA NA NA NA NA 0.15685219 NA
NA NA NA NA NA 0.26342475 NA
NA NA NA NA NA 0.06413051 NA
NA NA NA NA NA 0.0408179 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.15852165 NA
NA NA NA NA NA 0.25582152 NA
NA NA NA NA NA 0.26997072 NA
0.2014 0.1423 0.80019638 NA NA 0.45465211 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.1668483 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.02833247 NA
NA NA NA NA NA 0.12315229 NA
0.50890818 0.91837838 0.68212579 NA NA 0.12499341 NA
NA NA NA NA NA 0.0086825 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.54308227 NA
NA NA NA NA NA NA NA
0.50786335 0.80303697 0.7762834 NA NA 0.60369083 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.23330593 NA
NA NA NA NA NA 0.12389571 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
0.6354 0.6869 0.9829256 NA NA 0.30233239 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.41968964 NA
NA NA NA NA NA NA NA
0.02418 0.2865 0.498919 NA NA 0.51454894 NA
0.0665735 0.5524905 0.4013726 NA NA 0.76549915 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.73643393 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.55454352 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.41683178 NA
NA NA NA NA NA 0.57208911 NA
NA NA NA NA NA 0.56698619 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
0.6134 0.06574 0.27065025 NA NA 0.18126981 NA
NA NA NA NA NA 0.70591153 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.29900724 NA
NA NA NA NA NA 0.3176729 NA
NA NA NA NA NA 0.02451807 NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.09117366 NA
NA NA NA NA NA NA NA
NA NA NA NA NA NA NA
NA NA NA NA NA 0.11455664 NA
NA NA NA NA NA 0.24790589 NA
NA NA NA NA NA 0.19187347 NA
0.1507 0.9395 0.33194597 NA NA 0.27964835 NA
NA NA NA NA NA 0.3295431 NA
NA NA NA NA NA 0.16820361 NA
0.1328 0.7936 0.36321297 NA NA 0.59894436 NA
NA NA NA NA NA 0.19330851 NA
0.72802542 0.58101804 0.83944068 NA NA 0.4260727 NA
0.22980198 0.71984338 0.2399936 NA NA 0.27689755 NA
NA NA NA NA NA 0.2745691 NA
NA NA NA NA NA 0.46071569 NA
NA NA NA NA NA 0.45828143 NA
NA NA NA NA NA 0.26061343 NA
0.6422 0.02426 0.14563798 NA NA 0.122056 NA
NA NA NA NA NA 0.3215896 NA
NA NA NA NA NA 0.95286633 NA
NA NA NA NA NA 0.38972348 NA
0.20253526 0.44749783 0.74833753 NA NA 0.15761348 NA
0.06993934 0.35921939 0.58226971 NA NA 0.69357157 NA
NA NA NA NA NA 0.25539225 NA
NA NA NA NA NA 0.05719078 NA
0.00033778 0.52501134 0.00154943 NA NA 0.87613699 NA
0.2378 0.6183 0.6931728 NA NA 0.31245022 NA
NA NA NA NA NA 0.7148095 NA
NA NA NA NA NA 0.97005316 NA
NA NA NA NA NA 0.85415537 NA
NA NA NA NA NA 0.11215464 NA
NA NA NA NA NA 0.0392349 NA
0.08534261 0.8612808 0.1799027 NA NA 0.7485598 NA
NA NA NA NA NA 0.90652517 NA
NA NA NA NA NA 0.47949315 NA
NA NA NA NA NA 0.3714059 NA
0.86143723 0.26198279 0.4409276 NA NA 0.10302812 NA
0.2213 0.8292 0.45729668 NA NA 0.58757714 NA
NA NA NA NA NA 0.04871941 NA
0.3692296 0.4025456 0.2014335 NA NA 0.68662174 NA
0.30402712 0.15395328 0.05665042 NA NA 0.142163 NA
NA NA NA NA NA 0.08700808 NA
0.8276 0.8821 0.97536023 NA NA 0.26278634 NA
NA NA NA NA NA 0.31940303 NA
NA NA NA NA NA 0.2403967 NA
NA NA NA NA NA 0.58457827 NA
NA NA NA NA NA 0.19128478 NA
0.1204 0.4392 0.5996294 NA NA 0.72319665 NA
NA NA NA NA NA 0.54997037 NA
NA NA NA NA NA 0.81435728 NA
NA NA NA NA NA 0.75620152 NA
NA NA NA NA NA 0.99624407 NA
NA NA NA NA NA 0.63911057 NA
NA NA NA NA NA 0.10049966 NA
NA NA NA NA NA 0.12035067 NA
0.2677303 0.7767609 0.317963 NA NA 0.79279117 NA
NA NA NA NA NA 0.76370613 NA
0.95793002 0.218555 0.30494788 NA NA 0.64251089 NA
0.6754 0.4982 0.81817254 NA NA 0.24034196 NA
NA NA NA NA NA 0.21208528 NA
NA NA NA NA NA 0.73651201 NA
NA NA NA NA NA 0.62524058 NA
0.01358 0.5299 0.02339551 NA NA 0.94774001 NA
0.9747644 0.3903575 0.4958384 NA NA 0.51250773 NA
0.1106975 0.6452566 0.1366497 NA NA 0.66837044 NA
NA NA NA NA NA 0.57467305 NA
NA NA NA NA NA 0.69665234 NA
0.1574 0.61 0.52013662 NA NA 0.77414802 NA
0.7654 0.1405 0.34309138 NA NA 0.26594504 NA
NA NA NA NA NA 0.32810693 NA
NA NA NA NA NA 0.22322435 NA
0.5881566 0.7134589 0.92446 NA NA 0.88942274 NA
NA NA NA NA NA 0.62148402 NA
NA NA NA NA NA 0.25601982 NA
0.4501 0.5577 0.33396715 NA NA 0.59735381 NA
NA NA NA NA NA 0.09724081 NA
NA NA NA NA NA 0.34705617 NA
0.6808 0.2932 0.58276764 NA NA 0.42915965 NA
0.6757 0.3736 0.32514315 NA NA 0.48403139 NA
NA NA NA NA NA 0.26817251 NA
0.7112 0.6116 0.5065524 NA NA 0.57171912 NA
NA NA NA NA NA 0.20955192 NA
NA NA NA NA NA 0.92457813 NA
NA NA NA NA NA 0.33110685 NA
NA NA NA NA NA 0.1425831 NA
NA NA NA NA NA 0.59520166 NA
0.2139 0.9296 0.44653095 NA NA 0.78838664 NA
0.296395 0.7555287 0.6163462 NA NA 0.82284723 NA
0.68233583 0.02295411 0.03414887 NA NA 0.6785125 NA
NA NA NA NA NA 0.87978339 NA
NA NA NA NA NA 0.7683646 NA
NA NA NA NA NA 0.55683048 NA
0.91904756 0.0764398 0.1315036 NA NA 0.91728415 NA
NA NA NA NA NA 0.95301147 NA
0.0022729 0.30007224 0.15432999 NA NA 0.84480569 NA
0.56466901 0.55918639 0.3761643 NA NA 0.07213679 NA
NA NA NA NA NA 0.666966 NA
NA NA NA NA NA 0.40222989 NA
0.5666 0.3038 0.23439171 NA NA 0.44579898 NA
0.13073371 0.16882117 1 NA NA 0.57129406 NA
NA NA NA NA NA 0.76979137 NA
NA NA NA NA NA 0.80442018 NA
NA NA NA NA NA 0.80233604 NA
0.4310318 0.2525576 0.7433237 NA NA 0.46144911 NA
0.8723 0.8182 0.93846406 NA NA 0.66351093 NA
NA NA NA NA NA 0.48558458 NA
NA NA NA NA NA 0.28799001 NA
0.80109104 0.05546903 0.16320811 NA NA 0.80055867 NA
NA NA NA NA NA 0.74397187 NA
NA NA NA NA NA 0.50256295 NA
NA NA NA NA NA 0.94372016 NA
NA NA NA NA NA 0.69464205 NA
NA NA NA NA NA 0.32618954 NA
NA NA NA NA NA 0.54145645 NA
NA NA NA NA NA 0.48390516 NA
0.3695 0.04027 0.0278327 NA NA 0.27066487 NA
0.991292 0.7597839 0.81057764 NA NA 0.69261197 NA
NA NA NA NA NA 0.07847689 NA
0.84489773 0.23076125 0.2667411 NA NA 0.84645038 NA
NA NA NA NA NA 0.59830503 NA
NA NA NA NA NA 0.7739603 NA
0.63894777 0.09979864 0.09520175 NA NA 0.93752936 NA
NA NA NA NA NA 0.87083718 NA
NA NA NA NA NA 0.33432449 NA
NA NA NA NA NA 0.36162319 NA
NA NA NA NA NA 0.91186588 NA
NA NA NA NA NA 0.95706212 NA
NA NA NA NA NA 0.38183285 NA
NA NA NA NA NA 0.56666468 NA
0.6587 0.05263 0.22236742 NA NA 0.38473591 NA
NA NA NA NA NA 0.81596575 NA
NA NA NA NA NA 0.88961015 NA
0.5607345 0.98344896 0.66924627 NA NA 0.41419315 NA
0.60246735 0.75690146 0.53320203 NA NA 0.69263637 NA
NA NA NA NA NA 0.93473148 NA
0.2238 0.9373 0.4531622 NA NA 0.4920141 NA
0.90806253 0.92426029 0.87141938 NA NA 0.47318446 NA
0.101 0.52 0.09111806 NA NA 0.93235676 NA
NA NA NA NA NA 0.42126675 NA
0.3247661 0.57046008 0.24624197 NA NA 0.8443251 NA
0.5065 0.7481 0.84873788 NA NA 0.50201534 NA
NA NA NA NA NA 0.97798291 NA
0.18466042 0.9489321 0.30267955 NA NA 0.83104434 NA
0.4525 0.1831 0.59041686 NA NA 0.44176441 NA
0.7437 0.244 0.25895452 NA NA 0.71623809 NA
NA NA NA NA NA 0.89280654 NA
0.549 0.8745 0.71705271 NA NA 0.74827378 NA
0.07255 0.8807 0.28262544 NA NA 0.35018194 NA
NA NA NA NA NA 0.71266389 NA
NA NA NA NA NA 0.36647521 NA
NA NA NA NA NA 0.19562412 NA
0.003723 0.5319 0.01512246 NA NA 0.99024536 NA
NA NA NA NA NA 0.80987214 NA
0.6511 0.4841 0.38154954 NA NA 0.82306072 NA
NA NA NA NA NA 0.99185321 NA
NA NA NA NA NA 0.94648661 NA
0.32133145 0.70168741 0.29954785 NA NA 0.63125332 NA
REP2W
AY.W
OM
EN.P
.value
.1side
d
REP2W
AY.M
ENvs
WOM
EN.P
.value
.1side
d.xls
REP2W
AY.s
2.M
ENvs
WOM
EN.P
.value
.1side
d.xls.fd
r
REP2W
AY.s
2.GENDERCOM
BINED
.348
.P-v
alue
JOIN
T.MEN
.P.value
JOIN
T.WOM
EN.P
.value
JOIN
T.MEN
vsW
OM
EN.P
.value
DIS
COVE
RY.M
EN.E
ffect
DIS
COVE
RY.W
OM
EN.E
ffect
INSIL
ICO.M
EN.E
ffect
1.636E-06 0.6129 1.99E-29 6.18E-16 0.0069 0.0536 -0.0198
4.947E-12 0.3739 4.62E-37 6.95E-16 0.0098 0.0643 0.0037
2.416E-13 0.04847 2.41E-31 2.46E-11 0.0123 0.0565 -0.004
0.002902 0.5699 2.69E-11 8.41E-07 -0.0002 0.0276 -0.0165
3.208E-15 0.008342 7.07E-23 0.00000191 0.0097 0.0418 0.0104
0.00431 0.7613 3.45E-09 0.00026634 0.0071 0.0372 -0.02
5.865E-06 0.4106 4.17E-14 0.00000404 0.0004 0.0396 0.0192
0.009982 5.96E-08 0.1393 0.00163112 0.0347 0.0089 0.0462
0.0005171 0.1023 2.09E-09 0.00367778 0.0094 0.0317 -0.0043
0.0005024 0.2293 9.87E-12 0.00017141 0.0046 0.041 0.0009
1.037E-06 0.01945 1.36E-14 0.00036162 0.0104 0.0467 0.0147
1.392E-06 0.02257 3.01E-14 0.00041044 0.0105 0.0479 0.0199
0.00002547 0.09201 8.29E-11 0.00178471 0.005 0.0298 0.0126
4.051E-06 0.1815 5.13E-12 0.00022286 0.0018 0.0518 -0.0109
0.00001186 0.01383 1.14E-10 0.01136462 0.0122 0.0324 0.0153
7.778E-23 3.74E-10 4.11E-29 0.0021761 0.0238 0.0498 0.0386
0.004692 0.06756 1.46E-08 0.01492135 0.0115 0.0284 -0.0033
1.143E-15 1.16E-14 2.16E-27 0.02087848 0.0495 0.0726 NA
0.0004897 0.0411 2.66E-08 0.02146086 0.0103 0.0299 0.0292
3.586E-07 0.0000484 2.74E-14 0.03280731 0.0216 0.038 0.011
0.0000359 9.61E-09 0.003901 0.01536713 0.029 0.0097 0.0227
0.003018 0.3574 3.8E-11 0.00011949 0.0025 0.0738 -0.0278
0.0005788 8.89E-08 0.006095 0.04032345 0.0356 0.0144 0.0228
0.0001598 0.0006943 1.21E-10 0.06256536 0.0198 0.0375 0.0084
0.00001976 0.0009782 1.11E-10 0.05278588 0.0191 0.0392 0.0139
0.0002393 6.54E-08 0.04275 0.01864698 0.0305 0.0079 NA
0.001861 8.31E-07 0.008307 0.03845675 0.0605 0.0223 0.0633
3.156E-06 0.002859 8.94E-11 0.02819529 0.0111 0.0329 0.0187
3.919E-06 0.001936 3.99E-10 0.04900566 0.0214 0.0557 0.0477
4.438E-17 9.44E-08 3.51E-19 0.06213149 0.0214 0.052 0.0456
0.0005447 0.01188 1.22E-07 0.08083135 0.0103 0.0256 0.0079
5.566E-07 1.73E-11 0.0000798 0.02321416 0.0502 0.0192 0.051
3.263E-12 1.88E-08 2.77E-18 0.07999052 0.024 0.0417 0.0305
0.00001426 0.0002173 1.98E-11 0.06933716 0.016 0.0331 0.0244
0.0005109 4.73E-07 0.001501 0.11565048 0.0292 0.0131 0.018
6.363E-32 3.23E-20 1.04E-35 0.10744036 0.0338 0.0493 0.0423
5.4E-08 3.05E-10 0.0001015 0.04422817 0.0303 0.0099 0.0305
1.424E-10 1.48E-13 1.77E-08 0.0941396 0.0394 0.0213 0.038
0.0002623 0.0002009 1.45E-09 0.0873974 0.0204 0.0391 NA
0.00000229 5.5E-08 0.003345 0.03624367 0.0288 0.0049 0.0328
8.078E-07 0.0006479 7.11E-10 0.10462042 0.0113 0.028 0.0127
0.007811 0.1191 9.32E-08 0.01944422 0.0065 0.0279 0.0144
0.006387 0.0304 0.00000532 0.15402961 0.0121 0.0334 0.0148
0.004506 0.00000618 0.08141 0.0281175 0.0347 0.0026 0.0618
0.008483 0.0000013 0.007748 0.11481607 0.0777 0.0316 0.057
2.225E-15 3.66E-10 9.92E-21 0.10390032 0.0223 0.0418 0.0352
1.056E-06 5.71E-11 0.00000134 0.12216183 0.0502 0.0248 0.0109
0.00003146 0.003873 2.08E-07 0.17202532 0.0082 0.0258 0.0357
1.083E-08 2.76E-11 4.74E-07 0.14480029 0.0382 0.0181 0.0245
0.0005592 4.53E-08 0.000102 0.16173108 0.0367 0.0182 0.0035
0.0007917 0.1569 6.22E-07 0.07416785 0.0036 0.0577 0.0302
3.173E-06 1.77E-08 0.0000413 0.17202532 0.0322 0.0135 0.0253
0.0006834 0.00000417 0.002103 0.1805175 0.0382 0.013 0.0173
0.0002614 1.63E-07 0.001965 0.06807989 0.0306 0.0085 0.0259
0.003087 0.06956 0.00000191 0.05585604 0.0035 0.0234 -0.0016
5.36E-11 0.00000021 4.48E-14 0.20792019 0.0181 0.0367 0.0241
0.00802 0.0000206 0.04024 0.07559055 0.0469 0.004 0.0197
2.635E-07 0.0000108 3.32E-10 0.31689151 0.0164 0.034 0.0318
0.000305 0.00000534 0.0006788 0.21530236 0.0329 0.0127 0.0219
0.001237 0.0003599 0.0000051 0.67615135 0.0257 0.0546 0.0157
7.545E-11 4.49E-09 0.00000256 0.23692246 0.0273 0.0081 0.0262
0.006574 0.0000147 0.0177 0.07918347 0.0279 0.0058 0.0108
1.014E-11 1.63E-08 1.16E-13 0.33976638 0.024 0.0544 0.0494
1.41E-07 8.18E-07 1.16E-10 0.4646481 0.0472 0.0918 0.0927
0.006606 0.3105 0.00000219 0.03104337 0.0008 0.0734 0.0725
0.00002541 0.0006815 8.13E-07 0.41972125 0.0087 0.0273 0.0213
0.001075 0.00000024 0.0001004 0.41217058 0.0343 0.0169 NA
0.002326 0.0000159 0.0009521 0.31924327 0.0323 0.0108 -0.0013
0.0006208 0.003699 0.0000099 0.40382487 0.0056 0.0264 0.0195
0.0002192 0.0000681 8.9E-08 0.48524063 0.0122 0.0262 0.003
3.581E-06 1.31E-07 1.13E-09 0.85831929 0.02 0.0361 0.0334
0.00007665 0.0000123 2.77E-07 0.80891393 0.0184 0.0407 0.0238
0.003098 0.0001981 0.01447 0.22316737 0.0291 0.0023 0.0005
0.001313 0.02986 0.00001 0.22443835 0.0041 0.0324 0.0545
0.06746 0.08415 4.91E-08 0.00596178 0.0181 0.0511 NA
0.0898 6.61E-08 0.2697 9.01E-07 0.1795 -0.0562 0.1898
0.4722 7.84E-08 0.07283 2.03E-07 0.0228 -0.0063 0.015
0.03189 8.22E-08 0.5728 0.0000172 0.0608 -0.0104 0.0894
0.01489 1.21E-07 0.1235 0.00149087 0.0824 0.0132 0.0826
NA 1.94E-07 0.2455 0.00645267 0.152 0.036 NA
0.04264 2.88E-07 0.6484 0.00113748 0.0782 0.0086 NA
0.01912 0.724 0.0000003 0.00032591 -0.0023 0.0312 -0.0022
0.01094 0.5687 3.03E-07 0.00028068 -0.0156 0.0685 0.015
NA 0.00000045 0.987 0.00724403 0.3851 -0.002 NA
NA 4.97E-07 0.5799 0.00055306 0.819 -0.1206 NA
0.03743 5.08E-07 0.9572 0.00068727 0.0383 0.0017 0.0317
0.01499 0.1997 5.26E-07 0.02080605 0.0049 0.0281 0.0147
0.04649 5.42E-07 0.1094 0.01937488 0.0312 0.0095 NA
0.06057 0.1909 5.65E-07 0.01505715 0.0141 0.0347 -0.0189
NA 0.7429 5.98E-07 0.0000373 -0.1333 2.5743 NA
0.01645 6.29E-07 0.1794 0.00225157 0.0419 0.0021 0.028
NA 0.1704 6.34E-07 0.00017959 0.1142 0.7757 NA
0.02264 0.005988 7.19E-07 0.10978039 0.0145 0.0355 NA
0.04058 0.9422 8.44E-07 0.00090002 0.0002 0.0343 -0.0068
NA 0.3704 8.56E-07 0.00464963 0.0977 0.5326 NA
0.1405 8.64E-07 0.1053 0.00829472 0.027 0.0103 0.024
NA 8.67E-07 0.6665 0.00318677 0.6179 0.0608 NA
0.2994 8.82E-07 0.5421 0.00170145 0.0523 0.0061 0.0441
0.02359 0.00000102 0.008516 0.12729922 0.0318 0.0148 NA
0.1662 0.00000103 0.8802 0.0000908 0.0413 -0.0044 0.0366
0.06491 0.02522 0.0000011 0.13275406 0.0134 0.0296 0.0105
0.09791 0.00000111 0.2087 0.00575729 0.0427 0.0149 0.0146
0.9369 0.00000113 0.3655 0.0000301 0.0272 -0.0018 -0.0091
NA 0.00000125 0.8776 0.00065768 0.5526 0.0167 NA
0.03522 0.2439 0.00000135 0.01921278 0.0087 0.0407 -0.0036
0.01705 0.07854 0.00000142 0.05904917 0.0133 0.0412 0.0203
0.1228 0.00000147 0.3496 0.00377617 0.0246 0.0038 0.0059
NA 0.00000151 0.6078 0.00013225 0.038 -0.0039 NA
0.09276 0.00000153 0.1413 0.00668965 0.0646 0.0172 0.0521
0.4173 0.00000172 0.8888 0.00024413 0.0425 0.0024 0.031
0.03566 0.00000182 0.1161 0.00923873 0.0673 0.0126 0.0436
0.4326 0.00000189 0.8024 0.0016573 0.2231 -0.0117 NA
NA 0.00000206 0.383 0.00448134 0.047 0.0082 NA
NA 0.00000212 0.3199 0.00554856 0.4756 0.0938 NA
0.2189 0.00000214 0.9962 0.00030951 0.0442 -0.0042 0.033
0.1932 0.9564 0.00000217 0.00120198 -0.0322 0.634 0.4622
0.1017 0.00000224 0.2506 0.002182 0.0604 0.014 0.0413
0.1219 0.00000301 0.08834 0.02175671 0.0322 0.008 0.0134
NA 0.2354 0.00000309 0.01771812 0.0229 0.0863 NA
0.1457 0.7334 0.0000031 0.00106252 -0.0001 0.029 -0.0108
NA 0.00000321 0.3182 0.00838896 0.5393 0.1128 NA
0.4063 0.00000377 0.6822 0.0000858 0.067 -0.002 0.0378
0.05378 0.2067 0.00000387 0.01402808 0.0058 0.0342 NA
0.08685 0.00000393 0.1571 0.01050889 0.0284 0.0071 0.0204
NA 0.00000405 0.04887 0.0489603 0.0318 0.013 NA
NA 0.6562 0.00000406 0.00013829 0.0494 0.9195 NA
0.01032 0.1831 0.00000454 0.02862508 0.0029 0.0278 0.0128
0.07128 0.4387 0.0000047 0.01591064 0.005 0.0263 0.0024
0.685 0.00000479 0.1988 0.0000139 0.0369 -0.0131 0.0135
0.5389 0.00000486 0.1128 0.00000803 0.0219 -0.0085 0.0272
0.3154 0.3462 0.00000511 0.00024078 -0.0042 0.0325 -0.0161
NA 0.737 0.00000543 0.00033565 0.0309 0.6221 NA
NA 0.9839 0.00000558 0.0012033 -0.0013 0.2943 NA
NA 0.6965 0.00000562 0.0006309 0.0743 1.1691 NA
0.2447 0.00000583 0.8629 0.00078134 0.0515 -0.0025 0.0383
0.42 0.00000594 0.06623 0.00000278 0.0677 -0.0194 0.004
0.2208 0.00000594 0.4288 0.00413563 0.0243 0.0026 0.0189
0.01576 0.09502 0.00000594 0.07164474 0.0053 0.0262 0.0097
NA 0.877 0.00000604 0.00122601 -0.0013 0.0362 NA
0.2221 0.00000624 0.8434 0.00134802 0.0201 -0.0004 0.0206
NA 0.00000631 0.1755 0.0214135 0.0289 0.0084 NA
0.8992 0.00000665 0.2393 0.0000238 0.0588 -0.0077 0.0346
0.7496 0.00000719 0.7675 0.00043899 0.0647 -0.0027 0.0608
0.04823 0.00000764 0.1218 0.03031389 0.0362 0.0132 0.032
0.7485 0.1403 0.00000793 0.0000643 -0.0147 0.0784 -0.0831
NA 0.4074 0.00000799 0.00111368 0.048 0.3887 NA
NA 0.8157 0.00000815 0.00099374 -0.0262 0.4925 NA
NA 0.00000842 0.8468 0.00524854 0.7581 0.0375 NA
NA 0.00000854 0.2959 0.0120772 0.6325 0.1409 NA
NA 0.00000895 0.4255 0.00718998 0.0302 0.0051 NA
NA 0.00000937 0.5707 0.0076233 1.5319 0.2032 NA
NA 0.00000947 0.8017 0.0000862 1.334 -0.0454 NA
0.04935 0.00000975 0.05452 0.03667112 0.0295 0.0072 0.0126
NA 0.5914 0.00000978 0.0037228 0.0598 0.5386 NA
0.02635 0.2019 0.0000098 0.03461584 0.0004 0.0345 0.0255
NA 0.00001 0.1793 0.02570427 0.0318 0.0094 NA
0.3727 0.0000103 0.6878 0.00210163 0.0517 0.0021 0.0298
0.06196 0.0000104 0.499 0.01814292 0.2083 0.0354 0.0779
NA 0.5874 0.000011 0.0000828 -0.0478 0.5671 NA
NA 0.0000111 0.5845 0.0004076 0.029 -0.0035 NA
NA 0.4028 0.0000113 0.00939111 0.0389 0.2138 NA
0.2698 0.07565 0.0000118 0.10669492 0.0472 0.108 -0.0094
NA 0.0000126 0.4898 0.00014607 0.9431 -0.1242 NA
NA 0.496 0.0000126 0.01972326 0.1794 0.9897 NA
NA 0.0000128 0.2649 0.01007338 0.4001 0.0883 NA
0.6266 0.7467 0.0000129 0.01455645 0.0035 0.0529 0.0011
NA 0.3705 0.000013 0.00011177 -0.3863 2.1334 NA
0.02116 0.0000132 0.3061 0.01337968 0.0482 -0.0042 -0.0227
0.03983 0.07476 0.0000132 0.09733542 0.007 0.0359 0.0141
NA 0.0000134 0.4327 0.00920171 0.0296 0.0051 NA
NA 0.4435 0.0000137 0.00163343 0.0252 0.2085 NA
0.08683 0.0000139 0.5749 0.00297254 0.064 -0.0107 0.0087
NA 0.0000139 0.4672 0.01834149 0.3937 0.0735 NA
NA 0.9919 0.0000141 0.00028153 0.0004 0.2616 NA
0.06587 0.0000143 0.01286 0.10176266 0.0303 0.0125 0.0102
NA 0.0000147 0.3816 0.01235728 0.0429 0.0084 NA
NA 0.0000148 0.4687 0.0002608 0.3946 -0.0621 NA
0.2455 0.7292 0.0000152 0.00952312 0.0013 0.0225 0.0066
0.4639 0.0000154 0.6344 0.00020693 0.2341 -0.0688 0.0154
0.1618 0.0000158 0.9803 0.0008343 0.041 -0.0091 0.0093
NA 0.0000161 0.09952 0.02600102 0.0806 0.0261 NA
NA 0.722 0.0000163 0.0001418 -0.0328 0.6095 NA
NA 0.0000175 0.4541 0.01354927 0.0786 0.014 NA
0.391 0.3463 0.0000183 0.02482126 0.0094 0.0332 -0.0158
0.02325 0.1261 0.0000184 0.13162902 0.0072 0.0372 0.0246
NA 0.0000187 0.09438 0.05060602 0.0993 0.0368 NA
NA 0.99 0.0000188 0.00345294 0.0027 0.867 NA
0.2743 0.0000189 0.1019 0.03263229 0.0286 0.0104 0.012
0.1434 0.000019 0.5868 0.00257082 0.0393 -0.0017 0.0184
0.4805 0.0000192 0.6551 0.00039571 0.1074 0.0192 0.0505
NA 0.0000192 0.1551 0.05497477 0.3612 0.1261 NA
0.6794 0.00002 0.8869 0.00072349 0.0419 0.0062 0.0175
NA 0.00002 0.9287 0.001412 0.4487 0.008 NA
NA 0.00002 0.8084 0.00728691 0.3446 -0.0273 NA
0.498 0.0000208 0.8598 0.00057416 0.0429 0.0074 0.0123
0.4689 0.3411 0.0000214 0.00068951 -0.0092 0.0404 -0.0037
0.5938 0.0000218 0.09441 0.0000132 0.049 -0.0235 0.0193
0.07811 0.0000228 0.1875 0.02997321 0.0494 0.0096 0.015
0.1145 0.0000244 0.4622 0.00038391 0.0708 0.001 -0.0193
0.03114 0.1401 0.0000245 0.03460433 0.0518 0.3102 0.0253
0.2256 0.08252 0.0000249 0.11043621 0.0088 0.0294 -0.004
0.9294 0.000025 0.758 0.00048762 0.042 0.0004 0.0122
0.5319 0.5458 0.0000271 0.00869324 0.0112 0.1082 NA
0.06864 0.0000279 0.5476 0.00841622 0.0307 -0.0009 0.0137
0.9932 0.000029 0.888 0.00213984 0.0809 0.0077 0.0204
0.5416 0.00003 0.4714 0.00643061 0.0545 0.0063 0.0096
0.3017 0.5628 0.0000341 0.00239326 -0.008 0.0396 0.0076
0.7065 0.5025 0.0000348 0.04564227 0.0159 0.077 -0.0121
0.2033 0.3728 0.0000363 0.02848118 0.0131 0.0389 -0.0126
0.6238 0.0000367 0.4434 0.00021765 0.0602 -0.0154 0.0141
0.2718 0.5621 0.0000386 0.00514834 0.0012 0.1192 0.1529
0.1617 0.3543 0.0000387 0.00115285 -0.0505 0.165 0.0305
0.2749 0.0000396 0.7095 0.00594656 0.0314 0.0028 0.0093
0.04918 0.0363 0.0000443 0.13776876 0.0079 0.0282 NA
0.7777 0.0000454 0.4495 0.0116794 0.028 0.0065 0.0078
0.8829 0.5359 0.0000466 0.00252493 0.0001 0.0352 -0.0185
0.01047 0.00975 0.0000499 0.38697035 0.0076 0.0345 -0.0079
0.161 0.0000514 0.4417 0.00052739 0.0382 -0.0163 0.0102
0.1468 0.0000522 0.05411 0.05249828 0.037 0.0095 0.0038
0.02029 0.02287 0.000056 0.3681442 0.0086 0.0358 0.0443
0.02772 0.0000585 0.007274 0.20066119 0.0262 0.0088 0.0046
0.5585 0.02759 0.0000588 0.0000173 -0.0092 0.0212 -0.0199
0.8407 0.5042 0.0000593 0.00220377 -0.0003 0.0412 -0.028
0.04681 0.3209 0.0000603 0.04079247 -0.0006 0.0251 0.0125
0.6558 0.0000612 0.7153 0.00647029 0.0242 -0.001 -0.0142
0.7644 0.1209 0.0000633 0.0537029 0.0162 0.0458 -0.0082
0.8977 0.8298 0.0000725 0.01562916 0.0034 0.0339 -0.0043
0.3997 0.9488 0.0000728 0.00599515 0.0036 0.0505 -0.0177
0.04408 0.0000751 0.01382 0.19326719 0.0437 0.0169 0.0055
0.8025 0.1507 0.0000865 0.0002567 -0.0098 0.0513 -0.0377
0.4674 0.2107 0.000087 0.07439181 0.007 0.032 0.0041
0.7026 0.9683 0.000088 0.00614202 0.0059 0.0495 0.0117
0.4849 0.9238 0.0000939 0.00812262 0.0049 0.055 -0.0631
0.5552 0.7381 0.0000944 0.01816879 0.0049 0.038 -0.0081
0.4305 0.0001043 0.2117 0.0001413 0.0499 -0.009 0.0002
0.5052 0.000107 0.7654 0.00310983 0.2941 -0.0219 0.0528
0.964 0.0001102 0.2941 0.00029259 0.0687 -0.0212 -0.0056
0.7806 0.0001126 0.5146 0.01766621 0.1275 0.0283 0.0265
0.05599 0.02765 0.0001132 0.32433184 0.0088 0.0256 0.0089
0.5608 0.0001158 0.3197 0.01665196 0.0355 0.0064 0.0027
0.2676 0.0001184 0.3898 0.01349136 0.0431 -0.0006 -0.0036
0.1006 0.3493 0.0001252 0.10792681 0.0028 0.0387 0.0242
0.06318 0.003355 0.0001282 0.81423712 0.0121 0.0343 0.0459
0.3136 0.0001289 0.3551 0.01649717 0.0414 0.0028 0.0036
0.8486 0.7258 0.000135 0.00600833 0.0016 0.0367 -0.0201
0.7824 0.6546 0.000141 0.00749757 -0.0005 0.0377 -0.0179
0.2162 0.0639 0.000143 0.20765411 0.0066 0.0231 0.0156
0.9393 0.5831 0.0001459 0.00304327 -0.0056 0.0347 0.0183
0.4735 0.0001571 0.8902 0.00689914 0.0289 -0.0031 0.0016
0.4894 0.9093 0.0001587 0.01459816 0.0019 0.0332 -0.0122
0.8397 0.5546 0.0001725 0.00335852 -0.0017 0.0291 -0.0092
0.6718 0.0001755 0.9709 0.00368155 0.033 -0.0037 -0.0054
0.8804 0.00018 0.8019 0.0022 0.0379 -0.0048 -0.003
0.01224 0.02145 0.0001813 0.40980165 0.0016 0.0346 0.0204
0.5173 0.0001843 0.5926 0.0185024 0.022 0.0014 0.0136
0.3521 0.6681 0.0001987 0.02741226 -0.0009 0.0251 -0.0205
0.1915 0.0002056 0.2006 0.0240902 0.0575 0.0059 0.0074
0.2954 0.6811 0.0002077 0.03263229 -0.001 0.0284 0.0112
0.02988 0.07026 0.0002085 0.25730495 0.0038 0.0298 0.0171
0.1665 0.7734 0.0002137 0.01748255 -0.0103 0.1134 0.0288
0.9469 0.5792 0.000216 0.06313967 0.0069 0.0377 -0.0065
0.4956 0.7601 0.0002374 0.028259 0.0052 0.0349 -0.0252
0.4148 0.008953 0.0002451 0.50777856 0.0261 0.0585 0.077
0.4914 0.0002465 0.4236 0.02006882 0.049 0.0143 -0.0122
0.3607 0.0002704 0.3929 0.00069003 0.0696 -0.0016 0.0021
0.5395 0.0002723 0.3168 0.0517234 0.0399 0.0063 -0.0143
0.9799 0.273 0.000289 0.00183935 -0.0052 0.0323 -0.0174
0.9447 0.3589 0.0002892 0.00284758 -0.0072 0.0357 -0.0046
0.333 0.9822 0.0002893 0.01193385 -0.0045 0.0378 0.0054
0.4831 0.0002937 0.167 0.08836888 0.034 0.011 0.0232
0.8433 0.8483 0.0003076 0.0164845 0.0015 0.0466 -0.0119
0.1862 0.3405 0.0003119 0.08335794 0.0029 0.0428 0.0411
0.4696 0.4367 0.000312 0.00425346 -0.0024 0.0341 -0.0152
0.4134 0.4995 0.0003225 0.06233014 0.0201 0.1444 0.0396
0.6558 0.2726 0.0003316 0.00153498 -0.0064 0.0293 -0.0078
0.9882 0.9682 0.0003323 0.02477388 0.0035 0.0318 -0.0143
0.5891 0.0003416 0.6154 0.0151276 0.0334 0.0069 -0.0069
0.1087 0.02831 0.0003574 0.41490654 0.0106 0.032 0.0189
0.4266 0.7093 0.0003618 0.03050385 -0.0027 0.0247 0.0095
0.2597 0.0003869 0.602 0.02420446 0.0732 -0.0081 0.0253
0.6471 0.0004267 0.2302 0.05759253 0.0324 0.0048 -0.0089
0.4887 0.4508 0.0004454 0.081336 0.0021 0.0327 0.0126
0.06045 0.0004567 0.1808 0.00035641 0.0498 -0.0042 -0.0222
0.2683 0.0004802 0.01488 0.49105332 0.0343 0.0124 NA
0.2118 0.0004817 0.008928 0.36072344 0.037 0.0144 -0.0101
0.05125 0.1148 0.0005009 0.21695293 0.0004 0.029 -0.0085
0.9511 0.08832 0.000553 0.00031031 -0.0135 0.0391 -0.0188
0.5044 0.0005891 0.363 0.01717374 0.1305 0.0111 -0.0023
0.6533 0.4628 0.0006007 0.05779578 0.0494 0.2313 0.0079
0.8118 0.0007116 0.2761 0.00130772 0.0397 -0.014 0.0264
0.2208 0.09394 0.0007171 0.26627945 0.0099 0.0289 -0.0055
0.4084 0.6897 0.0007507 0.07483129 -0.0013 0.0347 0.0158
0.7083 0.0007518 0.4775 0.03310252 0.0441 0.0076 -0.0168
0.4715 0.9763 0.0007665 0.02937952 -0.0069 0.0409 0.019
0.4472 0.0008156 0.5575 0.00431454 0.0296 -0.0016 0.0105
0.2721 0.0008335 0.1356 0.16232914 0.0537 0.0126 0.0143
0.8026 0.8819 0.0008405 0.04790604 0.001 0.0373 0.0014
0.7637 0.5747 0.0008572 0.09198441 0.0072 0.0307 -0.0092
0.189 0.0008573 0.07495 0.18393783 0.0835 0.0135 -0.0006
0.8755 0.6175 0.0008771 0.08786769 0.0019 0.0355 0.0103
0.6176 0.5819 0.0008931 0.01025795 -0.0034 0.0298 -0.0036
0.7025 0.0008961 0.836 0.01358161 0.0477 -0.0013 -0.0287
0.1473 0.0009156 0.2726 0.00112084 0.0424 -0.0056 -0.0232
0.7016 0.8215 0.00101 0.01823618 0.0006 0.0278 -0.0066
0.9631 0.8202 0.001026 0.05769058 0.0015 0.0309 0.0017
0.4342 0.001091 0.9457 0.01045704 0.2142 0.0339 -0.0214
0.8504 0.001099 0.5055 0.00415066 0.0489 -0.0038 -0.0188
0.2201 0.001183 0.1542 0.15383155 0.0383 0.006 0.011
0.4233 0.7373 0.001221 0.02566518 0.0085 0.0573 -0.0361
0.5113 0.001223 0.1114 0.25912727 0.028 0.0068 NA
0.7989 0.4693 0.001274 0.15445637 0.0136 0.08 0.0087
0.3135 0.00128 0.9748 0.01084335 0.0912 0.0084 -0.0445
0.4484 0.001451 0.04642 0.42012829 0.0323 0.0085 NA
0.3571 0.001463 0.7192 0.02977979 0.5639 0.0286 -0.3431
0.6848 0.9149 0.001523 0.04147298 0.0021 0.0525 -0.0142
0.6234 0.4339 0.00172 0.01106809 -0.0051 0.0336 -0.0092
0.5028 0.6879 0.001921 0.11076007 -0.0048 0.045 0.0295
0.176 0.002555 0.8553 0.02466983 0.039 0.0044 -0.0384
0.3025 0.06144 0.002701 0.32716344 0.3567 1.1913 0.0657
0.1722 0.4682 0.003314 0.17643608 0.0091 0.0369 -0.0107
0.3005 0.00349 0.7207 0.06166119 0.0546 0.0163 -0.0051
0.9039 0.1355 0.003557 0.51988255 0.0107 0.0335 0.0114
0.2912 0.04055 0.003569 0.96665897 0.0169 0.05 0.024
0.7258 0.7793 0.003714 0.0773088 0.0325 0.175 -0.1239
0.654 0.5514 0.004019 0.01242802 -0.0859 0.2263 0.0321
0.1156 0.00443 0.3198 0.00438961 0.0589 -0.0099 -0.0516
0.2327 0.005187 0.2385 0.00449148 0.0317 -0.0052 0.0075
0.6157 0.005281 0.4209 0.13636318 0.0306 0.0112 -0.0093
0.4057 0.1468 0.005551 0.43438941 0.0026 0.0352 0.0076
0.6899 0.006043 0.5147 0.01420088 0.1959 -0.026 -0.0043
0.5928 0.006285 0.124 0.32132581 0.0517 0.0119 0.0209
0.3643 0.1577 0.006432 0.25759419 0.0417 0.1135 0.0103
0.8646 0.007085 0.3462 0.12898201 0.0383 0.0038 -0.026
0.7185 0.2265 0.009499 0.3692482 0.0049 0.0276 -0.0027
0.6056 0.7778 0.01295 0.05953748 0.0015 0.0429 0.0087
0.7866 0.3918 0.01471 0.30347334 0.0081 0.0353 -0.0009
0.4466 0.3255 0.01513 0.45606947 0.0079 0.0436 0.0127
0.2476 0.6976 0.01568 0.06466532 -0.0038 0.0411 -0.011
0.06063 0.5738 0.01984 0.04320525 0.0105 0.0654 0.0015
0.3235 0.02533 0.04637 0.00306041 0.5789 -0.3624 -0.1249
0.06011 0.7996 0.02768 0.11430398 0.0038 0.0353 -0.0177
0.01067 0.1827 0.03005 0.01654741 -0.0049 0.051 -0.0452
0.4994 0.1221 0.03079 0.74771428 0.0355 0.0152 0.0121
0.3785 0.9365 0.03097 0.21443006 -0.0023 0.0795 0.0102
0.6711 0.8042 0.03289 0.10415274 -0.0068 0.0336 0.0002
0.7711 0.6667 0.0473 0.37806669 -0.021 0.1176 0.0882
0.06796 0.05465 0.4683 0.0473717 0.0802 -0.003 -0.0535
0.1507 0.0638 0.8245 0.13164231 0.0415 0.0061 -0.0112
DIS
COVE
RY.W
OM
EN.E
ffect
INSIL
ICO.M
EN.E
ffect
INSIL
ICO.W
OM
EN.E
ffect
META
BOCHIP
.MEN
.Effe
ct
META
BOCHIP
.WOM
EN.E
ffect
REP2W
AY.M
EN.E
ffect
REP2W
AY.W
OM
EN.E
ffect
JOIN
T.MEN
.Effe
ct
JOIN
T.WOM
EN.E
ffect
0.057 -0.0106 0.0435 -0.0131 0.0514 -0.0025 0.0524
0.0651 -0.0022 0.0626 -0.0006 0.0641 0.0048 0.0642
0.0479 0.0128 0.0757 0.0087 0.062 0.0104 0.0595
0.0368 -0.0059 0.037 -0.0084 0.0369 -0.0028 0.031
0.0546 0.0245 0.068 0.0211 0.0603 0.0148 0.0512
0.0418 NA NA -0.02 0.0418 0.0023 0.039
0.0262 0.0049 0.0435 0.0082 0.0343 0.0042 0.0368
0.0086 NA NA 0.0462 0.0086 0.0374 0.0088
0.0343 0.0106 0.0104 0.0061 0.0222 0.0076 0.0263
0.0258 0.0097 0.0196 0.0071 0.0228 0.0059 0.0309
0.039 0.0166 0.0296 0.0162 0.0349 0.0131 0.0406
0.0347 0.0148 0.0357 0.0161 0.0351 0.0131 0.0411
0.031 0.0101 0.0193 0.0109 0.0257 0.0079 0.0278
0.0532 0.0302 0.0269 0.0197 0.0426 0.0099 0.047
0.0282 0.013 0.031 0.0138 0.0295 0.0129 0.031
0.049 0.0382 0.0578 0.0383 0.0527 0.0307 0.0513
0.0229 0.0097 0.0124 0.0051 0.0183 0.0084 0.0234
NA 0.0517 0.0704 0.0517 0.0704 0.0504 0.0718
0.0101 0.0024 0.0373 0.0097 0.0213 0.01 0.0253
0.0239 0.022 0.0376 0.018 0.0299 0.0199 0.0341
0.0126 0.0301 0.02 0.0268 0.0154 0.0281 0.0123
0.0326 0.0312 0.0316 0.0135 0.0322 0.0078 0.0519
0.0092 0.0212 0.0174 0.0218 0.0128 0.0283 0.0135
0.0162 0.0132 0.0226 0.0115 0.0192 0.0155 0.0271
0.0213 0.0198 0.0346 0.0179 0.0274 0.0185 0.0333
NA 0.0267 0.0165 0.0267 0.0165 0.0288 0.011
0.0376 NA NA 0.0633 0.0376 0.0611 0.0276
0.0248 0.0179 0.0257 0.0182 0.0252 0.0145 0.0291
0.034 0.0262 0.0551 0.0327 0.0447 0.027 0.0504
0.0469 0.038 0.0481 0.0406 0.0474 0.0336 0.0492
0.0159 0.0147 0.0196 0.0122 0.0175 0.0112 0.0217
0.0287 0.0306 0.0306 0.0375 0.0296 0.0445 0.0241
0.0345 0.0296 0.0344 0.0299 0.0345 0.0268 0.0382
0.0263 0.0119 0.013 0.0164 0.0205 0.0162 0.027
0.0198 0.0167 0.006 0.0171 0.0136 0.0232 0.0134
0.053 0.0536 0.0533 0.05 0.0531 0.0413 0.0511
0.0191 0.0228 0.0265 0.0254 0.0224 0.028 0.0159
0.0334 0.0281 0.0232 0.0318 0.0286 0.0358 0.0249
NA 0.0227 0.0273 0.0227 0.0273 0.0213 0.0352
0.027 0.0176 0.0108 0.0224 0.0195 0.0256 0.0124
0.0326 0.024 0.0108 0.0202 0.0229 0.0155 0.0255
0.0185 NA NA 0.0144 0.0185 0.0083 0.0247
0.0118 0.0104 0.0181 0.0116 0.0144 0.0118 0.0223
0.0223 0.001 0.0028 0.0148 0.0128 0.0241 0.0084
0.0141 0.0235 0.068 0.0371 0.0355 0.0614 0.0333
0.035 0.0346 0.0339 0.0348 0.0345 0.0284 0.0383
0.029 0.039 0.0296 0.0284 0.0293 0.0398 0.027
0.0189 0.0112 0.018 0.0194 0.0185 0.0135 0.0222
0.0222 0.0283 0.0362 0.027 0.0285 0.0329 0.0231
0.019 0.0297 0.0212 0.0179 0.0197 0.029 0.0189
0.0265 NA NA 0.0302 0.0265 0.0148 0.0378
0.0232 0.0175 0.0211 0.0202 0.0223 0.0265 0.0178
0.0323 0.0178 0.0056 0.0176 0.0204 0.0277 0.0168
0.0146 0.0087 0.024 0.0158 0.0183 0.0245 0.013
0.0147 0.0215 0.0115 0.0162 0.0131 0.0079 0.0194
0.0343 0.0369 0.0229 0.0326 0.0292 0.0249 0.0331
0.0163 0.0104 0.0219 0.0124 0.019 0.0286 0.0125
0.0172 0.027 0.0305 0.0287 0.023 0.022 0.0288
0.0321 NA NA 0.0219 0.0321 0.0304 0.0195
0.0123 0.0207 0.0136 0.0195 0.0129 0.0216 0.025
0.031 0.0257 0.033 0.0258 0.032 0.0266 0.0194
0.0209 NA NA 0.0108 0.0209 0.0238 0.0111
0.037 0.0368 0.028 0.04 0.0321 0.0335 0.0412
0.0326 0.0576 0.0716 0.0694 0.0503 0.0586 0.0704
0.036 NA NA 0.0725 0.036 0.0155 0.0577
0.0101 0.026 0.0217 0.0244 0.0154 0.0162 0.0214
NA 0.0135 0.0248 0.0135 0.0248 0.0255 0.0197
0.0223 0.0142 0.0149 0.009 0.019 0.0215 0.0148
0.0152 0.0227 0.0031 0.0216 0.0099 0.0132 0.0184
0.0124 0.0321 0.0107 0.0263 0.0116 0.0168 0.0208
0.0102 0.026 0.0185 0.0285 0.0139 0.0241 0.0252
0.0093 0.0395 0.0207 0.0336 0.0138 0.0253 0.0272
0.0313 NA NA 0.0005 0.0313 0.0219 0.0124
0.0142 NA NA 0.0545 0.0142 0.0152 0.0264
NA 0.0073 0.0327 0.0073 0.0327 0.0138 0.0455
0.0147 NA NA 0.1898 0.0147 0.1818 -0.0294
-0.001 0.0167 -0.0123 0.0163 -0.0067 0.0207 -0.0065
-0.0119 0.0554 0.0119 0.0621 0.0009 0.0612 -0.006
0.0262 NA NA 0.0826 0.0262 0.0824 0.0191
NA NA NA NA NA 0.152 0.036
NA 0.0505 0.0019 0.0505 0.0019 0.0656 0.006
0.0241 NA NA -0.0022 0.0241 -0.0023 0.0283
0.0432 NA NA 0.015 0.0432 -0.008 0.0569
NA NA NA NA NA 0.3851 -0.002
NA NA NA NA NA 0.819 -0.1206
0.0133 0.0216 -0.0037 0.0226 -0.0011 0.0296 0.0003
0.0173 NA NA 0.0147 0.0173 0.0072 0.0244
NA 0.016 0.0056 0.016 0.0056 0.0248 0.0081
0.0154 0.0121 0.0224 0.001 0.0185 0.0076 0.0267
NA NA NA NA NA -0.1333 2.5743
0.0158 NA NA 0.028 0.0158 0.0385 0.0083
NA NA NA NA NA 0.1142 0.7757
NA 0.0145 0.0119 0.0145 0.0119 0.0145 0.0266
0.0269 0.0008 0.0091 -0.0011 0.02 -0.0004 0.0264
NA NA NA NA NA 0.0977 0.5326
0.002 NA NA 0.024 0.002 0.0263 0.0076
NA NA NA NA NA 0.6179 0.0608
0.0061 NA NA 0.0441 0.0061 0.0516 0.0061
NA 0.0146 0.0113 0.0146 0.0113 0.0246 0.0136
0.0034 NA NA 0.0366 0.0034 0.0402 -0.001
0.0135 NA NA 0.0105 0.0135 0.0127 0.024
0.0314 0.0281 -0.0344 0.024 0.0006 0.0337 0.0079
-0.006 0.0162 -0.0078 0.0103 -0.0069 0.0217 -0.0037
NA NA NA NA NA 0.5526 0.0167
0.0112 0.0082 0.0205 0.0056 0.0153 0.007 0.0259
0.0271 NA NA 0.0203 0.0271 0.015 0.0364
-0.0081 0.0137 0.014 0.0122 0.0034 0.0202 0.0036
NA NA NA NA NA 0.038 -0.0039
0.0134 NA NA 0.0521 0.0134 0.0618 0.016
-0.0009 NA NA 0.031 -0.0009 0.0398 0.0009
0.0267 NA NA 0.0436 0.0267 0.0617 0.0174
NA -0.0911 0.3236 -0.0911 0.3236 0.1959 0.0106
NA NA NA NA NA 0.047 0.0082
NA NA NA NA NA 0.4756 0.0938
0.0112 NA NA 0.033 0.0112 0.043 0
0.7162 NA NA 0.4622 0.7162 -0.008 0.6377
0.007 NA NA 0.0413 0.007 0.0537 0.01
0.0023 0.0048 0.0105 0.0078 0.0059 0.0208 0.007
NA NA NA NA NA 0.0229 0.0863
0.0179 NA NA -0.0108 0.0179 -0.0021 0.0246
NA NA NA NA NA 0.5393 0.1128
-0.0046 NA NA 0.0378 -0.0046 0.0539 -0.0036
NA 0.0093 0.0171 0.0093 0.0171 0.0074 0.0279
0.0069 NA NA 0.0204 0.0069 0.0264 0.007
NA NA NA NA NA 0.0318 0.013
NA NA NA NA NA 0.0494 0.9195
0.0143 0.0089 0.013 0.0101 0.0137 0.0064 0.0208
0.0154 NA NA 0.0024 0.0154 0.0043 0.0219
0.0005 NA NA 0.0135 0.0005 0.0331 -0.0079
-0.0018 NA NA 0.0272 -0.0018 0.0224 -0.007
0.0158 NA NA -0.0161 0.0158 -0.0063 0.026
NA NA NA NA NA 0.0309 0.6221
NA NA NA NA NA -0.0013 0.2943
NA NA NA NA NA 0.0743 1.1691
0.0079 NA NA 0.0383 0.0079 0.0493 0.0016
-0.015 NA NA 0.004 -0.015 0.0535 -0.0175
0.0072 NA NA 0.0189 0.0072 0.0238 0.0037
0.0095 0.0102 0.0129 0.01 0.011 0.0076 0.0187
NA NA NA NA NA -0.0013 0.0362
0.0047 NA NA 0.0206 0.0047 0.0201 0.0008
NA NA NA NA NA 0.0289 0.0084
-0.0142 NA NA 0.0346 -0.0142 0.0521 -0.011
-0.0085 NA NA 0.0608 -0.0085 0.0644 -0.0038
0.0071 0.0048 0.0008 0.0132 0.0036 0.0215 0.0071
0.0359 NA NA -0.0831 0.0359 -0.0256 0.0641
NA NA NA NA NA 0.048 0.3887
NA NA NA NA NA -0.0262 0.4925
NA NA NA NA NA 0.7581 0.0375
NA NA NA NA NA 0.6325 0.1409
NA NA NA NA NA 0.0302 0.0051
NA NA NA NA NA 1.5319 0.2032
NA NA NA NA NA 1.334 -0.0454
0.0142 NA NA 0.0126 0.0142 0.0256 0.0096
NA NA NA NA NA 0.0598 0.5386
0.0157 0.0053 0.0022 0.0114 0.009 0.0062 0.0204
NA NA NA NA NA 0.0318 0.0094
0.0066 NA NA 0.0298 0.0066 0.0483 0.0038
0.0127 NA NA 0.0779 0.0127 0.1256 0.0224
NA NA NA NA NA -0.0478 0.5671
NA NA NA NA NA 0.029 -0.0035
NA NA NA NA NA 0.0389 0.2138
0.0298 0.0112 0.0105 0.0067 0.0208 0.0264 0.0585
NA NA NA NA NA 0.9431 -0.1242
NA NA NA NA NA 0.1794 0.9897
NA NA NA NA NA 0.4001 0.0883
0.0055 NA NA 0.0011 0.0055 0.0029 0.0311
NA NA NA NA NA -0.3863 2.1334
0.0148 0.0199 0.011 0.0124 0.0128 0.0269 0.0059
0.013 0.0246 0.0087 0.0222 0.011 0.0117 0.0266
NA NA NA NA NA 0.0296 0.0051
NA NA NA NA NA 0.0252 0.2085
0.0257 NA NA 0.0087 0.0257 0.0499 0.0054
NA NA NA NA NA 0.3937 0.0735
NA NA NA NA NA 0.0004 0.2616
0.012 NA NA 0.0102 0.012 0.0246 0.0123
NA NA NA NA NA 0.0429 0.0084
NA NA NA NA NA 0.3946 -0.0621
0.0107 NA NA 0.0066 0.0107 0.0018 0.0198
0.0334 NA NA 0.0154 0.0334 0.1833 -0.0156
0.0125 NA NA 0.0093 0.0125 0.0337 0.0002
NA NA NA NA NA 0.0806 0.0261
NA NA NA NA NA -0.0328 0.6095
NA NA NA NA NA 0.0786 0.014
0.0005 0.0043 0.0182 -0.0008 0.0081 0.0047 0.0201
0.0151 NA NA 0.0246 0.0151 0.0118 0.0268
NA NA NA NA NA 0.0993 0.0368
NA NA NA NA NA 0.0027 0.867
0.0047 NA NA 0.012 0.0047 0.0244 0.0082
0.0096 NA NA 0.0184 0.0096 0.0341 0.0034
-0.0492 NA NA 0.0505 -0.0492 0.0921 -0.0082
NA NA NA NA NA 0.3612 0.1261
-0.0115 NA NA 0.0175 -0.0115 0.0367 -0.001
NA NA NA NA NA 0.4487 0.008
NA NA NA NA NA 0.3446 -0.0273
-0.012 NA NA 0.0123 -0.012 0.0358 -0.0012
0.0102 NA NA -0.0037 0.0102 -0.0079 0.0283
-0.0002 NA NA 0.0193 -0.0002 0.0412 -0.0133
0.0148 0.011 0.0006 0.0116 0.0059 0.0244 0.0072
-0.0373 NA NA -0.0193 -0.0373 0.056 -0.0093
0.075 NA NA 0.0253 0.075 0.0397 0.1239
0.006 0.012 0.0023 0.0065 0.0043 0.0077 0.0173
-0.0051 NA NA 0.0122 -0.0051 0.0351 -0.0021
NA 0.0086 0.0156 0.0086 0.0156 0.01 0.0731
0.0144 0.0086 -0.0028 0.0101 0.0052 0.019 0.0026
-0.007 NA NA 0.0204 -0.007 0.0699 0.002
0.0069 NA NA 0.0096 0.0069 0.0446 0.0065
0.0098 NA NA 0.0076 0.0098 -0.0048 0.0274
0.0106 NA NA -0.0121 0.0106 0.0098 0.0467
0.0004 0.0038 0.0205 0.0002 0.0119 0.0051 0.0223
0.0023 NA NA 0.0141 0.0023 0.0473 -0.0071
-0.0216 NA NA 0.1529 -0.0216 0.0119 0.1017
0.0545 NA NA 0.0305 0.0545 -0.0328 0.1127
-0.0045 0.0102 0.0067 0.0099 0.0008 0.02 0.0017
NA 0.0137 0.0079 0.0137 0.0079 0.0104 0.021
-0.0017 NA NA 0.0078 -0.0017 0.023 0.0039
0.0079 NA NA -0.0185 0.0079 -0.0044 0.0231
0.0187 0.0302 -0.0058 0.0178 0.007 0.0131 0.0191
0.0058 0.013 0.0065 0.0123 0.0061 0.0262 -0.0047
0.014 NA NA 0.0038 0.014 0.0296 0.0114
0.0088 NA NA 0.0443 0.0088 0.0172 0.0262
0.0185 NA NA 0.0046 0.0185 0.021 0.0122
0.0009 NA NA -0.0199 0.0009 -0.0103 0.0165
0.0128 NA NA -0.028 0.0128 -0.0061 0.03
0.0184 0.0157 -0.0017 0.015 0.0076 0.0048 0.0184
0.0097 NA NA -0.0142 0.0097 0.0202 0.0017
-0.0058 NA NA -0.0082 -0.0058 0.0143 0.0408
0.0008 NA NA -0.0043 0.0008 0.0014 0.0218
0.0135 0.0025 0.0174 -0.0044 0.0153 -0.0005 0.0308
0.0248 0.0166 0.0032 0.0126 0.0158 0.0293 0.0164
0.0092 NA NA -0.0377 0.0092 -0.0148 0.0352
0.0124 0.0146 -0.0157 0.0112 0.0028 0.0079 0.0233
-0.0004 -0.0105 0.0159 -0.0045 0.0083 -0.0003 0.0249
0.0009 NA NA -0.0631 0.0009 -0.0012 0.0425
0.0085 0.0019 0.0015 -0.0007 0.0056 0.0019 0.0193
-0.01 NA NA 0.0002 -0.01 0.0371 -0.0095
-0.0028 NA NA 0.0528 -0.0028 0.1584 -0.0122
0.0032 NA NA -0.0056 0.0032 0.0561 -0.013
-0.015 NA NA 0.0265 -0.015 0.0837 0.0132
0.0053 0.0124 0.0068 0.0112 0.006 0.01 0.016
0.0048 NA NA 0.0027 0.0048 0.0275 0.0057
0.0148 NA NA -0.0036 0.0148 0.0325 0.0058
0.0105 NA NA 0.0242 0.0105 0.0079 0.0252
0.0003 NA NA 0.0459 0.0003 0.02 0.0221
0.0108 NA NA 0.0036 0.0108 0.0324 0.0063
0.0049 NA NA -0.0201 0.0049 -0.0026 0.0241
0.0076 NA NA -0.0179 0.0076 -0.0038 0.0246
0.0076 0.0094 -0.0026 0.0107 0.0026 0.0079 0.0153
-0.0056 NA NA 0.0183 -0.0056 -0.0041 0.0259
0.0038 0.0012 0.0363 0.0015 0.006 0.0204 0.0007
0.0062 0.0036 0.0063 -0.0006 0.0062 0.0006 0.0179
0.0029 NA NA -0.0092 0.0029 -0.0036 0.0201
0.0059 NA NA -0.0054 0.0059 0.0256 0.0002
0.0027 NA NA -0.003 0.0027 0.0281 -0.0015
0.0147 0.019 -0.0053 0.0193 0.0047 0.0116 0.0172
-0.0011 -0.0003 0.0076 0.0029 0.0032 0.0156 0.0021
0.0104 0.0142 -0.0045 0.0075 0.0029 0.002 0.0162
0.0106 NA NA 0.0074 0.0106 0.0357 0.0089
0.0043 NA NA 0.0112 0.0043 0.0023 0.0185
0.0087 0.0129 0.0051 0.0145 0.0072 0.0096 0.0177
0.0089 0.0044 0.0251 0.0074 0.0196 0.0035 0.044
0.0025 NA NA -0.0065 0.0025 0.0043 0.0227
-0.0033 NA NA -0.0252 -0.0033 0.0024 0.0251
-0.0155 0.01 0.0075 0.024 -0.0032 0.0254 0.0343
-0.0051 NA NA -0.0122 -0.0051 0.0346 0.0062
-0.0175 NA NA 0.0021 -0.0175 0.05 -0.0092
0.0135 0.0067 -0.0061 0.0018 0.0044 0.0203 0.0053
0.0055 NA NA -0.0174 0.0055 -0.0079 0.0209
0.0022 NA NA -0.0046 0.0022 -0.0066 0.0208
0.0024 0.0045 0.0134 0.0047 0.0069 -0.0001 0.0216
-0.0007 -0.0037 0.0092 0.0037 0.0033 0.0191 0.0068
0.0016 NA NA -0.0119 0.0016 -0.0018 0.0267
0.0073 -0.0038 0.006 0.0088 0.0067 0.0062 0.0214
-0.0018 NA NA -0.0152 -0.0018 -0.0052 0.0194
-0.1329 NA NA 0.0396 -0.1329 0.0232 0.1084
-0.001 NA NA -0.0078 -0.001 -0.0067 0.0189
0.0045 NA NA -0.0143 0.0045 -0.0003 0.02
-0.0029 NA NA -0.0069 -0.0029 0.0242 0.0028
0.0075 0.0112 0.0009 0.0131 0.0047 0.0118 0.0178
-0.0029 0.008 0.0026 0.0083 -0.0001 0.0016 0.014
-0.0065 -0.0075 0.0445 0.0057 0.0145 0.0369 0.005
0.0097 NA NA -0.0089 0.0097 0.0224 0.0065
0.0012 NA NA 0.0126 0.0012 0.005 0.0202
-0.0187 NA NA -0.0222 -0.0187 0.0345 -0.0105
NA -0.0009 0.0175 -0.0009 0.0175 0.0198 0.0142
0.0229 NA NA -0.0101 0.0229 0.0264 0.0172
0.0004 0.0225 0.0083 0.0126 0.0042 0.0072 0.0148
0.0085 -0.0051 0.006 -0.0081 0.0073 -0.0103 0.0193
0.018 NA NA -0.0023 0.018 0.0839 0.0145
0.027 NA NA 0.0079 0.027 0.0283 0.1316
-0.0077 -0.005 0.0104 0.002 0.0006 0.0192 -0.0056
-0.0022 0.0113 0.0113 0.0059 0.0044 0.0077 0.0147
0.003 NA NA 0.0158 0.003 0.003 0.02
0.0018 NA NA -0.0168 0.0018 0.0298 0.0053
0.0016 NA NA 0.019 0.0016 -0.0003 0.0243
0.0031 -0.0083 -0.0132 -0.004 -0.0052 0.0182 -0.003
0.0194 0.0023 0.004 0.0054 0.0126 0.0297 0.0126
0.002 NA NA 0.0014 0.002 0.0011 0.0201
0.0002 NA NA -0.0092 0.0002 0.0037 0.0182
0.0057 0.0036 0.0319 0.0027 0.0167 0.0332 0.0156
-0.0019 NA NA 0.0103 -0.0019 0.0037 0.0202
-0.0037 NA NA -0.0036 -0.0037 -0.0034 0.0179
0.0047 NA NA -0.0287 0.0047 0.0296 0.0015
-0.0115 NA NA -0.0232 -0.0115 0.0294 -0.0079
-0.0004 NA NA -0.0066 -0.0004 -0.0013 0.0166
-0.0001 NA NA 0.0017 -0.0001 0.0015 0.0181
-0.024 NA NA -0.0214 -0.024 0.1142 0.0018
0.013 0.0096 -0.0254 0.0031 -0.0046 0.0231 -0.0043
0.0137 0.0001 0.0031 0.0035 0.0087 0.0186 0.0075
0.0001 NA NA -0.0361 0.0001 -0.0039 0.0289
NA -0.0015 0.0102 -0.0015 0.0102 0.0159 0.008
0.0011 NA NA 0.0087 0.0011 0.0116 0.0406
-0.0111 NA NA -0.0445 -0.0111 0.0599 -0.0005
NA -0.0038 0.0147 -0.0038 0.0147 0.0169 0.0108
0.0908 NA NA -0.3431 0.0908 0.3616 0.0353
-0.0021 NA NA -0.0142 -0.0021 -0.0012 0.028
-0.0024 NA NA -0.0092 -0.0024 -0.0059 0.0187
-0.0013 NA NA 0.0295 -0.0013 0.004 0.0241
-0.0035 NA NA -0.0384 -0.0035 0.0238 0.0011
0.1213 NA NA 0.0657 0.1213 0.1903 0.3394
-0.0144 NA NA -0.0107 -0.0144 0.0057 0.0196
0.0089 -0.005 -0.0256 -0.005 -0.009 0.0214 0.0025
-0.0048 NA NA 0.0114 -0.0048 0.0109 0.0169
0.0026 NA NA 0.024 0.0026 0.0198 0.0203
-0.006 0.0261 -0.0011 -0.0151 -0.004 0.0077 0.0742
0.0175 0.0226 -0.0161 0.0251 -0.0025 -0.0175 0.0893
-0.0084 NA NA -0.0516 -0.0084 0.0335 -0.0093
-0.0095 -0.0108 -0.0008 -0.0058 -0.006 0.0143 -0.0056
-0.0042 0.0009 -0.0008 -0.0019 -0.0025 0.0134 0.0036
0.0011 0.0136 -0.0059 0.0122 -0.0023 0.0078 0.0135
-0.0148 NA NA -0.0043 -0.0148 0.0831 -0.0184
0.0107 -0.0109 0.0073 -0.004 0.0092 0.0202 0.0103
0.0549 0.0088 0.005 0.0089 0.0088 0.016 0.0355
0.0075 NA NA -0.026 0.0075 0.0203 0.0056
-0.0036 0.0095 -0.0005 0.0057 -0.0021 0.0053 0.0107
0.011 -0.0071 -0.0147 -0.0039 -0.0022 -0.0019 0.0153
0.0024 0.0031 -0.0132 0.0021 -0.0043 0.0051 0.0134
-0.0143 NA NA 0.0127 -0.0143 0.0091 0.0179
-0.0193 0.0145 0.0033 -0.0018 -0.0137 -0.0032 0.0166
-0.0237 -0.0289 -0.0029 -0.0217 -0.0144 -0.0056 0.022
-0.0231 NA NA -0.1249 -0.0231 0.1857 -0.1985
-0.0121 NA NA -0.0177 -0.0121 -0.0018 0.0128
-0.0231 NA NA -0.0452 -0.0231 -0.0142 0.0187
0.0072 -0.0238 0.006 -0.0158 0.0067 0.0081 0.0104
-0.0206 NA NA 0.0102 -0.0206 0.0013 0.0269
-0.0056 0.0035 -0.006 0.0028 -0.0058 -0.0013 0.0102
-0.0403 NA NA 0.0882 -0.0403 0.0107 0.0384
-0.0104 NA NA -0.0535 -0.0104 0.0279 -0.0076
-0.017 -0.0094 0.004 -0.0099 -0.0062 0.0115 -0.0013
JOIN
T.MEN
.Effe
ct
JOIN
T.WOM
EN.E
ffect
DIS
COVE
RY.M
EN.G
CIn
.GCOut
.Std
Err
DIS
COVE
RY.W
OM
EN.G
CIn
.GCOut
.Std
Err
INSIL
ICO.M
EN.G
CIn
.GCOut
.Std
Err
INSIL
ICO.W
OM
EN.G
CIn
.GCOut
.Std
Err
META
BOCHIP
.MEN
.GCIn
.GCOut
.Std
Err
META
BOCHIP
.WOM
EN.G
CIn
.GCOut
.Std
Err
REP2W
AY.M
EN.S
tdErr
0.00677802 0.00678439 0.01395492 0.00833055 0.00844 0.009894 0.0072
0.00749691 0.00740115 0.01516839 0.00904169 0.009152 0.01071 0.0078
0.0077023 0.00760674 0.01456166 0.00985443 0.008237 0.00969 0.0072
0.00605446 0.00583775 0.01828426 0.01053382 0.010097 0.011139 0.0088
0.00749691 0.00740115 0.01708972 0.00965125 0.00966 0.01122 0.0084
0.00842118 0.00842909 0.01820207 0.01056558 NA NA 0.0182
0.00708612 0.00709277 0.01526951 0.00914329 0.008338 0.009792 0.0073
0.0079 0.0074 0.0142 0.01 NA NA 0.0142
0.0069 0.0067 0.0114 0.0082 0.00747743 0.00811082 0.0063
0.0071 0.0068 0.0124 0.0085 0.00810932 0.00882051 0.0068
0.0077023 0.00760674 0.01719084 0.00975284 0.009355 0.01102 0.0082
0.00790769 0.00791512 0.01678635 0.00975284 0.00966 0.01132 0.0084
0.0065 0.006 0.0115 0.0082 0.0082 0.009 0.0067
0.00996164 0.0098682 0.02164024 0.01219105 0.01271 0.01479 0.011
0.0072 0.0067 0.0132 0.0094 0.0094 0.0102 0.0077
0.00677802 0.00668159 0.01375267 0.00833055 0.008237 0.00969 0.0071
0.0064 0.0058 0.011 0.0079 0.0082 0.009 0.0066
0.0086 0.0082 NA NA 0.01004326 0.01124338 0.01004326
0.00677802 0.00668159 0.01365155 0.00812737 0.008338 0.00969 0.0071
0.0067 0.0062 0.0118 0.0086 0.009 0.0098 0.0072
0.0064 0.0058 0.0115 0.008 0.0102 0.0102 0.0076
0.0117075 0.01141011 0.0223481 0.01401971 0.01464 0.01693 0.0122
0.0077 0.0074 0.0122 0.0088 0.00905717 0.00983436 0.0073
0.0066 0.0064 0.0105 0.0077 0.00789869 0.0082122 0.0063
0.0078 0.0073 0.0143 0.0099 0.0098 0.0108 0.0081
0.0071 0.0068 NA NA 0.0080994 0.00903674 0.0080994
0.0141 0.0129 0.0261 0.0178 NA NA 0.0261
0.0068 0.0063 0.0119 0.0085 0.0087 0.0097 0.007
0.0122 0.0112 0.0226 0.0165 0.0149 0.0163 0.0124
0.0104 0.0087 0.0135 0.0096 0.0097 0.0105 0.0079
0.0061 0.0057 0.0108 0.0078 0.0082 0.0089 0.0065
0.0089 0.0084 0.0171 0.012 0.0122 0.0133 0.0099
0.0066 0.0061 0.0116 0.0083 0.0086 0.0095 0.0069
0.006 0.0056 0.0107 0.0077 0.008 0.0088 0.0064
0.0065 0.006 0.0112 0.0079 0.008 0.0088 0.0065
0.0061 0.0057 0.0117 0.008 0.008 0.0088 0.0066
0.0061 0.0057 0.0112 0.0079 0.008 0.0088 0.0065
0.0067 0.0062 0.0115 0.0086 0.0088 0.0092 0.007
0.0074 0.0071 NA NA 0.00907133 0.0101926 0.00907133
0.0067 0.0061 0.0118 0.0081 0.008 0.0087 0.0066
0.0063 0.0058 0.0114 0.008 0.0081 0.0089 0.0066
0.0061 0.0057 0.0111 0.0079 NA NA 0.0111
0.0081 0.0076 0.01427755 0.0083405 0.008626 0.009818 0.0074
0.0078 0.0074 0.01534395 0.00891225 0.008319 0.00912 0.0073
0.0164 0.0166 0.0314 0.0244 0.0259 0.0301 0.02
0.0063 0.0057 0.011 0.0079 0.008 0.0088 0.0065
0.0084 0.0078 0.0144 0.0105 0.0112 0.0122 0.0088
0.0064 0.006 0.0117 0.0082 0.0083 0.0091 0.0068
0.0068 0.0064 0.0122 0.0089 0.0089 0.0098 0.0072
0.0069 0.0065 0.0124 0.0089 0.0112 0.0129 0.0083
0.0137 0.0126 0.01606918 0.0095091 NA NA 0.0161
0.0065 0.0061 0.0116 0.0083 0.0084 0.0093 0.0068
0.0086 0.0079 0.0141 0.0102 0.0104 0.0114 0.0084
0.0061 0.0057 0.0113 0.0079 0.0095 0.0099 0.0073
0.00542814 0.00521227 0.01555677 0.00921709 0.008448 0.009132 0.0074
0.0066 0.0061 0.0121 0.0085 0.0086 0.0095 0.007
0.0098 0.0093 0.01991665 0.01137081 0.01042 0.01158 0.0092
0.0068 0.0063 0.0125 0.0089 0.0092 0.0101 0.0074
0.0076 0.0071 0.014 0.0097 NA NA 0.014
0.01047513 0.01017658 0.01537064 0.00863533 0.00844 0.009894 0.0074
0.0061 0.0057 0.0127 0.0083 0.008 0.0087 0.0068
0.0063 0.0058 0.0112 0.0079 NA NA 0.0112
0.0093 0.0087 0.0151 0.0106 0.0089 0.0097 0.0077
0.017 0.0157 0.0287 0.0205 0.0204 0.0225 0.0166
0.0172 0.016 0.03383798 0.0188489 NA NA 0.0338
0.0066 0.0061 0.0119 0.0084 0.0084 0.0092 0.0069
0.0065 0.0063 NA NA 0.00755944 0.00851135 0.00755944
0.0068 0.0063 0.0126 0.0086 0.0089 0.0097 0.0073
0.0063 0.0058 0.0112 0.008 0.0082 0.009 0.0066
0.00511498 0.00489954 0.01646593 0.00901452 0.008242 0.009032 0.0074
0.0063 0.0058 0.0112 0.0079 0.0081 0.0089 0.0066
0.0078 0.0075 0.014 0.0097 0.0109 0.012 0.0086
0.0068 0.0063 0.0117 0.0086 NA NA 0.0117
0.0079 0.0073 0.0149 0.0104 NA NA 0.0149
0.0103 0.01 NA NA 0.01263507 0.01513128 0.01263507
0.0383 0.0338 0.07058558 0.04339409 NA NA 0.0706
0.00469743 0.0045868 0.01394048 0.00830551 0.007624 0.008229 0.0067
0.01409229 0.01365616 0.04404384 0.02532167 0.021739 0.023482 0.0195
0.0176 0.0168 0.03345025 0.01841013 NA NA 0.0335
0.0292 0.031 NA NA NA NA NA
0.0173 0.0168 NA NA 0.01900659 0.02091059 0.01900659
0.00718881 0.00719556 0.01466278 0.00863533 NA NA 0.0147
0.0162 0.0151 0.02824914 0.01637586 NA NA 0.0282
0.07630712 0.12227994 NA NA NA NA NA
0.1629 0.2179 NA NA NA NA NA
0.00883197 0.00884026 0.02517953 0.02336618 0.008338 0.009894 0.0079
0.0064 0.006 0.0116 0.0083 NA NA 0.0116
0.0065 0.0063 NA NA 0.00766743 0.00861643 0.00766743
0.0082 0.0075 0.0138 0.0102 0.0103 0.0114 0.0083
0.4064 0.5157 NA NA NA NA NA
0.0089 0.0084 0.01545895 0.00920236 NA NA 0.0155
0.08330107 0.15574273 NA NA NA NA NA
0.0071 0.0068 NA NA 0.00788342 0.0087215 0.00788342
0.00842118 0.00801791 0.0169886 0.00924488 0.009965 0.01163 0.0086
0.10908473 0.1082068 NA NA NA NA NA
0.0061 0.0057 0.0111 0.0081 NA NA 0.0111
0.1256 0.1411 NA NA NA NA NA
0.011 0.0104 0.03465091 0.03667341 NA NA 0.0347
0.0066 0.0064 NA NA 0.00777543 0.0087215 0.00777543
0.0094 0.0088 0.01703107 0.00996791 NA NA 0.017
0.0065 0.0061 0.0117 0.0083 NA NA 0.0117
0.0096 0.0088 0.0182 0.0124 0.012 0.0132 0.01
0.00542814 0.00521227 0.01606186 0.00952095 0.008861 0.009533 0.0078
0.11399093 0.10841529 NA NA NA NA NA
0.009 0.0083 0.01719133 0.00939354 0.0091 0.0106 0.008
0.0098 0.0093 0.0173 0.0129 NA NA 0.0173
0.00521937 0.00500378 0.01596084 0.00901452 0.007933 0.00863 0.0071
0.0079 0.0076 NA NA NA NA NA
0.0146 0.0132 0.0271 0.0191 NA NA 0.0271
0.0095 0.0089 0.01727465 0.00993665 NA NA 0.0173
0.0148 0.0136 0.0265 0.019 NA NA 0.0265
0.04300757 0.04367885 NA NA 0.139606 0.163772 0.1396
0.0099 0.0094 NA NA NA NA NA
0.1003 0.0943 NA NA NA NA NA
0.00960363 0.00906936 0.02757791 0.01488914 NA NA 0.0276
0.1508 0.1378 0.66543558 0.63133512 NA NA 0.6654
0.0141 0.0133 0.01912029 0.01145182 NA NA 0.0191
0.0061 0.0057 0.011 0.0079 0.0081 0.0089 0.0065
0.0193 0.0185 NA NA NA NA NA
0.00688072 0.00678439 0.01425829 0.00843214 NA NA 0.0143
0.1158 0.113 NA NA NA NA NA
0.0157 0.0144 0.01737626 0.01116593 NA NA 0.0174
0.0078 0.0076 NA NA 0.00874735 0.00998244 0.00874735
0.0066 0.0062 0.0115 0.0083 NA NA 0.0115
0.0069 0.0066 NA NA NA NA NA
0.1109637 0.19952583 NA NA NA NA NA
0.0068 0.0064 0.0122 0.0091 0.0083 0.0091 0.0069
0.0065 0.0062 0.0105 0.0075 NA NA 0.0105
0.00790769 0.00781233 0.01799982 0.00985443 NA NA 0.018
0.00511498 0.00500378 0.01666797 0.00921709 NA NA 0.0167
0.00739421 0.00729836 0.01587625 0.00914329 NA NA 0.0159
0.092 0.1368 NA NA NA NA NA
0.0643 0.0648 NA NA NA NA NA
0.1905 0.2575 NA NA NA NA NA
0.01191289 0.01161569 0.02669637 0.01452767 NA NA 0.0267
0.0134 0.0126 0.02499743 0.01464888 NA NA 0.025
0.00553253 0.00531652 0.01646593 0.00962224 NA NA 0.0165
0.0064 0.0058 0.0111 0.008 0.008 0.0088 0.0065
0.0084 0.008 NA NA NA NA NA
0.00469743 0.0045868 0.01424354 0.00830551 NA NA 0.0142
0.0064 0.0062 NA NA NA NA NA
0.0136 0.0134 0.02196799 0.0130878 NA NA 0.022
0.01492738 0.01449012 0.05212528 0.02927185 NA NA 0.0521
0.008 0.0076 0.0109 0.0088 0.0072668 0.00780666 0.006
0.0188941 0.01761748 0.04353875 0.02471395 NA NA 0.0435
0.05793495 0.08704497 NA NA NA NA NA
0.11242512 0.11039595 NA NA NA NA NA
0.1702 0.1941 NA NA NA NA NA
0.1421 0.1348 NA NA NA NA NA
0.0068 0.0064 NA NA NA NA NA
0.3457 0.3584 NA NA NA NA NA
0.3012 0.1808 NA NA NA NA NA
0.0066 0.0062 0.0121 0.0085 NA NA 0.0121
0.1114 0.1218 NA NA NA NA NA
0.0071 0.0069 0.0122 0.0087 0.00800401 0.00882051 0.0067
0.0072 0.007 NA NA NA NA NA
0.01191289 0.01182128 0.02790984 0.01544199 NA NA 0.0279
0.0471 0.0507 0.0358 0.0436 NA NA 0.0358
0.0881 0.129 NA NA NA NA NA
0.0066 0.0064 NA NA NA NA NA
0.0465 0.0487 NA NA NA NA NA
0.0213 0.0203 0.04430439 0.02427821 0.02348 0.02593 0.0207
0.21597732 0.17982343 NA NA NA NA NA
0.2635 0.2266 NA NA NA NA NA
0.0917 0.0792 NA NA NA NA NA
0.0104 0.0097 0.01896874 0.01047648 NA NA 0.019
0.43132832 0.48922398 NA NA NA NA NA
0.0097 0.0091 0.01911271 0.0110272 0.0088 0.0103 0.008
0.00793344 0.00771417 0.02485042 0.01377499 0.013394 0.014651 0.0118
0.0068 0.0065 NA NA NA NA NA
0.032882 0.04795292 NA NA NA NA NA
0.0133 0.0128 0.02267991 0.01441703 NA NA 0.0227
0.0906 0.1011 NA NA NA NA NA
0.03924962 0.06025388 NA NA NA NA NA
0.0067 0.0065 0.0107 0.0076 NA NA 0.0107
0.0099 0.0096 NA NA NA NA NA
0.0911 0.0857 NA NA NA NA NA
0.00542814 0.00521227 0.01697102 0.00962224 NA NA 0.017
0.0484 0.0474 0.08799908 0.04548322 NA NA 0.088
0.0089 0.0084 0.01625849 0.00973177 NA NA 0.0163
0.01868533 0.01584531 NA NA NA NA NA
0.0922 0.1414 NA NA NA NA NA
0.0183 0.0187 NA NA NA NA NA
0.00677802 0.00678439 0.01456166 0.00853373 0.00844 0.009894 0.0073
0.009 0.0086 0.01495044 0.00910011 NA NA 0.015
0.0232 0.022 NA NA NA NA NA
0.2151509 0.20260649 NA NA NA NA NA
0.0066 0.0064 0.0113 0.008 NA NA 0.0113
0.0092 0.0086 0.01601125 0.00935763 NA NA 0.016
0.0252 0.0236 0.04156077 0.02888799 NA NA 0.0416
0.0845 0.0887 NA NA NA NA NA
0.0097 0.0092 0.01869727 0.01106349 NA NA 0.0187
0.1052 0.0894 NA NA NA NA NA
0.0808 0.1126 NA NA NA NA NA
0.0096 0.009 0.01754098 0.01006963 NA NA 0.0175
0.0095 0.0086 0.01749471 0.01051669 NA NA 0.0175
0.0113 0.0106 0.01891046 0.01204824 NA NA 0.0189
0.0099 0.0093 0.01910373 0.01106349 0.007687 0.008505 0.0071
0.01450984 0.01480286 0.03272983 0.02441009 NA NA 0.0327
0.0365 0.0644 0.0398 0.033 NA NA 0.0398
0.0061 0.0057 0.0111 0.008 0.008 0.0088 0.0065
0.0095 0.009 0.01733702 0.00996791 NA NA 0.0173
0.0224 0.0221 NA NA 0.02473017 0.02826608 0.02473017
0.0069 0.0066 0.0112 0.0084 0.00716148 0.00780666 0.006
0.01848552 0.01850288 0.03933669 0.02336618 NA NA 0.0393
0.0121 0.0112 0.0227 0.0153 NA NA 0.0227
0.0093 0.0086 0.01830371 0.01031248 NA NA 0.0183
0.0165 0.0153 0.03120663 0.016681 NA NA 0.0312
0.0093 0.0087 0.01554718 0.01055129 0.008214 0.00912 0.0073
0.0135 0.0127 0.02162028 0.01352788 NA NA 0.0216
0.0213 0.0264 0.0773 0.07 NA NA 0.0773
0.04008472 0.03773686 0.0758645 0.03980567 NA NA 0.0759
0.0071 0.0068 0.0125 0.0084 0.00800401 0.00882051 0.0067
0.0066 0.0064 NA NA 0.00755944 0.00861643 0.00755944
0.0065 0.0062 0.0113 0.009 NA NA 0.0113
0.0081 0.0076 0.01442941 0.00850249 NA NA 0.0144
0.0075 0.0071 0.0121 0.0087 0.00842527 0.00912467 0.0069
0.00883197 0.00873747 0.01911217 0.01097194 0.01098 0.01295 0.0095
0.0083 0.0078 0.01554718 0.00911713 NA NA 0.0155
0.0087 0.0081 0.0154 0.0109 NA NA 0.0154
0.006 0.0056 0.0107 0.0077 NA NA 0.0107
0.0049062 0.00469105 0.01484964 0.00860937 NA NA 0.0148
0.0102 0.0096 0.01991665 0.011883 NA NA 0.0199
0.00595008 0.00583775 0.0179812 0.01083768 0.00917 0.010035 0.0082
0.00532375 0.00531652 0.01555677 0.00921709 NA NA 0.0156
0.00960363 0.01073728 0.0331339 0.03291817 NA NA 0.0331
0.0075 0.0069 0.0126 0.0091 NA NA 0.0126
0.012 0.0117 0.0198 0.0141 0.01432296 0.01551193 0.0116
0.0101 0.0093 0.0181 0.0125 0.0136 0.0148 0.0109
0.0113994 0.01141011 0.02426943 0.01452767 NA NA 0.0243
0.00720272 0.00708869 0.02343617 0.01347113 0.016279 0.018765 0.0134
0.0105 0.01 0.0167 0.012 0.01021564 0.01115237 0.0087
0.01294403 0.01240521 0.04131636 0.02258693 NA NA 0.0413
0.0082 0.0076 0.01486544 0.00857671 0.0087 0.0101 0.0075
0.01109131 0.01058776 0.0188088 0.01087035 NA NA 0.0188
0.0618 0.0582 0.05445864 0.05695951 NA NA 0.0545
0.01591809 0.01521348 0.03519067 0.02143593 NA NA 0.0352
0.0288 0.0251 0.03285028 0.03425322 NA NA 0.0329
0.0063 0.0058 0.0114 0.008 0.008 0.0088 0.0065
0.0082 0.0077 0.01437953 0.00854393 NA NA 0.0144
0.0096 0.0089 0.01769696 0.01051669 NA NA 0.0177
0.0097 0.0091 0.01733702 0.00945935 NA NA 0.0173
0.0078 0.0072 0.0141 0.0096 NA NA 0.0141
0.0097 0.0091 0.017439 0.01027305 NA NA 0.0174
0.00821579 0.00812071 0.01678635 0.00995602 NA NA 0.0168
0.0093 0.0086 0.01937667 0.00976449 NA NA 0.0194
0.00521937 0.00510803 0.01616288 0.0091158 0.008448 0.009333 0.0075
0.00772466 0.00771417 0.02990132 0.01458528 NA NA 0.0299
0.0065 0.0064 0.0107 0.0079 0.02274823 0.02950309 0.0097
0.0076 0.0072 0.01412456 0.00870737 0.008529 0.009223 0.0073
0.007 0.0066 0.0121 0.0091 NA NA 0.0121
0.0076 0.0072 0.0156488 0.00870737 NA NA 0.0156
0.0086 0.0081 0.01529737 0.00915421 NA NA 0.0153
0.0076 0.0071 0.01402295 0.00850249 0.007687 0.008505 0.0067
0.00511498 0.00500378 0.01505168 0.00891323 0.008242 0.008931 0.0072
0.00584569 0.00562926 0.01818324 0.00982481 0.008861 0.009734 0.008
0.0128 0.0116 0.01464532 0.00869112 NA NA 0.0146
0.0067 0.0065 0.0109 0.0078 NA NA 0.0109
0.0078 0.007 0.0118 0.0085 0.0091 0.01 0.0072
0.026 0.0233 0.03954006 0.02358596 0.0147 0.017 0.0138
0.0087 0.0081 0.01794891 0.00935763 NA NA 0.0179
0.00814221 0.00792266 0.02535551 0.01347113 NA NA 0.0254
0.01200454 0.01198823 0.03606342 0.02187792 0.018545 0.020471 0.0165
0.0108 0.0102 0.01951019 0.01208788 NA NA 0.0195
0.0163 0.015 0.02552761 0.01564401 NA NA 0.0255
0.00801039 0.00781233 0.01607849 0.00965125 0.008847 0.0104 0.0078
0.0082 0.0076 0.01526995 0.00878092 NA NA 0.0153
0.0082 0.0077 0.01499142 0.00864564 NA NA 0.015
0.00872927 0.00863468 0.01799982 0.01066717 0.01078 0.01275 0.0092
0.00739421 0.00729836 0.01425829 0.00853373 0.008745 0.0103 0.0075
0.0107 0.0099 0.01876477 0.01108676 NA NA 0.0188
0.0099 0.0093 0.01641918 0.01027305 0.01027 0.01172 0.0087
0.0076 0.007 0.01425869 0.00837251 NA NA 0.0143
0.03747504 0.0323161 0.08606732 0.0836628 NA NA 0.0861
0.007 0.0065 0.0127 0.009 NA NA 0.0127
0.008 0.0074 0.01539935 0.00854393 NA NA 0.0154
0.0077 0.0073 0.01422618 0.00860493 NA NA 0.0142
0.00729151 0.00719556 0.01587625 0.00904169 0.00905 0.01061 0.0079
0.00542814 0.00521227 0.01484964 0.00860937 0.007624 0.008329 0.0068
0.0153 0.0148 0.0223 0.0164 0.01832496 0.01956734 0.0142
0.0073 0.0067 0.0129 0.0092 NA NA 0.0129
0.0077 0.0074 0.0126 0.0091 NA NA 0.0126
0.0111 0.0104 0.02141632 0.01190047 NA NA 0.0214
0.0074 0.0072 NA NA 0.00885535 0.00987737 0.00885535
0.0086 0.008 0.016 0.0115 NA NA 0.016
0.0068 0.0065 0.0108 0.0077 0.00737211 0.00800943 0.0061
0.0095 0.0091 0.01688281 0.0097136 0.00885539 0.01027309 0.0078
0.0303 0.0224 0.04120092 0.02268209 NA NA 0.0412
0.055 0.0536 0.05420804 0.05490741 NA NA 0.0542
0.0084 0.0079 0.0162812 0.00929144 0.0087 0.0101 0.0077
0.0069 0.0067 0.0108 0.008 0.00747743 0.0082122 0.0061
0.0087 0.0081 0.01499142 0.00874735 NA NA 0.015
0.0101 0.0096 0.01818919 0.01178056 NA NA 0.0182
0.0101 0.0095 0.01718792 0.01114508 NA NA 0.0172
0.00668079 0.00656747 0.01959749 0.01174926 0.010612 0.01154 0.0093
0.01252907 0.01243804 0.02487616 0.01544199 0.01464 0.01734 0.0126
0.0088 0.0084 0.01423851 0.00858887 NA NA 0.0142
0.0075 0.0071 0.01453103 0.00850249 NA NA 0.0145
0.0162 0.015 0.02705317 0.01421253 0.01428938 0.01665636 0.0126
0.0085 0.0079 0.01597782 0.00949565 NA NA 0.016
0.0072 0.0067 0.0127 0.009 NA NA 0.0127
0.0102 0.0096 0.01830666 0.01042934 NA NA 0.0183
0.0099 0.0093 0.01991665 0.01147325 NA NA 0.0199
0.0067 0.0065 0.0112 0.008 NA NA 0.0112
0.0076 0.0072 0.0150391 0.00860493 NA NA 0.015
0.0461 0.0397 0.05365302 0.03564901 NA NA 0.0537
0.0107 0.0099 0.01961834 0.01143562 0.0107 0.0124 0.0094
0.0087 0.0081 0.0135 0.0096 0.00916248 0.01013852 0.0076
0.0138 0.0126 0.02217139 0.01267881 NA NA 0.0222
0.0064 0.0062 NA NA 0.00766743 0.00851135 0.00766743
0.0209 0.0178 0.02481569 0.01779123 NA NA 0.0248
0.0212 0.0199 0.03865135 0.02176667 NA NA 0.0387
0.007 0.0068 NA NA 0.0080994 0.00893166 0.0080994
0.12891831 0.10393273 0.24062483 0.29909958 NA NA 0.2406
0.0126 0.0119 0.0249857 0.01322274 NA NA 0.025
0.0085 0.0078 0.01678683 0.00929144 NA NA 0.0168
0.0115 0.0105 0.01958063 0.01159533 NA NA 0.0196
0.0088 0.0082 0.01778273 0.00983421 NA NA 0.0178
0.1555 0.2506 0.13455392 0.12678805 NA NA 0.1346
0.0086 0.0082 0.01879888 0.01147325 NA NA 0.0188
0.011 0.0104 0.01941609 0.0136819 0.0113 0.0132 0.0098
0.0082 0.0077 0.0157053 0.00884907 NA NA 0.0157
0.0126 0.0114 0.01505214 0.00879337 NA NA 0.0151
0.0398 0.0387 0.0729 0.0445 0.04486457 0.05302446 0.0382
0.0474 0.049 0.0734 0.0629 0.04339014 0.0520106 0.0374
0.0134 0.0121 0.02447236 0.01470294 NA NA 0.0245
0.00698342 0.00688718 0.01435941 0.00853373 0.008847 0.01051 0.0075
0.007 0.0067 0.0126 0.0085 0.00779338 0.00841497 0.0066
0.0079 0.0075 0.01483587 0.00891225 0.008319 0.00912 0.0073
0.0458 0.0499 0.04028307 0.03417571 NA NA 0.0403
0.0112 0.0106 0.02095095 0.01145182 0.01106924 0.01286629 0.0098
0.02433927 0.02580123 0.05025793 0.0550629 0.01322 0.01571 0.0128
0.0089 0.0084 0.01434021 0.00848662 NA NA 0.0143
0.0065 0.0063 0.0107 0.0077 0.00716148 0.00780666 0.006
0.0111 0.0099 0.01870821 0.01133352 0.0095 0.011 0.0085
0.00842118 0.0082235 0.01668523 0.00985443 0.00966 0.01132 0.0084
0.0106 0.0099 0.01866279 0.01108676 NA NA 0.0187
0.00985894 0.00925144 0.01820207 0.01188627 0.0242 0.02071 0.0145
0.01396684 0.01397995 0.02881994 0.01716906 0.01607 0.01907 0.014
0.125 0.1386 0.1111 0.1434 NA NA 0.1111
0.0084 0.008 0.01413681 0.00838437 NA NA 0.0141
0.0122 0.0115 0.0222476 0.01306928 NA NA 0.0222
0.0077 0.0073 0.01526995 0.00857671 0.0082 0.0096 0.0072
0.0195 0.0181 0.0306128 0.01717774 NA NA 0.0306
0.008 0.0075 0.01483587 0.00880981 0.007792 0.008608 0.0069
0.0294 0.0274 0.04597005 0.02730033 NA NA 0.046
0.0186 0.0172 0.02318843 0.0132923 NA NA 0.0232
0.0096 0.0092 0.0155 0.0107 0.00947843 0.01044268 0.0081
META
BOCHIP
.MEN
.GCIn
.GCOut
.Std
Err
META
BOCHIP
.WOM
EN.G
CIn
.GCOut
.Std
Err
REP2W
AY.M
EN.S
tdErr
REP2W
AY.W
OM
EN.S
tdErr
JOIN
T.MEN
.Std
Err
JOIN
T.WOM
EN.S
tdErr
DIS
COVE
RY.M
EN.E
AF
DIS
COVE
RY.W
OM
EN.E
AF
INSIL
ICO.M
EN.E
AF
INSIL
ICO.W
OM
EN.E
AF
0.0064 0.0049 0.0047 0.5844 0.5814 0.5858 0.5936
0.0069 0.0054 0.005 0.7219 0.7184 0.7164 0.7171
0.0069 0.0053 0.0051 0.4745 0.4737 0.4625 0.4596
0.0077 0.005 0.0047 0.2082 0.2078 0.1905 0.2025
0.0073 0.0056 0.0052 0.7189 0.7199 0.7387 0.7271
0.0106 0.0076 0.0066 0.7821 0.7835 0.7559 0.7772
0.0067 0.0051 0.0049 0.4135 0.4182 0.4284 0.4292
0.01 0.0069 0.0059 0.186 0.183 0.1809 0.1875
0.0058 0.0047 0.0044 0.6535 0.6537 0.6496 0.6559
0.0061 0.0049 0.0045 0.7177 0.7135 0.733 0.7213
0.0073 0.0056 0.0053 0.2484 0.249 0.2462 0.2477
0.0074 0.0058 0.0054 0.2343 0.2315 0.2354 0.2327
0.0061 0.0047 0.0043 0.4013 0.3958 0.3949 0.3975
0.0094 0.0074 0.0068 0.8616 0.8623 0.8741 0.8642
0.0069 0.0053 0.0048 0.7272 0.7275 0.7283 0.7241
0.0063 0.0049 0.0046 0.5038 0.5074 0.5183 0.5098
0.0059 0.0046 0.0041 0.368 0.3659 0.3934 0.383
0.01124338 0.0065 0.0066 0.8287 0.8289 NA NA
0.0062 0.0049 0.0045 0.49 0.483 0.484 0.4781
0.0065 0.0049 0.0045 0.2968 0.2978 0.3282 0.3034
0.0063 0.0049 0.0043 0.4627 0.4652 0.4663 0.4676
0.0108 0.0084 0.0078 0.9069 0.9069 0.8594 0.8925
0.0066 0.0053 0.0049 0.7691 0.7725 0.7207 0.7367
0.0056 0.0046 0.0042 0.3965 0.398 0.4096 0.3961
0.0073 0.0056 0.0052 0.2331 0.2245 0.2122 0.2113
0.00903674 0.0053 0.0054 0.6756 0.6745 NA NA
0.0178 0.0124 0.0104 0.9406 0.9431 0.9414 0.943
0.0064 0.0049 0.0045 0.3126 0.3124 0.3314 0.3173
0.0116 0.0087 0.0081 0.0785 0.0831 0.0795 0.0686
0.0071 0.0063 0.0055 0.2139 0.2106 0.2138 0.2164
0.0059 0.0044 0.0041 0.5653 0.5624 0.574 0.5806
0.0089 0.0066 0.0061 0.8748 0.8698 0.7852 0.8522
0.0063 0.0048 0.0044 0.6779 0.6728 0.6541 0.659
0.0058 0.0044 0.004 0.5251 0.5251 0.5157 0.5177
0.0059 0.0046 0.0042 0.4599 0.4626 0.452 0.4601
0.0059 0.0045 0.0041 0.5508 0.5461 0.5644 0.5585
0.0059 0.0044 0.0041 0.4469 0.4505 0.4528 0.4572
0.0063 0.0048 0.0044 0.3676 0.3695 0.3598 0.349
0.0101926 0.0057 0.0058 0.2433 0.2473 NA NA
0.0059 0.0047 0.0042 0.5039 0.5155 0.5145 0.5225
0.0059 0.0046 0.0041 0.5984 0.5991 0.5917 0.5986
0.0079 0.0053 0.0046 0.4466 0.4483 0.4527 0.4514
0.0064 0.0055 0.0049 0.599 0.5974 0.5876 0.5762
0.0064 0.0053 0.0048 0.3307 0.3306 0.3169 0.328
0.019 0.0127 0.0125 0.0489 0.0489 0.1513 0.1201
0.0059 0.0045 0.0041 0.5341 0.5353 0.5346 0.5271
0.008 0.0061 0.0056 0.1601 0.1626 0.2139 0.19
0.0061 0.0047 0.0043 0.6584 0.6604 0.6394 0.644
0.0066 0.0049 0.0046 0.271 0.2705 0.2968 0.2779
0.0073 0.0053 0.0049 0.2738 0.2695 0.2884 0.277
0.0095 0.0104 0.0076 0.7425 0.7434 0.7486 0.7431
0.0062 0.0047 0.0043 0.6721 0.6739 0.6623 0.6772
0.0076 0.006 0.0055 0.8278 0.8288 0.7645 0.7901
0.0062 0.0047 0.0042 0.4995 0.5081 0.4756 0.5039
0.0065 0.0044 0.0041 0.7337 0.7379 0.7301 0.7371
0.0063 0.0048 0.0044 0.3249 0.3227 0.3269 0.3303
0.0081 0.0067 0.0061 0.1981 0.2001 0.2032 0.1946
0.0067 0.005 0.0046 0.7237 0.7206 0.7408 0.7359
0.0097 0.0067 0.0057 0.2146 0.2158 0.2131 0.2207
0.0065 0.006 0.0055 0.4111 0.4117 0.4223 0.4239
0.006 0.0045 0.0041 0.4878 0.4895 0.5063 0.4966
0.0079 0.0055 0.0047 0.4547 0.4515 0.447 0.4501
0.0072 0.0059 0.0055 0.7554 0.7499 0.7496 0.7533
0.0152 0.0119 0.0109 0.0377 0.0374 0.0422 0.0398
0.0188 0.0153 0.0122 0.9473 0.9473 0.9475 0.9463
0.0062 0.0048 0.0043 0.6661 0.6642 0.667 0.6694
0.00851135 0.0049 0.0051 0.5718 0.5753 NA NA
0.0064 0.005 0.0045 0.3059 0.304 0.3129 0.3117
0.006 0.0046 0.0042 0.6117 0.6181 0.613 0.6121
0.0064 0.0042 0.0039 0.6806 0.6815 0.6965 0.6812
0.0059 0.0046 0.0041 0.6074 0.6047 0.5884 0.5947
0.0075 0.0058 0.0053 0.7738 0.7832 0.7554 0.772
0.0086 0.0059 0.0051 0.7142 0.7134 0.6795 0.7032
0.0104 0.007 0.006 0.2083 0.2112 0.195 0.2022
0.01513128 0.008 0.0083 0.1106 0.1104 NA NA
0.0434 0.0337 0.0267 0.0313 0.0299 0.0248 0.0238
0.0058 0.0038 0.0036 0.5071 0.5038 0.4932 0.4871
0.0172 0.0114 0.0107 0.9659 0.9664 0.9674 0.9689
0.0184 0.0156 0.0124 0.0557 0.0534 0.0552 0.0548
NA 0.0292 0.031 0.335 0.335 NA NA
0.02091059 0.0128 0.0131 0.9408 0.942 NA NA
0.0086 0.0065 0.0055 0.3617 0.3572 0.3666 0.353
0.0164 0.014 0.0111 0.0713 0.0705 0.0746 0.0716
NA 0.0763 0.1223 0.0292 0.0251 NA NA
NA 0.1629 0.2179 0.9802 0.9886 NA NA
0.0091 0.0059 0.0063 0.5641 0.5605 0.5368 0.5469
0.0083 0.0056 0.0049 0.484 0.4868 0.5127 0.4984
0.00861643 0.005 0.0051 0.3838 0.3815 NA NA
0.0076 0.0058 0.0053 0.8275 0.8277 0.7984 0.8191
NA 0.4064 0.5157 0.007 0.0099 NA NA
0.0092 0.0077 0.0062 0.6117 0.611 0.6195 0.6069
NA 0.0833 0.1557 0.9935 0.9978 NA NA
0.0087215 0.0053 0.0054 0.3341 0.3275 NA NA
0.0072 0.006 0.0054 0.3053 0.3062 0.3222 0.3139
NA 0.1091 0.1082 0.9959 0.9949 NA NA
0.0081 0.0053 0.0047 0.5156 0.5176 0.5384 0.5301
NA 0.1256 0.1411 0.0249 0.0165 NA NA
0.0367 0.0105 0.01 0.6358 0.6407 0.6721 0.6814
0.0087215 0.005 0.0052 0.6236 0.6199 NA NA
0.01 0.0082 0.0066 0.7657 0.7637 0.759 0.7714
0.0083 0.0057 0.0049 0.676 0.6775 0.6753 0.6778
0.009 0.0069 0.0063 0.8742 0.8726 0.8472 0.8605
0.0067 0.0045 0.0041 0.2658 0.2663 0.2406 0.2559
NA 0.114 0.1084 0.9964 0.9955 NA NA
0.007 0.006 0.0054 0.7089 0.7091 0.7124 0.7139
0.0129 0.0085 0.0075 0.8902 0.8909 0.8601 0.8767
0.0062 0.0042 0.0039 0.3305 0.3297 0.3621 0.3347
NA 0.0079 0.0076 0.2082 0.2126 NA NA
0.0191 0.0129 0.0109 0.9455 0.9425 0.8656 0.906
0.0099 0.0083 0.0066 0.2267 0.2258 0.2168 0.2259
0.019 0.0129 0.0111 0.9467 0.9476 0.9466 0.9509
0.1638 0.0411 0.0422 0.991 0.9921 NA NA
NA 0.0099 0.0094 0.1531 0.1522 NA NA
NA 0.1003 0.0943 0.0258 0.0261 NA NA
0.0149 0.0091 0.0077 0.0855 0.0882 0.0839 0.0883
0.6313 0.1471 0.1346 0.9952 0.9957 0.997 0.997
0.0115 0.0113 0.0087 0.8235 0.8293 0.8172 0.8307
0.0059 0.0044 0.0041 0.5012 0.5007 0.4827 0.5048
NA 0.0193 0.0185 0.9046 0.9036 NA NA
0.0084 0.0062 0.0053 0.6295 0.6324 0.6253 0.6254
NA 0.1158 0.113 0.0289 0.0256 NA NA
0.0112 0.0117 0.0088 0.3419 0.3448 0.3572 0.3475
0.00998244 0.0058 0.006 0.2117 0.2105 NA NA
0.0083 0.0057 0.005 0.3059 0.3021 0.3436 0.331
NA 0.0069 0.0066 0.6265 0.6294 NA NA
NA 0.111 0.1995 0.9811 0.9819 NA NA
0.0064 0.0048 0.0045 0.3483 0.344 0.3536 0.3526
0.0075 0.0055 0.0048 0.4497 0.4529 0.4467 0.4515
0.0099 0.0072 0.0061 0.7487 0.7486 0.7355 0.744
0.0092 0.0049 0.0044 0.6569 0.6571 0.6758 0.6721
0.0091 0.0067 0.0057 0.7147 0.7142 0.7218 0.7184
NA 0.092 0.1368 0.9548 0.9612 NA NA
NA 0.0643 0.0648 0.9395 0.9368 NA NA
NA 0.1905 0.2575 0.0123 0.016 NA NA
0.0145 0.0109 0.0091 0.9045 0.902 0.9057 0.9001
0.0146 0.0118 0.0095 0.1109 0.1086 0.1242 0.1091
0.0096 0.0052 0.0047 0.7461 0.747 0.7752 0.7551
0.0059 0.0046 0.0041 0.5303 0.5299 0.5502 0.5527
NA 0.0084 0.008 0.8014 0.7981 NA NA
0.0083 0.0045 0.004 0.5372 0.5367 0.5366 0.5383
NA 0.0064 0.0062 0.412 0.4102 NA NA
0.0131 0.0116 0.0094 0.8767 0.8805 0.8779 0.8776
0.0293 0.0144 0.013 0.0381 0.038 0.028 0.0257
0.0058 0.0048 0.0046 0.5119 0.5145 0.4857 0.5068
0.0247 0.0173 0.0143 0.0493 0.047 0.1044 0.0843
NA 0.0579 0.087 0.9386 0.9253 NA NA
NA 0.1124 0.1104 0.9959 0.9944 NA NA
NA 0.1702 0.1941 0.0183 0.0219 NA NA
NA 0.1421 0.1348 0.9811 0.9823 NA NA
NA 0.0068 0.0064 0.3781 0.3758 NA NA
NA 0.3457 0.3584 0.9975 0.9978 NA NA
NA 0.3012 0.1808 0.0024 0.0045 NA NA
0.0085 0.0058 0.005 0.3145 0.3164 0.3236 0.3238
NA 0.1114 0.1218 0.9838 0.9847 NA NA
0.0062 0.0049 0.0046 0.7398 0.7399 0.7328 0.7407
NA 0.0072 0.007 0.7346 0.7378 NA NA
0.0154 0.011 0.0094 0.9014 0.9029 0.9137 0.9106
0.0436 0.0285 0.0331 0.0947 0.101 0.2961 0.3782
NA 0.0881 0.129 0.8769 0.8796 NA NA
NA 0.0066 0.0064 0.6407 0.6447 NA NA
NA 0.0465 0.0487 0.904 0.9076 NA NA
0.0177 0.0148 0.0133 0.964 0.966 0.9722 0.9675
NA 0.216 0.1798 0.0054 0.0086 NA NA
NA 0.2635 0.2266 0.9862 0.9841 NA NA
NA 0.0917 0.0792 0.9748 0.977 NA NA
0.0105 0.0091 0.0071 0.1957 0.1953 0.2194 0.2081
NA 0.4313 0.4892 0.9543 0.9896 NA NA
0.0075 0.0062 0.0058 0.7844 0.7857 0.7702 0.7731
0.01 0.0066 0.0061 0.8816 0.8835 0.9069 0.8975
NA 0.0068 0.0065 0.6703 0.6721 NA NA
NA 0.0329 0.048 0.3889 0.3803 NA NA
0.0144 0.0115 0.0096 0.8778 0.8815 0.8818 0.8916
NA 0.0906 0.1011 0.0435 0.0315 NA NA
NA 0.0392 0.0603 0.8012 0.814 NA NA
0.0076 0.0057 0.0049 0.4356 0.4343 0.4408 0.4407
NA 0.0099 0.0096 0.1341 0.1336 NA NA
NA 0.0911 0.0857 0.9844 0.9864 NA NA
0.0096 0.0052 0.0046 0.2719 0.2687 0.2482 0.2591
0.0455 0.0424 0.0328 0.0097 0.0094 0.0105 0.0105
0.0097 0.0078 0.0063 0.2466 0.2462 0.2555 0.2467
NA 0.0187 0.0158 0.3134 0.3134 NA NA
NA 0.0922 0.1414 0.8758 0.8933 NA NA
NA 0.0183 0.0187 0.6736 0.6703 NA NA
0.0065 0.005 0.0047 0.5862 0.5934 0.5869 0.6115
0.0091 0.0077 0.0063 0.6437 0.6448 0.641 0.6486
NA 0.0232 0.022 0.0295 0.0302 NA NA
NA 0.2152 0.2026 0.9972 0.9957 NA NA
0.008 0.0057 0.005 0.6453 0.644 0.6472 0.6549
0.0094 0.008 0.0063 0.2456 0.2489 0.2439 0.26
0.0289 0.0216 0.0183 0.0288 0.0289 0.1173 0.0639
NA 0.0845 0.0887 0.9709 0.9761 NA NA
0.0111 0.0086 0.0071 0.8115 0.8141 0.8143 0.8244
NA 0.1052 0.0894 0.0829 0.0943 NA NA
NA 0.0808 0.1126 0.8214 0.8453 NA NA
0.0101 0.0084 0.0067 0.3098 0.3097 0.3051 0.3084
0.0105 0.0083 0.0067 0.3325 0.3334 0.3328 0.3501
0.012 0.0097 0.0079 0.1422 0.1405 0.1609 0.144
0.0067 0.0058 0.0054 0.1775 0.1782 0.1731 0.1786
0.0244 0.0133 0.0127 0.9417 0.9442 0.9337 0.9508
0.033 0.0269 0.0294 0.4989 0.5122 0.5011 0.5158
0.0059 0.0044 0.0041 0.5295 0.5272 0.5148 0.5206
0.01 0.0083 0.0067 0.6525 0.6569 0.6575 0.6653
0.02826608 0.0166 0.0174 0.974 0.9746 NA NA
0.0057 0.0045 0.0043 0.5566 0.5556 0.5324 0.5384
0.0234 0.0167 0.0145 0.043 0.0422 0.0439 0.0386
0.0153 0.0107 0.009 0.0708 0.0734 0.159 0.1201
0.0103 0.0083 0.0066 0.7642 0.768 0.7665 0.7662
0.0167 0.0146 0.0113 0.9332 0.9328 0.9324 0.9294
0.0069 0.0057 0.0054 0.664 0.6672 0.6777 0.6742
0.0135 0.0114 0.0093 0.1075 0.1055 0.1162 0.1025
0.07 0.0205 0.0247 0.5018 0.4924 0.5574 0.493
0.0398 0.0354 0.0274 0.0247 0.021 0.0167 0.0165
0.0061 0.0049 0.0045 0.6978 0.6979 0.7054 0.6898
0.00861643 0.005 0.0051 0.4077 0.4073 NA NA
0.009 0.0056 0.0051 0.5524 0.554 0.5689 0.5637
0.0085 0.0071 0.0057 0.4042 0.4012 0.3797 0.3992
0.0063 0.0051 0.0047 0.2429 0.2454 0.239 0.2382
0.0084 0.0065 0.0061 0.1716 0.1724 0.1709 0.1728
0.0091 0.0073 0.0059 0.6777 0.6739 0.6588 0.6651
0.0109 0.0076 0.0065 0.1524 0.155 0.1526 0.1543
0.0077 0.0052 0.0045 0.5117 0.5133 0.4959 0.5
0.0086 0.0047 0.0041 0.6445 0.6435 0.6372 0.6401
0.0119 0.0091 0.0075 0.2191 0.2211 0.2101 0.2101
0.0074 0.0048 0.0046 0.7803 0.7882 0.7997 0.7909
0.0092 0.005 0.0046 0.7008 0.704 0.7063 0.7204
0.0329 0.0092 0.0102 0.4641 0.466 0.5759 0.5663
0.0091 0.0064 0.0055 0.7305 0.7289 0.7228 0.7174
0.0104 0.0083 0.0078 0.9216 0.9229 0.8558 0.8867
0.0095 0.0074 0.0066 0.1074 0.1056 0.1716 0.1393
0.0145 0.0103 0.009 0.1033 0.1018 0.1204 0.0982
0.0109 0.0063 0.0059 0.8615 0.8666 0.8821 0.8786
0.0082 0.0067 0.0063 0.1346 0.1336 0.1403 0.1382
0.0226 0.0124 0.0109 0.0393 0.0406 0.0369 0.0397
0.0065 0.0055 0.0049 0.3259 0.3267 0.3211 0.3392
0.0109 0.0096 0.0076 0.8197 0.8225 0.8298 0.8227
0.057 0.0409 0.0407 0.9204 0.9126 0.8906 0.8961
0.0214 0.0145 0.0124 0.9177 0.9169 0.9261 0.9211
0.0343 0.0217 0.0203 0.1149 0.117 0.1023 0.1004
0.0059 0.0045 0.0041 0.3957 0.3944 0.3945 0.4076
0.0085 0.0071 0.0057 0.3889 0.3841 0.3801 0.3775
0.0105 0.0084 0.0068 0.2016 0.1994 0.1965 0.2033
0.0095 0.0085 0.0066 0.7135 0.7156 0.7146 0.7119
0.0096 0.0068 0.0058 0.2067 0.2073 0.2512 0.2375
0.0103 0.0085 0.0068 0.7834 0.7858 0.7795 0.7917
0.01 0.0074 0.0063 0.2153 0.2132 0.229 0.2198
0.0098 0.0084 0.0065 0.7271 0.7242 0.7421 0.7186
0.0065 0.0043 0.004 0.6993 0.7029 0.7227 0.7034
0.0146 0.0075 0.0068 0.8931 0.8939 0.9053 0.8968
0.0076 0.0054 0.0049 0.4028 0.4038 0.405 0.4011
0.0063 0.0053 0.0047 0.6017 0.603 0.6266 0.6159
0.0091 0.0061 0.0053 0.2861 0.2847 0.3091 0.2896
0.0087 0.0068 0.0055 0.3865 0.3869 0.3735 0.394
0.0092 0.0075 0.0061 0.6915 0.7008 0.675 0.7095
0.006 0.005 0.0046 0.3934 0.3916 0.4076 0.393
0.0063 0.0042 0.0039 0.2982 0.3029 0.3142 0.3053
0.0069 0.0047 0.0044 0.2435 0.2437 0.2367 0.249
0.0087 0.0096 0.007 0.3616 0.3618 0.3563 0.3614
0.0078 0.0057 0.005 0.3365 0.3371 0.367 0.3536
0.0065 0.0053 0.0048 0.6577 0.6625 0.6643 0.6667
0.0138 0.0122 0.0119 0.0565 0.0546 0.0651 0.0621
0.0094 0.0078 0.0061 0.7111 0.7076 0.7181 0.7043
0.0135 0.0078 0.0068 0.8845 0.8854 0.8812 0.8825
0.0149 0.0097 0.0093 0.9508 0.9535 0.9586 0.9603
0.0121 0.0094 0.0078 0.855 0.8558 0.8431 0.8536
0.0156 0.0137 0.0108 0.0801 0.0808 0.0867 0.082
0.0071 0.0056 0.0053 0.3081 0.3106 0.3358 0.3214
0.0088 0.0072 0.0058 0.3425 0.3421 0.336 0.3474
0.0086 0.0072 0.0057 0.6292 0.6306 0.6356 0.6259
0.0082 0.0063 0.0059 0.8137 0.8192 0.8194 0.8184
0.0066 0.0053 0.0049 0.6276 0.6318 0.6346 0.6268
0.0111 0.0093 0.0074 0.1735 0.1718 0.1804 0.1758
0.0077 0.0065 0.0059 0.2479 0.2455 0.2475 0.2536
0.0084 0.0067 0.0054 0.4982 0.4949 0.5031 0.4923
0.0837 0.0344 0.0301 0.9772 0.9754 0.9797 0.979
0.009 0.0061 0.0053 0.7524 0.7515 0.7414 0.7439
0.0085 0.0071 0.0056 0.5808 0.5729 0.5725 0.5599
0.0086 0.0068 0.0056 0.5891 0.5885 0.595 0.592
0.0069 0.0054 0.005 0.6989 0.7001 0.703 0.7006
0.006 0.0042 0.0039 0.3613 0.3626 0.3536 0.3564
0.0126 0.0104 0.0096 0.0508 0.0494 0.1785 0.1311
0.0092 0.0064 0.0054 0.7638 0.7636 0.7601 0.7614
0.0091 0.0066 0.0057 0.5037 0.5017 0.4893 0.4935
0.0119 0.0099 0.0078 0.8478 0.8467 0.8424 0.8493
0.00987737 0.0057 0.0058 0.2518 0.2505 NA NA
0.0115 0.0076 0.0066 0.8442 0.8422 0.8048 0.8314
0.0056 0.0045 0.0042 0.6208 0.6202 0.6165 0.6081
0.0071 0.006 0.0056 0.716 0.7168 0.7059 0.7205
0.0227 0.0244 0.0159 0.8666 0.8603 0.8741 0.8699
0.0549 0.0386 0.0384 0.1054 0.1142 0.8935 0.8906
0.0068 0.0057 0.0052 0.2967 0.2949 0.3056 0.2921
0.0057 0.0046 0.0043 0.4046 0.4027 0.3987 0.4084
0.0087 0.0075 0.0059 0.6462 0.6447 0.6621 0.6343
0.0118 0.0088 0.0074 0.7561 0.7591 0.7689 0.7568
0.0111 0.0087 0.0072 0.3914 0.3921 0.3974 0.3816
0.0082 0.0054 0.0051 0.8459 0.8479 0.8506 0.8541
0.0115 0.0089 0.0084 0.9104 0.9118 0.9095 0.9203
0.0086 0.0075 0.006 0.6273 0.6275 0.6246 0.6306
0.0085 0.0067 0.0054 0.583 0.5834 0.6 0.5952
0.0108 0.0099 0.0088 0.904 0.9011 0.9046 0.8942
0.0095 0.0075 0.0061 0.4671 0.4658 0.4413 0.4611
0.009 0.0063 0.0054 0.2432 0.2444 0.2438 0.2461
0.0104 0.0089 0.0071 0.2115 0.2142 0.2087 0.2099
0.0115 0.0089 0.0072 0.1738 0.1716 0.1667 0.1623
0.008 0.0057 0.005 0.3368 0.3392 0.3315 0.3346
0.0086 0.0068 0.0055 0.5471 0.5479 0.5552 0.5447
0.0356 0.035 0.0265 0.0302 0.0307 0.0281 0.0281
0.0084 0.0071 0.0064 0.8292 0.8307 0.8257 0.827
0.007 0.0057 0.0053 0.809 0.8091 0.7524 0.7819
0.0127 0.0117 0.0089 0.8617 0.8613 0.8514 0.8616
0.00851135 0.0049 0.005 0.4167 0.4183 NA NA
0.0178 0.016 0.0126 0.1704 0.1717 0.1661 0.1573
0.0218 0.0186 0.0147 0.959 0.9588 0.9573 0.9595
0.00893166 0.0053 0.0054 0.3548 0.3527 NA NA
0.2991 0.1136 0.0982 0.9893 0.9907 0.9901 0.991
0.0132 0.0113 0.0088 0.1371 0.1351 0.1328 0.1436
0.0093 0.0076 0.006 0.2899 0.2915 0.2862 0.2889
0.0116 0.0099 0.0078 0.1485 0.1505 0.1598 0.1558
0.0098 0.0079 0.0063 0.7561 0.7542 0.7664 0.7467
0.1268 0.1018 0.1131 0.9751 0.9734 0.9782 0.9829
0.0115 0.0078 0.0067 0.5999 0.6025 0.6024 0.6219
0.0095 0.0073 0.007 0.8341 0.8346 0.8333 0.8474
0.0088 0.0073 0.0058 0.5392 0.5361 0.5295 0.53
0.0088 0.0097 0.007 0.607 0.61 0.5764 0.5971
0.0341 0.0276 0.0256 0.9855 0.9852 0.9855 0.9858
0.0401 0.0294 0.031 0.9862 0.987 0.9847 0.99
0.0147 0.0118 0.0093 0.8239 0.8279 0.8613 0.832
0.0066 0.0051 0.0048 0.3662 0.3668 0.3883 0.3724
0.006 0.0048 0.0045 0.6726 0.6652 0.6701 0.6628
0.0064 0.0054 0.0049 0.3133 0.3133 0.3226 0.3236
0.0342 0.0303 0.0282 0.3259 0.3148 0.3503 0.3477
0.0086 0.0074 0.0067 0.1761 0.1765 0.1612 0.1756
0.0151 0.0113 0.013 0.1248 0.1252 0.115 0.1076
0.0085 0.0076 0.006 0.6221 0.6205 0.6322 0.6192
0.0055 0.0044 0.0041 0.4793 0.487 0.4857 0.4906
0.0079 0.0067 0.0062 0.76 0.7624 0.7443 0.7524
0.0074 0.0059 0.0055 0.2424 0.2439 0.2445 0.2447
0.0111 0.0092 0.0074 0.8164 0.8162 0.8185 0.8213
0.0103 0.0082 0.0069 0.4362 0.4334 0.401 0.4425
0.0128 0.0099 0.0094 0.9356 0.9357 0.9299 0.9372
0.1434 0.083 0.0997 0.9878 0.987 0.5809 0.2707
0.0084 0.0072 0.0058 0.4697 0.4658 0.4602 0.4594
0.0131 0.0107 0.0086 0.8912 0.8912 0.8916 0.89
0.0064 0.0053 0.0048 0.4416 0.442 0.4696 0.4563
0.0172 0.0164 0.0125 0.0796 0.0767 0.0739 0.0731
0.0062 0.0052 0.0048 0.6343 0.6354 0.6415 0.6422
0.0273 0.0248 0.0193 0.9423 0.9407 0.9388 0.9388
0.0133 0.0145 0.0105 0.159 0.1572 0.1551 0.1579
0.0075 0.0062 0.0058 0.8383 0.8418 0.8318 0.833
INSIL
ICO.M
EN.E
AF
INSIL
ICO.W
OM
EN.E
AF
META
BOCHIP
.MEN
.EAF
META
BOCHIP
.WOM
EN.E
AF
REP2W
AY.M
EN.E
AF
REP2W
AY.W
OM
EN.E
AF
JOIN
T.MEN
.EAF
JOIN
T.WOM
EN.E
AF
DIS
COVE
RY.M
EN.N
0.6009 0.6043 0.5969 0.598 0.5903 0.5902 34575.6
0.7151 0.7147 0.7154 0.7161 0.7188 0.7172 34600.8
0.4773 0.4795 0.4737 0.4697 0.4741 0.4715 34593.9
0.1768 0.1741 0.18 0.1891 0.1991 0.201 38367.4
0.7337 0.7334 0.7349 0.7298 0.726 0.7249 34599.3
NA NA 0.7559 0.7772 0.7775 0.7811 34597.7
0.4427 0.447 0.4394 0.4375 0.4261 0.4284 34596.3
NA NA 0.1809 0.1875 0.1848 0.1846 60519.9
0.6344 0.6338 0.639 0.6447 0.6456 0.6486 58610.2
0.7311 0.7286 0.7317 0.7248 0.725 0.7198 58617.7
0.265 0.2697 0.2607 0.2574 0.2542 0.2534 34600.9
0.2487 0.2493 0.2454 0.2398 0.2395 0.2359 34599.3
0.3913 0.3974 0.3925 0.3975 0.397 0.3966 59659.4
0.877 0.8726 0.8763 0.8676 0.8682 0.8651 34599.9
0.7582 0.7541 0.7481 0.7379 0.7369 0.7325 59668.8
0.5168 0.5205 0.5172 0.5143 0.5102 0.5111 34504.4
0.3809 0.382 0.3854 0.3826 0.3764 0.3741 60540.2
0.8312 0.8324 0.8312 0.8324 0.8298 0.8301 58318.4
0.4998 0.4964 0.4955 0.4857 0.4926 0.4845 34581.8
0.3277 0.3223 0.3279 0.3116 0.3112 0.3044 60394.2
0.5483 0.5525 0.5122 0.4999 0.4832 0.4811 59663.5
0.9103 0.9106 0.895 0.8999 0.9012 0.9032 34520.4
0.7725 0.775 0.7541 0.7537 0.7612 0.762 58616.9
0.3929 0.3893 0.3989 0.3929 0.3978 0.3951 58610.7
0.205 0.2032 0.2073 0.2076 0.2207 0.2161 59658.3
0.6819 0.6911 0.6819 0.6911 0.6783 0.6805 58315.7
NA NA 0.9414 0.943 0.9408 0.9431 60427.7
0.3277 0.3239 0.329 0.3202 0.3206 0.3162 57762.2
0.0856 0.0856 0.0838 0.0772 0.0811 0.0803 60327.2
0.2154 0.2189 0.2149 0.2175 0.2145 0.2147 34554.7
0.5649 0.5605 0.5682 0.5719 0.5667 0.567 59611.6
0.8763 0.8743 0.8456 0.8621 0.8617 0.8662 60488.4
0.6779 0.6782 0.6695 0.6673 0.6739 0.6701 59673.2
0.5113 0.5176 0.5129 0.5177 0.5194 0.5215 60542.1
0.4535 0.455 0.453 0.4578 0.4565 0.4602 60534.3
0.5526 0.547 0.5564 0.5533 0.5534 0.5496 60519.2
0.4409 0.4463 0.4449 0.4523 0.446 0.4514 60483.2
0.3627 0.3649 0.3616 0.3564 0.3647 0.3631 60494.4
0.2291 0.2251 0.2291 0.2251 0.2376 0.24 58323.1
0.5191 0.5197 0.5177 0.5212 0.5109 0.5184 59656.5
0.5993 0.604 0.5968 0.601 0.5976 0.6 60512.4
NA NA 0.4527 0.4514 0.448 0.4494 60489.5
0.6069 0.608 0.6017 0.5895 0.6005 0.5928 32916.1
0.3205 0.3197 0.3197 0.3239 0.3248 0.3268 38292.4
0.0589 0.0569 0.0963 0.095 0.068 0.0689 58903.7
0.5443 0.5473 0.5409 0.5361 0.5374 0.5357 60514.9
0.1489 0.1515 0.1734 0.1736 0.1664 0.168 60549.9
0.6547 0.6562 0.6496 0.6495 0.6543 0.655 60526.9
0.2813 0.2791 0.2867 0.2784 0.2784 0.2743 60238.3
0.2808 0.2723 0.2842 0.2755 0.2781 0.2722 60505.4
NA NA 0.7486 0.7431 0.7451 0.7432 15067.3
0.6554 0.6649 0.6578 0.6717 0.6653 0.6728 60363.8
0.8209 0.8236 0.801 0.805 0.8141 0.8164 60502.6
0.5251 0.5209 0.5046 0.5105 0.5016 0.5092 60505
0.7235 0.7211 0.725 0.729 0.7307 0.7344 38369.4
0.3154 0.3096 0.3193 0.3211 0.3223 0.3219 59588.4
0.1652 0.1604 0.1734 0.1778 0.185 0.1874 38303.8
0.7418 0.7434 0.7414 0.7392 0.7318 0.7293 60525.8
NA NA 0.2131 0.2207 0.2143 0.2175 60513.8
0.4304 0.4278 0.4285 0.4256 0.4227 0.4216 15354.7
0.5305 0.5318 0.5236 0.5134 0.5038 0.5008 60515.2
NA NA 0.447 0.4501 0.4528 0.451 59667.6
0.7218 0.7218 0.729 0.7362 0.7397 0.7418 57779.2
0.0411 0.0414 0.0415 0.0405 0.0396 0.039 59663.9
NA NA 0.9475 0.9463 0.9473 0.9469 38291.1
0.667 0.6681 0.667 0.6688 0.6665 0.6665 60497.2
0.561 0.5666 0.561 0.5666 0.5672 0.5722 58320
0.2834 0.2851 0.2932 0.3 0.3 0.302 60506.7
0.624 0.6276 0.6202 0.6189 0.6158 0.6185 60540.7
0.6932 0.6955 0.6939 0.6883 0.6849 0.684 38368.8
0.6086 0.6055 0.6017 0.5995 0.6047 0.6021 60463.9
0.842 0.8411 0.8093 0.7993 0.7898 0.7913 59668.6
NA NA 0.6795 0.7032 0.7054 0.7098 60556.4
NA NA 0.195 0.2022 0.2054 0.2082 59673.8
0.1131 0.1059 0.1131 0.1059 0.1116 0.109 58318.8
NA NA 0.0248 0.0238 0.0298 0.0276 24623
0.5342 0.5371 0.5248 0.5123 0.5129 0.5071 38347.3
0.9626 0.9645 0.9635 0.9665 0.9651 0.9664 37905.6
NA NA 0.0552 0.0548 0.0556 0.054 32931.4
NA NA NA NA 0.335 0.335 1886
0.9554 0.9541 0.9554 0.9541 0.9474 0.9467 56405.8
NA NA 0.3666 0.353 0.3626 0.3555 34492.3
NA NA 0.0746 0.0716 0.0721 0.071 32930.8
NA NA NA NA 0.0292 0.0251 739.99
NA NA NA NA 0.9802 0.9886 611.92
0.569 0.5652 0.5658 0.5624 0.565 0.5614 19246
NA NA 0.5127 0.4984 0.4907 0.4908 59239
0.3861 0.3809 0.3861 0.3809 0.3848 0.3813 58349.7
0.8076 0.8093 0.8043 0.8147 0.816 0.8213 60548.8
NA NA NA NA 0.007 0.0099 611.99
NA NA 0.6195 0.6069 0.6136 0.6091 32806.9
NA NA NA NA 0.9935 0.9978 2006
0.3523 0.3574 0.3523 0.3574 0.3423 0.3388 58312.5
0.3238 0.3212 0.3234 0.3167 0.3142 0.312 32711.5
NA NA NA NA 0.9959 0.9949 1840
NA NA 0.5384 0.5301 0.5209 0.5217 60530.7
NA NA NA NA 0.0249 0.0165 1484
NA NA 0.6721 0.6814 0.6391 0.6437 19713.4
0.6196 0.6212 0.6196 0.6212 0.6219 0.6204 58323.1
NA NA 0.759 0.7714 0.7641 0.7671 32930.1
NA NA 0.6753 0.6778 0.6758 0.6776 60529.6
0.8734 0.8729 0.8655 0.8663 0.87 0.8695 58556.2
0.2524 0.2551 0.2496 0.2555 0.2605 0.2622 38368.9
NA NA NA NA 0.9964 0.9955 1950
0.7147 0.7164 0.7142 0.715 0.7119 0.7125 34578
NA NA 0.8601 0.8767 0.8829 0.886 60549.8
0.3524 0.3565 0.3543 0.3461 0.3388 0.3362 38369.1
NA NA NA NA 0.2082 0.2126 58323.4
NA NA 0.8656 0.906 0.9275 0.9307 60458.8
NA NA 0.2168 0.2259 0.2244 0.2258 38304.1
NA NA 0.9466 0.9509 0.9467 0.9487 60256.6
0.9955 0.9931 0.9955 0.9931 0.9914 0.9922 23224.8
NA NA NA NA 0.1531 0.1522 58310.5
NA NA NA NA 0.0258 0.0261 3492
NA NA 0.0839 0.0883 0.0853 0.0882 36481
NA NA 0.997 0.997 0.9953 0.9958 11511
NA NA 0.8172 0.8307 0.8213 0.8301 22547.5
0.4811 0.4808 0.4817 0.4942 0.4921 0.4976 60509.4
NA NA NA NA 0.9046 0.9036 17771.8
NA NA 0.6253 0.6254 0.6287 0.6296 34569.9
NA NA NA NA 0.0289 0.0256 1522
NA NA 0.3572 0.3475 0.3488 0.3465 17074.7
0.2435 0.2397 0.2435 0.2397 0.2258 0.2212 58323.3
NA NA 0.3436 0.331 0.3152 0.3125 60529.8
NA NA NA NA 0.6265 0.6294 58297.9
NA NA NA NA 0.9811 0.9819 611.77
0.3536 0.3534 0.3536 0.353 0.3509 0.3485 59656.4
NA NA 0.4467 0.4515 0.4489 0.4523 58605.9
NA NA 0.7355 0.744 0.7466 0.7468 34536.6
NA NA 0.6758 0.6721 0.6585 0.6605 38369
NA NA 0.7218 0.7184 0.716 0.7158 34589.6
NA NA NA NA 0.9548 0.9612 611.75
NA NA NA NA 0.9395 0.9368 1075
NA NA NA NA 0.0123 0.016 612
NA NA 0.9057 0.9001 0.9047 0.9013 34601.6
NA NA 0.1242 0.1091 0.1139 0.1088 38305
NA NA 0.7752 0.7551 0.749 0.7489 38369.1
0.527 0.5255 0.5349 0.5404 0.5326 0.5351 59672.4
NA NA NA NA 0.8014 0.7981 58315.9
NA NA 0.5366 0.5383 0.5371 0.5371 38368.9
NA NA NA NA 0.412 0.4102 58288.5
NA NA 0.8779 0.8776 0.877 0.879 32848.7
NA NA 0.028 0.0257 0.0373 0.0356 36539.7
0.4766 0.4802 0.4794 0.4919 0.4911 0.5002 55446.3
NA NA 0.1044 0.0843 0.058 0.0596 31760.2
NA NA NA NA 0.9386 0.9253 612
NA NA NA NA 0.9959 0.9944 1688
NA NA NA NA 0.0183 0.0219 1699.47
NA NA NA NA 0.9811 0.9823 1482
NA NA NA NA 0.3781 0.3758 58321
NA NA NA NA 0.9975 0.9978 1998
NA NA NA NA 0.0024 0.0045 1878
NA NA 0.3236 0.3238 0.3166 0.319 60520.4
NA NA NA NA 0.9838 0.9847 1980
0.7219 0.7258 0.7252 0.7334 0.7321 0.7363 58545.5
NA NA NA NA 0.7346 0.7378 58315.9
NA NA 0.9137 0.9106 0.9033 0.9058 34601.6
NA NA 0.2961 0.3782 0.2224 0.2604 2915
NA NA NA NA 0.8769 0.8796 612
NA NA NA NA 0.6407 0.6447 58320.8
NA NA NA NA 0.904 0.9076 1094
0.9677 0.9669 0.9687 0.9672 0.9664 0.9667 38175.1
NA NA NA NA 0.0054 0.0086 1087.96
NA NA NA NA 0.9862 0.9841 580
NA NA NA NA 0.9748 0.977 3480
NA NA 0.2194 0.2081 0.2012 0.2012 32909.2
NA NA NA NA 0.9543 0.9896 700
0.695 0.6966 0.7082 0.7322 0.739 0.7538 34461.5
0.9073 0.9076 0.9072 0.9022 0.8896 0.8905 37044.6
NA NA NA NA 0.6703 0.6721 58244.1
NA NA NA NA 0.3889 0.3803 611.91
NA NA 0.8818 0.8916 0.8788 0.886 32729.6
NA NA NA NA 0.0435 0.0315 2595.97
NA NA NA NA 0.8012 0.814 611.99
NA NA 0.4408 0.4407 0.4371 0.437 58607.9
NA NA NA NA 0.1341 0.1336 57851.8
NA NA NA NA 0.9844 0.9864 6924
NA NA 0.2482 0.2591 0.2697 0.2665 38369.3
NA NA 0.0105 0.0105 0.0099 0.01 31862.2
NA NA 0.2555 0.2467 0.2486 0.2464 38301.1
NA NA NA NA 0.3134 0.3134 1206
NA NA NA NA 0.8758 0.8933 612
NA NA NA NA 0.6736 0.6703 6774.98
0.558 0.5577 0.5653 0.5885 0.5765 0.5908 34600.3
NA NA 0.641 0.6486 0.643 0.6466 32846.9
NA NA NA NA 0.0295 0.0302 53167.2
NA NA NA NA 0.9972 0.9957 1934
NA NA 0.6472 0.6549 0.6458 0.6483 58663.1
NA NA 0.2439 0.26 0.2452 0.254 32834.4
NA NA 0.1173 0.0639 0.0526 0.0429 36468.2
NA NA NA NA 0.9709 0.9761 3964
NA NA 0.8143 0.8244 0.8121 0.8183 38282.5
NA NA NA NA 0.0829 0.0943 615
NA NA NA NA 0.8214 0.8453 611.95
NA NA 0.3051 0.3084 0.3087 0.3091 32927.9
NA NA 0.3328 0.3501 0.3326 0.3401 32689
NA NA 0.1609 0.144 0.1471 0.142 33964.7
0.4685 0.4752 0.4273 0.365 0.3425 0.3012 38304.9
NA NA 0.9337 0.9508 0.9404 0.946 35788.4
NA NA 0.5011 0.5158 0.4999 0.5151 1700
0.5653 0.5651 0.548 0.5407 0.5382 0.5337 60555.3
NA NA 0.6575 0.6653 0.6537 0.6607 32924.7
0.9751 0.9759 0.9751 0.9759 0.9745 0.9751 57301.2
0.5481 0.544 0.5435 0.5414 0.5491 0.5475 58603.4
NA NA 0.0439 0.0386 0.0432 0.0408 32826.4
NA NA 0.159 0.1201 0.0903 0.0897 59546.1
NA NA 0.7665 0.7662 0.7647 0.7673 34580.4
NA NA 0.9324 0.9294 0.933 0.9312 32926.5
0.6783 0.682 0.6782 0.6787 0.6728 0.6743 38298.1
NA NA 0.1162 0.1025 0.1099 0.1041 30641.3
NA NA 0.5574 0.493 0.5057 0.4925 4642.99
NA NA 0.0167 0.0165 0.023 0.0189 14013.7
0.7178 0.7212 0.7142 0.7047 0.7065 0.7017 58614.4
0.43 0.4274 0.43 0.4274 0.4173 0.4144 58260.9
NA NA 0.5689 0.5637 0.5565 0.5571 60526.1
NA NA 0.3797 0.3992 0.3983 0.4003 36323.1
0.2454 0.2443 0.2433 0.2411 0.2431 0.243 58618.6
0.1679 0.1696 0.1686 0.1715 0.1702 0.1719 34588.7
NA NA 0.6588 0.6651 0.6735 0.6702 38303.2
NA NA 0.1526 0.1543 0.1524 0.1548 60541
NA NA 0.4959 0.5 0.5079 0.5087 60529.4
NA NA 0.6372 0.6401 0.6438 0.6427 38368
NA NA 0.2101 0.2101 0.2172 0.2168 38304.2
0.7828 0.7825 0.7863 0.7864 0.7824 0.7875 38364.8
NA NA 0.7063 0.7204 0.7014 0.7081 37161.3
NA NA 0.5759 0.5663 0.4728 0.4757 6300.98
NA NA 0.7228 0.7174 0.7285 0.7247 59668.4
0.9309 0.9313 0.9051 0.9069 0.9131 0.914 58607.8
0.0984 0.1006 0.1248 0.1232 0.1154 0.1142 60539.2
NA NA 0.1204 0.0982 0.1064 0.1004 34596.6
0.9011 0.9061 0.8949 0.888 0.869 0.873 38368.1
0.1471 0.1458 0.1452 0.1423 0.1409 0.1388 58375.8
NA NA 0.0369 0.0397 0.0391 0.0404 38252.5
0.3296 0.3283 0.3274 0.3346 0.3267 0.3313 34580
NA NA 0.8298 0.8227 0.8223 0.8226 23937.4
NA NA 0.8906 0.8961 0.9036 0.9042 2003
NA NA 0.9261 0.9211 0.9191 0.9183 28792.6
NA NA 0.1023 0.1004 0.1094 0.1112 6707.55
0.4372 0.4353 0.4231 0.4201 0.409 0.407 60552.8
NA NA 0.3801 0.3775 0.3867 0.3811 32926.6
NA NA 0.1965 0.2033 0.2004 0.201 34579.5
NA NA 0.7146 0.7119 0.7138 0.7138 32908.6
NA NA 0.2512 0.2375 0.2171 0.2182 56461.8
NA NA 0.7795 0.7917 0.7825 0.7884 32929.7
NA NA 0.229 0.2198 0.2179 0.2158 34601.2
NA NA 0.7421 0.7186 0.7299 0.7218 32919.1
0.7226 0.7276 0.7226 0.7152 0.7069 0.7076 38366.2
NA NA 0.9053 0.8968 0.8939 0.8945 35840.2
0.3891 0.3973 0.4021 0.4008 0.4026 0.4026 58616.5
0.5986 0.5996 0.6061 0.6082 0.604 0.6059 38302.6
NA NA 0.3091 0.2896 0.2919 0.2864 60542.6
NA NA 0.3735 0.394 0.384 0.3898 38304.3
NA NA 0.675 0.7095 0.6875 0.7046 32929.4
0.4867 0.4912 0.4684 0.4421 0.4356 0.4211 38304.5
0.3021 0.306 0.3049 0.3056 0.3004 0.3039 38317.6
0.2373 0.2357 0.2372 0.2423 0.2413 0.2431 38366.2
NA NA 0.3563 0.3614 0.3593 0.3615 15067.3
NA NA 0.367 0.3536 0.3449 0.3439 58617.1
0.6858 0.6759 0.6778 0.6706 0.6686 0.6668 45477.7
0.085 0.0856 0.0826 0.0776 0.0769 0.0716 26429.4
NA NA 0.7181 0.7043 0.7124 0.7062 32930.3
NA NA 0.8812 0.8825 0.8842 0.8847 37883.9
0.951 0.9511 0.9526 0.9554 0.9514 0.9542 37097.7
NA NA 0.8431 0.8536 0.8522 0.8549 38305.3
NA NA 0.0867 0.082 0.082 0.0814 30604.2
0.3196 0.3191 0.3234 0.3203 0.316 0.3159 34597.5
NA NA 0.336 0.3474 0.341 0.3444 34627.6
NA NA 0.6356 0.6259 0.6307 0.6285 32917.1
0.8216 0.8218 0.821 0.8198 0.8172 0.8195 34598.4
0.6569 0.6568 0.6508 0.639 0.639 0.6358 34596.3
NA NA 0.1804 0.1758 0.1752 0.1736 32893.4
0.2279 0.2288 0.2334 0.2428 0.2397 0.2439 32889.9
NA NA 0.5031 0.4923 0.4993 0.4938 34570.2
NA NA 0.9797 0.979 0.9776 0.9759 15572.8
NA NA 0.7414 0.7439 0.7498 0.7489 60546.6
NA NA 0.5725 0.5599 0.579 0.5673 32928.4
NA NA 0.595 0.592 0.5904 0.59 38303.3
0.7026 0.7009 0.7027 0.7007 0.7006 0.7004 34600.9
0.4254 0.4248 0.4104 0.3917 0.3804 0.3751 38364.8
0.0461 0.0466 0.0995 0.0962 0.077 0.0765 56258.7
NA NA 0.7601 0.7614 0.7629 0.7628 60424.5
NA NA 0.4893 0.4935 0.4998 0.4984 58491
NA NA 0.8424 0.8493 0.8467 0.8478 32879.3
0.2403 0.2435 0.2403 0.2435 0.2471 0.2481 58321.4
NA NA 0.8048 0.8314 0.8354 0.8387 60546.8
0.6133 0.6131 0.6143 0.6105 0.6172 0.6146 58611.6
0.7007 0.7022 0.7018 0.7119 0.7075 0.7138 32819.5
NA NA 0.8741 0.8699 0.8692 0.865 11244.7
NA NA 0.8935 0.8906 0.5052 0.4931 1945
0.33 0.335 0.3246 0.3118 0.3119 0.3046 34579.6
0.3725 0.3674 0.381 0.3884 0.3914 0.3944 58614.2
NA NA 0.6621 0.6343 0.6502 0.6399 32883.3
NA NA 0.7689 0.7568 0.7591 0.7582 37025.7
NA NA 0.3974 0.3816 0.3929 0.3877 32841.5
0.8497 0.8496 0.8499 0.8518 0.8473 0.8494 38171.4
0.9073 0.9068 0.9079 0.9143 0.9092 0.9131 33382.3
NA NA 0.6246 0.6306 0.6266 0.629 32828.6
NA NA 0.6 0.5952 0.5866 0.5882 38262
0.9021 0.9019 0.9026 0.8974 0.9031 0.8987 32792
NA NA 0.4413 0.4611 0.4614 0.4639 34573.4
NA NA 0.2438 0.2461 0.2433 0.245 60545.2
NA NA 0.2087 0.2099 0.2108 0.2122 32838.2
NA NA 0.1667 0.1623 0.1724 0.1679 38293.8
NA NA 0.3315 0.3346 0.3354 0.3374 58617
NA NA 0.5552 0.5447 0.5488 0.5466 38301.9
NA NA 0.0281 0.0281 0.0293 0.0293 16861.9
0.8172 0.8199 0.8191 0.8237 0.8235 0.8266 32633
0.807 0.8115 0.7898 0.7959 0.7981 0.8015 54853.9
NA NA 0.8514 0.8616 0.8588 0.8614 30597.1
0.4091 0.4112 0.4091 0.4112 0.4136 0.4158 58322.5
NA NA 0.1661 0.1573 0.1686 0.1645 11681.2
NA NA 0.9573 0.9595 0.9586 0.9591 32931.4
0.3559 0.3543 0.3559 0.3543 0.3553 0.3533 58097.2
NA NA 0.9901 0.991 0.9895 0.9907 2549
NA NA 0.1328 0.1436 0.1362 0.1389 32930.1
NA NA 0.2862 0.2889 0.2891 0.2904 34581.3
NA NA 0.1598 0.1558 0.1514 0.1529 32900.3
NA NA 0.7664 0.7467 0.7581 0.7511 38281.1
NA NA 0.9782 0.9829 0.9769 0.981 611.86
NA NA 0.6024 0.6219 0.6003 0.609 38298.1
0.8432 0.8427 0.8407 0.845 0.8378 0.8403 34540.4
NA NA 0.5295 0.53 0.5371 0.5335 32910.7
NA NA 0.5764 0.5971 0.5944 0.6019 15067.2
0.9916 0.9913 0.9899 0.9881 0.9878 0.9868 41987.1
0.987 0.9869 0.9864 0.9882 0.9863 0.9877 45799
NA NA 0.8613 0.832 0.8325 0.8296 30953.4
0.3964 0.3993 0.3942 0.3831 0.3792 0.3753 34600.8
0.6827 0.6799 0.6792 0.6714 0.6761 0.6686 58179.4
0.3112 0.3105 0.3139 0.3172 0.3136 0.3156 38304.4
NA NA 0.3503 0.3477 0.3397 0.3372 611.99
0.1568 0.1586 0.1578 0.1681 0.1657 0.1714 32848.9
0.1145 0.1128 0.1145 0.1124 0.1167 0.1157 3224
NA NA 0.6322 0.6192 0.6249 0.6199 32848.1
0.4816 0.4797 0.4829 0.4852 0.4812 0.486 58616.5
0.7407 0.7431 0.7414 0.7476 0.7483 0.7534 32224.5
0.2432 0.2468 0.2435 0.2456 0.243 0.2448 34561.9
NA NA 0.8185 0.8213 0.8169 0.8185 32928.3
0.3857 0.3675 0.3955 0.4239 0.4233 0.4292 27087.8
0.9247 0.9258 0.9259 0.9321 0.9308 0.9337 34588.5
NA NA 0.5809 0.2707 0.7605 0.641 2919
NA NA 0.4602 0.4594 0.4672 0.4628 32842.1
NA NA 0.8916 0.89 0.8913 0.8907 34567.3
0.4877 0.491 0.4836 0.4717 0.464 0.4588 34580.8
NA NA 0.0739 0.0731 0.078 0.0748 32641
0.5901 0.5916 0.6012 0.6163 0.6153 0.6241 38303.1
NA NA 0.9388 0.9388 0.9413 0.9397 27132.6
NA NA 0.1551 0.1579 0.1575 0.1576 15067.9
0.8274 0.8309 0.8286 0.8319 0.8326 0.8359 57099.4
JOIN
T.WOM
EN.E
AF
DIS
COVE
RY.M
EN.N
DIS
COVE
RY.W
OM
EN.N
INSIL
ICO.M
EN.N
INSIL
ICO.W
OM
EN.N
META
BOCHIP
.MEN
.N
META
BOCHIP
.WOM
EN.N
REP2W
AY.M
EN.N
REP2W
AY.W
OM
EN.N
42706.9 11217.5 32202.6 30801 23412 42018.5 55614.6
42735 11219 32203 30806 23414 42025 55617
42727.4 10311.7 31128.6 30798 23413 41109.7 54541.6
47468.6 11218.4 32242.5 35551 27692 46769.4 59934.5
42733 9254.97 30333 28795 22259 38050 52592
42733.5 9254.62 30332.7 NA NA 9254.62 30332.7
42729.2 9254.55 30332.6 30802 23411 40056.6 53743.6
73095.7 20339.6 41872.2 NA NA 20339.6 41872.2
67948.2 20331.1 41661.4 42055 32752 62386.1 74413.4
67956.4 18364 39789.9 42057 32745 60421 72534.9
42734.7 10312 31129 30783 23400 41095 54529
42734.5 10312 31127 30800 23409 41112 54536
72196.9 18179 39436 42015 32747 60194 72183
42735.9 10312 31129 30798 23412 41110 54541
72201.6 18373.2 39999.9 42043 32766 60416.2 72765.9
42637.3 11218.6 32203.7 30805 23415 42023.6 55618.7
73118.9 20338.9 41871.9 41236 32039 61574.9 73910.9
67589.1 NA NA 39128 29433 39128 29433
42710.9 11219 32204 30794 23410 42013 55614
72841.8 19387 40768 38534 30622 57921 71390
72183.4 18174.9 39438 26074 23911 44248.9 63349
42670.1 11219 32204 30785 23409 42004 55613
67957.4 19417.9 40581 38336 30152 57753.9 70733
67950 20331.4 41661.6 36564 31167 56895.4 72828.6
72188.5 19430 40788 42014 32762 61444 73550
67585 NA NA 39158 29461 39158 29461
73076.4 17127.7 38650.8 NA NA 17127.7 38650.8
69765.3 19430 40786 40649 30826 60079 71612
72801.1 18374.7 40000.8 41968 32613 60342.7 72613.8
50130.4 19069 40274 42046 32777 61115 73051
72992.8 20338.5 41871.6 40653 31712 60991.5 73583.6
73028.5 20340.1 41872.5 42016 32764 62356.1 74636.5
72206.9 19413 40774 41202 32174 60615 72948
73124.9 20338.3 41871.5 42045 32770 62383.3 74641.5
73110.4 20339.6 41872.2 42043 32770 62382.6 74642.2
73089.9 18269.3 40650 42006 32735 60275.3 73385
73050.3 19428.5 40787.6 42050 32781 61478.5 73568.6
73098.1 19402.8 40776.8 36502 31149 55904.8 71925.8
67592.5 NA NA 38346 29436 38346 29436
72185.5 19421 40787 42047 32774 61468 73561
73101 20339 41871.9 42050 32779 62389 74650.9
73027 19427.7 40781.8 NA NA 19427.7 40781.8
40703.6 11220 32213 30787 23412 42007 55625
47309.8 10317 31534 36664 28367 46981 59901
70343.6 18374.8 40000.9 18946 13614 37320.8 53614.9
73104.8 20339.2 41870.8 42036 32777 62375.2 74647.8
73128.5 20339.8 41872.2 42039 32775 62378.8 74647.2
73088.8 19423.5 40784.4 42045 32776 61468.5 73560.4
72771.9 19430 40789 42049 32784 61479 73573
73091.9 20340 41872.4 26188 18844 46528 60716.4
20478.8 10861.9 32063.8 NA NA 10861.9 32063.8
72896.7 19426.7 40786.7 41992 32713 61418.7 73499.7
73088.6 20340.2 41872.4 42049 32777 62389.2 74649.4
73092.7 18372.6 39999.7 28976 25797 47348.6 65796.7
47471.8 11218.8 32242.9 36427 28327 47645.8 60569.9
72832.6 17496 38860 41996 32756 59492 71616
47318.9 9260.91 30736.8 36670 28374 45930.9 59110.8
73096.7 20339.2 41872 42036 32778 62375.2 74650
73095.9 20339.9 41872.4 NA NA 20339.9 41872.4
19346.6 8894 29818 30806 23413 39700 53231
73089.5 14436.4 37172.3 42050 32777 56486.4 69949.3
72199.8 19092.2 40521.8 NA NA 19092.2 40521.8
69782.4 18743.6 40522.2 42017 32763 60760.6 73285.2
72326.5 19093.8 40522.8 42051 32438 61144.8 72960.8
47305.8 10318 31535 NA NA 10318 31535
72207.2 19424.8 40785.8 42051 32783 61475.8 73568.8
67588.9 NA NA 39166 29470 39166 29470
73059.4 18373.6 40000.1 42038 32771 60411.6 72771.1
73122.2 19401 40780 42038 32769 61439 73549
47471 9254.92 30371.9 36443 28337 45697.9 58708.9
73053.5 20339.7 41872.2 42019 32764 62358.7 74636.2
72202.3 18374.2 40000.4 42050 32779 60424.2 72779.4
73132.9 20338.5 41871.3 NA NA 20338.5 41871.3
72206.7 17458.6 38915.6 NA NA 17458.6 38915.6
67589 NA NA 35156 25747 35156 25747
33330 8776.96 30182 NA NA 8776.96 30182
47454.6 11218.9 32242.8 36408 28313 47626.9 60555.8
46924.7 11219 30372 36371 28249 47590 58621
40726 9256 30342 NA NA 9256 30342
2416 NA NA NA NA NA NA
65087 NA NA 39055 29302 39055 29302
42602.7 11218.3 32203.1 NA NA 11218.3 32203.1
40725.4 11219.9 32212.9 NA NA 11219.9 32212.9
345.99 NA NA NA NA NA NA
345.97 NA NA NA NA NA NA
23388 3332 3860 30727 23327 34059 27187
71139.3 18373.9 40000.2 NA NA 18373.9 40000.2
67592.1 NA NA 39156 29457 39156 29457
73129.5 20339.7 41872.2 41668 32394 62007.7 74266.2
345.99 NA NA NA NA NA NA
40283.6 10315.4 31503.5 NA NA 10315.4 31503.5
2051 NA NA NA NA NA NA
67581 NA NA 39157 29464 39157 29464
40314.1 10312 31129 23921 18696 34233 49825
1862 NA NA NA NA NA NA
73104.3 20339.6 41872.1 NA NA 20339.6 41872.1
1726 NA NA NA NA NA NA
23861.8 1964 1873 NA NA 1964 1873
67592.1 NA NA 39145 29449 39145 29449
40724.5 11219.5 32212.5 NA NA 11219.5 32212.5
73108.1 20339.3 41871.9 NA NA 20339.3 41871.9
69516.4 17454.7 38915.7 42024 32247 59478.7 71162.7
47470.7 11218.9 32243 35482 27660 46700.9 59903
1992 NA NA NA NA NA NA
42722.1 10315 31495 30125 22793 40440 54288
73132.5 20340.5 41872.7 NA NA 20340.5 41872.7
47468.4 10312 31168 36450 28338 46762 59506
67592.9 NA NA NA NA NA NA
72831.5 18024.7 39446.9 NA NA 18024.7 39446.9
47319.8 11224.9 32609 NA NA 11224.9 32609
72653.4 17127.7 38650.9 NA NA 17127.7 38650.9
26491 NA NA 7007 4443 7007 4443
67574.8 NA NA NA NA NA NA
3868 NA NA NA NA NA NA
45052.5 10312 31168 NA NA 10312 31168
16672 1027 1194 NA NA 1027 1194
29155.4 10861.2 32063.2 NA NA 10861.2 32063.2
73071.2 20340 41872.2 41580 32227 61920 74099.2
19865.9 NA NA NA NA NA NA
42702.8 11218.9 32203.9 NA NA 11218.9 32203.9
1799 NA NA NA NA NA NA
21174.6 10860.6 32092.7 NA NA 10860.6 32092.7
67592.5 NA NA 39170 29471 39170 29471
73120.9 20338.5 41871.5 NA NA 20338.5 41871.5
67577.1 NA NA NA NA NA NA
345.89 NA NA NA NA NA NA
72194.6 17457.5 38916.6 42049 32779 59506.5 71695.6
67948.2 20331.2 41661.3 NA NA 20331.2 41661.3
42666.8 10312 31129 NA NA 10312 31129
47471.2 9254.94 30371.9 NA NA 9254.94 30371.9
42720.7 10312 31125 NA NA 10312 31125
345.88 NA NA NA NA NA NA
1084 NA NA NA NA NA NA
345.97 NA NA NA NA NA NA
42735.6 9254.98 30333 NA NA 9254.98 30333
47320.5 9260.81 30736.8 NA NA 9260.81 30736.8
47471 11218.7 32242.7 NA NA 11218.7 32242.7
72205.6 20339.8 41872.3 42018 32764 62357.8 74636.3
67587 NA NA NA NA NA NA
47471.2 11218.6 32242.6 NA NA 11218.6 32242.6
67546.5 NA NA NA NA NA NA
40354.8 11221.6 32578.7 NA NA 11221.6 32578.7
42596.9 9135 30016 NA NA 9135 30016
63578 19059.5 40580.3 42054 32748 61113.5 73328.3
39331.5 9254.99 30372 NA NA 9254.99 30372
346 NA NA NA NA NA NA
1708 NA NA NA NA NA NA
611.74 NA NA NA NA NA NA
1780 NA NA NA NA NA NA
67591.2 NA NA NA NA NA NA
2054 NA NA NA NA NA NA
4801 NA NA NA NA NA NA
73083 19427.9 40787.9 NA NA 19427.9 40787.9
2032 NA NA NA NA NA NA
67881.8 19416 40580 42059 32746 61475 73326
67584.1 NA NA NA NA NA NA
42735.9 9254.98 30333 NA NA 9254.98 30333
2292 5897.67 4697.82 NA NA 5897.67 4697.82
346 NA NA NA NA NA NA
67590.7 NA NA NA NA NA NA
1039 NA NA NA NA NA NA
47196.8 11225 32610 36589 27357 47814 59967
785.927 NA NA NA NA NA NA
725 NA NA NA NA NA NA
4547 NA NA NA NA NA NA
40715.1 10312.4 31137.2 NA NA 10312.4 31137.2
722 NA NA NA NA NA NA
42614.1 9257.7 30696.7 31025 23442 40282.7 54138.7
45471.5 10311.8 31167.7 36433 28328 46744.8 59495.7
67525.1 NA NA NA NA NA NA
345.98 NA NA NA NA NA NA
40242.5 11222.8 32578.8 NA NA 11222.8 32578.8
1810 NA NA NA NA NA NA
346 NA NA NA NA NA NA
67946.7 19420.4 40578.5 NA NA 19420.4 40578.5
67151.2 NA NA NA NA NA NA
14189.4 NA NA NA NA NA NA
47471.1 10311.9 31167.9 NA NA 10311.9 31167.9
38365.9 8251 30083 NA NA 8251 30083
47319.4 10868 32254 NA NA 10868 32254
2306 NA NA NA NA NA NA
346 NA NA NA NA NA NA
7238.99 NA NA NA NA NA NA
42735.4 10311 31129 30795 23406 41106 54535
40352.9 11222.7 32578.7 NA NA 11222.7 32578.7
61031.7 NA NA NA NA NA NA
1965 NA NA NA NA NA NA
67956.3 18363.7 39789.5 NA NA 18363.7 39789.5
40621.3 11220 32213 NA NA 11220 32213
44678.7 11105 30471 NA NA 11105 30471
4398 NA NA NA NA NA NA
47293.6 10318 31535 NA NA 10318 31535
785 NA NA NA NA NA NA
345.96 NA NA NA NA NA NA
40722.3 9255.72 30341.7 NA NA 9255.72 30341.7
40308.8 8350.33 29621.4 NA NA 8350.33 29621.4
41943.7 11221.7 32569.6 NA NA 11221.7 32569.6
47320.4 10318 31535 36639 28360 46957 59895
43455.5 11219 32243 NA NA 11219 32243
611.99 1373 1994 NA NA 1373 1994
73127.6 19421.9 40786.9 42047 32781 61468.9 73567.9
40717.9 9255.22 30341.2 NA NA 9255.22 30341.2
66299.1 NA NA 38992 29250 38992 29250
67945 17446.6 38707.5 42024 32728 59470.6 71435.5
40316.4 9134.99 30333 NA NA 9134.99 30333
71983.7 20340.8 41872.9 NA NA 20340.8 41872.9
42730.9 9257.92 30696.8 NA NA 9257.92 30696.8
40722 9255.95 30341.9 NA NA 9255.95 30341.9
47312.1 10317.4 31534.2 36667 28374 46984.4 59908.2
37809 11220 32213 NA NA 11220 32213
3580 357 356 NA NA 357 356
16564.9 7400.96 27712 NA NA 7400.96 27712
67954.4 17454.6 38707.6 42061 32752 59515.6 71459.6
67511.1 NA NA 39164 29467 39164 29467
73083.2 18701.4 39302.5 NA NA 18701.4 39302.5
44793.2 11224.9 32610 NA NA 11224.9 32610
67957.2 20330.9 41661.3 42064 32754 62394.9 74415.3
42719 10311.8 31128.8 30806 23415 41117.8 54543.8
47318.5 11224.6 32609.6 NA NA 11224.6 32609.6
73119.4 19092.8 40522.4 NA NA 19092.8 40522.4
73114.3 20338.5 41871.6 NA NA 20338.5 41871.6
47470.1 10312 31168 NA NA 10312 31168
47319.3 11224.8 32609.9 NA NA 11224.8 32609.9
47466.4 10311.7 31167.5 36356 28258 46667.7 59425.5
45164.4 10311 31168 NA NA 10311 31168
6776.94 2325 2386 NA NA 2325 2386
72200.6 20340.3 41872.5 NA NA 20340.3 41872.5
67944.3 20331.5 41661.7 42065 32701 62396.5 74362.7
73105.9 19427 40789 42039 32769 61466 73558
42728.7 9255 30333 NA NA 9255 30333
47469.6 11218.6 32242.6 21377 15403 32595.6 47645.6
67614 19084.3 40311.6 42000 32698 61084.3 73009.6
47364.5 9254.97 30372 NA NA 9254.97 30372
42731 11218.7 32569.8 31028 23439 42246.7 56008.8
30937.4 10857.5 31688.6 NA NA 10857.5 31688.6
2059 1964 1871 NA NA 1964 1871
36907 6324.72 26451.6 NA NA 6324.72 26451.6
10014 6261 6229 NA NA 6261 6229
73103.3 20338.8 41871.7 42033 32763 62371.8 74634.7
40720.4 11219.4 32211.4 NA NA 11219.4 32211.4
42730.5 11221.8 32569.9 NA NA 11221.8 32569.9
40698.9 10312.4 31137.5 NA NA 10312.4 31137.5
70016.6 18374.3 40000.6 NA NA 18374.3 40000.6
40724 10312.7 31137.7 NA NA 10312.7 31137.7
42735.2 11218.9 32204 NA NA 11218.9 32204
40714.2 8348.97 29267 NA NA 8348.97 29267
47469.8 10311.7 31167.8 36451 28337 46762.7 59504.8
44345 6975 27304 NA NA 6975 27304
67954.6 20330.2 41661 4773 2472 25103.2 44133
47317.3 11224.3 32609.3 30740 24468 41964.3 57077.3
73114.5 20339.7 41871.9 NA NA 20339.7 41871.9
47319.9 9260.42 30736.3 NA NA 9260.42 30736.3
40723.9 11219.9 32212.9 NA NA 11219.9 32212.9
47320.1 11225 32610 36657 28364 47882 60974
47412.3 11218.9 32242.8 36440 28335 47658.9 60577.8
47470 10312 31168 36426 28312 46738 59480
19691.7 10862 32064 NA NA 10862 32064
67955.3 20330.3 41661.2 NA NA 20330.3 41661.2
60214.9 19979 41355.3 36933 28677 56912 70032.3
34610.2 9257.93 30182 31034 23405 40291.9 53587
40724.8 8348.84 29266.9 NA NA 8348.84 29266.9
46992 8347.99 29297 NA NA 8347.99 29297
45528.8 11218.9 32242.9 32638 25231 43856.9 57473.9
47320.9 11224.7 32609.7 NA NA 11224.7 32609.7
40355.5 11223 32579 NA NA 11223 32579
42731.1 11218.3 32203.4 30782 23395 42000.3 55598.4
42727.4 10314.9 31495 NA NA 10314.9 31495
40705.4 11219.9 32212.9 NA NA 11219.9 32212.9
42735.5 11219 32204 30792 23403 42011 55607
42730 11218.6 32203.6 30805 23414 42023.6 55617.6
40693.6 11219.8 32212.8 NA NA 11219.8 32212.8
40620.3 11219.3 32212.4 28902 21894 40121.3 54106.4
42721.8 11221.1 32569.2 NA NA 11221.1 32569.2
17727.9 6168 6117 NA NA 6168 6117
73113.3 20339.2 41872 NA NA 20339.2 41872
40715.8 9255.46 30341.5 NA NA 9255.46 30341.5
47318.8 11217.6 32598.7 NA NA 11217.6 32598.7
42732.1 10312 31129 30775 23396 41087 54525
47465.7 10312 31168 36424 28321 46736 59489
65763.1 20322.7 41649.8 40255 31637 60577.7 73286.8
73001.1 20339.7 41872.2 NA NA 20339.7 41872.2
67945 19084.2 40311.4 NA NA 19084.2 40311.4
40648.9 10313 31138 NA NA 10313 31138
67591.1 NA NA 39167 29469 39167 29469
73122.5 18374.5 40000.7 NA NA 18374.5 40000.7
67952.4 20330.4 41660.9 42060 32748 62390.4 74408.9
40307.9 10316 31504 30914 23361 41230 54865
17174.2 7521.31 27478 NA NA 7521.31 27478
1971 1964 1873 NA NA 1964 1873
42731.1 9258 30697 31030 23435 40288 54132
67952.8 20329.3 41660.3 42062 32751 62391.3 74411.3
40642.7 11219.8 32212.8 NA NA 11219.8 32212.8
45370.5 9260.54 30736.6 NA NA 9260.54 30736.6
40347.9 8968.76 30407.6 NA NA 8968.76 30407.6
47388.5 11218.7 32242.7 36449 28335 47667.7 60577.7
40428.7 10312 31129 29960 22712 40272 53841
40312.1 11222.2 32576.2 NA NA 11222.2 32576.2
47251.9 10318 31535 NA NA 10318 31535
40263.2 10316 31504 31027 23450 41343 54954
42723.6 10314.3 31494.3 NA NA 10314.3 31494.3
73121.5 20339.8 41872.3 NA NA 20339.8 41872.3
40336 10316 31504 NA NA 10316 31504
47310.1 10317.9 31534.9 NA NA 10317.9 31534.9
67955.6 20329.4 41660.4 NA NA 20329.4 41660.4
47317.8 11224.9 32609.8 NA NA 11224.9 32609.8
23535.5 10861.8 32093.8 NA NA 10861.8 32093.8
40264 11221.7 32569.7 31034 23447 42255.7 56016.7
66717.7 19422.8 40578.8 42065 32753 61487.8 73331.8
40351.4 10316 31504 NA NA 10316 31504
67591.9 NA NA 39161 29460 39161 29460
18830.7 6261 27122.8 NA NA 6261 27122.8
40725.9 9135.93 30342 NA NA 9135.93 30342
67358 NA NA 37504 28778 37504 28778
4793 2315 1832 NA NA 2315 1832
40724.4 9255.9 30341.8 NA NA 9255.9 30341.8
42732.1 9256.84 30695.7 NA NA 9256.84 30695.7
40687 11219.9 32212.9 NA NA 11219.9 32212.9
47297.7 11225 32610 NA NA 11225 32610
345.92 1373 1993 NA NA 1373 1993
47312.9 9260.39 30736.4 NA NA 9260.39 30736.4
42685.8 10314.9 31494.9 30996 23413 41310.9 54907.9
40703.9 9255.36 30341.4 NA NA 9255.36 30341.4
20478.5 10861.9 32063.9 NA NA 10861.9 32063.9
45127.6 14079 34878 38989 24957 53068 59835
54087.5 9290.99 34384 30373 20920 39664 55304
37935 8350.78 29621.8 NA NA 8350.78 29621.8
42734.9 11219 32203.9 28173 21216 39392 53419.9
67502.5 14837 35362 41670 32614 56507 67976
47320 11225 32609.9 36661 28373 47886 60982.9
346 1373 1993 NA NA 1373 1993
40355.1 9258.82 30705.8 30579 23439 39837.8 54144.8
4371 1964 1871 30804 23416 32768 25287
40353.4 11222 32578 NA NA 11222 32578
67954.4 19418.7 40580.7 42062 32746 61480.7 73326.7
39874.6 9257.52 30696.3 30128 22898 39385.5 53594.3
42676.8 11218.8 32203.7 30806 23414 42024.8 55617.7
40722.7 11219.5 32212.5 NA NA 11219.5 32212.5
34578.3 8893.96 29818 3660 5146 12554 34964
42724.7 10312 31129 30804 23324 41116 54453
2073 3932.01 2826.98 NA NA 3932.01 2826.98
40349.7 11223 32578.9 NA NA 11223 32578.9
42722.3 11222 32570 NA NA 11222 32570
42731.6 11222 32570 31032 23447 42254 56017
40119.7 11222.9 32578.9 NA NA 11222.9 32578.9
47319.1 11224.8 32609.9 36645 28364 47869.8 60973.9
32301.9 8897.95 30044.9 NA NA 8897.95 30044.9
20478.6 8897.67 30190.6 NA NA 8897.67 30190.6
65661.2 17118.4 40311.6 42064 32753 59182.4 73064.6
REP2W
AY.M
EN.N
REP2W
AY.W
OM
EN.N
JOIN
T.MEN
.N
JOIN
T.WOM
EN.N
76594.1 98321.5
76625.8 98352
75703.6 97269
85136.8 107403
72649.3 95325
43852.3 73066.2
74652.9 96472.8
80859.5 114968
120996 142362
119039 140491
75695.9 97263.7
75711.3 97270.5
119853 144380
75709.9 97276.9
120085 144968
76528 98256
122115 147030
97446.4 97022.1
76594.8 98324.9
118315 144232
103912 135532
76524.4 98283.1
116371 138690
115506 140779
121102 145738
97473.7 97046
77555.4 111727
117841 141377
120670 145415
95669.7 123181
120603 146576
122844 147665
120288 145155
122925 147766
122917 147753
120794 146475
121962 146619
116399 145024
96669.1 97028.5
121124 145746
122901 147752
79917.2 113809
74923.1 96328.6
85273.4 107211
96224.5 123958
122890 147753
122929 147776
121995 146649
121717 146345
107033 133808
25929.2 52542.6
121782 146396
122892 147738
107854 138889
86015.2 108042
119080 144449
84234.7 106430
122901 147747
80853.7 114968
55054.7 72577.6
117002 143039
78759.8 112722
118540 143068
120809 145287
48609.1 78840.8
121973 145776
97486 97058.9
120918 145830
121980 146671
84066.7 106180
122823 147690
120093 144982
80894.9 115004
77132.4 111122
93474.8 93336
33400 63512
85974.2 108010
85495.6 105546
42187.4 71068
1886 2416
95460.8 94389
45710.6 74805.8
44150.7 72938.3
739.99 345.99
611.92 345.97
53305 50575
77612.9 111140
97505.7 97049.1
122556 147396
611.99 345.99
43122.3 71787.1
2006 2051
97469.5 97045
66944.5 90139.1
1840 1862
80870.3 114976
1484 1726
21677.4 25734.8
97468.1 97041.1
44149.6 72937
80868.9 114980
118035 140679
85069.8 107374
1950 1992
75018 97010.1
80890.3 115005
85131.1 106974
58323.4 67592.9
78483.5 112278
49529 79928.8
77384.3 111304
30231.8 30934
58310.5 67574.8
3492 3868
46793 76220.5
12538 17866
33408.7 61218.6
122429 147170
17771.8 19865.9
45788.8 74906.7
1522 1799
27935.3 53267.3
97493.3 97063.5
80868.3 114992
58297.9 67577.1
611.77 345.89
119163 143890
78937.1 109610
44848.6 73795.8
47623.9 77843.1
44901.6 73845.7
611.75 345.88
1075 1084
612 345.97
43856.6 73068.6
47565.8 78057.3
49587.8 79713.7
122030 146842
58315.9 67587
49587.5 79713.8
58288.5 67546.5
44070.3 72933.5
45674.7 72612.9
116560 136906
41015.2 69703.5
612 346
1688 1708
1699.47 611.74
1482 1780
58321 67591.2
1998 2054
1878 4801
79948.3 113871
1980 2032
120020 141208
58315.9 67584.1
43856.6 73068.9
8812.67 6989.82
612 346
58320.8 67590.7
1094 1039
85989.1 107164
1087.96 785.927
580 725
3480 4547
43221.6 71852.3
700 722
74744.2 96752.8
83789.4 104967
58244.1 67525.1
611.91 345.98
43952.4 72821.3
2595.97 1810
611.99 346
78028.3 108525
57851.8 67151.2
6924 14189.4
48681.2 78639
40113.2 68448.9
49169.1 79573.4
1206 2306
612 346
6774.98 7238.99
75706.3 97270.4
44069.6 72931.6
53167.2 61031.7
1934 1965
77026.8 107746
44054.4 72834.3
47573.2 75149.7
3964 4398
48600.5 78828.6
615 785
611.95 345.96
42183.6 71064
41039.3 69930.2
45186.4 74513.3
85261.9 107215
47007.4 75698.5
3073 2605.99
122024 146696
42179.9 71059.1
96293.2 95549.1
118074 139380
41961.4 70649.4
79886.9 113857
43838.3 73427.7
42182.4 71063.9
85282.5 107220
41861.3 70022
4999.99 3936
21414.7 44276.9
118130 139414
97424.9 96978.1
79227.5 112386
47548 77403.2
121014 142372
75706.5 97262.8
49527.8 79928.1
79633.8 113642
80867.9 114986
48680 78638.1
49529 79929.2
85032.5 106892
47472.3 76332.4
8625.98 9162.94
80008.7 114073
121004 142307
122005 146664
43851.6 73061.7
70963.7 95115.2
119460 140624
47507.5 77736.5
76826.7 98739.8
34794.9 62626
3967 3930
35117.3 63358.6
12968.5 16243
122925 147738
44146 72931.8
45801.3 75300.4
43221 71836.4
74836.1 110017
43242.4 71861.7
45820.1 74939.2
41268.1 69981.2
85128.9 106975
42815.2 71649
83719.7 112088
80266.9 104395
80882.3 114986
47564.7 78056.2
44149.3 72936.8
86186.5 108294
85976.5 107990
85104.2 106950
25929.3 51755.7
78947.4 109616
102390 130247
66721.3 88197.2
41279.1 69991.7
46231.9 76289
80954.6 103003
49530 79930.6
41827.2 72934.5
76597.8 98329.5
44942.5 74222.4
44137 72918.3
76609.4 98342.5
76619.9 98347.6
44113.2 72906.4
73011.2 94726.7
45791.3 75291
21740.8 23844.9
80885.8 114985
42183.9 71057.3
49520.9 79917.5
75687.9 97257.1
85100.8 106955
116836 139050
80764.2 114873
77575.2 108256
43192.3 71786.9
97488.4 97060.1
78921.3 113123
121002 142361
74049.5 95172.9
18766 44652.2
3909 3844
74867.6 96863.1
121006 142364
44103.1 72855.5
46286.2 76107.1
41810.3 70755.5
85839.1 107966
73654.3 94269.7
44050.8 72888.3
48580 78786.9
74135 95217.2
44887.7 74217.9
80885 114994
43154.2 71840
48611.7 78845
78946.4 109616
49526.8 79927.6
27723.7 55629.3
74888.7 96280.7
116342 140050
40913.1 71855.4
97483.5 97051.9
17942.2 45953.5
42067.3 71067.9
95601.2 96136
4864 6625
42186 71066.2
43838.1 73427.8
44120.2 72899.9
49506.1 79907.7
1984.86 2338.92
47558.5 78049.3
75851.3 97593.7
42166.1 71045.3
25929.1 52542.4
95055.1 104963
85463 109392
39304.2 67556.8
73992.8 96154.8
114686 135478
86190.4 108303
1984.99 2339
72686.7 94499.9
35992 29658
44070.1 72931.4
120097 141281
71610 93468.9
76586.7 98294.5
44147.8 72935.2
39641.8 69542.3
75704.5 97177.7
6851.01 4899.98
44065.1 72928.6
45789.3 75292.3
76834.8 98748.6
43863.9 72698.6
86172.9 108293
36030.6 62346.8
23965.6 50669.2
116282 138726
COLOURING
VARIABLE
MarkerName
Gene
Trait
Gender
CHR
POS_B36
Effect_allele_adj
Other_allele_adj
DISCOVERY.MEN.p.fdr
DISCOVERY.WOMEN.p.fdr
DISCOVERY.MEN.GCIn.GCOut.P.value
DISCOVERY.WOMEN.GCIn.GCOut.P.value
DISCOVERY.MENvsWOMEN.GCIn.GCOut.P.value
INSILICO.MEN.GCIn.GCOut.P.value
INSILICO.WOMEN.GCIn.GCOut.P.value
INSILICO.MENvsWOMEN.GCIn.GCOut.Goncalo.P.value
METABOCHIP.MEN.GCIn.GCOut.P.value
METABOCHIP.WOMEN.GCIn.GCOut.P.value
METABOCHIP.MENvsWOMEN.GCIn.GCOut.Goncalo.P.value
REP2WAY.MEN.P.value.1sided
REP2WAY.WOMEN.P.value.1sided
REP2WAY.MENvsWOMEN.P.value.1sided.xls
REP2WAY.s2.MENvsWOMEN.P.value.1sided.xls.fdr
REP2WAY.s2.GENDERCOMBINED.348.P-value
JOINT.MEN.P.value
JOINT.WOMEN.P.value
JOINT.MENvsWOMEN.P.value
DISCOVERY.MEN.Effect
DISCOVERY.WOMEN.Effect
INSILICO.MEN.Effect
INSILICO.WOMEN.Effect
METABOCHIP.MEN.Effect
METABOCHIP.WOMEN.Effect
REP2WAY.MEN.Effect
REP2WAY.WOMEN.Effect
JOINT.MEN.Effect
JOINT.WOMEN.Effect
DISCOVERY.MEN.GCIn.GCOut.StdErr
DISCOVERY.WOMEN.GCIn.GCOut.StdErr
INSILICO.MEN.GCIn.GCOut.StdErr
INSILICO.WOMEN.GCIn.GCOut.StdErr
METABOCHIP.MEN.GCIn.GCOut.StdErr
METABOCHIP.WOMEN.GCIn.GCOut.StdErr
REP2WAY.MEN.StdErr
REP2WAY.WOMEN.StdErr
JOINT.MEN.StdErr
JOINT.WOMEN.StdErr
DISCOVERY.MEN.EAF
DISCOVERY.WOMEN.EAF
INSILICO.MEN.EAF
INSILICO.WOMEN.EAF
METABOCHIP.MEN.EAF
METABOCHIP.WOMEN.EAF
REP2WAY.MEN.EAF
REP2WAY.WOMEN.EAF
JOINT.MEN.EAF
JOINT.WOMEN.EAF
DISCOVERY.MEN.N
DISCOVERY.WOMEN.N
INSILICO.MEN.N
INSILICO.WOMEN.N
METABOCHIP.MEN.N
METABOCHIP.WOMEN.N
REP2WAY.MEN.N
REP2WAY.WOMEN.N
JOINT.MEN.N
JOINT.WOMEN.N
DESCRIPTION
SNP exhibits genome-wide significant association in joint (discovery+follow-up) stage in women (JOINT.WOMEN.P-Value < 5e-8)
SNP exhibits genome-wide significant association in joint (discovery+follow-up) stage in men (JOINT.MEN.P-Value < 5e-8)
SNP exhibits genome-wide significant association in joint (discovery+follow-up) stage in women and in men (JOINT.WOMEN.P-Value < 5e-8 & JOINT.MEN.P-Value < 5e-8)
DESCRIPTION
SNP identifier
Nearest gene
Trait for which the SNP was selected for in the Discovery stage
Gender for which the SNP was selected for in the Discovery stage
Chromosome
Base Position on build 36
Allele to which the effect has been estimated
Other allele
Discovery-Stage FDR-adjusted MEN P-Value
Discovery-Stage FDR-adjusted WOMEN P-Value
Discovery-Stage MEN P-Value
Discovery-Stage WOMEN P-Value
Discovery-Stage Sex-Difference P-Value
Follow-Up Insilico Stage MEN P-Value
Follow-Up Insilico Stage WOMEN P-Value
Follow-Up Insilico Stage Sex-Difference P-Value
Follow-Up MetaboChip Stage MEN P-Value
Follow-Up MetaboChip Stage WOMEN P-Value
Follow-Up MetaboChip Stage Sex-Difference P-Value
Follow-Up Stage MEN P-Value 1-sided
Follow-Up Stage WOMEN P-Value 1-sided
Follow-Up Stage MENvsWOMEN P-Value 1-sided
Follow-Up Stage MENvsWOMEN FDR-adjusted P-Value 1-sided
Follow-Up Stage Gender-combined Overall P-Value
JOINT-Stage MEN P-Value
JOINT-Stage WOMEN P-Value
JOINT-Stage Sex-Difference P-Value
Discovery-Stage MEN Effect
Discovery-Stage WOMEN Effect
Follow-Up Insilico Stage MEN Effect
Follow-Up Insilico Stage WOMEN Effect
Follow-Up MetaboChip Stage MEN Effect
Follow-Up MetaboChip Stage WOMEN Effect
Follow-Up Stage MEN Effect
Follow-Up Stage WOMEN Effect
JOINT-Stage MEN Effect
JOINT-Stage WOMEN Effect
Discovery-Stage MEN Standard Error
Discovery-Stage WOMEN Standard Error
Follow-Up Insilico Stage MEN Standard Error
Follow-Up Insilico Stage WOMEN Standard Error
Follow-Up MetaboChip Stage MEN Standard Error
Follow-Up MetaboChip Stage WOMEN Standard Error
Follow-Up Stage MEN Standard Error
Follow-Up Stage WOMEN Standard Error
JOINT-Stage MEN Standard Error
JOINT-Stage WOMEN Standard Error
Discovery-Stage MEN Allele frequency of Effect_allele_adj
Discovery-Stage WOMEN Allele frequency of Effect_allele_adj
Follow-Up Insilico Stage MEN Allele frequency of Effect_allele_adj
Follow-Up Insilico Stage WOMEN Allele frequency of Effect_allele_adj
Follow-Up MetaboChip Stage MEN Allele frequency of Effect_allele_adj
Follow-Up MetaboChip Stage WOMEN Allele frequency of Effect_allele_adj
Follow-Up Stage MEN Allele frequency of Effect_allele_adj
Follow-Up Stage WOMEN Allele frequency of Effect_allele_adj
JOINT-Stage MEN Allele frequency of Effect_allele_adj
JOINT-Stage WOMEN Allele frequency of Effect_allele_adj
Discovery-Stage MEN Samplesize
Discovery-Stage WOMEN Samplesize
Follow-Up Insilico Stage MEN Samplesize
Follow-Up Insilico Stage WOMEN Samplesize
Follow-Up MetaboChip Stage MEN Samplesize
Follow-Up MetaboChip Stage WOMEN Samplesize
Follow-Up Stage MEN Samplesize
Follow-Up Stage WOMEN Samplesize
JOINT-Stage MEN Samplesize
JOINT-Stage WOMEN Samplesize
SNP exhibits genome-wide significant association in joint (discovery+follow-up) stage in women (JOINT.WOMEN.P-Value < 5e-8)
SNP exhibits genome-wide significant association in joint (discovery+follow-up) stage in men (JOINT.MEN.P-Value < 5e-8)
SNP exhibits genome-wide significant association in joint (discovery+follow-up) stage in women and in men (JOINT.WOMEN.P-Value < 5e-8 & JOINT.MEN.P-Value < 5e-8)
Short name Full name Design Total Sample size (N) Call rate* Other exclusions Samples in
analyses (N) Anthropometric assessment method References
LifeLines LifeLines Population-based 3,900 ≥ 95% [exclude if <95%]
1) non-Caucasian (Principle Components Analysis);2) related individuals (pi-hat > 0.4); 3) unexpected duplicates; 4) gender mismatch
3,367 measured 1
PREVEND Prevention of Renal and Vascular Endstage Disease Population-based 3,920 ≥95%1) ethnic outliers; 2) related individuals and duplicates; 3) missing phenotype
3,622 measured 2
QIMR Twin study at Queensland Instutite of Medical Rearch Population-based 11,930 ≥ 95%
1) age < 18;2) ethnic outliers;3) related individuals and duplicates;4) Missing body weight and height
3,627 measured or self-reported 3
PLCO2 controls Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Population-based case-control 1,216 >98%
1) sex discordance with genetic data;2) heterozygosity;3) ancestry outliers;4) related individuals and duplicates;5) missing phenotype data
1,193 self-report 4
PLCO2 cases Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Population-based case-control 3,003 >98%
1) sex discordance with genetic data;2) heterozygosity;3) ancestry outliers;4) related individuals and duplicates;5) missing phenotype data
2,976 self-report 4
ADVANCE-CAD cases Atherosclerotic Disease, VAscular FuNction, & GenetiC Epidemiology study
Population-based case control study of CAD
974 ≥ 95% 1) sex discrepancies 663 measured 5-8
ADVANCE-CAD controls Atherosclerotic Disease, VAscular FuNction, & GenetiC Epidemiology study
Population-based case control study of CAD
705 ≥ 95% 1) sex discrepancies 895 measured 5-8
AMC-PAS Academic Medical Centre Amsterdam Premature Atherosclerosis Study CAD cases 706 0.97
1) heterozygosity;2) ethnic outliers; 3) duplicates; 4) missing phenotypes; 5) call rate< 0.95
490 measured 9
B58C nonGWAS 1958 British Birth Cohort Population-based 2,359 For SNPs with MAF >=5%: >=95%; For SNPs with >=1% MAF<5%: >=99%
1) MAF>=1%; 2) genotype clustering;3) call rate;4) HWE;5) MI of alleles; 6) concordance rate; 7) correct SNP mapping
2,211 measured 10-13
BHS nonGWAS metabochip Busselton Health Study Population-based 270 ≥99% 1) Relatedness 267 measured 14
CARDIOGENICS CARDIOGENICS CAD case-control 806 0.98
1) heterozygosity; 2) ethnic outliers; 3) duplicates; 4) missing phenotypes; 5) call rate< 0.95
754 measured 15
D2D2007 cases FIN-D2D study Population-based 457 ≥ 98.15%1) Missing BMI, age, age<18, or is not T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
457 measured 16
D2D2007 controls FIN-D2D study Population-based 2,231 ≥ 98.15%1) Missing BMI, age, age<18., or has diabetes; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
2,231 measured 16
DILGOM Dietary, life style, and genetic determinants of obesity and metabolic syndrome Population-based 3,997 ≥ 95%
1) heterozygosity <23.9% or >27.6%;2) ethnic outliers;3) related individuals and duplicates
3,938 measured 17,18
DPS cases Diabetes Prevention Study Population-based 89 ≥ 98.15%1) Missing BMI, age, age<18, or is not T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
89 measured 19
DPS controls Diabetes Prevention Study Population-based 383 ≥ 98.15%1) Missing BMI, age, age<18., or has diabetes; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
383 measured 19
DR'S EXTRA cases DR'S EXTRA Population-based 111 ≥ 98.15%1) Missing BMI, age, age<18, or is not T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
121 measured 20
Study Sample QC
Follow-Up Stage - Insilico:
Follow-Up Stage - MetaboChip:
DR'S EXTRA controls DR'S EXTRA Population-based 1,174 ≥ 98.15%1) Missing BMI, age, age<18., or has diabetes; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
1,174 measured 20
EAS Edinburgh Artery Study Population-based 750 ≥ 95% 1) Missing body weight and height 729 Measured 21
EGCUT metabochip CAD cases Estonian Genome Center of University of Tartu - Cardiovascular Disease cases Case-Controls 700 ≥ 84.6% 1) Missing body weight and height;
2) Cryptic relatednessmeasured 22
EGCUT metabochip controls Estonian Genome Center of University of Tartu - Controls Case-Controls 942 ≥ 84.6% 1) Missing body weight and height;
2) Cryptic relatednessmeasured 22
EGCUT metabochip DB cases Estonian Genome Center of University of Tartu - Type 2 Diabetes cases Case-Controls 968 ≥ 84.6% 1) Missing body weight and height;
2) Cryptic relatednessmeasured 22
ELY Ely Study Population-based 1,625 ≥ 95%1) Missing body weight and height; 2) Heterozygosity; 3) gender check
1,600 measured 23
EPIC cases EPIC (European Prospective Investigation into Cancer) Norfolk Cohort, DM cases Population-based 735 ≥ 95%
1) Missing body weight and height, or case-control status; 2) Heterozygosity; 3) gender check
727 measured 24
EPIC controls EPIC (European Prospective Investigation into Cancer) Norfolk Cohort, non-DM controls Population-based 978 ≥ 95%
1) Missing body weight and height, or case-control status; 2) Heterozygosity; 3) gender check
963 measured 24
Fenland Fenland Study Population-based 3,251 ≥ 95%1) Missing body weight and height; 2) Heterozygosity; 3) gender check
3,186 measured 25
FUSION stage 2 cases FUSION stage 2 case-control 1,039 ≥ 98.15%1) Missing BMI, age, age<18, or is not T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
1,039 measured 26
FUSION stage 2 controls FUSION stage 2 case-control 1,890 ≥ 98.15%1) Missing BMI, age, age<18., or has diabetes; 2) Gender discrepancy or anomaly;3) Unexplained duplicate sample
1,890 measured 26
GLACIER Gene x Lifestyle interactions And Complex traits Involved in Elevated disease Risk Prospective cohort study 6,311 ≥ 95%
1) Missing phenotype; 2) Duplicates; 3) Call rate; 4) Heterozygosoty; 5) Gender fails
6,047 measured 27,28
GO-DARTS cases GO-DARTS cases Population-based 3,582 For SNPs with MAF >=5% : >=95%; For SNPs with >=1% MAF<5%: >=99%
1) MAF>=1%; 2) genotype clustering; 3) call rate; 4) HWE; 5) MI of alleles; 6) concordance rate; 7) correct SNP mapping
3,313 measured 29
GO-DARTS controls GO-DARTS controls Population-based 3,962 For SNPs with MAF >=5% : >=95%; For SNPs with >=1% MAF<5%: >=99%
1) MAF>=1%; 2) genotype clustering; 3) call rate; 4) HWE; 5) MI of alleles; 6) concordance rate; 7) correct SNP mapping
3,709 measured 29
Heinz Nixdorf Recall Study Heinz Nixdorf Recall Study Population-based 4,570 ≥ 97%
1) heterozygosity <21% or >26%; 2) ethnic outliers = 15; 3) related individuals and duplicates = 37; 4) Missing body weight = 26 and height = 18
4,518 30
HUNT cases HUNT2Population-based, although T2D case-control samples selected for metabochip typing
578 ≥ 98.15%1) Missing BMI, age, age<18, or is not T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
578 measured 31
HUNT controls HUNT2Population-based, although T2D case-control samples selected for metabochip typing
756 ≥ 98.15%1) Missing BMI, age, age<18, or is T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
756 measured 31
IMPROVE Population-based 3,426 ≥ 95%1) ambiguous sex; 2) cryptic relatedness; 3) non-european descent
3,426 measured 32
KORA S3
Cooperative Health Research in the Region of Augsburg (third survey), KOoperative Gesundheitsforschung in der Region Augsburg (dritte Studie)
Population-based 3,113 0.93 none 3,113 measured 33
KORA S4
Cooperative Health Research in the Region of Augsburg (forth survey), KOoperative Gesundheitsforschung in der Region Augsburg (vierte Studie)
Population-based 3,028 0.93 none 3,028 measured 33
LURIC cases Ludwigshafen Risk and Cardiovascular Health Study case-control 2,281 ≥ 95% 1) Gender ambiguity; 2) Missing hip and waist measurement, age < 18
2,251 measured 34
LURIC controls Ludwigshafen Risk and Cardiovascular Health Study case-control 648 ≥ 95% 1) Gender ambiguity; 2) Missing hip and waist measurement, age < 18
644 measured 34
METSIM cases Metabolic Syndrome In MenPopulation-based, although T2D case-control samples selected for metabochip typing
1,214 ≥ 98.15%1) Missing BMI, age, age<18, or is not T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
1,214 measured 35
METSIM controls Metabolic Syndrome In MenPopulation-based, although T2D case-control samples selected for metabochip typing
957 ≥ 98.15%1) Missing BMI, age, age<18, or has diabetes 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
957 measured 35
MORGAM MOnica Risk, Genetics, Archiving and Monograph Population-based ~2,650 ≥ 95%
1) heterozygosity <18.1% or >20.7%;2) >10.0% discordance with Sequenom genotypes; 3) ethnic outliers; 4) related individuals and duplicates
2,528 measured 36-39
MORGAM cases MOnica Risk, Genetics, Archiving and Monograph CVD cases from population-based follow-up cohorts. Baseline and incident cases.
~2,150 ≥ 95%
1) heterozygosity <18.1% or >20.7%;2) >10.0% discordance with Sequenom genotypes; 3) ethnic outliers; 4) related individuals and duplicates
2,065 measured 36-39
NSHD MRC National Survey of Health & Development Birth cohort 5,362 ≥ 95%1) Missing body weight and height; 2) Heterozygosity; 3) gender check
988 measured 40,41
PIVUS Prospective Investigation of the Vasculature in Uppsala Seniors Population-based 999 ≥90%
1) Related individuals and duplicates; 2) Heterozygosity, (F-mean(F))/sd(Z) ≥ 5; 3) Missing all phenotypes
978 measured 42
SCARFSHEEP case-control 2,899 ≥ 95%1) ambiguous sex; 2) cryptic relatedness; 3) non-european descent
3,201 measured
STR Swedish Twin Registry Population-based 2,702 ≥90% 1) Heterozygosity, (F-mean(F))/sd(Z) ≥ 5; 2) Missing all phenotypes
2,430 measured 43
T2D – WTCCC nonGWAS Wellcome Trust Case Control Consortium - T2D non GWAS Population-based 1,335 For SNPs with MAF >=5% : >=95%;
For SNPs with >=1% MAF<5%: >=99%
1) MAF>=1%; 2) genotype clustering; 3) call rate; 4) HWE; 5) MI of alleles;6) concordance rate; 7) correct SNP mapping
1,077 measured
THISEAS The Hellenic study of Interactions between Snps and Eating in Atherosclerosis Susceptibility CAD case-control 1,887 0.97
1) heterozygosity; 2) ethnic outliers; 3) duplicates; 4) missing phenotypes; 5) call rate < 0.95
1,413 measured 44
Tromsø cases TromsøPopulation-based, although T2D case-control samples selected for metabochip typing
709 ≥ 98.15%1) Missing BMI, age, age<18, or is not T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
709 measured 45
Tromsø controls TromsøPopulation-based, although T2D case-control samples selected for metabochip typing
709 ≥ 98.15%1) Missing BMI, age, age<18, or is T2D; 2) Gender discrepancy or anomaly; 3) Unexplained duplicate sample
709 measured 45
ULSAM Uppsala Longitudinal Study of Adult Men Population-based 1,221 ≥90%1) Related individuals and duplicates; 2) Heterozygosity, (F-mean(F))/sd(Z) ≥ 5; 3) Missing all phenotypes
1,116 measured 46
WHITEHALL The Whitehall II study Cohort of London-based civil servants 3,413 ≥ 95%1) Missing body weight and height; 2) Heterozygosity; 3) gender check
3,377 measured 47,48.
Cohort Platform Genotype calling algorithm MAF Call rate* p for HWE SNPs that met
QC criteriaImputation software MAF Imputation quality* SNPs in meta-
analysisAnalyses software
LifeLines Illumina Cyto SNP12 v2 GenomeStudio ≥ 1% ≥ 95% > 10-4 257.581 BEAGLE v3.1.0 >0% no filtering on imputation quality 2,472,812 SNPtest
PLCO2 controls Illumina HumanHap 550K; Illumina HumanHap 610K Bead Studio
exc. monomorphic SNPs
≥ 90% - 525,262 IMPUTE ≥1% proper-info ≥ 0.40 2,538,067 SNPtest
PLCO2 cases Illumina HumanHap 550K; Illumina HumanHap 610K Bead Studio
exc. monomorphic SNPs
≥ 90% - 525,262 IMPUTE ≥1% proper-info ≥ 0.40 2,564,030 SNPtest
PREVEND Illumina HumanCytoSNP-12 GenomeStudio ≥ 1% >95% 0.0001 232,571 BEAGLE ≥1% at meta-level 2,289,210 PLINK
QIMR Illumina HumanHap 370 or 610 BeadStudio ≥ 1% ≥ 95% > 10-6 271,069 MACH NA NA 2,543,887 PLINK
Follow-Up Stage - Insilico
Inclusion criteriaInclusion criteria
Genotyping Imputation Association analyses
Study Trait n mean SD median min max correlation with BMI
correlation with height n mean SD median min max correlation
with BMIcorrelation with height
Age (yrs) 1,373 56.2 9.6 54 21.9 87.6 0.1 -0.3 1,994 54.8 10 52 23.3 89 0.2 -0.3
BMI (kg/m²) 1,373 26.9 3.6 26.4 17 48.9 1 -0.1 1,994 26.5 4.6 25.6 15.2 51 1 -0.2
Weight (kg) 1,373 88 13.1 86 53 165 0.8 0.5 1,994 74.2 12.9 72 43 135 0.9 0.3
Height (m) 1,373 1.8 0.1 1.8 1.6 2 -0.1 1 1,994 167.6 6.3 168 145 189 -0.2 1
WC (cm) 1,373 98.2 10.5 98 71 158 0.8 0.1 1,993 89.8 11.9 89 60 139 0.8 0
Hip (cm) 1,373 100.2 7.3 100 78 153 0.7 0.3 1,993 102 10.1 101 69 181 0.8 0.1
WHR 1,373 1 0.1 1 0.7 1.3 0.5 -0.1 1,993 0.9 0.1 0.9 0.5 1.3 0.4 -0.1
Age (yrs) 649 63.6 5.2 64 55 74 -0.2 -0.1 544 63.6 5.2 64 55 74 -0.1 -0.1
BMI (kg/m²) 645 27 3.9 26.5 17.2 40.5 1 0 544 26.4 5 25.7 16.7 50.3 1 -0.1
Weight (kg) 645 86.6 14 83.9 52.2 145.1 0.9 0.5 544 70.3 14.2 68 41.3 149.7 0.9 0.3
Height (m) 649 1.8 0.1 1.8 1.6 2 0 1 544 1.6 0.1 1.6 1.5 1.9 -0.1 1
WC (cm) - - - - - - - - - - - - - - - -
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 2,042 64.2 5.1 64 55 74 -0.1 -0.1 934 64 5.3 64 55 74 0 -0.1
BMI (kg/m²) 2,040 27.5 4.2 26.9 15.9 50.2 1 0 933 26.7 5.1 25.9 16.5 52.2 1 -0.1
Weight (kg) 2,040 87.6 14.8 85.3 52.2 176.9 0.9 0.4 933 71 14.5 68 40.8 137.9 0.9 0.3
Height (m) 2,042 1.8 0.1 1.8 1.6 2.1 0 1 934 1.6 0.1 1.6 1.2 1.9 -0.1 1
WC (cm) - - - - - - - - - - - - - - - -
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 1,870 50.9 12.8 50 28 75 0.2 -0.3 1,752 48.2 12 47 28 75 0.3 -0.4
BMI (kg/m²) 1,870 26.4 3.7 26 17.2 44.7 1 -0.2 1,752 25.8 4.8 25 17.1 53.7 1 -0.2
Weight (kg) 1,870 85.1 12.5 84 49 146 0.9 0.4 1,752 72.3 13.2 70 44.9 144.5 0.9 0.2
Height (m) 1,870 1.8 0.1 1.8 1.6 2.1 -0.2 1 1,752 1.7 0.1 1.7 1.5 1.9 -0.2 1
WC (cm) 1,868 94.5 11.2 94 31 141.5 0.8 0 1,752 83.3 13 81.5 57 150 0.9 -0.1
Hip (cm) 1,868 100.1 6.7 100 70 128 0.8 0.2 1,752 101 10.4 100 68 170 0.9 0
WHR 1,868 0.9 0.1 0.9 0.3 1.4 0.6 -0.2 1,752 0.8 0.1 0.8 0.5 1.4 0.4 -0.2
Age (yrs) 1,470 44.7 16.3 44 18 91 0.3 -0.2 2,157 44 15.3 42 18 90 0.3 -0.2
BMI (kg/m²) 1,470 26 3.9 25.6 14.8 60.9 1 -0.1 2,157 25 5.1 23.9 14.2 64.5 1 -0.2
Weight (kg) 1,470 82.2 13.2 81 47 180 0.9 0.4 2,157 66.6 13.7 64 34 160 0.9 0.2
Height (m) 1,470 1.8 0.1 1.8 1.5 2 -0.1 1 2,157 1.6 0.1 1.6 1.3 2 -0.2 1
WC (cm) - - - - - - - - - - - - - - - -
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 675 61.5 8.2 61.2 34 87.5 -0.2 -0.1 220 66.2 6.3 66.4 47.9 80.1 -0.8 -0.2
BMI (kg/m²) 675 29.1 4.8 28.2 17.8 53.7 1 0 220 29 6.4 28 16.9 66.1 1 -0.2
Weight (kg) 675 90.3 16 87.9 48.4 164.7 0.9 0.4 220 75.6 16.5 73.4 44.9 149.1 0.9 0.2
Height (m) 675 1.8 0.1 1.8 1.6 2 0 1 220 1.6 0.1 1.6 1.4 1.8 -0.2 1
WC (cm) 675 99.9 12 98.4 70.2 148 0.9 0.2 217 89.2 14.1 88.4 59.9 132.3 0.9 0
Hip (cm) 0 - - - - - - - 0 - - - - - - -
WHR 0 - - - - - - - 0 - - - - - - -
Age (yrs) 420 65.8 2.9 65.3 61 72.3 0 0 243 65.7 2.9 65.5 60.6 71.2 -0.1 -0.1
Women
Follow-Up Stage - Insilico:
LifeLines
PLCO2 controls
PLCO2 cases
ADVANCE-CAD cases
PREVEND
QIMR
Follow-Up Stage - MetaboChip:
Men
BMI (kg/m²) 420 28.4 4.5 27.6 19.9 46.6 1 -0.1 243 28 6.2 27 17.4 50.4 1 -0.1
Weight (kg) 420 87.9 14.9 85.2 59.6 136.4 0.9 0.4 243 73.7 16.5 70.7 44.2 128.2 0.9 0.2
Height (m) 420 1.8 0.1 1.8 1.6 2 -0.1 1 243 1.6 0.1 1.6 1.4 1.8 -0.1 1
WC (cm) 419 99.5 12.6 98.5 66.5 154 0.9 0.1 243 85.8 13.4 84.8 58.7 131.6 0.9 0
Hip (cm) - - - - - - - - 0 - - - - - - -
WHR - - - - - - - - 0 - - - - - - -
Age (yrs) 368 43.5 5.1 44.5 24 50 -0.1 -0.1 122 42.8 5.6 44 25 50 0.1 -0.1
BMI (kg/m²) 368 27.1 3.8 26.7 18.5 40.6 1 0.1 122 26.2 5.1 25.3 17.4 41.2 1 -0.1
Weight (kg) 368 88.1 14.8 86 50 150 0.9 0.5 122 73.1 14.8 70 49 122 0.9 0.3
Height (m) 368 1.8 0.1 1.8 1.6 2 0.1 1 122 1.7 0.1 1.7 1.5 1.8 -0.1 1
WC (cm) - - - - - - - - - - - - - - - -
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 1,234 45 0 45 45 45 - - 902 45 0 45 45 45 - -
BMI (kg/m²) 1,232 27.8 4.2 27.3 16.5 53.6 1 -0.02 902 26.6 5.3 25.3 17.7 54.3 1 -0.16
Weight (kg) 1,234 85.9 14.8 84.6 -9 158.9 0.89 0.41 902 70.1 14.3 67 42 143.5 0.92 0.23
Height (m) 1,234 1.76 0.07 1.76 1.56 1.98 -0.02 1 902 1.62 0.06 1.63 1.22 1.84 -0.16 1
WC (cm) 1,234 98.1 11.8 97.2 -9 151.2 0.8 0.2 902 83.9 14.3 82.4 -9 133.8 0.76 0.05
Hip (cm) 1,234 105.3 9.1 105.1 -9 152.4 0.64 0.26 902 103.9 13.8 102.4 -9 157.6 0.71 0.1
WHR 1,234 0.9 0.5 0.9 -9 1.2 0.08 0.01 902 0.8 0.7 0.8 -9 1.1 0.02 0.06
Age (yrs) 85 70.2 8.6 71.2 53 91.1 -0.1 -0.2 43 70.4 9.6 71.7 42.1 91.6 -0.1 -0.5
BMI (kg/m²) 82 27.4 3.7 26.5 18 38.7 1 -0.1 42 25.8 3.9 25.2 18.7 37.9 1 0.1
Weight (kg) 82 82.4 12.3 81.5 59 109 0.9 0.4 42 66.5 11.8 66.7 46 100.6 0.9 0.5
Height (m) 83 1.7 0.1 1.7 1.6 1.9 -0.1 1 42 1.6 0.1 1.6 1.5 1.8 0.1 1
WC (cm) 80 99.8 10.5 99.4 69 127 0.9 0.1 40 84.6 10.4 83.4 65.2 119 0.9 0.1
Hip (cm) 79 102.5 8.4 101.8 84.9 137 0.8 0.1 40 101.1 9.1 99.3 86 136 0.9 0.2
WHR 79 1 0.1 1 0.8 1.1 0.4 0.1 40 0.8 0.1 0.8 0.7 1 0.4 -0.1
Age (yrs) 88 69.6 9 71.6 35.9 87.3 0.1 -0.2 51 70.7 9.9 71.8 41.6 88.1 0 -0.2
BMI (kg/m²) 87 26.2 3.4 25.6 18 36.4 1 0 51 26.8 5.2 25.5 19.4 44.5 1 0.1
Weight (kg) 87 77.5 11.7 77 51.4 107.6 0.9 0.5 51 68.6 14.2 66 49.8 107 1 0.4
Height (m) 87 1.7 0.1 1.7 1.6 1.9 0 1 51 1.6 0.1 1.6 1.5 1.7 0.1 1
WC (cm) 86 94.4 9.6 94.8 71.5 129.5 0.9 0.2 51 84.9 11.8 81.5 67.2 116 0.9 0.2
Hip (cm) 85 99 6.6 99.5 82 111.2 0.8 0.4 51 103.9 12.1 100.8 88.8 140.2 0.9 0.2
WHR 85 0.9 0.1 0.9 0.8 1.1 0.5 -0.1 51 0.8 0.1 0.8 0.7 0.9 0.2 0.1
Age (yrs) 476 55.7 8.3 56 26 87 0 -0.2 278 54.2 7.6 55 39 79 0.1 -0.1
BMI (kg/m²) 476 27.7 4.1 27.1 17.1 42.2 1 -0.1 278 26 4.4 25.3 17.7 43.8 1 0
Weight (kg) 476 86.4 13.8 84 36 133 0.9 0.4 278 70.1 13 68 43 127 0.9 0.4
Height (m) 476 1.8 0.1 1.8 1.5 2 -0.1 1 278 1.6 0.1 1.7 1.5 1.8 0 1
WC (cm) - - - - - - - - - - - - - - - -
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 270 63.1 7.8 65 45 74 -0.1 -0.2 187 63.7 7.1 65 45 74 -0.1 -0.3
BMI (kg/m²) 270 29.9 5 29.1 20.2 48.3 1 0 187 31.4 6.1 30.7 19.3 52.7 1 0.1
Weight (kg) 270 92.3 16.5 90.4 57.7 150 0.9 0.4 187 81.7 16.7 79.1 49.9 137.4 0.9 0.3
Height (m) 270 1.8 0.1 1.8 1.6 1.9 0 1 187 1.6 0 1.6 1.5 1.7 0.1 1
WC (cm) 269 107.7 12.2 106 79 150 0.9 0.2 187 101.1 14.9 101.5 67 145 0.9 0.1
Hip (cm) 270 104.6 9 103 84.5 145 0.9 0.3 187 109.1 11.6 108 85 152 0.9 0.2
WHR 269 1 0.1 1 0.8 1.2 0.5 0.1 187 0.9 0.1 0.9 0.7 1.1 0.5 0
ADVANCE-CAD controls
AMC-PAS
B58C non GWAS
BHS nonGWAS metabochip Cases
BHS nonGWAS metabochip Controls
CARDIOGENICS
D2D2007 cases
Age (yrs) 1,014 59.6 8.4 60 45 74 0 -0.3 1,217 58.8 8.2 58 45 74 0.1 -0.3
BMI (kg/m²) 1,014 26.8 3.7 26.5 16.5 48.9 1 0 1,217 27 4.9 26.3 17.2 61.3 1 -0.1
Weight (kg) 1,014 83.1 13.3 81.5 46.5 160 0.8 0.5 1,217 71.5 13.5 69.8 41.9 158.6 0.9 0.3
Height (m) 1,014 1.8 0.1 1.8 1.4 2 0 1 1,217 1.6 0.1 1.6 1.4 1.8 -0.1 1
WC (cm) 1,014 98.1 10.9 97 63 149 0.9 0.1 1,215 88.9 12.2 87.5 62 150 0.9 0
Hip (cm) 1,014 99.6 6.8 99 79 141 0.8 0.3 1,215 102.2 9.4 101 79.5 150 0.9 0.1
WHR 1,014 1 0.1 1 0.8 1.2 0.7 -0.1 1,214 0.9 0.1 0.9 0.7 1.2 0.6 0
Age (yrs) 1,797 53.3 13.5 55 25 74 0.2 -0.3 2,139 51.7 13.6 53 25 74 0.2 -0.4
BMI (kg/m²) 1,791 27.2 4.2 26.7 15.8 63.1 1 -0.1 2,139 26.9 5.4 25.8 16 52.5 1 -0.2
Weight (kg) 1,791 84 14.1 82.2 50.1 192.6 0.9 0.4 2,139 70.8 14.2 68.5 38.5 144.5 0.9 0.2
Height (m) 1,797 1.8 0.1 1.8 1.5 2 -0.1 1 2,138 1.6 0.1 1.6 1.4 1.8 -0.2 1
WC (cm) 1,787 96.8 12 95.5 64 172 0.9 0.1 2,122 87 13.5 85 58 143 0.9 0
Hip (cm) 1,790 100.5 7.6 100 80.5 161 0.9 0.3 2,122 102 10.8 100.5 75.5 162 0.9 0
WHR 1,784 1 0.1 1 0.8 1.2 0.6 -0.2 2,116 0.9 0.1 0.8 0.7 1.1 0.6 -0.1
Age (yrs) 32 56 6.7 58.6 43.7 64.8 -0.1 -0.2 57 54.9 6.2 54.9 43.3 67.8 -0.1 -0.2
BMI (kg/m²) 32 30.6 3.1 31.5 24.4 37.8 1 -0.1 57 32.9 4.4 32.2 25.6 45.8 1 -0.3
Weight (kg) 32 94 11.4 90 78.2 122.5 0.9 0.3 57 87.4 12.5 86.6 67 136.5 0.8 0.3
Height (m) 32 1.8 0.1 1.8 1.7 1.9 -0.1 1 57 1.6 0.1 1.6 1.5 1.8 -0.3 1
WC (cm) 32 107.2 9.2 105.5 88.3 127 0.8 0.2 57 103 10.3 102.5 82.3 126 0.7 0.1
Hip (cm) 32 106.2 6.5 105.2 97 119 0.8 0.2 57 114 8.6 113.6 99 140 0.8 0.1
WHR 32 1 0 1 0.9 1.1 0.3 0 57 0.9 0.1 0.9 0.8 1 0.3 0
Age (yrs) 116 56.4 7.1 59 41 65.9 0.1 -0.3 267 55 7.3 56.9 40.1 67.9 -0.2 -0.2
BMI (kg/m²) 116 29.5 3.5 29.1 23.5 44.8 1 0 267 31.7 4.8 30.6 24 50.5 1 0.1
Weight (kg) 116 90.6 12.4 89 62.9 148.1 0.8 0.5 267 83 14.3 80 52.9 131.1 0.9 0.5
Height (m) 116 1.8 0.1 1.8 1.6 1.9 0 1 267 1.6 0.1 1.6 1.4 1.8 0.1 1
WC (cm) 116 103.1 9.3 102.3 83.5 139 0.8 0.2 265 99.3 11.3 98 78 139 0.8 0.2
Hip (cm) 116 104.9 7.6 104.7 88 143.5 0.8 0.3 267 112.1 10.8 110 90.3 161 0.9 0.2
WHR 116 1 0 1 0.9 1.1 0.4 0 265 0.9 0.1 0.9 0.7 1.1 0.2 0.1
Age (yrs) 542 66.4 5.4 66.1 57.4 78.5 -0.1 -0.3 632 66.4 5.2 66.2 57.7 78.7 0 -0.3
BMI (kg/m²) 542 27.1 3.5 26.8 19.3 44.2 1 0.1 632 27.2 4.6 26.3 16 48.6 1 -0.1
Weight (kg) 542 82.1 12.4 80.8 51.3 135.9 0.9 0.5 632 69.5 12.2 67.9 41.9 143.2 0.9 0.3
Height (m) 542 1.7 0.1 1.7 1.6 1.9 0.1 1 632 1.6 0.1 1.6 1.4 1.8 -0.1 1
WC (cm) 542 97.5 10.1 96.6 73 136.5 0.9 0.3 632 87.4 12 86.3 59.5 130.5 0.9 0
Hip (cm) 542 98.9 7.2 99 78 134 0.8 0.4 632 101.2 9.4 99.8 78.5 139.5 0.9 0.1
WHR 542 1 0.1 1 0.8 1.1 0.6 0 632 0.9 0.1 0.9 0.7 1 0.6 -0.1
Age (yrs) 60 69.1 5.9 70.8 57.8 78.1 -0.2 -0.4 61 68.3 5.7 69.7 57.9 77.7 0 -0.4
BMI (kg/m²) 60 29.4 4.8 28.7 21 41.2 1 0.2 61 32.4 6.1 31.7 20 48.4 1 -0.1
Weight (kg) 60 86.7 16.4 83.7 47.6 120.5 0.9 0.5 61 81.8 16.2 80.6 54.1 129.9 0.9 0.2
Height (m) 60 1.7 0.1 1.7 1.5 2 0.2 1 61 1.6 0.1 1.6 1.4 1.7 -0.1 1
WC (cm) 60 104.4 12.8 104.3 80 133.8 0.9 0.3 61 103.3 14.4 101.8 72 136.5 0.9 0
Hip (cm) 60 103.3 10.4 101 81 132.5 0.9 0.4 61 110.3 11.5 109 91 145 0.9 0
WHR 60 1 0.1 1 0.9 1.1 0.5 0 61 0.9 0.1 0.9 0.8 1.2 0.5 0
Age (yrs) 352 64.7 5.6 64.8 54.7 75.4 0 -0.2 377 64.2 5.7 63.9 54.9 75.2 0 -0.2
BMI (kg/m²) 352 25.3 3.1 25.2 16.7 39.6 1 -0.1 377 25.3 4.2 24.6 17.4 51.5 1 -0.1
Weight (kg) 352 75 10.6 74.3 48.8 123.9 0.8 0.5 377 64.4 11.4 63.1 38.9 118.9 0.9 0.4
Height (m) 352 1.7 0.1 1.7 1.5 1.9 -0.1 1 377 1.6 0.1 1.6 1.4 1.8 -0.1 1
WC (cm) - - - - - - - - - - - - - - - -
Hip (cm) - - - - - - - - - - - - - - - -
DILGOM
DPS cases
DPS controls
DR'S EXTRA Controls
D2D2007 controls
DR'S EXTRA Cases
EAS
WHR - - - - - - - - - - - - - - - -
Age (yrs) 355 63.5 10.2 64 36 94 -0.2 -0.3 613 64.5 10.5 64 32 93 -0.3 -0.3
BMI (kg/m²) 354 32.6 4.7 31.9 20.5 51.4 1 0 613 33.7 5.7 32.9 21.2 56.9 1 0
Weight (kg) 354 100.8 16.1 99 62 160 0.9 0.4 613 88.3 16.3 86 47 160 0.9 0.4
Height (m) 355 1.8 0.1 1.8 1.6 2 0 1 613 1.6 0.1 1.6 1.4 1.8 0 1
WC (cm) 272 111.7 11.2 110.5 82 145 0.8 0.1 417 104.6 14.2 103 62 150 0.8 0.3
Hip (cm) 272 110.1 11.2 110 70 155 0.6 0.1 417 116 14 115 63 165 0.8 0.3
WHR 272 1 0.1 1 0.7 1.6 0.2 -0.1 417 0.9 0.1 0.9 0.7 1.1 0.2 0
Age (yrs) 341 54.4 11 55 35 86 0.2 -0.3 601 50 10.1 49 34 93 0.2 -0.3
BMI (kg/m²) 340 22.8 2.5 22.7 16.7 29.4 1 -0.2 600 22.1 2.5 22.1 14.6 35.5 1 -0.1
Weight (kg) 340 70.9 8.5 70 48 95 0.8 0.5 600 59.5 7.6 60 41 99 0.8 0.5
Height (m) 340 1.8 0.1 1.8 1.5 2 -0.2 1 600 1.6 0.1 1.6 1.4 1.8 -0.1 1
WC (cm) 340 84.1 6.8 85 54 110 0.5 0.2 600 72.8 5.8 73 52 105 0.7 0.1
Hip (cm) 340 94.9 7.7 96 57 115 0.4 0.2 600 95.1 7.2 95 64 122 0.6 0.3
WHR 340 0.9 0.1 0.9 0.7 1.2 0.1 0 600 0.8 0.1 0.8 0.6 1.2 0.2 -0.1
Age (yrs) 355 63.5 10.2 64 36 94 -0.2 -0.3 613 64.5 10.5 64 32 93 -0.3 -0.3
BMI (kg/m²) 354 32.6 4.7 31.9 20.5 51.4 1 0 613 33.7 5.7 32.9 21.2 56.9 1 0
Weight (kg) 354 100.8 16.1 99 62 160 0.9 0.4 613 88.3 16.3 86 47 160 0.9 0.4
Height (m) 355 1.8 0.1 1.8 1.6 2 0 1 613 1.6 0.1 1.6 1.4 1.8 0 1
WC (cm) 272 111.7 11.2 110.5 82 145 0.8 0.1 417 104.6 14.2 103 62 150 0.8 0.3
Hip (cm) 272 110.1 11.2 110 70 155 0.6 0.1 417 116 14 115 63 165 0.8 0.3
WHR 272 1 0.1 1 0.7 1.6 0.2 -0.1 417 0.9 0.1 0.9 0.7 1.1 0.2 0
Age (yrs) 744 61.5 9.1 61.5 35.7 77.4 0 -0.3 857 60.8 9.2 60.2 36.3 78.9 0.1 -0.3
BMI (kg/m²) 744 27.4 4 26.8 16 45.8 1 0 855 27.3 5.4 26.3 16.9 59.3 1 -0.1
Height (m) 744 1.7 0.1 1.7 1.6 2 0 1 855 1.6 0.1 1.6 1.5 1.8 -0.1 1
Hip (cm) 736 105.3 7.6 104.5 85.2 139.3 0.8 0.3 852 107.1 11.8 105.3 80.1 171 0.9 0.1
WC (cm) 736 100 10.6 99.4 71.3 144 0.8 0.1 853 87.6 12.6 85.9 57.3 143.3 0.8 0
Weight (kg) 744 83.1 13.3 81 48.5 134.5 0.9 0.4 856 71.1 14.3 68.5 38 145 0.9 0.3
WHR 735 0.9 0.1 0.9 0.8 1.1 0.5 -0.1 852 0.8 0.1 0.8 0.6 1 0.3 -0.1
Age (yrs) 432 61.5 8.1 62 41 77 0 -0.2 295 62.1 8.3 63 41 77 -0.2 -0.2
BMI (kg/m²) 432 29.1 3.8 28.6 19.6 49.1 1 0 291 30.1 5.1 29.8 19.5 45.5 1 0.1
Height (m) 432 1.7 0.1 1.7 1.5 1.9 0 1 294 1.6 0.1 1.6 1.4 1.8 0.1 1
Hip (cm) 432 106.6 7.4 105.8 88.8 141.9 0.8 0.3 295 110 11.4 108.6 85 151.6 0.9 0.3
WC (cm) 432 103.5 10 103 79 145.6 0.8 0.2 295 92.8 12.5 92 64.4 141.3 0.9 0.2
Weight (kg) 432 87.6 12.9 86.2 56 160 0.8 0.5 292 77.1 14.6 75 45.8 124.4 0.9 0.4
WHR 432 1 0.1 1 0.8 1.1 0.4 0 295 0.8 0.1 0.8 0.7 1.2 0.3 0
Age (yrs) 411 59.4 9.2 60 40 79 0.1 -0.2 552 58.4 9.6 58 39 77 0.2 -0.3
BMI (kg/m²) 410 26.4 3.3 26.1 16.9 40.3 1 -0.1 551 25.9 4 25.3 16.3 46 1 -0.1
Height (m) 410 1.7 0.1 1.7 1.5 2 -0.1 1 552 1.6 0.1 1.6 1.4 1.8 -0.1 1
Hip (cm) 410 102.5 6.3 102.3 83.2 125.3 0.8 0.3 549 102.7 8.6 101.5 81.6 153.8 0.8 0.2
WC (cm) 411 94.9 9.7 94.4 71.8 134 0.8 0.1 550 81.5 10.3 79.9 56.5 122.1 0.8 0
Weight (kg) 411 79.8 11.3 78.4 51 135 0.8 0.5 551 67.2 11.2 65.4 41.2 126.6 0.9 0.4
WHR 410 0.9 0.1 0.9 0.8 1.2 0.6 -0.1 549 0.8 0.1 0.8 0.6 1 0.5 -0.1
Age (yrs) 1,488 46.9 7.2 46.7 30.9 59.9 0.1 -0.1 1,698 46.9 7 47.1 30.5 60 0.2 -0.1
BMI (kg/m²) 1,486 27 4.1 26.5 16.4 50.6 1 -0.1 1,698 26.5 5.5 25.4 16.9 59.9 1 -0.1Body fat percentage (%) 1,465 23.7 5.7 23.8 5.4 42.8 0.8 -0.1 1,667 35.7 7.2 35.6 12.8 57.7 0.9 0.1
Height (m) 1,486 1.8 0.1 1.8 1.6 2 -0.1 1 1,698 1.6 0.1 1.6 1.4 1.9 -0.1 1
EGCUT metaboc DB cases
ELY
EPIC Cases
EPIC Controls
Fenland
EGCUT metaboc CAD cases
EGCUT metaboc controls
Hip (cm) 1,485 103.2 7.2 102.5 83.4 155 0.8 0.3 1,698 103.6 11 101.7 78.7 180.4 0.9 0.2
WC (cm) 1,485 96.4 11.2 95.3 65.6 149 0.9 0.1 1,698 85.2 12.8 82.8 59 144.3 0.9 0.1
Weight (kg) 1,486 85.4 14.1 83.4 52 177.6 0.9 0.4 1,698 71.2 15.5 67.9 41.5 181 0.9 0.3
WHR 1,484 0.9 0.1 0.9 0.8 1.2 0.7 -0.1 1,698 0.8 0.1 0.8 0.5 1.2 0.5 -0.1
Age (yrs) 585 58.5 9.1 59 28 82 -0.1 -0.1 454 61.1 8 61 34.4 89 -0.1 -0.2
BMI (kg/m²) 585 30.2 5 29.7 19.7 53 1 0 454 31.7 5.8 31 17.8 53.5 1 0
Weight (kg) 585 92.3 17.2 89.9 42.2 165 0.9 0.4 454 81.5 16 79.1 48 137.2 0.9 0.4
Height (m) 585 1.7 0.1 1.8 1.4 2 0 1 454 1.6 0.1 1.6 1.5 1.8 0 1
WC (cm) 585 105.5 13.2 104 73 149 0.9 0.2 452 99.2 13.8 98.5 62 142.5 0.9 0.2
Hip (cm) 585 106.2 9.6 105 74 164 0.9 0.3 452 110.9 11.8 109 84 147.5 0.9 0.2
WHR 585 1 0.1 1 0.7 1.2 0.6 0 452 0.9 0.1 0.9 0.6 1.2 0.3 0.1
Age (yrs) 1,043 55.6 7.9 56 41.3 74.8 0 -0.1 847 56.7 8.3 57 41 74.7 0.3 -0.3
BMI (kg/m²) 1,043 26.5 3.5 26.2 15.8 39.2 1 0 847 26.6 4.6 25.8 17.2 57.2 1 -0.2
Weight (kg) 1,043 81.1 12.6 80 46.5 130 0.9 0.5 847 69 12.2 67 43.2 153.8 0.9 0.3
Height (m) 1,043 1.7 0.1 1.7 1.5 2 0 1 847 1.6 0.1 1.6 1.4 1.8 -0.2 1
WC (cm) 1,040 94.9 10.1 94 68 155 0.8 0.2 843 85 11.3 83.5 58 128 0.8 0
Hip (cm) 1,040 100.4 6.6 100 76 129 0.8 0.3 843 101.7 8.6 101 72 140 0.9 0.1
WHR 1,040 0.9 0.1 0.9 0.8 1.9 0.6 0.1 843 0.8 0.1 0.8 0.7 1.3 0.5 -0.1
Age (yrs) 2,381 50.1 8.3 50 30 62 0.1 -0.2 3,666 49.3 8.8 50 29 64 0.2 -0.2
BMI (kg/m²) 2,381 26.1 3.4 25.8 17.8 59 1 -0.2 3,666 25.5 4.4 24.8 16 57.9 1 -0.2
Weight (kg) 2,381 81.7 11.4 80.9 51 135 0.8 0.4 3,666 68.6 11.7 67 40 146 0.9 0.3
Height (m) 2,381 1.8 0.1 1.8 1.5 2.1 -0.2 1 3,666 1.6 0.1 1.6 1.2 1.9 -0.2 1
WC (cm) 874 97 10.1 96 71 156 0.8 0.1 1,445 86.7 11.7 85 59 131 0.9 0.1
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 1,929 63.2 9.5 64 36 88 -0.26 -0.18 1,351 64 9.8 66 36 89 -0.33 -0.18
BMI (kg/m²) 1,924 31.1 5.6 30.3 16.2 61.5 1 -0.06 1,346 32.9 7.1 32 16.4 62.3 1 0
Weight (kg) 1,925 94.3 18.2 91.7 46.9 177.8 0.91 0.35 1,347 84.6 19.3 82.6 42.2 164 0.94 0.35
Height (m) 1,928 1.74 0.07 1.74 1.5 2 -0.06 1 1,348 1.6 0.06 1.6 1.4 1.86 0 1
WC (cm) 1,750 108.5 13.4 107 74 164 0.89 0.13 1,215 103.7 15.2 103 62 177 0.84 0.16
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 1,918 60.2 11.1 61 36 79 0.01 -0.26 1,789 58 11.4 57 36 79 0.01 -0.24
BMI (kg/m²) 1,918 27.3 4 26.9 16.2 54.9 1 -0.08 1,788 26.8 5 26 14.3 51.6 1 -0.15
Weight (kg) 1,918 84.6 13.3 83.8 46.9 168 0.88 0.4 1,788 70.5 13.5 68.6 33 125.6 0.91 0.27
Height (m) 1,918 1.76 0.07 1.76 1.51 1.98 -0.08 1 1,789 1.62 0.07 1.62 1.43 1.85 -0.15 1
WC (cm) 1,917 98.5 10.7 98 69 172 0.86 0.11 1,787 86.7 12.3 86 61 153 0.84 0.02
Hip (cm) - - - - - - - - - - - - - - - -
WHR - - - - - - - - - - - - - - - -
Age (yrs) 2,261 59.6 7.8 60 45 76 0.1 -0.3 2,256 59.6 7.8 60 45 76 0.1 -0.2
BMI (kg/m²) 2,250 28 4.9 27.6 18.1 49.4 1 -0.1 2,242 27.4 5.9 26.9 16.5 59.2 1 -0.2
Weight (kg) 2,252 85.7 14.8 84.5 53.5 150 0.9 0.4 2,242 72 15.2 70.8 43.3 150 0.9 0.2
Height (m) 2,256 1.7 0.6 1.8 1.5 2 -0.1 1 2,244 1.6 0.8 1.6 1.4 1.8 -0.2 1
WC (cm) 2,256 100 12.5 99.3 48.6 172 0.9 0.1 2,246 88 14.4 87.2 46 144.7 0.9 0
Hip (cm) 2,256 102 10.5 101.3 77.7 160.4 0.8 0.2 2,245 103.6 13.9 103 57 160.6 0.9 0.1
WHR 2,255 0.9 0.6 1 0.5 1.2 0.4 -0.1 2,245 0.8 0.7 0.9 0.5 1.3 0.4 -0.1
Age (yrs) 299 67.3 11.3 70 27 90 -0.2 -0.2 279 70.7 11.2 73 27 92 -0.2 -0.3
BMI (kg/m²) 299 28.1 3.7 27.9 19.4 45.6 1 0 279 30.3 5.2 30 18.4 47.1 1 -0.1
Heinz Nixdorf Recall Study
FUSION2 cases
FUSION2 controls
GLACIER
GO-DARTS cases
GO-DARTS controls
Weight (kg) 299 85.8 12.9 85 54.5 135 0.9 0.4 279 77 13.9 77 42.5 120 0.9 0.3
Height (m) 299 1.7 0.1 1.8 1.6 1.9 0 1 279 1.6 0.1 1.6 1.4 1.8 -0.1 1
WC (cm) 297 98.8 9.5 99 77 133 0.8 0.1 273 94.5 12.2 94 60 130 0.9 0
Hip (cm) 297 104.4 6.6 104 88 131 0.7 0.3 273 109.5 10.9 108 83 150 0.8 0
WHR 297 0.9 0.1 0.9 0.8 1.2 0.5 -0.1 273 0.9 0.1 0.9 0.7 1.1 0.4 0
Age (yrs) 394 63.9 14.5 68 20 90 0 -0.4 362 67.6 13.9 71 20 92 0 -0.5
BMI (kg/m²) 394 26.5 3.3 26.3 17.8 39.3 1 0 362 27.6 4.5 27.3 17.5 42 1 0
Weight (kg) 394 80.5 11.6 79.7 52 131.5 0.8 0.5 362 71.1 12.4 70.5 42 112 0.9 0.4
Height (m) 394 1.7 0.1 1.7 1.5 1.9 0 1 362 1.6 0.1 1.6 1.4 1.8 0 1
WC (cm) 394 93.5 8.7 94 70 121 0.8 0.1 359 86.7 11 86 63 117 0.8 0
Hip (cm) 394 102 5.6 102 85 123 0.7 0.2 358 104.5 9.7 104 84 134 0.9 0.1
WHR 394 0.9 0.1 0.9 0.8 1.1 0.5 0 358 0.8 0.1 0.8 0.7 1.1 0.4 -0.1
Age (yrs) 1,666 64 5.3 64.5 54.5 79.5 -0.1 0 1,783 64.4 5.5 64.6 54.5 79.8 0 0
BMI (kg/m²) 1,665 27.4 3.6 27.1 18.9 47.2 1 0.1 1,783 27.1 4.8 26.5 15.9 47.5 1 0.1
Weight (kg) 1,665 83.5 13.2 82 51.4 160 0.8 0.6 1,783 70.3 14.1 68.4 39 131 0.9 0.4
Height (m) 1,665 1.7 0.1 1.7 1.5 2 0.1 1 1,783 1.6 0.1 1.6 1.4 1.8 0.1 1
WC (cm) 1,664 98.7 10.8 98 64 150 0.8 0.3 1,775 89.6 12.5 89 54 145 0.8 0.2
Hip (cm) 1,664 101.7 8.1 101 73 155 0.5 0 1,775 102.8 10.8 102 67 160 0.3 0
WHR 1,664 1 0.1 1 0.7 1.5 0.7 0.4 1,775 0.9 0.1 0.9 0.6 1.3 0.8 0.3
Age (yrs) 604 40.9 13.3 37 25 74 0.2 -0.4 674 40.9 12.7 38 25 74 0.3 -0.4
BMI (kg/m²) 599 26.5 3.4 26.2 18 41 1 -0.1 659 25.2 4.7 24.1 16.9 41 1 -0.2
Weight (kg) 599 82.4 11.6 81 52.3 132 0.8 0.4 659 66.7 12.2 64.2 43.6 132 0.9 0.2
Height (m) 603 1.8 0.1 1.8 1.6 2 -0.1 1 671 1.6 0.1 1.6 1.4 2 -0.2 1
WC (cm) 603 92.8 9.3 92 70.5 127 0.9 0 660 79.2 11.4 76.5 59 127 0.9 -0.1
Hip (cm) 603 102.9 6.2 102.5 86 125 0.8 0.3 660 101.3 9.6 100 79 125 0.9 0
WHR 603 0.9 0.1 0.9 0.8 1.1 0.6 -0.2 660 0.8 0.1 0.8 0.6 1.1 0.5 -0.3
Age (yrs) 585 42.7 15.8 36 24 75 0.3 -0.5 637 41.2 14.8 36 24 75 0.3 -0.5
BMI (kg/m²) 582 26.6 3.6 26.4 16.3 41.8 1 -0.2 624 25.9 5.1 25.3 15.8 41.8 1 -0.2
Weight (kg) 582 82.7 11.7 81.5 52.3 136.5 0.8 0.4 624 68.9 13.4 67.2 41.1 136.5 0.9 0.2
Height (m) 585 1.8 0.1 1.8 1.6 2 -0.2 1 632 1.6 0.1 1.6 1.4 2 -0.2 1
WC (cm) 585 94.4 10 93.5 65.4 134.2 0.9 -0.1 624 82.2 12 80.6 61 134.2 0.9 -0.1
Hip (cm) 585 104.2 6.4 103.8 87.2 136.1 0.8 0.2 624 103.9 10 102.8 81.9 136.1 0.9 0
WHR 585 0.9 0.1 0.9 0.7 1.1 0.6 -0.4 624 0.8 0.1 0.8 0.6 1.1 0.5 -0.3
Age (yrs) 1,678 63.1 9.8 63.8 26.9 88.5 -0.1 -0.2 573 66.2 9.6 67.2 34.2 92.1 -0.4 -0.1
BMI (kg/m²) 1,678 27.5 3.8 27.1 17.5 57.1 1 -0.1 573 27.2 4.6 27 16.4 46.1 1 -0.1
Weight (kg) 1,678 82.7 12.7 81.8 51 185 0.9 0.4 573 70.5 12.9 70 43 122.3 0.9 0.4
Height (m) 1,678 1.7 0.1 1.7 1.5 2 -0.1 1 573 1.6 0.1 1.6 1.5 1.8 -0.1 1
WC (cm) 1,652 101 10.7 100 61 165 0.8 0.1 566 94.9 13.3 94 63 135 0.8 0.1
Hip (cm) 1,652 102.5 8.9 102 66 165 0.7 0.2 566 103.8 11.5 103 70 150 0.8 0.2
WHR 1,652 1 0.1 1 0.6 1.6 0.3 -0.1 566 0.9 0.1 0.9 0.7 1.2 0.3 0
Age (yrs) 329 55 12.3 55.6 18.6 87.9 0.1 -0.3 315 62.1 11 62.7 27 90.7 0 -0.2
BMI (kg/m²) 329 27.3 3.7 26.7 16.3 40.3 1 -0.1 315 27.3 4.9 26.5 16.8 44.8 1 -0.1
Weight (kg) 329 85 12.6 83 54.8 130 0.8 0.4 315 71.9 13.4 70 41 125 0.9 0.3
Height (m) 329 1.8 0.1 1.8 1.6 2 -0.1 1 315 1.6 0.1 1.6 1.4 1.9 -0.1 1
WC (cm) 326 99.4 10.6 98 68 139 0.8 0 310 92.9 12.4 93 58 134 0.8 0.1
Hip (cm) 326 102.2 8.3 101.5 75 138 0.7 0.1 310 104 11.7 103 71 147 0.8 0.1
WHR 326 1 0.1 1 0.7 1.2 0.4 -0.1 310 0.9 0.1 0.9 0.7 1.2 0.2 0
Age (yrs) 2,172 59.5 8 59.9 25.1 76.4 0 -0.1 356 57.8 9.1 59.1 27.3 73.8 0.2 -0.2
HUNT cases
HUNT controls
IMPROVE
KORA S3 (noGWA)
KORA S4 (noGWA)
LURIC cases
LURIC controls
BMI (kg/m²) 2,169 26.9 4 26.5 16.7 51.9 1 0 353 27.6 4.9 26.8 15.4 51.1 1 -0.1
Weight (kg) 2,169 80.6 13.3 79.6 42.8 154 0.9 0.4 354 69.8 13.6 68.1 40.2 134 0.9 0.4
Height (m) 2,168 1.7 0.1 1.7 1.5 1.9 0 1 353 1.6 0.1 1.6 1.4 1.8 -0.1 1
WC (cm) 1,158 95.3 11 94.5 64 144 0.9 0.1 321 85.3 12.3 84 60.5 121 0.9 0.1
Hip (cm) 1,158 100.7 7.6 100 74.5 144 0.8 0.3 321 103.5 9.4 102 81.5 144 0.9 0.2
WHR 1,158 0.9 0.1 1 0.7 1.2 0.6 -0.1 321 0.8 0.1 0.8 0.7 1.1 0.6 -0.1
Age (yrs) 1,780 58.8 7.8 58.6 25.5 75.8 0 -0.1 285 58.1 8.6 59.7 30.6 74.1 0.1 -0.3
BMI (kg/m²) 1,715 27.5 3.9 27.2 17 48 1 0 250 29.1 5.7 28.4 17.9 50.7 1 -0.3
Weight (kg) 1,716 81.7 12.8 80.6 50.2 129 0.9 0.4 250 72.7 14.1 71.4 46.9 132 0.9 0.1
Height (m) 1,715 1.7 0.1 1.7 1.5 2 0 1 250 1.6 0.1 1.6 1.4 1.8 -0.3 1
WC (cm) 991 97.5 10.7 96.5 72 138.5 0.9 0.1 226 88.9 13.4 87.5 61.5 131 0.9 -0.1
Hip (cm) 992 101 7.8 100 75 137 0.8 0.2 226 105.8 10.3 104.8 82.5 147.5 0.9 0
WHR 991 1 0.1 1 0.7 1.2 0.5 0 226 0.8 0.1 0.8 0.6 1.4 0.4 -0.1
Age (yrs) 466 53 53 53 53 522 53 53 53 53
BMI (kg/m²) 464 27.6 4.2 27 18.2 43.1 1 -0.1 515 27.7 5.5 26.6 18.6 57.1 1 -0.1
Height (m) 464 1.7 0.1 1.7 1.5 1.9 -0.1 1 520 1.6 0.1 1.6 1.4 1.8 -0.1 1
Hip (cm) 463 103.8 7.1 103 89 143 0.8 0.3 519 106.2 10.9 105 75 148 0.9 0.1
WC (cm) 463 98 10.8 97 74 135 0.8 0.1 519 86.8 13.3 85 63 159 0.9 0.1
Weight (kg) 464 83.5 13.4 81.3 54.4 136.5 0.9 0.4 516 72 14.6 69.8 42.2 154 0.9 0.3
WHR 463 0.9 0.1 0.9 0.8 1.1 0.6 0 518 0.8 0.1 0.8 0.6 1.1 0.4 0
Age (yrs) 490 70.1 0.2 70.1 69.8 72.3 0.1 -0.1 488 70.3 0.1 70.3 69.9 70.8 -0.1 0
BMI (kg/m²) 490 27 3.7 26.9 17.7 43.4 1 0 488 27.1 4.9 26.5 16.6 49.8 1 -0.1
Weight (kg) 490 83.7 13 82 53 138 0.9 0.4 488 71.3 13.2 71 42 126 0.9 0.3
Height (m) 490 1.8 0.1 1.8 1.6 2 0 1 488 1.6 0.1 1.6 1.5 1.8 -0.1 1
WC (cm) 485 94.9 10.4 95 64 134 0.9 0.1 483 87.7 11.6 87 60 134 0.9 0
Hip (cm) 485 100.3 6.8 100 86 130 0.8 0.3 483 101.4 9.3 101 71 143 0.9 0.1
WHR 485 0.9 0.1 0.9 0.6 1.2 0.6 -0.1 483 0.9 0.1 0.9 0.6 1.1 0.5 -0.1
Age (yrs) 956 56.7 7.2 57 28 70 -0.1 -0.2 332 59.6 7.5 60.5 39 70 -0.1 -0.3
BMI (kg/m²) 945 26.7 3.5 26.4 18 40.3 1 0 331 26.7 4.9 26 16.8 44 1 0
Weight (kg) 738 83.8 12.7 83 49 148 0.9 0.4 264 71 14.4 70 43 120 0.9 0.4
Height (m) 737 1.8 0.1 1.8 1.6 2 0 1 264 1.6 0.1 1.6 1.4 1.8 0 1
WC (cm) 949 98.4 9.5 98 76 132 0.8 0.2 329 89 13.2 88 60 134 0.8 0.1
Hip (cm) 949 101.6 7.1 101 82 135 0.7 0.3 328 103.6 11.1 102.5 55 142 0.9 0.2
WHR 956 1 0.1 1 0.8 1.2 0.5 0 331 0.9 0.1 0.9 0.6 1.1 0.3 0
Age (yrs) 1,256 57.3 7 57 41 70 0 -0.2 532 60.5 7.1 61 41 70 0.1 -0.2
BMI (kg/m²) 1,252 25.8 3.4 25.3 16 42.3 1 -0.1 526 25.4 3.9 24.9 17.5 45.3 1 -0.1
Weight (kg) 974 81.7 11.6 81 50.4 134 0.8 0.4 441 68.2 10.3 68 41 112 0.9 0.3
Height (m) 974 1.8 0.1 1.8 1.6 2 -0.1 1 441 1.6 0.1 1.6 1.5 1.8 -0.1 1
WC (cm) 1,248 95.7 9.7 95 57 133 0.8 0.1 528 85.7 11.3 84 59 122 0.8 0.1
Hip (cm) 1,246 99.6 7.6 100 53 135 0.6 0.2 526 101 9.1 101 56 134 0.8 0
WHR 1,254 1 0.1 1 0.6 1.8 0.5 0 530 0.8 0.1 0.8 0.6 1.4 0.4 0.1
Age (yrs) 1,046 74.3 9 75.2 45.8 93 -0.1 -0.2 1,384 76.1 9.7 78.2 39.8 103.8 -0.1 -0.2
BMI (kg/m²) 838 25.1 3.4 24.8 14.5 38.6 1 -0.1 1,378 25 4.2 24.5 14.1 46.1 1 0
Weight (kg) 1,043 76.7 11.7 76 45 132 0.8 0.5 1,377 63.8 11.7 63 35 126 0.9 0.4
Height (m) 808 1.7 0.1 1.7 1.5 2 -0.1 1 1,377 1.6 0.1 1.6 1.4 1.8 0 1
WC (cm) 563 96.6 9.4 96 71 130 0.8 0.1 780 85.5 10 84 61 131 0.8 0
Hip (cm) 563 100.8 8 101 80 131 0.7 0.1 778 99.3 10 99 49 133 0.7 0.1
WHR 563 1 0.1 1 0.8 1.2 0.4 0.1 778 0.9 0.1 0.9 0.6 1.6 0.2 0
MORGAM
MORGAM cases
NSHD
PIVUS
SCARFSHEEP cases
SCARFSHEEP controls
STR
Age (yrs) 626 56.3 10.2 57 20.8 87 -0.19 -0.11 448 56.4 11.1 57.9 19.4 80.1 -0.15 -0.11
BMI (kg/m²) 624 31.2 5.6 30.4 16.8 60.3 1 0.04 445 33.8 7.6 33 18.7 59.6 1 -0.05
Weight (kg) 624 96.6 19.2 95 57 190.5 0.92 0.42 445 88.2 20.9 84.7 43 165.5 0.94 0.3
Height (m) 625 1.8 0.1 1.8 1.6 2.2 0.04 1 445 1.6 0.1 1.6 1.4 1.8 -0.05 1
WC (cm) 606 1.1 0.1 1.1 0.8 2 0.87 0.19 431 1 0.2 1 0.6 1.5 0.86 0.09
Hip (cm) 606 1.1 0.1 1.1 0.9 2.2 0.76 0.22 431 1.2 0.2 1.1 0.8 1.7 0.89 0.09
WHR 604 1 0.1 1 0.8 1.3 0.48 0.05 431 0.9 0.1 0.9 0.7 1.2 0.14 0.01
Age (yrs) 867 58.2 12.7 58 24 89 -0.1 -0.4 628 61.3 13.8 64 25 91.9 0.3 -0.5
BMI (kg/m²) 806 28.4 4.1 27.9 18.4 44 1 -0.1 604 28.6 5.2 28 17.7 49.6 1 -0.3
Weight (kg) 806 85.3 13.7 84 48 140 0.8 0.5 604 71.9 13.5 71.2 5.5 161 0.9 0.3
Height (m) 806 1.7 0.1 1.7 1.6 2 -0.1 1 604 1.6 0.1 1.6 1.3 1.8 -0.3 1
WC (cm) 674 101.2 11.9 100 51 193 0.7 0.1 408 91.3 13.7 90 63.5 134 0.7 -0.1
Hip (cm) 540 104 9 104 44 138 0.7 0.2 400 105.7 11.6 105 62.5 148 0.8 0
WHR 540 1 0.1 1 0.5 1.9 0.3 0 400 0.9 0.1 0.9 0.4 1.2 0.3 -0.1
Age (yrs) 352 57.7 11.1 57 28 82 -0.3 -0.2 357 62.1 13.4 64 26 89 -0.2 -0.3
BMI (kg/m²) 352 28.6 4 28.6 18.3 46.1 1 0 357 29.8 5.5 29.4 17.3 48 1 0
Weight (kg) 352 87.8 14.7 87 52.9 144.4 0.8 0.5 357 76.7 15.4 75.6 38.4 129.1 0.9 0.4
Height (m) 352 1.7 0.1 1.7 1.5 2 0 1 357 1.6 0.1 1.6 1.4 1.8 0 1
WC (cm) 194 102.3 10.4 102 73 139.5 0.8 0.2 188 97.5 12.9 97 50 133.5 0.9 0
Hip (cm) 194 105.8 7 105 87 125 0.8 0.3 188 111.5 11.5 110 83.5 149 0.9 0.1
WHR 194 1 0.1 1 0.7 1.5 0.5 0.1 188 0.9 0.1 0.9 0.4 1.1 0.3 -0.1
Age (yrs) 354 57.9 11.2 57.5 28 82 0 -0.2 355 62 13.4 64 26 89 0.2 -0.4
BMI (kg/m²) 354 25.8 3.3 25.8 18.3 39.9 1 0.1 355 26 4.2 25.4 16 44 1 -0.2
Weight (kg) 354 79.7 12.3 79 50.9 132.2 0.9 0.5 355 67.9 11.1 67.1 36 108.9 0.9 0.3
Height (m) 354 1.8 0.1 1.8 1.6 2 0.1 1 355 1.6 0.1 1.6 1.4 1.8 -0.2 1
WC (cm) 168 94.3 9.9 93 75 121 0.9 0.3 183 85.3 10.6 84 62 130 0.8 0.1
Hip (cm) 168 103 6.4 103 89 122 0.7 0.4 183 103.8 8.6 103 82 135 0.9 0.2
WHR 168 0.9 0.1 0.9 0.8 1.1 0.7 0.1 183 0.8 0.1 0.8 0.7 1 0.5 -0.1
Age (yrs) 1,116 71 0.6 71 69.4 74.1 -0.1 0 - - - - - - - -
BMI (kg/m²) 1,112 26.3 3.4 25.9 16.7 46.3 1 -0.1 - - - - - - - -
Weight (kg) 1,116 80.4 11.4 79.5 46 138.7 0.9 0.4 - - - - - - - -
Height (m) 1,112 1.7 0.1 1.8 1.6 2 -0.1 1 - - - - - - - -
WC (cm) 1,095 94.8 9.5 94 51 137 0.9 0.1 - - - - - - - -
Hip (cm) 1,095 100.2 7.1 100 51 141 0.8 0.3 - - - - - - - -
WHR 1,095 0.9 0.1 0.9 0.8 1.1 0.6 -0.1 - - - - - - - -
Age (yrs) 2,555 60.7 5.9 59.6 50.7 73.7 0 -0.1 822 61.1 6 60.6 50.5 73.3 0.1 -0.2
BMI (kg/m²) 2,548 26.6 3.7 26.3 17.9 48.7 1 -0.1 820 27.3 5.5 26.2 15.8 49 1 -0.1
Height (m) 2,550 1.8 0.1 1.8 1.4 2 -0.1 1 821 1.6 0.1 1.6 1.4 1.9 -0.1 1
Hip (cm) 2,554 99.9 6.6 99.4 76 156 0.8 0.3 820 102.5 10.8 101.1 73.2 142.2 0.9 0.1
WC (cm) 2,554 95.1 10.4 94.5 66.6 138 0.9 0.1 821 86.4 13.5 85.2 55.2 132.5 0.9 0
Weight (kg) 2,549 81.7 12.3 80.4 43 144.2 0.8 0.4 821 71 14.8 68.7 38.9 138.3 0.9 0.3
WHR 2,554 1 0.1 0.9 0.7 1.2 0.7 -0.1 820 0.8 0.1 0.8 0.7 1.1 0.6 -0.1
Tromsø controls
ULSAM
WHITEHALL
T2D - WTCCCnon GWAS
THISEAS
Tromsø cases
MEN WOMEN Sex-Diff MEN WOMEN Sex-Diff MEN WOMEN Sex-Diff
SNP Traita Sexa Geneb Pc Pc Pd Pe Pe Pf Pc Pc Pd
rs16970956 HEIGHT M DBF4B 1.24E-05 0.231 8.69E-03 5.70E-04 0.195 0.015 5.96E-08 0.139 1.63E-03
rs12887636 BMI W PRKD1 0.174 2.27E-06 0.013 0.164 5.83E-05 0.03 0.102 2.09E-09 3.68E-03
rs6091540 BMI W ZFP64 0.519 1.79E-09 7.33E-05 0.149 9.67E-05 0.043 0.229 9.87E-12 1.71E-04
rs1443512 WHRadjBMI W HOXC13 0.184 1.43E-09 6.36E-04 0.027 9.95E-07 0.045 0.023 3.01E-14 4.10E-04
rs718314 WHRadjBMI W ITPR2 / SSPN 0.177 8.29E-10 6.11E-04 0.025 9.00E-07 0.044 0.019 1.36E-14 3.62E-04
rs4460442 HEIGHT W FBP1 0.441 5.76E-07 2.03E-03 0.051 1.13E-05 0.051 0.092 8.29E-11 1.78E-03
rs6921207 HEIGHT W EPB41L2 0.071 1.20E-06 0.031 0.221 1.01E-03 0.068 0.068 1.46E-08 0.015
rs4325879 HEIGHT W CCNL1 0.088 1.58E-06 0.024 0.036 9.95E-06 0.064 0.014 1.14E-10 0.011
rs1316952 WHRadjBMI W DNAH10 0.857 1.53E-07 2.69E-04 0.036 3.03E-06 0.057 0.182 5.13E-12 2.23E-04
rs1936805 WHRadjBMI W RSPO3 / C6orf173 4.46E-04 9.10E-14 5.25E-03 2.97E-08 3.45E-17 0.065 3.74E-10 4.11E-29 2.18E-03
Discovery Follow-up Joint
≤ 50 yrs > 50 yrs Age-diff ≤ 50 yrs > 50 yrs Age-diff ≤ 50 yrs > 50 yrs ≤ 50 yrs > 50 yrs ≤ 50 yrs > 50 yrsSNP Pa Pa Pb Pa Pa Pb Pc Pc N N N Nrs6717858 7.55E-14 1.98E-16 0.513 0.631 0.25 0.262 6.22E-06 1.02E-09 29,767 46,547 20,358 26,972rs2820443 2.85E-13 2.02E-18 0.941 0.972 0.05 0.185 1.81E-06 9.47E-05 30,054 46,564 20,365 26,999rs1358980 1.12E-08 1.07E-11 0.812 0.218 0.544 0.583 4.62E-03 1.01E-04 28,977 46,561 19,455 26,969rs11743303 1.28E-06 2.72E-04 0.176 0.34 0.581 0.283 0.017 7.25E-03 30,764 49,427 21,371 27,531rs2371767 1.90E-06 1.44E-08 0.863 0.399 0.612 0.763 0.013 1.67E-03 27,783 44,761 19,358 26,041rs10478424 3.06E-03 3.37E-05 0.741 0.507 0.514 0.354 0.015 0.04 28,926 45,814 19,356 26,039rs4684854 3.37E-04 3.70E-07 0.686 0.369 0.217 0.135 2.27E-03 0.029 28,929 45,816 19,356 26,023
Footnotes:a P-value for sex- and age-group specific association.b P-value for difference between the two age-groups within each of the sexes.c P-value for difference between the two sexes within each of the age-groups.
WOMEN MEN Sex-diff WOMEN MEN
SNP Gene Effect P Effect P Effect P Effect P Effect P Effect P
rs6717858 GRB14; COBLL1
-0.014 1.89E-03 -0.014 1.01E-03 -6.60E-03 0.142 -1.10E-03 0.785 -0.013 7.49E-03 -0.017 7.01E-04
rs2820443 LYPLAL; SLC30A10
-4.90E-03 0.303 -0.014 2.31E-03 -0.017 6.02E-04 -0.021 2.80E-06 -0.019 5.15E-04 -0.018 9.46E-04
rs1358980 VEGFA -0.017 3.15E-04 -0.012 6.01E-03 -8.80E-03 0.065 -7.40E-03 0.103 -0.019 2.65E-04 -0.019 7.17E-04
rs11743303 MAP3K1 -7.40E-03 0.191 -1.60E-03 0.758 -6.80E-03 0.237 -6.70E-03 0.203 -3.50E-03 0.588 -7.90E-03 0.226
rs2371767 ADAMTS9 -0.015 2.59E-03 -0.016 5.47E-04 -1.20E-03 0.82 6.50E-03 0.163 -0.017 3.24E-03 -0.018 1.68E-03
rs10478424 HSD17B4 9.40E-03 0.168 -4.80E-03 0.43 -2.10E-03 0.755 -1.10E-03 0.858 5.10E-03 0.529 -2.30E-03 0.771
rs4684854 PPARG -6.00E-04 0.886 4.40E-03 0.303 8.50E-03 0.068 -1.90E-03 0.658 4.50E-03 0.378 3.70E-03 0.483
BMI Height WeightMEN WOMEN MEN WOMEN MEN WOMEN
Phenotype Database Pathway # genesa exp OLb obs OLc Pd FDRe
ht PANTHER_BIOLOGICAL_PROCESS Other_amino_acid_metabolism 30 1 6 1.10E-03 8.58E-02
wc Panther Nicotine_degradation 10 0 3 4.50E-03 7.48E-02
whr GOTERM post-Golgi vesicle-mediated transport 40 2 10 6.00E-06 3.93E-02
whr KEGG KEGG_LONG_TERM_POTENTIATION 70 3 11 7.00E-04 6.00E-02
whr Ingenuity PPAR.Signaling 19 1 5 1.40E-03 2.88E-02
wcadjbmi PANTHER_MOLECULAR_FUNCTION Kinase 30 1 8 8.10E-05 6.50E-03
wcadjbmi PANTHER_MOLECULAR_FUNCTION Annexin 71 3 11 5.00E-04 3.12E-02
wcadjbmi Panther p53_pathway_feedback_loops_2 13 1 4 3.00E-03 9.37E-02
hipadjbmi GOTERM protein deubiquitination 14 1 5 1.94E-04 7.12E-02
hipadjbmi GOTERM negative regulation of proteolysis 10 0 4 7.00E-04 8.03E-02
Footnotes:a Number of genes that belong to the pathway; b Expected overlap between the genes in the pathway and a random gene set of size 900, i.e. number of genes as expected by chance; c Observed overlap between the genes in the pathway and the observed gene set (of size 900) with scores among the top 5%, i.e. number of genes observed in the pathway; d P-value are generated using MAGENTA; e FDR computed based on 10,000 permutations.
SNP Chr Position Effect allele Gene Tissue Sex Effect P Padj d Peak SNP e r2 f P Padj
g Pdiff
rs6717858 2 165247906 T SLC38A11 SATa Men -0.409 4.20E-06 0.67 rs10184126 0.14 2.70E-39 8.60E-32 0.5
rs6717858 2 165247906 T SLC38A11 SATa Women -0.334 6.10E-06 0.58 rs10184126 0.14 8.40E-58 3.70E-50
rs6717858 2 165247906 T GRB14 SATa Men 0.424 2.80E-06 0.24 rs10195252 0.93 2.20E-07 0.02 0.37
rs6717858 2 165247906 T GRB14 SATa Women 0.324 9.70E-06 0.0004 rs4599138 0.04 2.00E-08 7.60E-07
rs2371767 3 64693297 G ADAMTS9 SATa Men -0.516 8.50E-07 0.012 rs17678140 0.1 3.20E-07 4.40E-03 0.07
rs2371767 3 64693297 G ADAMTS9 SATa Women -0.282 8.00E-04 0.0023 rs9311936 <0.01 3.60E-04 1.00E-03
rs2371767 3 64693297 G ADAMTS9 SATb Men -0.342 4.10E-04 0.81 rs4128353 0.85 2.00E-05 0.22 0.08
rs2371767 3 64693297 G ADAMTS9 SATb Women -0.085 0.45 0.69 rs1523464 <0.01 0.002 7.00E-04
rs10478424 5 118816919 A 229814_at Lymphocytesc Men 0.3331 1.10E-06 0.83 rs12332329 0.45 7.83E-10 0.01 0.85
rs10478424 5 118816919 A 229814_at Lymphocytesc Women 0.3134 4.62E-05 0.91 rs12332329 0.45 9.56E-08 0.02
Footnotes:a SAT from DeCode (252 males, 351 females), b MolOBB (abdominal SAT 31 men, 21 women),c lymphocytes from childhood asthma study (214 males, 181 females).d P-value of the identified SNP after conditioning on the peak SNP associated with the transcript.e SNP with the strongest association with the transcript in the regionf Correlation between the identified SNP and peak SNP associated with the transcriptg P-value of the peak SNP after conditioning on the identified SNP
Locus Gene Center Tissuea Target
Expression in females (mean ± s.e.m.)
Expression in males (mean ± s.e.m.)
P for sex-differenceb
1 GRB14 H Inguinal fat 1417673_at 551.97 ± 106.63 1,566.03 ± 49.78 0.046
1 GRB14 O Liver scl0003079.1_4-S 8.44 ± 0.0085 8.49 ± 0.0091 0.012
1 GRB14 R Brown fat 0.09 ± 0.01 0.15 ± 0.01 1.00E-031 GRB14 R Inguinal fat 0.093 ± 0.01 0.043 ± 0.01 4.00E-03
2 LYPLAL1 H Gonadal fat 1451490_at 617.37 ± 39.56 475.99 ± 37.77 0.024
2 LYPLAL1 H Inguinal fat 1451490_at 329.03 ± 45.33 288.10 ± 26.02 0.047
2 LYPLAL1 O Liver scl15797.5_597-S 8.34 ± 0.0146 8.26 ± 0.0139 5.58E-03
2 LYPLAL1 O Liver scl000982.1_2-S 7.75 ± 0.0049 7.73 ± 0.0049 0.049
2 LYPLAL1 R Liver 0.52 ± 0.02 0.33 ± 0.03 2.00E-032 SLC30A10 O Liver GI_38073697-S 7.88 ± 0.0049 7.91 ± 0.0055 0.022
3 VEGFA H Inguinal fat 1451959_a_at 61.76 ± 4.46 105.56 ± 6.77 1.61E-053 VEGFA H Gonadal fat 1420909_at 696.67 ± 50.75 486.79 ± 35.76 6.31E-03
3 VEGFA R Inguinal fat 0.84 ± 0.07 1.10 ± 0.09 0.038
4 MAP3K1 H Gonadal fat 1424850_at 131.51 ± 4.98 170.27 ± 9.52 5.64E-03
4 MAP3K1 O Liver scl43508.21.1_5-S 9.27 ± 0.0121 9.22 ± 0.0109 0.038
5 ADAMTS9 H Inguinal fat 1431399_at 68.36 ± 6.77 102.34 ± 6.96 5.44E-03
5 ADAMTS9 H Gonadal fat 1430352_at 358.70 ± 6.52 279.57 ± 20.70 7.87E-03
5 ADAMTS9 H Inguinal fat 1430352_at 224.57 ± 31.70 306.07 ± 27.42 0.028
5 ADAMTS9 R Liver 0.03 ± 0.002 0.018 ± 0.003 7.00E-03
5 ADAMTS9 R Gonadal fat 0.84 ± 0.14 1.26 ± 0.06 0.017
5 ADAMTS9 R Inguinal fat 0.41 ± 0.05 0.64 ± 0.07 0.026
5 PSMD6 H Inguinal fat 1423696_a_at 1,384.27 ± 139.45 1,719.63 ± 52.19 0.015
5 PSMD6 H Inguinal fat 1423697_at 1,194.53 ± 110.45 1,374.40 ± 59.79 0.035
5 PSMD6 H Gonadal fat 1423697_at 1,519.93 ± 36.80 1,688.76 ± 59.16 0.036
6 FAM170A O Liver GI_38083584-S 7.89 ± 0.0030 7.91 ± 0.0036 0.022
6 HSD17B4 H Inguinal fat 1417369_at 2,149.23 ± 268.15 2,742.14 ± 164.74 0.033
6 HSD17B4 H Inguinal fat 1455777_x_at 2,260.16 ± 299.06 2,799.51 ± 129.30 0.041
6 PRR16 O Liver ri|C130086K02|PX00172C15|AK081911|1925-S 7.86 ± 0.0030 7.88 ± 0.0036 0.027
7 MKRN2 O Liver scl29606.9_357-S 8.62 ± 0.0079 8.56 ± 0.0085 2.88E-047 PPARG H Gonadal fat 1420715_a_at 1,441.21 ± 127.58 1,023.71 ± 49.18 0.016
7 PPARG O Liver scl29611.11.1_50-S 8.02 ± 0.0103 7.95 ± 0.0091 1.63E-03
7 PPARG R Liver 0.07 ± 0.08 0.04 ± 0.01 0.011
Footnotes:a inguinal fat in mice relates to subcutaneous fat in humans; gonadal fat relates to visceral adipose fatb P-values < 0.003 (=0.05/19) are considered significant (printed in bold) accounting for the 7 independent loci tested in Oxford and in Houston and the 5 loci tested in Regensburg (5+7+7=19)
s.e.m. = standard error of the mean,
Variable Adjusted for BMI N Mean SD N Mean SD
BMI [kg/m²] - 1696 27.85 3.63 1757 27.25 4.67
HEIGHT [cm] - 1696 174.05 6.18 1758 161.2 5.74
WEIGHT [kg] - 1696 84.38 12.23 1758 70.71 12.49
HIP [cm] - 1695 104.42 6.89 1755 105.05 9.74
HIP [cm] yes 1695 104.42 3.86 1754 105.05 4.58
WAIST [cm] - 1695 98.08 9.67 1756 85.27 11.01
WAIST [cm] yes 1695 98.08 4.58 1755 85.28 5.19
WHR - 1695 0.94 0.05 1755 0.81 0.06
WHR yes 1695 0.94 0.04 1754 0.81 0.05
MEN WOMEN
Gene Universe primer (5´-3´) Reverse primer (5´-3´)VEGFA ctc agg gtt tcg gga acc aga aaa tgg cga atc cag tc
ADAMTS9 ggc ggt tac tgt gga aag tg tct cct atg gct tcc tct tca g
GRB14 cat gga caa aag ata aaa cac tat caa cct gtt gag ctg gta gaa ctc c
LYPLAL1 aaa gca tct gtt gtt tac cag ga gct cat ggt taa gat tcg gaa
PPAR tta tag ctg tca tta ttc tca gtg gag ggg tgg gac ttt cct gct a
Page 1 of 17
Text S1: Supplementary Note
Double genomic control correction in the meta-analysis
Sex-specific standard errors and P-values were genomic control (GC) corrected computing the
study-specific lambda factor and a second GC correction was performed on the meta-analyzed
result[50]. While all genome-wide available SNPs were used for GC correcting the in-silico
studies, for metabochip studies, we only used a subset of 4,427 SNPs for GC correction: Most
of the SNPs had been selected for the metabochip due to metabolic trait associations that would
result in overestimated lambda factors, but these 4,427 SNPs selected for QT-interval
association onto the metabochip were deemed to be least associated with anthropometric traits
The lambda factors for GWAS have been reported previously[49,51,52] and the lambda factors
for in-silico follow up studies ranged from 0.99 to 1.15 and for metabochip follow up studies from
0.89 to 1.13 except for one large study lambda=1.25.
Power considerations for the discovery
We evaluated the power of the two genome-wide screening approaches (the sex-specific scan
and the sex-difference scan) to select sex-sensitive SNPs into follow-up[53]. For this, we
assumed a certain genetic effect in women and varied the effect in men from OED to CED
(Figure S4A). We found that the sex-specific scan had higher power for SSE signals (no effect
in men) compared to the sex-difference scan, while the sex-difference scan had higher power
for OED signals. It can also be seen that the overall scan (man and women combined) as
currently usually applied in GWAS had good power for CED signals, but less for SSE and none
for OED.
Specifically, to provide an example for the WHRadjBMI and height analyses in the
discovery (34,629 men, 42,969 women for WHRadjBMI; 60,587 men, 73,137 women for height),
the power of the sex-specific scan to select, at 5% FDR (corresponding to a P-value of 2x10-5 in
our data), an SSE signal (i) such as the LYPLAL1 SNP (bwomen = 0.064, bmen = 0, MAF = 0.28,
R²women= 0.00167, R²men=0) was 99%, (ii) for a signal such as the PPARG SNP (bwomen = 0.034,
bmen = 0, MAF=0.42, R²women = 0.00057, R²men = 0), the power was 81%, (iii) for a medium-sized
height signal in one sex and none in the other (e.g. rs572169 from GHSR, bwomen =0.030, bmen =
0, MAF = 0.31, R²women= 0.00039, R²men = 0, from Lango et al.), the power was 78%. We had
80% power to detect sex-specific signals for height with an R² of 0.000485 in women and 0 in
men. The power via the sex-difference scan to select an OED signal at α = 2x10-5 with effect
sizes that were (i) half of the LYPLAL1 effect (signed R²women = + 0.000835 and signed R²men = -
Page 2 of 17
0.000835) was 99%, (ii) for effect sizes half of the PPARG effect (signed R²women = +0.000285
and signed R²men = -0.000285), the power was 66%, (iii) for effect sizes half of a medium height
signal (e.g. rs572169, signed R²women = + 0.000195, signed R²men = - 0.000195), the power was
79%. Note that the power to select such signals using the sex-specific scan was 98%
(LYPLAL1), 21% (PPARG) or 32% (height gene GHSR), respectively.
Power considerations in the follow-up
When comparing the power of the sex-difference test of the 348 SNPs in the follow-up without
and with a prior filter for a main effect (P-value of association combined in men and women <
0.01), it can be seen that there is a higher power with the prior filter for CED or SSE signals.
This is due to the fact that the main effect filter utilizes the knowledge that the effect is not OED.
For example, the power to detect a signal such as PPARG was 79% without the filter and 87%
with the filter (see Figure S4B).
Specifically for the example of WHRadjBMI and height analyses (47,896 men, 60,936
women for WHRadjBMI; 62,395 men, 74,657 women for height), the power to establish sex-
difference in our follow-up at 5% FDR (corresponding to a sex-difference P-value of 4.2x10-3 in
our data) was (i) 99% for a women-only signal such as the LYPLAL1, (ii) 87% for a women-only
signal such as PPARG, (iii) 78% for a women-only signal such as the height signal specified in
the previous chapter. We had 80% power to establish a sex-difference with R²women=0.0045,
R²men=0 for WHRadjBMI or R²women= 0.00035, R²men=0 for height.
Literature search and bio-informatic analyses regarding function of genes and variants at
the seven loci
To explore any potentially functional elements underlying the regions of association
(ranging from 7kbp to 2337kbp in size), we searched the UCSC and Ensembl genome browsers
and found: (i) two of the seven regions (GRB14/COBLL1 and HSD17B4) had one or more
protein coding genes overlapping the region of the association signal (COBLL1 at
GRB14/COBLL1; DMXL1, DTWD2, FAM170A, HSD17B4, PRR16, and TNFAIP8 at HSD17B4),
making these seven protein-coding genes potential candidates to explain the observed
association. (ii) Four of the seven regions (GRB14/COBLL1, LYPLAL1/SLC30A10, ADAMTS9,
and HSD17B4) had a total of seven annotated non-coding transcripts including a snoRNA
(SNORA70F at GRB14/COBLL1), a processed pseudogene (ZC3H11B at
LYPLAL1/SLC30A10), a lincRNA (ADAMTS9-AS2 at ADAMTS9), and several microRNAs
(MIR548AN at ADAMTS9; MIR1244-1, MIR1244-2, and MIR1244-3 at HSD17B4) overlapping
Page 3 of 17
the region of association signal. (iii) In the remaining three loci (VEGFA, PPARG, and MAP3K1)
we did not find any known coding genes or non-coding transcripts overlapping the regions of
association. However, all three of these regions were relatively near to the protein-coding region
of the genes (3.7kb downstream of VEGFA, 13kb downstream of PPARG, and 116kb upstream
of MAP3K1) and thus could potentially be involved with cis-regulatory elements that have not
yet been reported and/or annotated.
More details by locus as derived by searching several catalogues (copy number tagging
SNPs, NHGRI GWAS), functional annotation data bases (SIFT, SNPinfo), as well as PubMed
and OMIM, are given below:
1. GRB14 / COBLL1 (2q24.3, selected for WHRadjBMI), lead marker rs6717858, with
association signal extending across ~49kb of chromosome 2, ranging from 165216-165265kb. Two
genes (COBLL1 and SNORA70F) overlap this signal region, as does a previously reported SNP
association with WHRadjBMI in tight LD with our lead marker (rs10195252: ~26.5kb, ~0.001cM,
r2=0.94, D'=1.0)[51]. Heid et al.[49] also presented eQTL data which suggested that growth factor
receptor-bound protein 14 (GRB14) expression was associated with rs10195252 genotype and not
COBLL1[51]. Our region lies ~30-79kb upstream of GRB14, which is a member of a family of SH2-
containing adaptors. The GRB14 protein binds directly to the insulin receptor[54,55], and likely has
an inhibitory effect on receptor tyrosine kinase signaling as well as on insulin receptor signaling,
thereby regulating growth and metabolism. Grb14-deficient mice exhibit enhanced body weight,
mainly explained by increased lean mass on normal diet, improved glucose homeostasis despite
lower circulating insulin levels, and enhanced insulin signaling in liver and skeletal muscle[56].
Grb14 expression is increased in adipose tissue of insulin-resistant animal models and type 2
diabetic human patients[57], suggesting that Grb14 may modulate insulin sensitivity. The WHR
signal appears to be distinct from a GRB14 locus previously reported as associated with both
smoking initiation and current smoking (rs4423615: ~101kb, ~0.19cM, r2<0.001, D’=0.01 with lead
marker)[58]. Cordon-bleu protein-like 1 (COBLL1) may be involved in neural tube formation[59], is
expressed at higher levels in tumors associated with good prognosis in mesothelioma after
surgery[60], and its knockdown led to increased apoptosis in both normal and tumor cells[61]. Our
bio/informatical analyses did not identify any potentially functional entity.
2. LYPLAL1 / SLC30A10 (1q41, WHRadjBMI), lead marker rs2820443, with association signal
extending across ~62kb of chromosome 1, ranging from 217793-217855kb. One gene (ZC3H11B)
overlaps this signal region, as does a previously reported SNP associated with WHRadjBMI
(rs4846567: ~2.8kb, ~0.0002cM, r2 = 0.96, D’ = 1.0 with lead marker)[51]. Zinc finger CCCH-type
containing 11B (ZC3H11B) is a pseudogene with no known function. Another previously reported
Page 4 of 17
SNP association with WHRadjBMI lies ~82-144kb from our association region (rs2605100: ~109kb,
~0.04cM, r2 = 0.68, D’ = 0.84 with lead marker)[62]. Excluding ZC3H11B, our signal region is
nearest to SLC30A10 (~299-361kb downstream) and LYPLAL1 (~340-402kb downstream). Solute
carrier family 30, member 10 (SLC30A10) belongs to a family of membrane transporters involved in
intracellular zinc homeostasis and is expressed in brain and liver[63]. LYPLAL1 encodes
lysophospholipase-like 1 protein, which is thought to act as a triglyceride lipase and is reported to
be up-regulated in subcutaneous adipose tissue of obese subjects[64]. Intergenic variants near
LYPLAL1 have also been associated with fatty liver disease (rs12137855: ~305kb, ~0.22cM, r2 =
0.1, D’ = 0.40 with lead marker)[65].
Our bio-informatical analyses found several SNPs moderately correlated with our lead SNP
that are putative transcription factor binding sites (rs7538503: r2 = 0.78, rs2605101: r2 = 0.72,
rs2605098: r2 = 0.66, rs2605100: r2 = 0.62).
3. VEGFA (6p21.1, WHRadjBMI), lead marker rs1358980, with association signal extending
across ~7kb of chromosome 6, ranging from 43872-43865kb. No genes overlap this signal region,
but it does include a SNP previously associated with WHRadjBMI (rs6905288: ~5.6kb, ~0.01cM, r2
= 0.5, D’ = 0.91 with lead marker)[49]. The associated region is located 3.7-10.7kb downstream of
vascular endothelial growth factor A (VEGFA). Multiple variants and mutations in VEGFA are risk
factors for diabetic retinopathy[66-68], and variants in VEGFA have been nominally associated with
Type 2 Diabetes (T2D)[69]. VEGFA is proposed as a key mediator of adipogenesis and
angiogenesis[70], is highly expressed in adipose tissue, and has increased expression during
adipocyte differentiation[71-74]. VEGFA serum concentrations are elevated in overweight and
obese patients compared with lean subjects[75] and decrease after weight loss following bariatric
surgery, behaving similarly to other hormones related to adipose mass, such as leptin and
insulin[76]. Variants near VEGFA have also been associated with kidney function (rs881858: ~42kb,
0.2cM, r2 = 0.01, D’ = 0.18 with lead marker)[77] and advanced age related macular degeneration
(rs4711751: ~64kb, 0.2cM, r2 = 0.04, D’ = 0.21 with lead marker in 1000G data)[78] although both
appear likely to be distinct from our signal.
Our bio/informatical analyses did not identify any potentially functional entity.
4. ADAMTS9 (3p14.1, WHRadjBMI), lead marker rs2371767, with association signal extending
across ~31kb of chromosome 3, ranging from 64704-64673kb. Two genes (ADAMTS9-AS2 and
MIR548AN) overlap this signal region, as do three previously reported SNP associations, one with
WHRadjBMI (rs6795735: ~12.9kb, ~0.004cM, r2=0.311, D'=1.0 with lead marker) [51], and two with
T2D (rs4607103: ~6.4kb, ~0.001cM, r2=0.90, D'=1.0; and rs4411878: ~14.6kb, ~0.005cM, r2=0.85,
D'=0.95)[69,79]. The T2D association is possibly mediated through decreased insulin sensitivity of
Page 5 of 17
peripheral tissues[80]. MIR548AN is a microRNA which primarily maps to the X chromosome but
also maps with 96.4% identity (full length transcript with 3 base mismatches) within our signal
region. The function of MIR548AN is not known. ADAMTS9-AS2 is a long non-coding RNA which is
an antisense for ADAMTS9. Our region is located ~25-56kb upstream of ADAMTS9. ADAMTS9 is a
member of the disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family, a
group of genes encoding metalloproteases that lack transmembrane domains and are secreted into
the extracellular matrix[81]. Members of the ADAMTS family have been implicated in control of
organ shape during development and inhibition of angiogenesis[82].
Our bio/informatical analyses did not identify any pontially functional entity.
5. HSD17B4 (5q23.1), lead marker rs10478424, with association signal extending across
~2337kb of chromosome 5, ranging from 117911-120249kb. Nine genes (DMXL1, DTWD2,
FAM170A, HSD17B4, MIR1244-1, MIR1244-2, MIR1244-3, PRR16, and TNFAIP8) overlap this
signal region. The lead marker, rs10478424, is located in an intronic region of hydroxysteroid (17-
beta) dehydrogenase 4 (HSD17B4). The protein encoded by HSD17B4 is a bifunctional enzyme
that is involved in the peroxisomal beta-oxidation pathway for fatty acids. Mutations in this gene are
known to cause DBP deficiency, an autosomal-recessive disorder of peroxisomal fatty acid beta-
oxidation that is generally fatal within the first two years of life[83,84]. Expression levels of
HSD17B4 have been associated with prostate cancer severity[85], and it is also a significant
independent predictor of poor patient outcome[86].
Our bio-informatical analyses found that our lead marker is in a predicted transcription factor
binding site (TFBS) and could therefore potentially influence regulation of transcription of an
alternative putative protein-coding splice variant of HSD17B4. Interestingly, one of the transcription
factors predicted to bind at this site is PPARG, which itself is located near one of the other
association regions reported here. In addition, several proxies in moderate LD with the lead marker
disrupt predicted microRNA bindings sites (rs1045241: r2 = 0.53, rs1045242: r2 = 0.53, rs11064: r2 =
0.53) and are also possible candidates for functional explanations of the association signal at this
locus. It should also be noted that there was one CNV tagging SNP (rs1948325) in that region that
showed nominal significance in women (P=0.054, P=0.281) consistent with the women-only
association signal of WHRadjBMI, but this would not hold significance when accounting for the
multiple testing conducted in the CNV tagging SNP analysis (6016 SNPs tested).
6. PPARG (3p25.1, WHRadjBMI), lead marker rs4684854, with association signal extending
across ~10kb of chromosome 3, ranging from 12463-12473kb. No known genes overlap this region.
However, it does lie approximately 13kb downstream of the well known type 2 diabetes
susceptibility gene, peroxisome proliferator-activated receptor gamma (PPARG), although the T2D
Page 6 of 17
associated SNP appears to be distinct from our locus (rs1801282: ~96kb, ~0.11cM, r2=0.04,
D'=0.61 with lead marker)[26,87,88]. The protein product encoded by PPARG is PPAR-gamma
which is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in
the pathology of numerous diseases including obesity[89-92], diabetes[93,94], atherosclerosis[95]
and cancer[93,96-98]. Interestingly, previous studies of the Pro12Ala polymorphism in the PPAR
gene have demonstrated genotype–by-sex interaction with BMI[99], fatty acid concentrations during
the first 24h after birth were related to PPARG expression in female but not in male lambs[100], and
female 12Ala mutation carriers had greater risk of developing abdominal obesity than female non-
carriers while male 12Ala mutation carriers had no significant increase in risk[101].
Our bio/informatical analyses did not identify any potentially functional entity.
7. MAP3K1 (5q11.2, WCadjBMI), lead marker rs11743303, with association signal extending
across ~198kb of chromosome 5, ranging from 55832-56030kb. No known genes overlap this
region, but it does overlap with another SNP (rs6867983: ~5.8kb, 0.02cM, r2=0.71, D'=1.0 with lead
marker) reported as a suggestive association with triglyceride level[102]. The associated region
also lies ~116-314kb upstream of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), a
serine/threonine kinase that occupies a pivotal role in a network of phosphorylating enzymes
integrating cellular responses to a number of mitogenic and metabolic stimuli, including insulin (MIM
176730) and many growth factors[82]. Mutations in MAP3K1 are associated with gonadal
dysgenesis[103], and a SNP within MAP3K1 (rs889312: ~172kb, 0.44cM, r2=0.005, D'=0.10 with
lead marker) has been reported to be associated with breast cancer[104,105], possibly as a gene-
gene interaction with BRCA2[106]. It is also ~384-582kb upstream of ankyrin repeat domain 55
(ANKRD55), which harbors SNPs reported to be associated with longevity (rs415407: ~445kb,
1.1cM, r2=0.005, D'=0.12 with lead marker)[107], Rheumatoid Arthritis (rs6859219: ~421kb, 0.93cM,
r2=0.008, D'=0.10 with lead marker)[108], and Celiac Disease (rs1020388: ~300kb, 0.71cM,
r2=0.003, D'=0.11 with lead marker)[109].
Our bio/informatical analyses did not identify any pontially functional entity.
Human tissue eQTL
Subcutaneous adipose tissue and whole blood from deCode: As described previously[110], 603
(252 males, 351 females) individuals with adipose tissue and 747 (312 males, 435 females)
individuals with whole blood samples were genotyped with the Illumina 317K or 370K platform
and HapMap imputation performed. Gene expression profiles were conducted using RNA from
the adipose and blood samples using a custom-made human array with 23,720 unique
oligonucleotide probes. Cis associations were tested separately by gender by regressing the
Page 7 of 17
mean logarithm (log10) expression ratio (MLR) on the number of effect alleles adjusting for age
(and the differential cell count for the blood analyses) and accounting for familial relatedness.
Only cis associations with a P-value < 1x10-5 corresponding to an FDR < 5% in either sex are
reported.
Subcutaneous adipose tissue and whole blood from MolOBB: Seventy-three individuals were
recruited to donate subcutaneous adipose tissue from the abdominal wall and gluteus [In press
Plos Genetics]. Total RNA was extracted from the fat tissue using TRIreagent and hybridized
onto the Affymetrix Human Genome U133 Plus 2.0 gene-expression microarrays (hgu133plus2
arrays), containing 17,726 non-overlapping probes. Subjects were genotyped with the Illumina
317K Beadchip chip array and imputation conducted using IMPUTE. After quality control filters
were applied to the expression and genotype data, 52 individuals (31 male, 21 female) with
abdominal adipose tissue, 62 subjects with gluteal fat (35 male, 27 female), and 65 subjects
with whole blood (36 male, 29 female) remained for eQTL analysis. Cis associations within
500kb of each gene were evaluated by regressing expression level on genotype and adjusting
for plate effects. Two models were tested: 1) assuming the same slope in each gender (e.g.,
gender-homogeneity effects) and 2) assuming a different slope for each gender (e.g., gender-
specific effects). Only those associations with an FDR < 1% in either sex are presented.
Lymphoblastoid cell lines from a childhood asthma study. As described previously [111],
peripheral blood lymphocytes were transformed into lymphoblastoid cell lines for 206 families of
European descent (214 male, 181 female). Using extracted RNA, gene expression was
assessed with the Affymetrix HG-U133 Plus 2.0 chip. Genotyping was conducted using the
Illumina Human1M Beadchip and Illumina HumanHap300K Beadchip, and imputation performed
using data from Phase II HapMap CEU population. SNPs were tested for cis associations
(defined as genes within 1 Mb), adjusting for non-genetic effects in the gene expression value.
Only cis associations that reached a P<6.8x10-5 (FDR of 1%) in either sex were included in the
table.
Lymphoblastoid cell lines from the International HapMap Project: As described previously[112],
transcription profiling was done on Epstein-Barr virus-transformed lymphoblastoid cell lines from
the original 379 individuals in the four HapMap populations (CEU: 54 females, 55 males; CHB:
42 females, 38 males; JPT: 40 females, 42 males; YRI: 53 females, 55 males) using the
Illumina human whole-genome expression (WG-6 version 1) arrays, which contain 47,294
probes. The genotype data from HapMap 3 was used to evaluate the associations with
expression. Cis associations within a 2 Mb window centered on the gene were tested using
Page 8 of 17
Spearman rank correlation[112], stratified by sex and population. A threshold of P < 1.0 x 10-5
was used to determine nominal significance, but no associations reached this level.
Mouse expression
There were three experiments on mouse expression in Regensburg, Oxford and Houston. The
genes explored via PCR in Regensburg are given in Table S13A, the genes explored via
Illumina array in Oxford and Houston in Table S13B. Details of the three experiments are given
below:
Mouse experiment at the Regensburg center:
At the Regensburg University, mice (7 female and 7 male animals) were purchased from
Charles River Laboratories (Sulzfeld, Germany) at an age of 7 weeks. Body weight of the
female mice was 16.7 + 0.7 g and of the male mice 20.3 + 1.4 g (p = 0.001). After 3 weeks of
acclimatisation, animals were killed and respective organs were immediately removed. Total
RNA was isolated with TRIzol reagent from GIBCO (Carlsbad, CA), oligonucleotides used for
amplification using LightCycler technology were synthesized by Metabion (Planegg-Martinsried,
Germany) and are listed in the table. Real-time RT-PCR was performed as recently
described[113], and the specificity of the PCRs was confirmed by sequencing of the amplified
DNA fragments (Geneart, Regensburg,Germany). For quantification of the results, RNA was
reverse transcribed, and cDNA was serially diluted and used to create a standard curve for each
of the genes analyzed. The second-derivative maximum method was used for quantification
with the LightCycler software. Values were normalized to 18s rRNA expression and are given as
arbitrary units.
Mouse experiment at the Oxford center:
Animals: Original Northport Heterogeneous Stock (HS) mice were obtained from Robert
Hitzemann of the Oregon Health Sciences Unit (Portland, Oregon). At the time the animals
arrived, they had descended from 50 generations of pseudorandom breeding that commenced
with eight founder strains: A/J, AKR/J, BALBc/J, CBA/J, C3H/HeJ, C57BL/6J, DBA/2J, and
LP/J[114]. The animals were bred for phenotyping in a colony established at the University of
Oxford. They were housed at a maximum of six per cage (median of four) and maintained on a
12:12 light:dark cycle with ad libitum access to food and water.
Gene Expression Assays: From a pool of over 1940 HS mice (1000 males), the most unrelated
animals (based on genome-wide genotyping of 13.5k SNPs using Illumina’s BeadArray
platform[115]) were assayed for gene expression in several tissues, including the liver (n = 273
Page 9 of 17
with 139 males). As detailed by Huang and colleagues[116], the tissues were frozen in liquid
nitrogen and homogenised. RNA was extracted from the tissue and mRNA was amplified.
Labelled mRNA was hybridised to the Illumina Mouse WG-6 v1 BeadArray platform, which
contains 47.4k unique RNA probe sequences.
Gene Expression Data Preprocessing: To extract data from the images produced by the
BeadArray platform, the images were imported into the Gene Expression module (V 1.6.0) of
the Illumina GenomeStudio (V 2010.1) without invoking any data adjustment procedures. The
data were exported to R[117] using the Bioconductor package lumi[118], where one outlying
liver array and five hippocampus arrays, as visualised in cluster dendrograms, were removed
from further analysis. Subsequently, lumi was employed to subtract background noise from the
arrays, and apply variance stabilising transformation and robust spline normalisation. Only
probes identified by Barbosa-Morais and co-workers[119] as “good” or “perfect” matches to the
genome, and only probes expressed in at least 5% of animals at a 0.95 detection level (as per
GenomeStudio), were retained, leaving 13718 liver and 15737 hippocampus probes.
Annotations aligning the probes with physical locations of the mouse genome were also
obtained from Barbosa-Morais and colleagues. ComBat was used to remove batch effects[120].
Mapping human genes to mouse genes: We first mapped human gene names to Ensembl gene
IDs using the DAVID gene ID conversion tool[116] (http://david.abcc.ncifcrf.gov/). We manually
replaced three genes which have alternate names (ATAD4 with PRR15L, FBXL10 with KDM2B,
and MIRHG1 with MIR17HG) and could not convert NIACR2. Then we looked for mouse
orthologs using the BioMart webservice (http://www.biomart.org/), keeping only genes with one
to one orthologs. We found mouse orthologs for 134 out of 156 human genes at 18 loci.
Testing for Sex-Specific Gene Expression: All probes corresponding to the list of mouse genes
of interest were fit into a linear model.
Mouse experiment at the Houston center:
Animals: The study was performed using 21 male, 21 female C57/BL6 mice fed from day 21
(after weaning) or 12 weeks on an HF diet (4.7 Kcal g–1 and 45% calories from fat; Research
Diets, Inc., New Brunswick, NJ, US. Mice were single caged and maintained at a controlled
temperature (22 °C) and a 12 h light–dark cycle (light on from 0800 to 2000 h). Daily food intake
and body weight were monitored. All procedures were approved by the animal care and use
committee of the University of Cincinnati.
Tissue collection: After 12 weeks of exposure to the diet, animals were killed during the first 2 h
of the beginning of the light cycle after a 12-h fast. All females were killed in the proestrus phase
of their estrus cycle. Two different WAT depots, FGWAT and IWATF, were rapidly dissected
Page 10 of 17
and the orientation of the fat pad was maintained. Half of the fat pad was rapidly frozen for
microarray analysis, and the other half of the fat pad was rapidly frozen for validation of target
genes. Samples were rapidly frozen in liquid nitrogen and stored at 70 °C for RNA analysis.
RNA isolation: GWAT/IWAT were homogenized in 800 ml Trizol reagent (Invitrogen, Carlsbad,
CA, USA), and total cellular RNA was isolated according to the specifications of the
manufacturer. Total RNA was further purified using the RNeasy Mini kit (Qiagen, Valencia, CA,
USA). The quality and concentration of the RNA was determined by measuring the absorbance
at 260 and 280 nm, and RNA integrity was confirmed by bioanalysis (Agilent 2100 Bioanalyzer;
Agilent Technologies,Santa Clara, CA, USA).
Microarray analysis: For the microarray analysis, seven independent pooled samples were
analyzed from GWAT and IWAT fat pads. Each sample comprised a pool of tissue from three
animals (for pooled samples, reverse transcription was performed on each sample individually
and equal amounts of complementary DNA (cDNA) were pooled); thus, samples were obtained
from a total of 21 mice. GWAT/IWAT adipose RNA pools were generated from the following
groups of mice: males and females. To identify genes that were differentially expressed in the
two WAT fat pads, comparisons were made between normalized signal intensity from the
control group (males) and experimental groups (female) from each experiment. Each total RNA
sample was processed according to protocols recommended by the manufacturers. In brief,
total RNA is reverse-transcribed with an oligo-dT primer and double-stranded cDNA is
generated. The cDNA serves as a template for the in vitro transcription reaction that produces
amplified amounts of biotin-labeled antisense mRNA. This biotinylated RNA is referred to as
labeled cRNA. After fragmentation, the cRNA is hybridized onto oligonucleotide microarrays
(Mouse Genome 430 2.0; 40 000 mouse probe sets). A GeneChip Operating System absolute
expression analysis was performed for each Gene-Chip genome array hybridization. After the
initial analysis, the absolute analysis was re-run using global scaling to an average target
intensity of 350. The scaling allows for the direct comparison of hybridization values from the
different targets analyzed in this project (and with any additional GeneChip sample assays using
the same array type).
REFERENCES
1. Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, et al. (2008) Universal risk factors for multifactorial diseases: LifeLines: a three-‐generation population-‐based study. European journal of epidemiology 23: 67-‐74.
Page 11 of 17
2. Pinto-‐Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, et al. (2000) Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. Journal of the American Society of Nephrology : JASN 11: 1882-‐1888.
3. Medland SE, Nyholt DR, Painter JN, McEvoy BP, McRae AF, et al. (2009) Common variants in the trichohyalin gene are associated with straight hair in Europeans. American journal of human genetics 85: 750-‐755.
4. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, et al. (2011) Genome-‐wide meta-‐analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS genetics 7: e1002033.
5. Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, et al. (2006) Statin and beta-‐blocker therapy and the initial presentation of coronary heart disease. Annals of internal medicine 144: 229-‐238.
6. Taylor-‐Piliae RE, Norton LC, Haskell WL, Mahbouda MH, Fair JM, et al. (2006) Validation of a new brief physical activity survey among men and women aged 60-‐69 years. American journal of epidemiology 164: 598-‐606.
7. Iribarren C, Go AS, Husson G, Sidney S, Fair JM, et al. (2006) Metabolic syndrome and early-‐onset coronary artery disease: is the whole greater than its parts? Journal of the American College of Cardiology 48: 1800-‐1807.
8. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, et al. (2008) Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-‐ethnic ADVANCE study. Human molecular genetics 17: 2320-‐2328.
9. Samani NJ, Deloukas P, Erdmann J, Hengstenberg C, Kuulasmaa K, et al. (2009) Large scale association analysis of novel genetic loci for coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology 29: 774-‐780.
10. Strachan DP, Rudnicka AR, Power C, Shepherd P, Fuller E, et al. (2007) Lifecourse influences on health among British adults: effects of region of residence in childhood and adulthood. International journal of epidemiology 36: 522-‐531.
11. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, et al. (2009) Genome-‐wide association study and meta-‐analysis find that over 40 loci affect risk of type 1 diabetes. Nature genetics 41: 703-‐707.
12. (2007) Genome-‐wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-‐678.
13. Power C, Elliott J (2006) Cohort profile: 1958 British birth cohort (National Child Development Study). International journal of epidemiology 35: 34-‐41.
14. James AL, Knuiman MW, Divitini ML, Hui J, Hunter M, et al. (2010) Changes in the prevalence of asthma in adults since 1966: the Busselton health study. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 35: 273-‐278.
15. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, et al. (2007) Genomewide association analysis of coronary artery disease. The New England journal of medicine 357: 443-‐453.
16. Kotronen A, Yki-‐Jarvinen H, Mannisto S, Saarikoski L, Korpi-‐Hyovalti E, et al. (2010) Non-‐alcoholic and alcoholic fatty liver disease -‐ two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-‐D2D survey. BMC public health 10: 237.
17. Konttinen H, Mannisto S, Sarlio-‐Lahteenkorva S, Silventoinen K, Haukkala A (2010) Emotional eating, depressive symptoms and self-‐reported food consumption. A population-‐based study. Appetite 54: 473-‐479.
18. Inouye M, Silander K, Hamalainen E, Salomaa V, Harald K, et al. (2010) An immune response network associated with blood lipid levels. PLoS genetics 6.
Page 12 of 17
19. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England journal of medicine 344: 1343-‐1350.
20. Kouki R, Schwab U, Lakka TA, Hassinen M, Savonen K, et al. (2010) Diet, fitness and metabolic syndrome -‐ The DR's EXTRA Study. Nutrition, metabolism, and cardiovascular diseases : NMCD.
21. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, et al. (1991) Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International journal of epidemiology 20: 384-‐392.
22. Nelis M, Esko T, Magi R, Zimprich F, Zimprich A, et al. (2009) Genetic structure of Europeans: a view from the North-‐East. PloS one 4: e5472.
23. Forouhi NG, Luan J, Hennings S, Wareham NJ (2007) Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-‐2000. Diabetic medicine : a journal of the British Diabetic Association 24: 200-‐207.
24. Day N, Oakes S, Luben R, Khaw KT, Bingham S, et al. (1999) EPIC-‐Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. British journal of cancer 80 Suppl 1: 95-‐103.
25. Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, et al. (2009) Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature genetics 41: 25-‐34.
26. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genome-‐wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316: 1341-‐1345.
27. Renstrom F, Payne F, Nordstrom A, Brito EC, Rolandsson O, et al. (2009) Replication and extension of genome-‐wide association study results for obesity in 4923 adults from northern Sweden. Human molecular genetics 18: 1489-‐1496.
28. Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, et al. (2003) Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort -‐ evaluation of risk factors and their interactions. Scandinavian journal of public health Supplement 61: 18-‐24.
29. Kimber CH, Doney AS, Pearson ER, McCarthy MI, Hattersley AT, et al. (2007) TCF7L2 in the Go-‐DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia 50: 1186-‐1191.
30. Stang A, Moebus S, Dragano N, Beck EM, Mohlenkamp S, et al. (2005) Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response. European journal of epidemiology 20: 489-‐496.
31. Holmen J, Midthjell K, Krüger Ø, Langhammer A, Holmen TL, et al. (2003) The Nord-‐Trøndelag Health Study 1995-‐97 (HUNT 2): Objectives, contents, methods and participation. Science And Technology 13: 19-‐32.
32. Baldassarre D, Nyyssonen K, Rauramaa R, de Faire U, Hamsten A, et al. (2010) Cross-‐sectional analysis of baseline data to identify the major determinants of carotid intima-‐media thickness in a European population: the IMPROVE study. European heart journal 31: 614-‐622.
33. Wichmann H, Gieger C, Illig T (2005) KORA-‐gen-‐resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67: 26.
34. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, et al. (2001) Rationale and design of the LURIC study-‐-‐a resource for functional genomics, pharmacogenomics and long-‐term prognosis of cardiovascular disease. Pharmacogenomics 2: S1-‐73.
35. Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM, Kuusisto J, et al. (2009) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58: 1212-‐1221.
36. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, et al. (2005) MORGAM (an international pooling of cardiovascular cohorts). International journal of epidemiology 34: 21.
Page 13 of 17
37. Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, et al. (2005) Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. International journal of epidemiology 34: 413-‐421.
38. Ferrario M, Sega R, Chatenoud L, Mancia G, Mocarelli P, et al. (2001) Time trends of major coronary risk factors in a northern Italian population (1986-‐1994). How remarkable are socioeconomic differences in an industrialized low CHD incidence country? International journal of epidemiology 30: 285-‐297.
39. Ferrario MM, Veronesi G, Chambless LE, Sega R, Fornari C, et al. (2011) The contribution of major risk factors and job strain to occupational class differences in coronary heart disease incidence: the MONICA Brianza and PAMELA population-‐based cohorts. Occup Environ Med 68: 717-‐722.
40. Wadsworth M, Kuh D, Richards M, Hardy R (2006) Cohort Profile: The 1946 National Birth Cohort (MRC National Survey of Health and Development). International journal of epidemiology 35: 49-‐54.
41. Hardy R, Wills AK, Wong A, Elks CE, Wareham NJ, et al. (2010) Life course variations in the associations between FTO and MC4R gene variants and body size. Human molecular genetics 19: 545-‐552.
42. Lind L, Fors N, Hall J, Marttala K, Stenborg A (2005) A comparison of three different methods to evaluate endothelium-‐dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arteriosclerosis, thrombosis, and vascular biology 25: 2368-‐2375.
43. Lichtenstein P, Sullivan PF, Cnattingius S, Gatz M, Johansson S, et al. (2006) The Swedish Twin Registry in the third millennium: an update. Twin research and human genetics : the official journal of the International Society for Twin Studies 9: 875-‐882.
44. Theodoraki EV, Nikopensius T, Suhorutsenko J, Peppes V, Fili P, et al. (2010) Fibrinogen beta variants confer protection against coronary artery disease in a Greek case-‐control study. BMC medical genetics 11: 28.
45. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I (2011) Cohort profile: The Tromso Study. International journal of epidemiology.
46. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L (2005) Insulin resistance and risk of congestive heart failure. JAMA : the journal of the American Medical Association 294: 334-‐341.
47. Marmot M, Brunner E (2005) Cohort Profile: the Whitehall II study. International journal of epidemiology 34: 251-‐256.
48. Jensen AC, Barker A, Kumari M, Brunner EJ, Kivimaki M, et al. (2011) Associations of common genetic variants with age-‐related changes in fasting and postload glucose: evidence from 18 years of follow-‐up of the Whitehall II cohort. Diabetes 60: 1617-‐1623.
49. Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, et al. (2010) Meta-‐analysis identifies 13 new loci associated with waist-‐hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nature genetics 42: 949-‐960.
50. Devlin B, Roeder K (1999) Genomic control for association studies. Biometrics 55: 997-‐1004. 51. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al. (2010) Association analyses of
249,796 individuals reveal 18 new loci associated with body mass index. Nature genetics 42: 937-‐948.
52. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, et al. (2010) Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467: 832-‐838.
53. Behrens G, Winkler TW, Gorski M, Leitzmann MF, Heid IM (2011) To stratify or not to stratify: power considerations for population‚Äêbased genome‚Äêwide association studies of quantitative traits. Genetic epidemiology 35: 867-‐879.
Page 14 of 17
54. Holt LJ, Siddle K (2005) Grb10 and Grb14: enigmatic regulators of insulin action-‐-‐and more? The Biochemical journal 388: 393-‐406.
55. Depetris RS, Hu J, Gimpelevich I, Holt LJ, Daly RJ, et al. (2005) Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Molecular cell 20: 325-‐333.
56. Cooney GJ, Lyons RJ, Crew AJ, Jensen TE, Molero JC, et al. (2004) Improved glucose homeostasis and enhanced insulin signalling in Grb14-‐deficient mice. The EMBO journal 23: 582-‐593.
57. Cariou B, Capitaine N, Le Marcis V, Vega N, Bereziat V, et al. (2004) Increased adipose tissue expression of Grb14 in several models of insulin resistance. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18: 965-‐967.
58. Vink JM, Smit AB, de Geus EJ, Sullivan P, Willemsen G, et al. (2009) Genome-‐wide association study of smoking initiation and current smoking. American journal of human genetics 84: 367-‐379.
59. Carroll EA, Gerrelli D, Gasca S, Berg E, Beier DR, et al. (2003) Cordon-‐bleu is a conserved gene involved in neural tube formation. Developmental biology 262: 16-‐31.
60. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, et al. (2003) Using gene expression ratios to predict outcome among patients with mesothelioma. Journal of the National Cancer Institute 95: 598-‐605.
61. Gordon GJ, Bueno R, Sugarbaker DJ (2011) Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro. BMC cancer 11: 169.
62. Lindgren CM, Heid IM, Randall JC, Lamina C, Steinthorsdottir V, et al. (2009) Genome-‐wide association scan meta-‐analysis identifies three Loci influencing adiposity and fat distribution. PLoS genetics 5: e1000508.
63. Seve M, Chimienti F, Devergnas S, Favier A (2004) In silico identification and expression of SLC30 family genes: an expressed sequence tag data mining strategy for the characterization of zinc transporters' tissue expression. BMC Genomics 5: 32.
64. Steinberg GR, Kemp BE, Watt MJ (2007) Adipocyte triglyceride lipase expression in human obesity. Am J Physiol Endocrinol Metab 293: E958-‐964.
65. Speliotes EK, Yerges-‐Armstrong LM, Wu J, Hernaez R, Kim LJ, et al. (2011) Genome-‐wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS genetics 7: e1001324.
66. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, et al. (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 139: 476-‐481.
67. Abhary S, Burdon KP, Gupta A, Lake S, Selva D, et al. (2009) Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci 50: 5552-‐5558.
68. Al-‐Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, et al. (2008) Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes 57: 218-‐228.
69. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-‐analysis of genome-‐wide association data and large-‐scale replication identifies additional susceptibility loci for type 2 diabetes. Nature genetics 40: 638-‐645.
70. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, et al. (2007) Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes 56: 1517-‐1526.
71. Claffey KP, Wilkison WO, Spiegelman BM (1992) Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 267: 16317-‐16322.
Page 15 of 17
72. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, et al. (1997) Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-‐mediated angiogenesis. J Surg Res 67: 147-‐154.
73. Soukas A, Socci ND, Saatkamp BD, Novelli S, Friedman JM (2001) Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem 276: 34167-‐34174.
74. Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, et al. (2001) Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-‐L1 adipocytes. Diabetes 50: 1166-‐1170.
75. Silha JV, Krsek M, Sucharda P, Murphy LJ (2005) Angiogenic factors are elevated in overweight and obese individuals. International journal of obesity 29: 1308-‐1314.
76. Garcia de la Torre N, Wass JA, Turner HE (2002) Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57: 425-‐441.
77. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, et al. (2010) New loci associated with kidney function and chronic kidney disease. Nature genetics 42: 376-‐384.
78. Yu Y, Bhangale TR, Fagerness J, Ripke S, Thorleifsson G, et al. (2011) Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-‐related macular degeneration. Human molecular genetics 20: 3699-‐3709.
79. van Hoek M, Dehghan A, Witteman JC, van Duijn CM, Uitterlinden AG, et al. (2008) Predicting type 2 diabetes based on polymorphisms from genome-‐wide association studies: a population-‐based study. Diabetes 57: 3122-‐3128.
80. Boesgaard TW, Gjesing AP, Grarup N, Rutanen J, Jansson PA, et al. (2009) Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients-‐-‐EUGENE2 study. PloS one 4: e7236.
81. Tang BL (2001) ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 33: 33-‐44.
82. Pruitt KD, Tatusova T, Maglott DR (2007) NCBI reference sequences (RefSeq): a curated non-‐redundant sequence database of genomes, transcripts and proteins. Nucleic acids research 35: D61-‐65.
83. Suzuki Y, Jiang LL, Souri M, Miyazawa S, Fukuda S, et al. (1997) D-‐3-‐hydroxyacyl-‐CoA dehydratase/D-‐3-‐hydroxyacyl-‐CoA dehydrogenase bifunctional protein deficiency: a newly identified peroxisomal disorder. American journal of human genetics 61: 1153-‐1162.
84. van Grunsven EG, van Berkel E, Ijlst L, Vreken P, de Klerk JB, et al. (1998) Peroxisomal D-‐hydroxyacyl-‐CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency. Proceedings of the National Academy of Sciences of the United States of America 95: 2128-‐2133.
85. True L, Coleman I, Hawley S, Huang CY, Gifford D, et al. (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 103: 10991-‐10996.
86. Rasiah KK, Gardiner-‐Garden M, Padilla EJ, Moller G, Kench JG, et al. (2009) HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol 301: 89-‐96.
87. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007) Replication of genome-‐wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316: 1336-‐1341.
88. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. (2007) Genome-‐wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331-‐1336.
Page 16 of 17
89. Ristow M, Muller-‐Wieland D, Pfeiffer A, Krone W, Kahn CR (1998) Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. The New England journal of medicine 339: 953-‐959.
90. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-‐Lozano P, et al. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Molecular cell 4: 585-‐595.
91. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, et al. (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Molecular cell 4: 611-‐617.
92. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, et al. (2006) The human obesity gene map: the 2005 update. Obesity 14: 529-‐644.
93. Murphy GJ, Holder JC (2000) PPAR-‐gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends in pharmacological sciences 21: 469-‐474.
94. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-‐883.
95. Galgani A, Valdes A, Erlich HA, Mano C, Cheng S, et al. (2010) Homozygosity for the Ala allele of the PPARgamma2 Pro12Ala polymorphism is associated with reduced risk of coronary artery disease. Dis Markers 29: 259-‐264.
96. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, et al. (1999) Peroxisome proliferator-‐activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90: 75-‐80.
97. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, et al. (1999) Loss-‐of-‐function mutations in PPAR gamma associated with human colon cancer. Molecular cell 3: 799-‐804.
98. Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-‐activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-‐9121.
99. Morini E, Tassi V, Capponi D, Ludovico O, Dallapiccola B, et al. (2008) Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity 16: 1467-‐1470.
100. Duffield JA, Vuocolo T, Tellam R, McFarlane JR, Kauter KG, et al. (2009) Intrauterine growth restriction and the sex specific programming of leptin and peroxisome proliferator-‐activated receptor gamma (PPARgamma) mRNA expression in visceral fat in the lamb. Pediatr Res 66: 59-‐65.
101. Chen CH, Lu ML, Kuo PH, Chen PY, Chiu CC, et al. (2011) Gender differences in the effects of peroxisome proliferator-‐activated receptor gamma2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 35: 239-‐245.
102. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, et al. (2010) Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology 30: 2264-‐2276.
103. Pearlman A, Loke J, Le Caignec C, White S, Chin L, et al. (2010) Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. American journal of human genetics 87: 898-‐904.
104. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007) Genome-‐wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-‐1093.
105. Lu PH, Yang J, Li C, Wei MX, Shen W, et al. (2011) Association between mitogen-‐activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects. Breast Cancer Res Treat 126: 663-‐670.
106. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, et al. (2008) Common breast cancer-‐predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. American journal of human genetics 82: 937-‐948.
Page 17 of 17
107. Sebastiani P, Solovieff N, Puca A, Hartley SW, Melista E, et al. (2010) Genetic signatures of exceptional longevity in humans. Science 2010.
108. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. (2010) Genome-‐wide association study meta-‐analysis identifies seven new rheumatoid arthritis risk loci. Nature genetics 42: 508-‐514.
109. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, et al. (2011) Meta-‐analysis of genome-‐wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-‐HLA shared loci. PLoS genetics 7: e1002004.
110. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, et al. (2008) Genetics of gene expression and its effect on disease. Nature 452: 423-‐428.
111. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, et al. (2007) A genome-‐wide association study of global gene expression. Nature genetics 39: 1202-‐1207.
112. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, et al. (2007) Population genomics of human gene expression. Nature genetics 39: 1217-‐1224.
113. Bauer S, Wanninger J, Schmidhofer S, Weigert J, Neumeier M, et al. (2011) Sterol regulatory element-‐binding protein 2 (SREBP2) activation after excess triglyceride storage induces chemerin in hypertrophic adipocytes. Endocrinology 152: 26-‐35.
114. Demarest K, Koyner J, McCaughran J, Cipp L, Hitzemann R (2001) Further characterization and high-‐resolution mapping of quantitative trait loci for ethanol-‐induced locomotor activity. Behavior genetics 31: 79-‐91.
115. Valdar W, Solberg LC, Gauguier D, Burnett S, Klenerman P, et al. (2006) Genome-‐wide genetic association of complex traits in heterogeneous stock mice. Nature genetics 38: 879-‐887.
116. Huang GJ, Shifman S, Valdar W, Johannesson M, Yalcin B, et al. (2009) High resolution mapping of expression QTLs in heterogeneous stock mice in multiple tissues. Genome research 19: 1133-‐1140.
117. Team R (2010) R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria.
118. Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-‐1548.
119. Barbosa-‐Morais NL, Dunning MJ, Samarajiwa SA, Darot JFJ, Ritchie ME, et al. (2010) A re-‐annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic acids research 38: e17-‐e17.
120. Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-‐127.
Page 1 of 18
Text S2: Extended Acknowledgements
Cohort Acknowledgements (funding, personal, groups, …)
Discovery Stage
ADVANCE The ADVANCE study was supported by a grant from the Reynold's Foundation and NHLBI grant HL087647.
AGES Midlife The Age, Gene/Environment Susceptibility Reykjavik Study has been funded by NIH contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, (VSN: 00-063) and the Data Protection Authority. The researchers are indebted to the participants for their willingness to participate in the study.
Amish We gratefully acknowledge our Amish liaisons, field workers and clinic staff and the extraordinary cooperation and support of the Amish community without which these studies would not have been possible. The Amish studies are supported by grants and contracts from the NIH, including U01 HL072515, U01 HL84756, the University of Maryland General Clinical Research Center, grant M01 RR 16500, the Mid-Atlantic Nutrition and Obesity research Center, grant NIH P30 DK072488, and by National Research Initiative Competitive Grant no. 2007-35205-17883 from the USDA National Institute of Food and Agriculture. We thank our Amish research volunteers for their long-standing partnership in research, and the research staff at the Amish Research Clinic for their hard work and dedication.
ARIC The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.
B58C-WTCCC and B58C-T1DGC
We acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. (http://www.b58cgene.sgul.ac.uk/). Genotyping for the B58C-WTCCC subset was funded by the Wellcome Trust grant 076113/B/04/Z. The B58C-T1DGC genotyping utilized resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. B58C-T1DGC GWAS data were deposited by the Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research (CIMR), University of Cambridge, which is funded by Juvenile Diabetes Research Foundation International, the Wellcome Trust and the National Institute for Health Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895).
Page 2 of 18
Cohort Acknowledgements (funding, personal, groups, …)
BRIGHT The BRIGHT study is supported by the Medical Research Council of Great Britain (G9521010D) and the British Heart Foundation (PG/02/128). The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. We also acknowledge the contribution of Chris Wallace for the analysis. This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit which is supported and funded by the National Institute of Health Research.
CAD_WTCCC CAD-WTCCC (WTCCC Coronary Artery Disease cases) - Collection of the CAD-WTCCC cases (BHF Family Heart Study) was funded by the British Heart Foundation and the Medical Research Council and genotyping by the Wellcome Trust as part of the WTCCC. We thank the members of the BHF Family Heart Study Research Group for recruitment. N.J.S. holds a personal chair supported by the BHF and also holds a UK NIHR Senior Investigator Award.
CAPS The CAPS study was supported by grants from the Swedish Research Council, the Swedish Cancer Society, and the National Cancer Institute. E.I. was supported by grants from the Swedish Research Council, the Swedish Heart - Lung Foundation, the Swedish Society of Medicine, the Swedish Foundation for Strategic Research, and the Royal Swedish Academy of Science while working with this article.
CHS This CHS research was supported by NHLBI contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 and NHLBI grants HL080295, HL075366, HL087652, HL105756 with additional contribution from NINDS. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. See also http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping was supported in part by National Center for Research Resources CTSI grant UL 1RR033176, National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
COLAUS The CoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (33CSCO-122661). The authors thank Vincent Mooser, Dawn Waterworth, Peter Vollenweider and Gérard Waeber, Co-PIs of the CoLaus study. Special thanks to Murielle Bochud, Yolande Barreau, Mathieu Firmann, Vladimir Mayor, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection. JSB is supported by the Centre Hospitalier Universitaire Vaudois and the University of Lausanne, Switzerland, the Swiss National Science Foundation (grants nb 310000-112552) and the European Union HEALTH-F4-2007-201550 HYPERGENES grant.
deCODE We would like to thank participants in deCODE cardiovascular- and obesity studies and collaborators for their cooperation. The research performed at deCODE Genetics was part funded through the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007- 201413.
Page 3 of 18
Cohort Acknowledgements (funding, personal, groups, …)
DGI The Botnia (DGI) study have been supported by grants from Folkha ̈lsan Research Foundation, Sigrid Juselius Foundation, Ministry of Education, Nordic Center of Excellence in Disease Genetics, Gyllenberg Foundation, Swedish Cultural Foundation in Finland, Finnish Diabetes Research Foundation, Foundation for Life and Health in Finland, Finnish Medical Society, Paavo Nurmi Foundation, Perklén Foundation, Ollqvist Foundation, Na ̈rpes Health Care Foundation, the Municipal Health Care Center and Hospital in Jakobstad, Health Care Centers in Vasa, Na ̈rpes and Korsholm. This work was also partially supported by NIH grant R01-DK075787 to JNH and March of Dimes grant 6-FY-09-507 to JNH.
EGCUT EGCUT received financing by FP7 grants (201413, 245536), also received targeted financing from Estonian Government SF0180142s08 and from the European Union through the European Regional Development Fund, in the frame of Centre of Excellence in Genomics and Estoinian Research Infrastructure’s Roadmap. We acknowledge EGCUT and Estonian Biocentre personnel, especially Ms. M. Hass and Mr V. Soo
EPIC The EPIC Norfolk Study is funded by Cancer Research United Kingdom and the Medical Research Council.
ERF (EUROSPAN)
The genotyping for the ERF study was supported by EUROSPAN (European Special Populations Research Network) and the European Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study was further supported by grants from the Netherlands Organisation for Scientific Research, Erasmus MC, the Centre for Medical Systems Biology (CMSB) and the Netherlands Brain Foundation (HersenStichting Nederland). We are grateful to all patients and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection. We would also like to acknowledge Internationale Stichting Alzheimer Onderzoek (ISAO) and Hersenstichting Netherlands.
FamHS The Family Heart Study (FamHS) was supported by NIH grants R01-HL-087700 and R01-HL-088215 (Michael A. Province, PI) from NHLBI; and R01-DK-8925601 and R01-DK-075681 (Ingrid B. Borecki, PI) from NIDDK.
FENLAND The Fenland Study is funded by the Wellcome Trust and the Medical Research Council, as well as by the Support for Science Funding programme and CamStrad. We are grateful to all the volunteers for their time and help, and to the General Practitioners and practice staff for help with recruitment. We thank the Fenland Study co-ordination team and the Field Epidemiology team of the MRC Epidemiology Unit for recruitment and clinical testing.
FRAM This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center.
Page 4 of 18
Cohort Acknowledgements (funding, personal, groups, …)
FTC Finnish Twin cohort is supported by the European Commission under the programme 'Quality of Life and Management of the Living Resources' of 5th Framework Programme (no. QLG2-CT-2002-01254). S.R was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (213506 and 129680), Academy of Finland (251217), the Finnish foundation for Cardiovascular Research and the Sigrid Juselius Foundation. J.K. has been supported by the Academy of Finland Centre of Excellence in Complex Disease Genetics.
Genmets Genmets was supported through funds from The European Community's Seventh Framework Programme (FP7/2007-2013), BioSHaRE Consortium, grant agreement 261433. V.S. was supported by the Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular research, and the Finnish Academy (grant number 129494).
GERMIFS1 and GERMIFS2
GerMIFS1, GerMIFS2: Supported by the Deutsche Forschungsgemeinschaft and the German Federal Ministry of Education and Research (BMBF) in the context of the German National Genome Research Network (NGFN-2 and NGFN-plus), the FP6 and FP7 EU funded integrated projects Cardiogenics (LSHM-CT-2006-037593), ENGAGE (201413), the bi-national BMBF/ANR funded project CARDomics (01KU0908A), and the Nordic Center of Cardiovascular Research (NCCR).
KORA The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFNPlus, project number 01GS0834, 01GS0823), software development for sex-specific GWAMAS was partly funded by BMBF 01ER1206; additional funds were from the University of Ulm. Furthermore, the research was supported within the Munich Center of Health Sciences (MC Health) as part of LMU innovative.
MICROS For the MICROS study, we thank the primary care practitioners in the villages of the Val Venosta and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, and the South Tyrolean Sparkasse Foundation.
Migen The MIGen study was supported by the National Heart, Lung, and Blood Institute's STAMPEED genomics research program (R01 HL087676) and the National Center for Research Resources (U54 RR020278). This work was also partially supported by NIH grant K23-DK080145 to EKS, NIH grant R01-DK075787 to JNH and March of Dimes grant 6-FY-09-507 to JNH.
NBS-WTCCC We acknowledge use of DNA from The UK Blood Services collection of Common Controls (UKBS-CC collection), funded by the Wellcome Trust grant 084183/Z/07/Z and by NIHR programme grant to NHSBT (RP-PG-0310-1002). The collection was established as part of the Wellcome Trust Case Control Consortium (WTCCC)
Page 5 of 18
Cohort Acknowledgements (funding, personal, groups, …)
NFBC1966 NFBC1966 received financial support from the Academy of Finland (project grants 104781, 120315, 129269, 1114194, Center of Excellence in Complex Disease Genetics and SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European Commission (EURO-BLCS, Framework 5 award QLG1-CT-2000-01643), NHLBI grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH (5R01MH63706:02), ENGAGE project and grant agreement HEALTH-F4-2007-201413, and the Medical Research Council, UK (G0500539, G0600705, PrevMetSyn/SALVE).
The DNA extractions, sample quality controls, biobank up-keeping and aliquotting was performed in the National Public Health Institute, Biomedicum Helsinki, Finland and supported financially by the Academy of Finland and Biocentrum Helsinki. We thank Professor (emeriti) Paula Rantakallio (launch of NFBC1966 and 1986), and Ms Outi Tornwall and Ms Minttu Jussila (DNA biobanking). The authors would like to acknowledge the contribution of the late Academian of Science Leena Peltonen.
NHS This study was supported by grants HL71981, CA65725, CA87969, CA49449, CA67262, CA50385 and 5UO1CA098233 from the National Institutes of Health. Dr. Lu Qi is a recipient of the American Heart Association Scientist Development Award (0730094N)
NSPHS The Northern Swedish Population Health Study (NSPHS) was funded by the Swedish Medical Research Council (project number K2007-66X-20270-01-3), and the Foundation for Strategic Research (SSF). The NSPHS as part of EUROSPAN (European Special Populations Research Network) was also supported by European Commission FP6 STRP grant number 01947 (LSHG-CT-2006-01947). This work was also supported by the Swedish Society for Medical Research (ÅJ). The authors are grateful for the contribution of district nurse Svea Hennix for data collection and Inger Jonasson for logistics and coordination of the health survey. Finally, the authors thank all the community participants for their interest and willingness to contribute to the study.
NTRNESDA Funding was obtained from the Netherlands Organization for Scientific Research (NWO: MagW/ZonMW): Genetic basis of anxiety and depression (904-61-090); Genetics of individual differences in smoking initiation and persistence (NWO 985-10-002); Resolving cause and effect in the association between exercise and well-being (904-61-193); Twin family database for behavior genomics studies (480-04-004); Twin research focusing on behavior (400-05-717); Genetic determinants of risk behavior in relation to alcohol use and alcohol use disorder (Addiction-31160008); Genotype/phenotype database for behavior genetic and genetic epidemiological studies (40-0056-98-9032); Spinozapremie (SPI 56-464-14192); CMSB: Center for Medical Systems Biology (NWO Genomics); NBIC/BioAssist/RK/2008.024); BBMRI –NL: Biobanking and Biomolecular Resources Research Infrastructure (184.021.007); the VU University: Institute for Health and Care Research (EMGO+ ) and Neuroscience Campus Amsterdam (NCA); the European Science Foundation (ESF): Genomewide analyses of European twin and population cohorts (EU/QLRT-2001-01254); European Community's Seventh Framework Program (FP7/2007-2013): ENGAGE (HEALTH-F4-2007-201413); the European Science Council (ERC) Genetics of Mental Illness (230374); Rutgers University Cell and DNA Repository cooperative agreement (NIMH U24 MH068457-06); Collaborative study of the genetics of DZ twinning (NIH R01D0042157-01A); the Genetic Association Information Network, a public–private partnership between the NIH and Pfizer Inc., Affymetrix Inc. and Abbott Laboratories.
Page 6 of 18
Cohort Acknowledgements (funding, personal, groups, …)
ORCADES ORCADES was supported by the Chief Scientist Office of the Scottish Government, the Royal Society, and the European Union framework program 6 European Special Populations Research Network project [contract LSHG-CT-2006-018947]. ORCADES would like to acknowledge the invaluable contributions of Lorraine Anderson, the research nurses in Orkney, and the administrative team in Edinburgh. DNA extraction for ORCADES was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh, Scotland and SNP genotyping was performed by Helmholtz Zentrum München, GmbH, Neuherberg, Germany.
PLCO The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was funded by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH
PROCARDIS European Commission (LSHM-CT-2007-037273), the Swedish Heart-Lung Foundation, the Swedish Research Council (8691), the Knut and Alice Wallenberg Foundation, the Foundation for Strategic Research, the Torsten and Ragnar Söderberg Foundation, the Strategic Cardiovascular Programme of Karolinska Institutet and the Stockholm County Council, the Stockholm County Council (560183) and the Wellcome trust core award [090532/Z/09/Z]. MF acknowledges support from the British Heart Foundation Centre of Research Excellence, Oxford.
RS1 The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS database, and Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.
RunMC The RUNMC Nijmegen Biomedical Study was made possible by research investment grants of the Radboud University Nijmegen Medical Centre and the Municipality of Nijmegen.
Sardinia We thank all the volunteers who generously participated in this study, Monsignore Piseddu, Bishop of Ogliastra and the mayors and citizens of the Sardinian towns (Lanusei, Ilbono, Arzana, and Elini). This work was supported by the Intramural Research Program of the National Institute on Aging (NIA), National Institutes of Health (NIH). The SardiNIA (“Progenia”) team was supported by Contract NO1-AG-1–2109 from the NIA; the efforts of GRA were supported in part by contract 263-MA-410953 from the NIA to the University of Michigan and by research grant HG002651 and HL084729 from the NIH (to GRA).
SASBAC The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the United States National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation.
SEARCH Paul Pharoah, Douglas Easton, Simon Gayther and the SEARCH and UKOPS teams. SEARCH was funded by Cancer Research UK (C490/A10124 and C490/A8339).
Page 7 of 18
Cohort Acknowledgements (funding, personal, groups, …)
SHIP SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to Individualized Medicine (GANI_MED)’ funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the ‘Center of Knowledge Interchange’ program of the Siemens AG and the Caché Campus program of the InterSystems GmbH.
T2D-WTCCC Research funding for sample collection, genotyping and data analysis for the T2D-WTCCC and other cohorts for which the Oxford group had responsibility came from the British Diabetes Association, BDA Research, Diabetes UK, Oxford NIHR Biomedical Research Centre, European Commission (ENGAGE: HEALTH-F4-2007-201413; EURODIA: LSHG-CT-2004-518153, Wellcome Trust (072960, 076113/B/04/Z, 076113/K/04/Z, 083270, 085301, 079557, 081682, 075491) UK Medical Research Council (G0000649, G0601261) and NIDDK (R01-DK-073490). In addition, Cecilia Lindgren is funded by WT086596/Z/08/Z (Wellcome Trust Research Career Development Fellowship); Reedik Mägi is funded by European Commission under the Marie Curie Intra-European Fellowship; and Mark McCarthy receivespersonal funding from the Oxford NIHR Biomedical Research Centre.
TwinsUK The study was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F2-2008-ENGAGE and the European Union FP-5 GenomEUtwin Project (QLG2-CT-2002-01254) and Framework 6 Project EUroClot. The study also receives support from the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London We thank the staff from the TwinsUK, the DNA Collections and Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation; Quality Control of the Twins UK cohort for genotyping (in particular Amy Chaney, Radhi Ravindrarajah, Douglas Simpkin, Cliff Hinds, and Thomas Dibling); Paul Martin and Simon Potter of the DNA and Genotyping Informatics teams for data handling; Le Centre National de Génotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by Aarno Palotie.
VIS The CROATIA-Vis study was funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants. (108-1080315-0302). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of Split and Zagreb Medical Schools, Institute for Anthropological Research in Zagreb and Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Vis cohort was performed in the core genotyping laboratory of the Wellcome Trust Clinical Research Facility at the Western General Hospital, Edinburgh, Scotland, UK.
Page 8 of 18
Follow-Up Stage - Insilico
Cohort Acknowledgements (funding, personal, groups, …)
BHS The Busselton Health Study acknowledges the generous support for the 1994/5 follow-up study from Healthway, Western Australia and the numerous Busselton community volunteers who assisted with data collection and the study participants from the Shire of Busselton. The Busselton Health Study is supported by The Great Wine Estates of the Margaret River region of Western Australia. The BHS gratefully acknowledges the assistance of the Western Australian DNA Bank (NHMRC Enabling Facility) with DNA samples and the support provided by the Ark (NHMRC Enabling Facility) for this study.
COROGENE The study was supported in part by the Aarno Koskelo Foundation, the Finnish Foundation for Cardiovascular Research, and the EVO funds of Helsinki University Central Hospital. The Corogene study is not supported by industry and all presentations have been carried out in academic environment.
FinGesture FinGesture (Finnish Genetic Study of Arrhythmic Events) - We thank the study participants. We also thank Kari Kaikkonen and Marja-Leena Kortelainen for study concept and design, and data acquisition and interpretation. The FinGesture cohort is supported by the Juselius Foundation (Helsinki, Finland) and the Council of Health of the Academy of Finland (Helsinki, Finland). Authors would like to thank Guillaume Lettre, Jean-Claude Tardif, Juhani Juntila, Philipe Goyette and Sylvain Foisy for their contributions to the design, implementation and analysis of the GWA study of the FinGesture cohort. In addition, we would like to acknowledge the support of the Montreal Heart Institute Foundation.
GOOD Financial support was received from the Swedish Research Council (K2010-54X-09894-19-3, 2006-3832 and K2010-52X-20229-05-3), the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg's Foundation, Petrus and Augusta Hedlunds Foundation, the Västra Götaland Foundation, the Göteborg Medical Society, the Novo Nordisk foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS. We would like to acknowledge Maria Nethander at the Genomics core facility at the University of Gothenburg for statistical analyses. We would like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and # 01 IG 07015 G for access to their grid resources. We would also like to thank Karol Estrada, Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands for advice regarding the grid resources.
HBCS Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland (Grant No. 120386 and 125876 to JGE), the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, the European Science Foundation (EuroSTRESS), the Wellcome Trust (Grant No. 89061/Z/09/Z and 089062/Z/09/Z), Samfundet Folkhälsan, Finska Läkaresällskapet and the Signe and Ane Gyllenberg foundation. We thank all study participants as well as everybody involved in the Helsinki Birth Cohort Study.
Page 9 of 18
Cohort Acknowledgements (funding, personal, groups, …)
HYPERGENES funding: HYPERGENES (FP7 - HEALTH-F4-2007-201550); INTEROMICS (MIUR - CNR Italian Flagship Project). To HYPERGENES consortium took part: 1) University of Milano and Fondazione Filarete with Daniele Cusi, Project Coordinator, Cristina Barlassina, Erika Salvi, Sara Lupoli, Maurizio Marconi, Gianna Petrini, Vincenzo Toschi,. 2) Katholieke Universiteit Leuven, with Jan Staessen, Jan Staessen, Tatiana Kuznetsova, Lutgarde Thijs. 3) Jagiellonian University Medical College, Krakow, with Kalina Kawecka-Jaszcz, Katarzyna Stolarz, Agnieszka Olszanecka, Wiktoria Wojciechowska. 4) IBM Israel – Science and Technology LTD, with Amnon Shabo, Ariel Frakash, Simona Cohen, Boaz Carmeli, Dan Pelleg, Michal Rosen-Zvi, Hani Neuvrith-Telem. 5) I.M.S. – Istituto di Management Sanitario S.r.l., Milan, with Pietro Conti, Costanza Conti, Mariella D’Alessio. 6) Institute of Internal Medicine, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, with Yuri Nikitin, Sofia Malyutina, M. Voevoda, Andrew Ryabikov, E. Pello, Maxim Ryabikov. 7) Imperial College of Science, Technology and Medicine, with Paolo Vineis and Clive J Hoggart. 8) INSERM – Institut National de la Santé et de la Recherche Médicale U772, with Xavier Jeunemaitre, Pierre-François Plouin, Anne-Paule Gimenez-Roqueplo, Rosa Vargas-Poussou, Geneviève Beaurain. 9) University of Warwick. Cardiovascular Medicine & Epidemiology Group, Clinical Sciences Research Institute, with Francesco P Cappuccio, Michelle A Miller, Chen Ji 10) Università degli Studi di Sassari. Hypertension and cardiovascular prevention centre, with Nicola Glorioso, Chiara Maria Troffa, Giuseppe Argiolas, Francesca Fau, Silvia Pitzoi. 11) STMICROELECTRONICS SRL, with Enrico Rosario Alessi. 12) Universite de Lausanne. Department of Medical Genetics, with Carlo Rivolta, Jacques S. Beckmann, Zoltan Kutalik, Paola Benaglio. 13) Pharnext S.A.S., Paris, with Daniel Cohen and Ilya Chumakov. 14) Softeco Sismat Spa, Genova, with Stefano Bianchi. 15) Shanghai Institute of Hypertension, with Jiguang Wang and Li Yan. 16) Charles University in Prague. Department of Internal Medicine II, Pilsen, with Jan Filipovsky, Otto Mayer, Milan Hromadka, Jitka Seidlerova, Milena Dolejsova, Lukas Handl. 17) Università degli Studi di Padova. Department of Clinical and Experimental Medicine, with Edoardo Casiglia, Valerie Tikhonoff, Laura Schiavon, Anna Bascelli, Elisa Pagnin. 18) Medical University of Gdansk. Hypertension Unit, Department of Hypertension and Diabetology, with Krzysztof Narkiewicz, Marzena Chrostowska, Radoslaw Szczech, Michal Hoffmann. 19) University Vita-Salute San Raffaele, with Paolo Manunta, Chiara Lanzani, Maria Teresa Sciarrone, Lorena Citterio, Laura Zagato.
Page 10 of 18
Cohort Acknowledgements (funding, personal, groups, …)
LifeLines Cohort Study
The LifeLines Cohort Study, and generation and management of GWAS genotype data for the LifeLines Cohort Study is supported by the Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation. We thank Behrooz Alizadeh, Annemieke Boesjes, Marcel Bruinenberg, Noortje Festen, Ilja Nolte, Lude Franke, Mitra Valimohammadi for their help in creating the GWAS database, and Rob Bieringa, Joost Keers, René Oostergo, Rosalie Visser, Judith Vonk for their work related to data-collection and validation. The authors are grateful to the study participants, the staff from the LifeLines Cohort Study and Medical Biobank Northern Netherlands, and the participating general practitioners and pharmacists. Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation and the VU University Amsterdam.
MGS The Molecular Genetics of Schizophrenia project was carried out by 10 research sites and PIs: Pablo V. Gejman, Study Coordinator (Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem, Evanston, IL, and Department of Psychiatry and Behavioral Sciences, University of Chicago, Chicago, IL), Douglas F. Levinson (Stanford University), Bryan J. Mowry (University of Queensland), Donald Black (University of Iowa), Robert Freedman (University of Colorado), C. Robert Cloninger (Washington University), Jeremy Silverman (Mt. Sinai Medical School), Nancy Buccola (Louisiana State University - New Orleans), William Byerley (University of California at San Francisco), and Farooq Amin (Emory University). This study was supported by NIH R01 grants (MH67257 to N.G.B., MH59588 to B.J.M., MH59571 to P.V.G., MH59565 to R.F., MH59587 to F.A., MH60870 to W.F.B., MH59566 to D.W.B., MH59586 to J.M.S., MH61675 to D.F.L., MH60879 to C.R.C., and MH81800 to P.V.G.), MH79469 to P.V.G., and MH79470 to D.F.L.), NARSAD (National Alliance for Research on Schizophrenia and Depression) Young Investigator Awards (to J.D. and A.R.S.), the Genetic Association Information Network (GAIN), the Walter E. Nichols, M.D., and Eleanor Nichols endowments, at Stanford University, and by The Paul Michael Donovan Charitable Foundation. Genotyping was carried out by the Genotyping and Analysis at the Broad Institute of Harvard and MIT (S. Gabriel and D.B.M.), which is supported by grant U54 RR020278 from the National Center for Research Resources. Genotyping of half of the control sample presented here was carried out with support from GAIN. The GAIN quality control team (G.R. Abecasis and J. Paschall) made important contributions to the project.
PLCO2 The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was funded by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH
PREVEND PREVEND genetics is supported by the Dutch Kidney Foundation (Grant E033), the EU project grant GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health (grant LM010098), The Netherlands organisation for health research and development (NWO VENI grant 916.761.70), and the Dutch Inter University Cardiology Institute Netherlands (ICIN).
Page 11 of 18
Cohort Acknowledgements (funding, personal, groups, …)
QIMR We are grateful to the twins and their families for their generous participation in these studies. We would like to thank staff at the Queensland Institute of Medical Research: Dixie Statham, Ann Eldridge and Marlene Grace for sample collection, Anjali Henders, Megan Campbell, Lisa Bowdler, Steven Crooks and staff of the Molecular Epidemiology Laboratory for sample processing and preparation, Scott Gordon, Brian McEvoy, Belinda Cornes and Beben Benyamin for data QC and preparation, and David Smyth and Harry Beeby for IT support. We acknowledge funding from the Australian National Health and Medical Research Council (NHMRC grants 241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485, 613672, 613601 and 1011506), the U.S. National Institute of Health (grants AA07535, AA10248, AA014041, AA13320, AA13321, AA13326 and DA12854) and the Australian Research Council (ARC grants DP0770096 and DP1093900).
RS2, RS3 The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS database, and Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.
Sorbs This work was supported by grants from the Interdisciplinary Centre for Clinical Research at the University of Leipzig (B27 to AT, PK) from the German Diabetes Association (to AT, PK), a Travel Grant from BIF (to AT) and by the DHFD, Diabetes Hilfs- und Forschungsfonds Deutschland (PK). We thank all those who participated in the study. Sincere thanks are given to Anke Tönjes who was significantly involved in the design and performing of the Sorbs study. We also thank Knut Krohn (Microarray Core Facility of the Interdisciplinary Centre for Clinical Research, University of Leipzig) for the genotyping support. Reedik Mägi acknowledges financial support from the European Commission under a Marie Curie Intra-European Fellowship. The research of Inga Prokopenko is funded in part through the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007- 201413.
WGHS The WGHS is supported by HL 043851 and HL69757 from the National Heart, Lung, and Blood Institute and CA 047988 from the National Cancer Institute, the Donald W. Reynolds Foundation and the Fondation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen.
YFS The Young Finns Study has been financially supported by the Academy of Finland: grants 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi), the Social Insurance Institution of Finland, Kuopio, Tampere and Turku University Hospital Medical Funds (grant 9M048 for TeLeht), Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation of Cardiovascular Research and Finnish Cultural Foundation, Tampere Tuberculosis Foundation and Emil Aaltonen Foundation (T.L). The expert technical assistance in the statistical analyses by Irina Lisinen is gratefully acknowledged.
Page 12 of 18
Cohort Acknowledgements (funding, personal, groups, …)
Follow-Up Stage - Metabochip
ADVANCE The ADVANCE study was supported by a grant from the Reynold's Foundation and NHLBI grant HL087647.
AMC-PAS AMC-PAS is greatful to M.D. Trip MD, PhD and S. Sivapalaratnam MD for their input in collecting the data.
B58C noGWAS Collection of DNA in the 1958 Birth Cohort was funded by the Medical Research Council grant G0000934 and Wellcome Trust grant 068545/Z/02. Dr Sue Ring and Dr Wendy McArdle (University of Bristol), and Mr Jon Johnson (Centre for Longitudinal Studies, Institute of Education, London) are thanked for help with data linkage. Work was undertaken at Great Ormond Street Hospital /University College London, Institute of Child Health which received a proportion of funding from the Department of Health's National Institute of Health Research ('Biomedical Research Centres' funding). The Medical Research Council provides funds for the MRC Centre of Epidemiology for Child Health.
BHS The Busselton Health Study (BHS) acknowledges the generous support for the 1994/5 follow-up study from Healthway, Western Australia and the numerous Busselton community volunteers who assisted with data collection and the study participants from the Shire of Busselton. The Busselton Health Study is supported by The Great Wine Estates of the Margaret River region of Western Australia.
CARDIOGENICS
Sample collection in the Cardiogenics Consortium (http://www.cardiogenics.eu/web/) was funded by the 6th Framework Program of the European Union (LSHM-CT-2006-037593) and supported through the Cambridge Bioresource which is funded by the NIHR Cambridge Biomedical research Centre. We thank all the participants and clinicians involved in the recruitment process at Cambridge and Leicester (UK), Luebeck and Regensburg (Germany), and Paris (France).
CARDIOGENICS / THISEAS / AMC-PAS
This work was funded by the Wellcome Trust. We like to thank the members of the WTSI GenotypingFacility in particualr Sarah Edkins and Cordelia Langford
DIAGEN The DIAGEN study was supported by the Commission of the European Communities, Directorate C - Public Health and Risk Assessment, Health & Consumer Protection, Grant Agreement number - 2004310 and by the Dresden University of Technology Funding Grant, Med Drive. We are grateful to all of the patients who cooperated in this study and to their referring physicians and diabetologists in Saxony.
DILGOM The DILGOM study has been funded by the Academy of Finland (grant numbers 139635, 129494, 118065, 129322, 250207), the Orion-Farmos Research Foundation, the Finnish Foundation for Cardiovascular Research, and the Sigrid Jusélius Foundation.
DPS The DPS has been financially supported by grants from the Academy of Finland (117844 and 40758, 211497, and 118590; The EVO funding of the Kuopio University Hospital from Ministry of Health and Social Affairs (5254), Finnish Funding Agency for Technology and Innovation (40058/07), Nordic Centre of Excellence on Systems biology in controlled dietary interventions and cohort studies, SYSDIET (070014), The Finnish Diabetes Research Foundation, Yrjö Jahnsson Foundation (56358), Sigrid Juselius Foundation, Juho Vainio Foundation and TEKES grants 70103/06 and 40058/07.
Page 13 of 18
Cohort Acknowledgements (funding, personal, groups, …)
DR's EXTRA The DR.s EXTRA Study was supported by grants to R. Rauramaa by the Ministry of Education and Culture of Finland (627;2004-2011), Academy of Finland (102318; 123885), Kuopio University Hospital , Finnish Diabetes Association, Finnish Heart Association, Päivikki and Sakari Sohlberg Foundation and by grants from European Commission FP6 Integrated Project (EXGENESIS); LSHM-CT-2004-005272, City of Kuopio and Social Insurance Institution of Finland (4/26/2010).
EAS The EAS was funded by the British Heart Foundation. Genotyping was funded by the Chief Scientist Office, Scotland, and undertaken at the Wellcome Trust Clinical Research Facility in Edinburgh.
EGCUT EGCUT received financing by FP7 grants (201413, 245536), also received targeted financing from Estonian Government SF0180142s08 and direct funding from the ministries of research and science and social affairs. EGCUT studies are funded by University of Tartu in the frame of Center of Translational Genomics and by the European Union through the European Regional Development Fund, in the frame of Centre of Excellence in Genomics. We acknowledge EGCUT personelle, especially Ms. M. Hass and Mr V. Soo. EGCUT data analyzes were carried out in part in the High Performance Computing Center of University of Tartu.
Ely The MRC Ely Study was funded by the Medical Research Council and the Wellcome Trust. We are most grateful to all study participants and to the staff of the St. Mary’s Street Surgery, Ely. We thank all the staff who worked on the study.
EPIC The EPIC Norfolk Study is funded by Cancer Research United Kingdom and the Medical Research Council.
FENLAND The Fenland Study is funded by the Wellcome Trust and the Medical Research Council, as well as by the Support for Science Funding programme and CamStrad. We are grateful to all the volunteers for their time and help, and to the General Practitioners and practice staff for help with recruitment. We thank the Fenland Study co-ordination team and the Field Epidemiology team of the MRC Epidemiology Unit for recruitment and clinical testing.
FIN-D2D 2007 The FIN-D2D study has been financially supported by the hospital districts of Pirkanmaa, South Ostrobothnia, and Central Finland, the Finnish National Public Health Institute (current National Institute for Health and Welfare), the Finnish Diabetes Association, the Ministry of Social Affairs and Health in Finland, the Academy of Finland (grant number 129293),Commission of the European Communities, Directorate C-Public Health (grant agreement no. 2004310) and Finland’s Slottery Machine Association.
FUSION Support for FUSION was provided by NIH grants R01-DK062370 (to M.B.), R01-DK072193 (to K.L.M.), and intramural project number 1Z01-HG000024 (to F.S.C.). Genome-wide genotyping was conducted by the Johns Hopkins University Genetic Resources Core Facility SNP Center at the Center for Inherited Disease Research (CIDR), with support from CIDR NIH contract no. N01-HG-65403.
Page 14 of 18
Cohort Acknowledgements (funding, personal, groups, …)
GLACIER The GLACIER Study was funded by grants from the Swedish Diabetes Association, Swedish Heart-Lung Foundation, Swedish Research Council, Medical Research Foundation of Umeå University, and Novo Nordisk (all to PWF). We thank the participants for there outstanding contributions to the GLACIER Study. We also thank the staff of the Umeå Medical Biobank, especially Göran Hallmans, Åsa Agren, John Hutilainen, and Ann-Marie Ahren for data reteival and organisation and Kerstin Enqusit and Tore Johansson for expert assistance with DNA extraction and plating. The GLACIER Study is nested within the Västerbottens Intervention Project (VIP); we thank the staff of the VIP Study for phenotype data collection, particularly Lars Wennehall who leads the VIP Study. Inês Barroso acknowledges funding from the Wellcome Trust grant 098051, United Kingdom NIHR Cambridge Biomedical Research Centre and the MRC Centre for Obesity and Related Metabolic Diseases. We would like to thank Emma Gray, Douglas Simpkin, Sarah Hunt and staff of the WTSI Sample Logistics, Genotyping and Variation Informatics Facilities.
GO-DARTS We acknowledge the support of the Health Informatics Centre, University of Dundee for managing and supplying the anonymised data and NHS Tayside, the original data owner. We are grateful to all the participants who took part in the Go-DARTS study, to the general practitioners, to the Scottish School of Primary Care for their help in recruiting the participants, and to the whole team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. Financial Disclosure: The Wellcome Trust provides support for Wellcome Trust United Kingdom Type 2 Diabetes Case Control Collection (Go-DARTS) and the Scottish Health Informatics Programme. Further informatics support is provided by the Chief Scientist Office of Scotland. This work was also supported by the UK Medical Research Council (G0601261)
HNR We thank the Heinz Nixdorf Foundation, Germany, for the generous support of this study. We acknowledge the support of the Sarstedt AG & Co. (Nümbrecht, Germany) concerning laboratory equipment. We are grateful to Prof. Karl-Heinz Joeckel (Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital of Essen, University of Duisburg-Essen, Essen, Germany) and Prof. Dirk Schadendorf (Clinic Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany) for funding this study. We are also thankful to Dr. Thomas W Mühleisen (Institute of Human Genetics, University of Bonn, Bonn, Germany) for carrying out the genotyping.
HUNT2 The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health.
IMPROVE The IMPROVE study was supported by the European Commission (Contract number: QLG1-CT-2002-00896), the Swedish Heart-Lung Foundation, the Swedish Research Council (projects 8691 and 0593), the Knut and Alice Wallenberg Foundation, the Torsten and Ragnar Söderberg Foundation, the Foundation for Strategic Research, the Stockholm County Council (project 562183), the Strategic Cardiovascular and Diabetes Programmes of Karolinska Institutet and Stockholm County Council, Academy of Finland (Grant #110413) the British Heart Foundation (RG2008/08 and RG2008/014) and the Italian Ministry of Health (Ricerca Corrente).
Page 15 of 18
Cohort Acknowledgements (funding, personal, groups, …)
KORA The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFNPlus, project number 01GS0834, 01GS0823) and through additional funds from the University of Ulm. Furthermore, the research was supported within the Munich Center of Health Sciences (MC Health) as part of LMU innovative. The KORA analysts in Regensburg were supported by the Bundesministerium für Bildung und Forschung/BMBF (01ER1206).
LURIC LURIC received funding through the 6th Framework Program (integrated project Bloodomics, grant LSHM-CT-2004-503485) and 7th of Framework Program (integrated project AtheroRemo, Grant Agreement number 201668) of the European Union. The authors extend appreciation to the participants of the LURIC study without their collaboration this article would not have been written. We thank the LURIC study team either temporarily or permanently involved in patient recruitment, sample and data handling, and the laboratory staff at the Ludwigshafen General Hospital and the Universities of Freiburg and Ulm, Germany.
METSIM The METSIM study was funded by the Academy of Finland (grants no. 77299 and 124243).
Page 16 of 18
Cohort Acknowledgements (funding, personal, groups, …)
MORGAM The MORGAM study was part funded through the European Community's Sixth Framework Programme Cardiogenics project, grant agreement LSHM-CT-2006-037593 and Seventh Framework Programme ENGAGE project, grant agreement HEALTH-F4-2007-201413. Sites and key personnel of contributing MORGAM Centres: Finland FINRISK, National Institute for Health and Welfare, Helsinki: V. Salomaa (principal investigator), A. Juolevi, E. Vartiainen, P. Jousilahti; ATBC, National Institute for Health and Welfare, Helsinki: J. Virtamo (principal investigator), H. Kilpeläinen; MORGAM Data Centre, National Institute for Health and Welfare, Helsinki: K. Kuulasmaa (responsible person), Z. Cepaitis, A. Haukijärvi, B. Joseph, J. Karvanen, S. Kulathinal, M. Niemelä, O. Saarela; MORGAM Central Laboratory, National Institute for Health and Welfare, Helsinki: M. Perola (responsible person), P. Laiho, M. Sauramo. France National Coordinating Centre, National Institute of Health and Medical Research (U258), Paris: P. Ducimetière (national coordinator), A. Bingham; PRIME/Strasbourg, Department of Epidemiology and Public Health, EA 3430, University of Strasbourg, Faculty of Medicine, Strasbourg: D. Arveiler (principal investigator), B. Haas, A. Wagner; PRIME/Toulouse, Department of Epidemiology, Toulouse University School of Medicine, Toulouse: J. Ferrières (Principal Investigator), J-B. Ruidavets, V. Bongard, D. Deckers, C. Saulet, S. Barrere; PRIME/Lille, Department of Epidemiology and Public Health, INSERM U744-Université Lille Nord de France – Institut Pasteur de Lille: P. Amouyel (principal investigator), M. Montaye, B. Lemaire, S. Beauchant, D. Cottel, C. Graux, N. Marecaux, C. Steclebout, S. Szeremeta; MORGAM Laboratory, INSERM U937, Paris: F. Cambien (responsible person), L. Tiret, V. Nicaud. Italy Centro Ricerche EPIMED - Epidemiologia e Medicina Preventiva, Dipartimento di Medicina Clinica e Sperimentale. Università degli Studi dell'Insubria, Varese: M. Ferrario (principal investigator), G. Veronesi and Dipartimento di Medicina Sperimentale. Università degli Studi Milano-Bicocca, Monza: G. Cesana, P Brambilla. United Kingdom PRIME/Belfast, Queen's University Belfast, Belfast, Northern Ireland: F. Kee (principal investigator) A. Evans (former principal investigator), J. Yarnell, E. Gardner; MORGAM Coordinating Centre, Queen's University Belfast, Belfast, Northern Ireland: A. Evans (MORGAM coordinator), S. Cashman, F Kee. MORGAM Management Group: A. Evans (chair, Belfast, UK), S. Blankenberg (Hamburg, Germany), F. Cambien (Paris, France), M. Ferrario (Varese, Italy), K. Kuulasmaa (Helsinki, Finland), A. Palotie (Cambridge, UK), M. Perola (Helsinki, Finland), A. Peters (Neuherberg, Germany), V. Salomaa (Helsinki, Finland), H. Tunstall-Pedoe (Dundee, Scotland), P.G. Wiklund (Umeå, Sweden); Previous members: K. Asplund (Stockholm, Sweden), L. Peltonen (Helsinki, Finland), D. Shields (Dublin, Ireland), B. Stegmayr (Umeå, Sweden).
Page 17 of 18
Cohort Acknowledgements (funding, personal, groups, …)
NSHD This work was funded by the Medical Research Council. We are very grateful to the members of this birth cohort for their continuing interest and participation in the study.
PIVUS Genotyping was performed by the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se). We thank Tomas Axelsson, Ann-Christine Wiman and Caisa Pöntinen for their excellent assistance with genotyping. The SNP Technology Platform is supported by Uppsala University, Uppsala University Hospital and the Swedish Research Council for Infrastructures. E.I. is supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Foundation for Strategic Research, and the Royal Swedish Academy of Science.
SCARFSHEEP The SCARFSHEEP study was supported by the Swedish Heart-Lung Foundation, the Swedish Research Council (projects 8691 and 0593), the Knut and Alice Wallenberg Foundation, the Torsten and Ragnar Söderberg Foundation, the Foundation for Strategic Research, the Stockholm County Council (project 562183) and the Strategic Cardiovascular and Diabetes Programmes of Karolinska Institutet and Stockholm County Council.
STR This work was supported by grants from the National Institutes of Health (AG028555, AG08724, AG04563, AG10175, AG08861), the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Foundation for Strategic Research, the Royal Swedish Academy of Science, and ENGAGE (within the European Union Seventh Framework Programme, HEALTH-F4-2007-201413). Genotyping was performed by the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se). We thank Tomas Axelsson, Ann-Christine Wiman and Caisa Pöntinen for their excellent assistance with genotyping. The SNP Technology Platform is supported by Uppsala University, Uppsala University Hospital and the Swedish Research Council for Infrastructures.
T2D-WTCCC Research funding for sample collection, genotyping and data analysis for the T2D-WTCCC and other cohorts for which the Oxford group had responsibility came from the British Diabetes Association, BDA Research, Diabetes UK, Oxford NIHR Biomedical Research Centre, European Commission (ENGAGE: HEALTH-F4-2007-201413; EURODIA: LSHG-CT-2004-518153, Wellcome Trust (072960, 076113/B/04/Z, 076113/K/04/Z, 083270, 085301, 079557, 081682, 075491) UK Medical Research Council (G0000649, G0601261) and NIDDK (R01-DK-073490). In addition, Cecilia Lindgren is funded by WT086596/Z/08/Z (Wellcome Trust Research Career Development Fellowship); Reedik Mägi is funded by European Commission under the Marie Curie Intra-European Fellowship; and Mark McCarthy receivespersonal funding from the Oxford NIHR Biomedical Research Centre.
THISEAS Recruitment for THISEAS was partially funded by a research grant (PENED 2003) from the Greek General Secretary of Research and Technology; we thank all the dieticians and clinicians for their contribution to the project.
Page 18 of 18
Cohort Acknowledgements (funding, personal, groups, …)
Tromsø
The Tromsø study has been supported by the University of Tromsø and the Norwegian Research Council (project number 185764).
ULSAM Genotyping was performed by the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se). We thank Tomas Axelsson, Ann-Christine Wiman and Caisa Pöntinen for their excellent assistance with genotyping. The SNP Technology Platform is supported by Uppsala University, Uppsala University Hospital and the Swedish Research Council for Infrastructures. E.I. is supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Foundation for Strategic Research, and the Royal Swedish Academy of Science.
Whitehall II The WHII study has been supported by grants from the Medical Research Council; Economic and Social Research Council; BHF; Health and Safety Executive; Department of Health; National Heart Lung and Blood Institute (HL36310), US, NIH: National Institute on Aging (AG13196), US, NIH; Agency for Health Care Policy Research (HS06516); and the John D and Catherine T MacArthur Foundation Research Networks on Successful Midlife Development and Socioeconomic Status and Health. Genotyping in WHII was supported by BHF grant PG/07/133/24260. Whitehall II genotyping was in part supported by a MRC-GSK pilot programme grant (ID 85374).